

# EXHIBIT 2



Deposition of:  
**Patrick Lappert, M.D.**

*September 30, 2021*

In the Matter of:  
**Kadel, et al vs. Folwell**

Veritext Legal Solutions  
800-734-5292 | [calendar-dmv@veritext.com](mailto:calendar-dmv@veritext.com) |

1           IN THE UNITED STATES DISTRICT COURT  
2           FOR THE MIDDLE DISTRICT OF NORTH CAROLINA

3  
4  
5  
6  
7           CIVIL ACTION NO.:   1:19-cv-272-LCB-LPA

8  
9           MAXWELL KADEL, et al.

10                   Plaintiffs

11  
12           v.

13  
14           DALE FOLWELL, et al.

15                   Defendants

16  
17  
18           REMOTE VIDEOTAPED VIDEOCONFERENCE

19                   DEPOSITION TESTIMONY OF:

20                           PATRICK LAPPERT, M.D.

21                                   September 30, 2021  
22  
23

A P P E A R A N C E S

FOR THE PLAINTIFFS (via remote  
videoconference):

Dmitriy Tishyevich, Esq.

MCDERMOTT, WILL & EMERY

One Vanderbilt Avenue

New York, New York 10017

dtishyevich@mwe.com

Tara L. Borelli, Esq.

LAMBDA LEGAL DEFENSE AND EDUCATION FUND

158 West Ponce de Leon Avenue, Suite 105

Decatur, Georgia 30030

tborelli@lambdalegal.com

Omar Gonzalez-Pagan, Esq.

LAMBDA LEGAL DEFENSE AND EDUCATION FUND

120 Wall Street, 19th Floor

New York, New York 1005

ogonzalez-pagan@lambdalegal.com

1 FOR THE DEFENDANTS (via remote  
2 videoconference):

3  
4 John G. Knepper, Esq.  
5 LAW OFFICE OF JOHN G. KNEPPER LLC  
6 1720 Carey Avenue, Suite 590  
7 Cheyenne, Wyoming 82001  
8 john@knepperllc.com  
9

10 Kevin G. Williams, Esq.  
11 BELL, DAVIS & PITT  
12 100 North Cherry Street, Suite 600  
13 Winston-Salem, North Carolina 27101  
14 kwilliams@belldavispitt.com  
15  
16

17 ALSO PRESENT (via remote  
18 videoconference):

19  
20 Andrew Baker, Videographer  
21  
22  
23

## I N D E X

EXAMINATION BY:	PAGE
Mr. Tishyevich	11
Mr. Knepper	472
REEXAMINATION BY:	
Mr. Tishyevich	489

## E X H I B I T S

FOR THE PLAINTIFFS:	MARKED
Exhibit 1 Lappert Expert Report	12
Exhibit 2 ABPlasticSurgery.org	27
Exhibit 3 Brandt - Lappert Declaration	34
Exhibit 4 Brandt - Supplemental Order, 08/02/2021	37
Exhibit 5 Utah Legislature - Answers for Joint Interim Committee	55
Exhibit 6 "Alabama bill that would criminalize treatment for transgender minors headed to full Alabama Senate,"	62

1	rocketcitynow.com		
2	Exhibit 7	ASPS - "State Focus on	108
3		Gender Affirmation	
4		Intensifies"	
5	Exhibit 8	ASPS - 2021 State Policy	116
6		Priorities	
7	Exhibit 9	Lappert Resumé	127
8	Exhibit 10	Code of Ethics of the	171
9		American Society of Plastic	
10		Surgeons	
11	Exhibit 11	Federal Register, Vol, 59,	223
12		No. 22 - November 18, 1994	
13	Exhibit 12	FDA, Understanding	230
14		Unapproved Use of Approved	
15		Drugs "Off Label"	
16	Exhibit 13	FDA, "Off-Label" and	232
17		Investigational Use of	
18		Marketed Drugs, Biologics,	
19		and Medical Devices	
20	Exhibit 14	American Academy of	239
21		Pediatrics Policy Statement,	
22		Off-Label Use of Drugs in	
23		Children	

1	Exhibit 15	Yackey, Off-label Medication	256
2		Prescribing Patterns in	
3		Pediatrics: An Update	
4	Exhibit 16	FDA Botox Cosmetic	263
5		2017-10-02 Approval Letter	
6	Exhibit 17	Sugrue 2019, Levels of	299
7		Evidence in Plastic and	
8		Reconstructive Surgery	
9		Research: Have We Improved	
10		Over the Past 10 Years?	
11	Exhibit 18	Reversal Surgery in	326
12		Regretful Male-to-Female	
13		Transsexuals After Sex	
14		Reassignment Surgery	
15		(Djordjevic)	
16	Exhibit 19	(Exhibit number not used)	---
17	Exhibit 20	Wiepjes 2018, The Amsterdam	339
18		Cohort of Gender Dysphoria	
19		Study (1972-2015)	
20	Exhibit 21	Wilson 2017, Regret In	355
21		Surgical Decision Making: A	
22		Systematic Review of Patient	
23		and Physician Perspectives	



1	Exhibit 22	Exposito-Campos, A Typology	361
2		of Gender Detransition and	
3		Its Implications for	
4		Healthcare Providers	
5	Exhibit 23	BCBS NC - Corporate Medical	375
6		Policy, update July 2021	
7	Exhibit 24	Dhejne, Long-Term Follow-Up	388
8		of Transsexual Persons	
9		Undergoing Sex Reassignment	
10		Surgery: Cohort Study in	
11		Sweden	
12	Exhibit 25	Finnish Guidelines 2020	394
13		Minors, Unofficial	
14		Translation	
15	Exhibit 26	WPATH Standards of Care,	396
16		Version 7	
17	Exhibit 27	Carmichael, Short-term	411
18		outcomes of pubertal	
19		suppression in a selected	
20		cohort of 12 to 15 year old	
21		young people with persistent	
22		gender dysphoria in the UK	
23	Exhibit 28	2020 Cochrane Database of	414

## Systematic Reviews

Exhibit 29	Tradition 70/30 PPO Plan	419
	Benefits Booklet, 2017	
Exhibit 30	Aetna, Gender Affirming	427
	Surgery Policy	
Exhibit 31	Cigna Medical Coverage	430
	Policy, Treatment of Gender	
	Dysphoria	
Exhibit 32	United Healthcare Medical	434
	Policy, Gender Dysphoria	
	Treatment	
Exhibit 33	Lappert Denver Conference	451
	Presentation	
Exhibit 34	Plastic surgeon: Sex-change	463
	operation 'utterly	
	unacceptable' and a form of	
	'child abuse',	
	LifeSiteNews.com	

(Exhibits attached to transcript.)

1                   I, Lane C. Butler, a Court  
2           Reporter and Notary Public, State of  
3           Alabama at Large, acting as Notary,  
4           certify that on this date, pursuant to  
5           the Federal Rules of Civil Procedure,  
6           there came before me via remote  
7           videoconference from Decatur, Alabama,  
8           commencing at approximately 8:30 a.m.  
9           Central, on the 30th day of September,  
10          2021, PATRICK LAPPER, M.D., witness in  
11          the above cause, for oral examination,  
12          whereupon the following proceedings were  
13          had:

14  
15                   THE VIDEOGRAPHER:   Good morning.  
16          We are going on the record at 8:31 a.m.,  
17          Thursday, September 30th, 2021.   This is  
18          Media Unit 1 of the videorecorded  
19          deposition of Dr. Patrick Lappert as  
20          taken by counsel for plaintiff in the  
21          matter of Kadel, et al. v. Folwell, et  
22          al., filed in the United States District  
23          Court for the Middle District of North

1 Carolina, Civil Action No.

2 1:19-cv-272-LCB-LPA.

3 This deposition is being  
4 recorded remote via Zoom located in  
5 Decatur, Alabama. My name is Andrew  
6 Baker from the firm Veritext Legal  
7 Solutions. I am the videographer. The  
8 court reporter is Lane Butler, also from  
9 Veritext Legal Solutions.

10 Will counsel now state their  
11 appearance and affiliations for the  
12 record. The court reporter will swear in  
13 the witness. Thank you. We may proceed.

14 MR. TISHYEVICH: This is Dmitriy  
15 Tishyevich from McDermott, Will & Emery,  
16 LLP, for plaintiffs.

17 MR. KNEPPER: My name is John  
18 Knepper. I represent three of the  
19 defendants in this matter: the North  
20 Carolina State Health Plan for Teachers  
21 and State Employees; Dale Folwell, the  
22 treasurer for the State of North  
23 Carolina; and Dee Jones, the executive

1 administrator of the North Carolina State  
2 Health Plan. I'll be defending Dr.  
3 Lappert's deposition.  
4

5 PATRICK LAPPERT, M.D.,  
6 having first been duly sworn,  
7 was examined and testified as follows:  
8

9 EXAMINATION BY MR. TISHYEVICH:

10 Q. Good morning, Doctor.

11 A. Good morning, sir.

12 Q. State your full name for the  
13 record.

14 A. Patrick Walter Lappert.

15 Q. Any reason you're not able to  
16 give complete and truthful testimony  
17 today?

18 A. There is no reason.

19 Q. You've been retained as an  
20 expert by defendants in this case;  
21 correct?

22 A. I have.

23 Q. You've prepared an expert

1       report; right?

2           A.     I have.

3           Q.     So, I've premarked Exhibit 1.  
4     Open that, and let me know when you have  
5     it.

6     (Exhibit 1 was marked for identification  
7     and is attached.)

8           A.     Okay. I have it.

9           Q.     This report contains all the  
10    opinions that you intend to offer in this  
11    case; correct?

12          A.     It does.

13          Q.     All right. Without telling me  
14    any conversations that you had with  
15    counsel, what did you do to prepare for  
16    your deposition today?

17          A.     Well, I reviewed the -- the  
18    documents. I guess it's called the  
19    complaint. I reviewed the patient  
20    records. And then, I reviewed the  
21    literature, pertinent journal articles,  
22    publications, and had conversations with  
23    -- with counsel, Mr. Kadel [sic], and his

1 staff at various times.

2 Q. When you say "patient records,"  
3 are you talking about the medical records  
4 for the individual plaintiffs?

5 A. Yes. The ones that were -- that  
6 were given to me to review.

7 Q. And when you say "the  
8 literature," are you referring to some of  
9 the studies that you cite in your report?

10 A. Yes.

11 Q. Have you reviewed any studies --  
12 strike that.

13 In preparing for your deposition  
14 today, have you reviewed additional  
15 studies that are not cited in your  
16 report?

17 A. No. The report contains all of  
18 the studies that I -- that I reviewed  
19 that I consider pertinent. I glossed  
20 some but didn't see them as germane. So  
21 all the ones that were -- that were  
22 germane to my opinion are -- are in the  
23 -- in the document.

1           Q.     Understood.   And you mentioned  
2           that you met with or spoke with Mr.  
3           Knepper in preparing for today?

4           A.     I have.

5           Q.     Okay.   Again, without disclosing  
6           any substance of the conversation, how  
7           many times did you speak or meet with  
8           him?

9           A.     Three or four times, I think.

10          Q.     And when did those conversations  
11          take place?

12          A.     Well, as recently as yesterday  
13          evening and I think a couple of meetings  
14          back in May, I think it was.   I'd have to  
15          look at my calendar, but.

16          Q.     Last evening, you spoke --  
17          strike that.

18                    You know that Dr. Hruz was  
19          deposed yesterday; right?

20          A.     I'd heard, yes.

21          Q.     And so before yesterday, when  
22          was the last time that you spoke with Mr.  
23          Knepper to prepare for your deposition?



1           A.     I want to say it's a couple of  
2 weeks ago. I'm not exactly sure.

3           Q.     How long was the conversation  
4 with Mr. Knepper last night?

5           A.     A little less than an hour.

6           Q.     Did he provide you with copies  
7 of any of the exhibits that were used at  
8 Dr. Hruz's deposition?

9           A.     No, he did not.

10          Q.     Did he provide you with any --  
11 any portions of that deposition  
12 transcript?

13          A.     No.

14          Q.     And then going in reverse  
15 chronological order, you mentioned you  
16 may have spoken a couple of weeks ago?

17          A.     I think. I don't know exactly  
18 -- I don't know exactly when that was,  
19 Mr. Tishyevich. I want to say three  
20 weeks ago perhaps. I'm not exactly sure.

21          Q.     Do you recall roughly how long  
22 that conversation was?

23          A.     About the same duration. I

1 think it was perhaps an hour, perhaps an  
2 hour.

3 Q. Okay. All right. You -- in the  
4 course of -- strike that.

5 In the course of working on this  
6 case, have you ever communicated with Dr.  
7 Hruz?

8 A. Not directly. I've spoken with  
9 Dr. Hruz, but in the matter at hand, I  
10 have not spoken with him about it.

11 MR. TISHYEVICH: For the court  
12 reporter, that's H-R-U-Z. And I'll try  
13 and spell things as we go to make it a  
14 little easier.

15 Q. How about Dr. McHugh?  
16 M-C-H-U-G-H. Have you spoken with him in  
17 the course of working on this case?

18 A. I've never spoken directly to  
19 him, no.

20 Q. How about Dr. Levine?  
21 L-E-V-I-N-E.

22 A. I have not spoken with Dr.  
23 Levine.

1           Q.     But you have met Dr. Hruz before  
2     working on this case; right?

3           A.     Yes.

4           Q.     And is the same true for Dr.  
5     Levine?

6           A.     I've never met Dr. Levine.

7           Q.     All right. About how many hours  
8     do you estimate you've spent working on  
9     your expert report?

10          A.     Somewhere around maybe 60 hours.  
11     I could -- I could look for that number,  
12     but I'm going to estimate it at about 60  
13     hours, something like that.

14          Q.     You're aware that the individual  
15     plaintiffs in this case have been  
16     deposed; right?

17          A.     Yes, I've heard.

18          Q.     Were you provided with  
19     deposition transcripts or any portion of  
20     their testimony?

21          A.     I have -- I have not seen those,  
22     no.

23          Q.     Okay. You're aware that other

1 experts in this case have also already  
2 been deposed?

3 A. Yes.

4 Q. Have you been provided with  
5 deposition transcripts or any portion of  
6 their deposition testimony?

7 A. I -- I saw a transcript of Dr.  
8 McHugh's.

9 Q. Was that the only tran- --  
10 strike that.

11 Was Dr. McHugh's transcript the  
12 only expert deposition transcript you've  
13 seen?

14 A. It's the only one I've read. I  
15 -- I think that -- yeah, I think it's the  
16 only one I read. Yes, sir.

17 Q. Okay. All right. So throughout  
18 your report, you use this term --

19 A. Could I amend that last answer?

20 Q. Of course.

21 A. I -- I did read portions of Dr.  
22 Brown's transcript, actually, some days  
23 back. My -- my apologies.

1           Q.     No.   And I should say that.   If  
2           at any point in time in your deposition  
3           you want to go back and amend your  
4           answer, that is totally fine.

5           A.     Thank you.

6           Q.     Okay.   So in your report, you  
7           use this term "transgender treatment  
8           industry."   Right?

9           A.     Yes.

10          Q.     And you and Dr. Levine and Dr.  
11          McHugh all use this term in your reports.  
12          Were you aware of that?

13          A.     Oh, I was aware that the -- no,  
14          I wasn't aware that they were using it,  
15          actually.

16          Q.     Is it coincidental that the  
17          three of you are using this term?

18          A.     I -- I think it's sort of  
19          becoming a common term lately.   I don't  
20          know where it came from.   I was trying to  
21          think about that.   I don't know who  
22          originated it, but I've -- I don't know  
23          even if it was me that originated it,

1       actually, since I've been speaking about  
2       this subject for some time now. But it  
3       seemed like an apt term, so it doesn't  
4       surprise me that others are using it.

5           Q.     You don't know who came up with  
6       that term?

7           A.     I don't.

8           Q.     It's possible that it was you?

9           A.     It wouldn't surprise me.

10          Q.     And you mentioned that it's  
11       becoming more commonly used. Is that  
12       right?

13          A.     It seems to be. I don't know.  
14       I don't know how common it is, but it's  
15       kind of a small circle of people talking  
16       about these things.

17          Q.     Are you aware of a single  
18       peer-reviewed scientific article that has  
19       used the term "transgender treatment  
20       industry"?

21          A.     I am not.

22          Q.     Do you know what PubMed is?

23       P-U-B-M-E-D.

1           A.     Yes.

2           Q.     It's a search engine maintained  
3 by the National Institute of Health;  
4 right?

5           A.     Yes.   That's my understanding.

6           Q.     It's a search engine for  
7 scientific articles, basically; right?

8           A.     Yes.

9           Q.     So I'll represent to you that I  
10 ran a search in PubMed for the phrase  
11 transgender treatment industry, in  
12 quotation marks, and came back with zero  
13 results for that phrase.

14               MR. KNEPPER:   Objection to form.

15           Q.     Do you find that surprising?

16           A.     No.

17           Q.     Okay.   What does that lack of  
18 results tell you about whether this term  
19 is a commonly used term in this field?

20               MR. KNEPPER:   Objection to form.

21           A.     I wouldn't expect it to be a  
22 commonly used term, and it doesn't  
23 surprise me that you didn't find it.

1 Q. Yeah. "Transgender treatment  
2 industry" is not a commonly used term in  
3 the field of treatment and diagnosis of  
4 gender dysphoria; right?

5 MR. KNEPPER: Objection to form.

6 A. I would agree.

7 Q. Yeah. It's a term that, as far  
8 as I can tell, is fairly idiosyncratic to  
9 the opinions that you and the other  
10 defendant experts are using in this case.  
11 Does that sound right?

12 MR. KNEPPER: Objection to form.

13 A. That sounds right to me, yeah.

14 Q. Okay. Look at page 1 of your  
15 expert report, Exhibit 1.

16 A. All right.

17 Q. I see it says, "Declaration of  
18 Patrick Lappert, MD." You see that?

19 A. Yes.

20 Q. Under that, it says, "Board  
21 Certified in Surgery and Plastic  
22 Surgery." Do you see that?

23 A. I do.



1           Q.     Let's talk about your  
2           certifications. Let's start with plastic  
3           surgery. You originally received your  
4           board certification in plastic surgery in  
5           1997; correct?

6           A.     That's correct.

7           Q.     Then you got recertified in  
8           2008; correct?

9           A.     That's correct.

10          Q.     That board certificate was only  
11          valid for ten years; correct?

12          A.     Correct.

13          Q.     And your plastic board -- strike  
14          that.

15                 And your plastic surgery board  
16          certificate expired at the end of 2018;  
17          correct?

18          A.     Correct.

19          Q.     Well, why did you decide not to  
20          renew your board certificate past 2018?

21          A.     Well, I'm a -- I'm a solo  
22          practitioner, and the main reason for  
23          maintaining that expensive certificate

1        was that many hospitals required it in  
2        order to have privileges. Several years  
3        ago, a lot of hospitals started dropping  
4        that requirement, so it didn't make sense  
5        for a surgeon who is within three years  
6        of retirement to expend all that money  
7        and time to maintain a certification that  
8        was no longer necessary for me in terms  
9        of maintaining my practice.

10       Q.     Do you currently have admitting  
11       privileges at any hospital?

12       A.     No.

13       Q.     When was the last time you had  
14       admitting privileges in any hospital?

15       A.     A year ago.

16       Q.     What hospital was that?

17       A.     Crestwood Hospital, Huntsville,  
18       Alabama.

19       Q.     So within the last year at  
20       least, I take it you haven't performed  
21       any surgeries at a hospital. Right?

22       A.     That's correct. A -- a year  
23       ago, I retired from active surgical

1 practice.

2 Q. Were you doing surgeries in 2019  
3 after your plastic -- plastic surgery  
4 board certificate expired?

5 A. Yes.

6 Q. When -- just can we pin this  
7 down more? What -- what month do you  
8 think you stopped performing surgeries?

9 A. Let's see. This is November of  
10 2021, so it would have been August of  
11 2020.

12 Q. All right. You are not  
13 currently board-certified in plastic  
14 surgery; correct?

15 A. Correct.

16 Q. And you have not been  
17 board-certified in plastic surgery since  
18 2018; correct?

19 A. Correct.

20 Q. For over two and a half years at  
21 this point; right?

22 A. Correct.

23 Q. So this page 1 of your report

1       says that you're board-certified in  
2       plastic surgery. Do you think it's  
3       appropriate for you to make that  
4       representation even though you don't have  
5       an active certification?

6               MR. KNEPPER: Objection, form.

7       A. Well, appropriate in terms of --  
8       I don't understand the question.

9       Q. Let me be more specific.

10      A. Okay.

11      Q. Do you know what the Amer- --  
12      I'll go back.

13             You know what the American Board  
14      of Plastic Surgery is; right?

15      A. Certainly.

16      Q. Do you know what the American  
17      Board of Plastic Surgery has to say about  
18      doctors who represent that they're  
19      board-certified when they don't have an  
20      active certification?

21             MR. KNEPPER: Objection, form.

22      A. They discourage it. I -- I  
23      suspect that the -- the document -- well,

1 I didn't prepare that -- that particular  
2 part of the document, although I signed  
3 it, certainly. But I see your point,  
4 yes.

5 Q. Okay. I'm going to introduce  
6 another exhibit. You'll see it in a  
7 minute. Let me know when you have it,  
8 Doctor.

9 (Exhibit 2 was marked for identification  
10 and is attached.)

11 A. I have it.

12 Q. This is a printout from the -- a  
13 web page from the American Board of  
14 Plastic Surgery. Go to page 2.

15 A. All right. I'm there.

16 Q. Middle of the page, it says in  
17 bold letters, "Guidelines for Stating  
18 Certification Status." Do you see that?

19 A. I do.

20 Q. Look at the third paragraph.

21 A. All right.

22 Q. It says, "ABPS does not mandate  
23 the specifics of how diplomates state

1       their certification, except to assert  
2       that diplomates should not state or imply  
3       that they are certified if their  
4       certification has expired."

5               Do you see that?

6           A.     I do.

7           Q.     All right.  You understand that  
8       under this guidance from the ABPS, you  
9       are not supposed to be representing that  
10      you are board-certified in plastic  
11      surgery because you do not have a current  
12      certification; correct?

13               MR. KNEPPER:  Objection, form.

14          A.     Yes, I understand it.

15          Q.     Let's look at what else it says.  
16      Towards the bottom of page 2, it says,  
17      "We ask that you follow these guidelines  
18      throughout your career to accurately  
19      state your ABPS certification."  Do you  
20      see that?

21          A.     I do.

22          Q.     The first bullet says,  
23      "Diplomates of ABPS must accurately state

1       their certification status at all times."

2       Do you see that?

3           A.     I do.

4           Q.     And you understand what this  
5       means; right?

6           A.     I do.

7                   MR. KNEPPER:  Objection, form.

8           Q.     Page 3, next bullet says,  
9       "Diplomates with expired time-limited  
10      certification or those whose  
11      certification is revoked may not claim  
12      Board certification by ABPS and must  
13      revise all descriptions of their  
14      qualifications accordingly."  Right?

15                  MR. KNEPPER:  Objection to form.

16           A.     Yes.  Yes, I see that.

17           Q.     And you understand what that  
18      means; right?

19                  MR. KNEPPER:  Objection to form.

20           A.     I do.

21           Q.     Your expert report is not in  
22      compliance with this guidance from the  
23      ABPS; correct?

1 MR. KNEPPER: Objection, form.

2 A. The -- the one line there under  
3 my name is not in compliance. That's  
4 correct.

5 Q. And the same is true of your CV;  
6 right?

7 A. Well, the CV states that I have  
8 been board-certified by the American  
9 Board of Surgery and have been  
10 board-certified by the ABPS in 1997 and  
11 2008, yes. Have been.

12 Q. And look back at this page 3  
13 from the ABPS. It says, "When a  
14 physician misrepresents certification  
15 status, ABPS may notify local  
16 credentialing bodies, licensing bodies,  
17 law enforcement agencies and others." Do  
18 you see that?

19 A. I do.

20 Q. All right. And you understand  
21 what this means; right?

22 MR. KNEPPER: Objection to form.

23 A. Yes.



1           Q.     Okay.  Are you going to update  
2     your expert report so that it comports  
3     with this guidance from the ABPS?

4                     MR. KNEPPER:  Objection to form.

5           A.     Certainly.

6           Q.     Okay.  So that's plastic  
7     surgery.  Let's talk about your board  
8     certification in surgery next.  So, go  
9     back to your expert report, page 1.

10          A.     Okay.

11          Q.     You received your board  
12     certification in surgery in 1992;  
13     correct?

14          A.     Was it '92 or '91?  '92, yes,  
15     sir.

16          Q.     And that certification expired  
17     in 2002; right?

18          A.     Yes.

19          Q.     And you had not renewed that  
20     after 2002; right?

21          A.     Correct.

22          Q.     You're not currently  
23     board-certified in surgery; correct?

1           A.     Correct.

2           Q.     You have not been  
3 board-certified in surgery since 2002;  
4 correct?

5           A.     Since 2002, yes, sir.

6           Q.     That's over nineteen years;  
7 right?

8                   So, I showed you this guidance  
9 from the American Board of Plastic  
10 Surgery. How about the American Board of  
11 Surgery? What do you think they have to  
12 say about doctors who make these kind of  
13 representations?

14                   MR. KNEPPER: Objection, form.

15           A.     I'm sure it's probably the same.

16           Q.     Yeah. Would it surprise you  
17 that the American Board of Surgery does  
18 not allow doctors to represent that they  
19 are board-certified in surgery unless  
20 they have a current board certificate?

21                   MR. KNEPPER: Objection, form.

22           A.     It would not surprise me, no.

23           Q.     All right. You are currently

1       serving as an expert in another case,  
2       Brandt v. Rutledge.   B-R-A-N-D-T.  
3       Correct?

4           A.     Yes.

5           Q.     That's a case pending in federal  
6       court in Arkansas; right?

7           A.     Correct.

8           Q.     In that case, you were retained  
9       by the defendants, by the State of  
10      Arkansas; right?

11          A.     Yes.

12          Q.     Dr. Hruz, who is one of the  
13      defendants -- strike that. Dr. Hruz, who  
14      is one of the experts in this case, is  
15      also serving as an expert for defendants  
16      in that Brandt case; right?

17          A.     That's my understanding, yes.

18          Q.     And the same is true for Dr.  
19      Levine; right?

20          A.     I didn't know about Dr. Levine,  
21      but.

22          Q.     And you submitted an expert  
23      declaration in that Brandt case in July

1 of this year; correct?

2 A. I believe that was when I  
3 submitted it, yes.

4 Q. All right. Let's look at it.  
5 And let me know when you get the exhibit,  
6 Doctor.

7 (Exhibit 3 was marked for identification  
8 and is attached.)

9 A. Here it is. Let's see. All  
10 right.

11 Q. All right. Page 1 says,  
12 "Declaration of Dr. Patrick Lappert."  
13 That's you; right?

14 A. Yes.

15 Q. Fair to say that there is at  
16 least some overlap between the opinions  
17 that you're offering in this case and the  
18 opinions that you're offering in that  
19 Brandt case; right?

20 MR. KNEPPER: Form.

21 A. Well, given that the subject  
22 matter is the same, I would expect some  
23 overlap, yes, sir.

1           Q.     Go to page 5 of that  
2     declaration.

3           A.     All right. I'm there.

4           Q.     You say under Section II,  
5     "'Gender affirming' treatments are  
6     experimental." Right?

7           A.     Yes.

8           Q.     It's basically the same opinion  
9     that you offered in this case; right?

10          A.     Yes, sir.

11          Q.     Go to page 29 of your  
12     declaration. See there's a paragraph 63?

13          A.     Yes, sir.

14          Q.     And toward the end of that  
15     paragraph, you talk about the national  
16     reviews in England, Sweden, and Finland  
17     and other reviews like Cochrane, Griffin,  
18     and Carmichael. You see that?

19          A.     Yes, sir.

20          Q.     You relied -- you relied on all  
21     those studies for your opinions in this  
22     case as well; right?

23          A.     I did.

1           Q.     Okay. Go to page 38 of your  
2           declaration. Do you see that it's the  
3           section titled "Concluding Opinions" and  
4           it goes through the next --

5           A.     Yes, sir.

6           Q.     -- few pages?

7                     We don't need to go through  
8           these individually, but you agree there's  
9           a lot of overlap between the opinions  
10          you're offering in that Brandt case and  
11          the opinions you're offering in this  
12          case; right?

13                   MR. KNEPPER: Objection to form.

14          A.     Yes.

15          Q.     The Brandt case involves a  
16          challenge to an Arkansas law which bans  
17          doctors from providing various types of  
18          gender-affirming treatments to  
19          adolescents; correct?

20          A.     Yes.

21          Q.     Including puberty blockers and  
22          cross-sex hormones and gender-affirming  
23          surgery; correct?

1           A.     Yes.

2                   MR. KNEPPER:  Objection.

3           Q.     Have you kept up with what's  
4 going on in that case in Arkansas?

5                   MR. KNEPPER:  Objection, form.

6           A.     I haven't heard anything perhaps  
7 in the last several weeks.

8           Q.     Well, are you aware that in July  
9 of this year, the judge in that case held  
10 that the State is prohibited from  
11 enforcing the ban while the case is being  
12 decided?

13          A.     I've heard that.

14          Q.     All right.  And as part of that  
15 order, the judge made some factual  
16 findings.  Are you aware of that?

17          A.     I'm not -- haven't read the  
18 details.

19          Q.     All right.  Let me show you.

20          A.     Okay.

21          Q.     Let me introduce one more  
22 exhibit.

23                 (Exhibit 4 was marked for identification

1       and is attached.)

2           A.     I have it now.

3           Q.     Okay.   So, this is a  
4       supplemental order from Judge Moody in  
5       Arkansas dated August 2nd, 2021.   Do you  
6       see that?

7           A.     I see that, yes.

8           Q.     This first paragraph says,  
9       "After further consideration, the Court  
10      supplements the ruling made at the  
11      conclusion of the July 21, 2021 hearing  
12      to include the following findings."   Do  
13      you see that?

14          A.     I do.

15          Q.     By the way, did you testify live  
16      at that July 2021 hearing?

17          A.     No.

18          Q.     Do you know if any of the other  
19      experts testified live at that hearing?

20          A.     I don't know.

21          Q.     Go to page 7.

22          A.     All right.

23          Q.     All right.   Look at the last



1 paragraph.

2 A. Okay.

3 Q. The second sentence in that last  
4 paragraph says, "Gender-affirming  
5 treatment is supported by medical  
6 evidence that has been subject to  
7 rigorous study." Right? Do you see  
8 that?

9 A. That's what it says, yes, sir.

10 Q. And that finding by the Court in  
11 Arkansas is contrary to the opinions that  
12 you offered in that case; right?

13 A. Apparently so, yes.

14 Q. And it's also contrary to the  
15 opinions that Dr. Hruz and Dr. Levine  
16 offered in that case; right?

17 A. Yes.

18 MR. KNEPPER: Objection to form.

19 A. It appears to be, yes.

20 Q. And it's also contrary to the  
21 opinions that you and Dr. Hruz and Dr.  
22 Levine are offering in this case; right?

23 A. Yes.

1           Q.     Look at the next sentence.  It  
2     says, "Every major expert medical  
3     association recognizes that  
4     gender-affirming care for transgender  
5     minors may be medically appropriate and  
6     necessary to improve the physical and  
7     mental health of transgender people."

8                     That's what it says; right?

9           A.     That's what it says, yes, sir.

10          Q.     That's also contrary to the  
11     opinions that you and Dr. Hruz and Dr.  
12     Levine are offering in both these cases;  
13     right?

14          A.     Yes, it certainly is.

15          Q.     In fact, according to this  
16     order, every major expert medical  
17     association disagrees with you because  
18     they've all taken a position that this  
19     treatment is in fact medically necessary;  
20     right?

21                     MR. KNEPPER:  Objection to form.

22          A.     Apparently so, yes.

23          Q.     All right.  Look at page 6.

1 Look at the last paragraph. You see it  
2 says that -- the third sentence says,  
3 "The consensus recommendation of medical  
4 organizations is that the only effective  
5 treatment for individuals at risk of or  
6 suffering from gender dysphoria is to  
7 provide gender-affirming care." Do you  
8 see that?

9 A. I do.

10 Q. You see there's a Footnote 3?

11 A. Let me get my glasses on here.  
12 Footnote 3. I don't see Footnote 3.  
13 Let's see.

14 Q. The bottom of page 6.

15 A. I see it now, yes.

16 Q. Footnote 3 has a long list of  
17 medical organizations that all have taken  
18 the position that gender-affirming care  
19 is medically appropriate for individuals  
20 with gender dysphoria; right?

21 MR. KNEPPER: Objection to form.

22 A. Yeah, the consensus  
23 recommendations. Those are consensus

1        recommendations. And yes, I was aware  
2        that those were the positions taken by  
3        those organizations even before the  
4        judge's opinion.

5            Q.        Yeah. By my count, Footnote 3  
6        lists 18 different professional medical  
7        organizations, and as I read this  
8        footnote, every single one of them takes  
9        the view that's contrary to the opinions  
10       that you and Dr. Hruz and Dr. Levine are  
11       offering; right?

12            MR. KNEPPER:    Objection to form.

13            A.        Yes. There's a consensus of  
14        consensus on this, exactly, yes, sir.

15            Q.        And you're not aware of a single  
16        professional medical organization that  
17        submitted anything in this Brandt case  
18        and said that they agree with the  
19        opinions that you and Dr. Hruz and  
20        Dr. Levine are offering; right?

21            A.        Well, I'm aware of at least one  
22        professional organization that -- that  
23        disagrees with that, yeah, the

1        pediatric -- American Pediatric --  
2        American Association of Pediatricians.

3            Q.     Do you know if they submitted  
4        anything to the Court in this Brandt case  
5        to that effect?

6            A.     I'm not aware. I don't know.

7            Q.     Okay. Look back to your report,  
8        Exhibit 1.

9            A.     Okay.

10          Q.     And go to page 5.

11          A.     Okay.

12          Q.     See there's paragraph 11?

13          A.     Yes.

14          Q.     And you say that "Affirmation  
15        Treatments are Currently Experimental."  
16        And then you say, "are not generally  
17        accepted by the relevant scientific  
18        community." Right?

19          A.     Yes, I say that, absolutely.

20          Q.     Well, apparently, there's at  
21        least eighteen different professional  
22        medical organizations that all say that  
23        you and Dr. Hruz and Dr. Levine are wrong

1       and that these gender-affirming  
2       treatments are, in fact, medically  
3       appropriate; right?

4           A.     Well, I --

5                   MR. KNEPPER:   Object.

6           A.     I would say that part of the  
7       difficulty here is a misunderstanding  
8       about how those consensus opinions are  
9       arrived at.  They're not arrived at  
10      scientifically.  So minus a scientific  
11      opinion, those are -- those are consensus  
12      opinions.

13                   For example, in plastic surgery,  
14      there was a controversy some years ago  
15      about the use of fat grafting in breast  
16      reconstruction, and there was a concern  
17      about whether it would promote malignant  
18      degeneration.  The American Society of  
19      Plastic and Reconstructive Surgeons came  
20      out with a consensus statement  
21      essentially recommending against, if not  
22      outright forbidding, the use of fat  
23      grafting in breast reconstruction or

1 cosmetic surgery. But I was never  
2 polled. I was a member of the American  
3 Society of Plastic Surgery, but I was  
4 never polled.

5 These consensus statements do  
6 not poll the scientific or professional  
7 community. They're the work product of  
8 a -- of small committees where they  
9 perhaps will review scientific literature  
10 and come to an opinion within that  
11 relatively small group.

12 So I think the misunderstanding  
13 is that because, for example, the  
14 American Medical Association or the  
15 American Pediatric Society has a  
16 statement making this claim, it's not, by  
17 definition, supported by the membership  
18 of that -- that society. It is the work  
19 product of a committee, and it's -- and  
20 it doesn't -- it doesn't lay out the  
21 scientific basis for those opinions for  
22 the membership to review, as was the case  
23 in -- and it turns out that seven, eight

1        years later, the American Society of  
2        Plastic and Reconstructive Surgery  
3        rescinded their prohibition when the  
4        membership basically chimed in and said  
5        this is incorrect and this is our  
6        evidence, here's the science. And the  
7        American Society rescinded that consensus  
8        statement that they had made ten years  
9        earlier.

10                So I imagine that similar things  
11        are going on here. Committees generates  
12        consensus statements. The consensus  
13        statements are published. And one gets  
14        the impression that the entire membership  
15        supports the statement when that in fact  
16        is not the case. And when these  
17        consensus statements are published, they  
18        don't publish the supporting scientific  
19        literature. They merely make the  
20        statement. So I think this is the case  
21        here as well.

22                Q.     You are not a member of the,  
23        let's say, American Medical Association;



1 right?

2 A. Not -- not any longer, no.

3 Q. And your -- I hear you  
4 speculating that there's a committee that  
5 came to this decision at the AMA; right?

6 MR. KNEPPER: Objection, form.

7 A. Well, if the AMA functions like  
8 the American Society of Plastic Surgery  
9 or other -- other professional bodies  
10 like that, professional organizations  
11 like that, I would expect that's how they  
12 make their consensus statements, yes.

13 Q. You personally do not know how  
14 the AMA came to issue this consensus  
15 statement, do you?

16 MR. KNEPPER: Objection.

17 A. I have no personal knowledge,  
18 no.

19 Q. You have no personal knowledge  
20 what scientific literature they reviewed  
21 in coming up with that consensus  
22 statement, do you?

23 A. That's the difficulty. Yes,

1       sir.

2           Q.     Yeah.

3           A.     Correct.

4           Q.     You have no idea, in short, how  
5       the AMA came to reach this consensus  
6       statement; right?

7                   MR. KNEPPER:   Objection to form.

8           A.     I have no personal knowledge of  
9       it, no.

10          Q.     How about the American Pediatric  
11       Society?   You're not a member of that;  
12       right?

13          A.     No.

14          Q.     You have no idea how the  
15       American Pediatric Society came to  
16       support this consensus statement; right?

17          A.     Well, in that case, I do have  
18       friends who are members of the American  
19       Pediatric Society, I think it is.   And  
20       they, in conversation, have told me that  
21       this is how the process works.   I don't  
22       have personal -- personal knowledge of  
23       it, no.

1           Q.     Are those friends on the  
2           committee at the APA that decided to  
3           adopt this consensus statement?

4           A.     Not to my knowledge.

5           Q.     So they also -- strike that.

6                     How about the American  
7           Psychiatric Association?  You're not a  
8           member of that --

9           A.     No.

10          Q.     -- right?

11          A.     No.

12          Q.     You have no idea on what basis  
13          they decided to support this consen- --  
14          what you call consensus -- consensus  
15          statement about the necessity of  
16          treatment for gender dysphoria, do you?

17          A.     No.

18          Q.     So, Doctor, I hear you  
19          criticizing these organizations, but you  
20          do not have firsthand knowledge of how  
21          any of those organizations came to reach  
22          these positions, do you?

23                     MR. KNEPPER:  Objection to form.

1           A.     No.

2           Q.     And you do not know what  
3     scientific literature they relied on, do  
4     you?

5           A.     No.

6                     MR. KNEPPER:   Objection to form.

7           A.     Other than to say that I'm  
8     familiar with the current literature, and  
9     I -- and whenever these -- these  
10    consensus statements are supported with  
11    references to the scientific literature,  
12    that literature I have reviewed. That  
13    was part of the process of generating my  
14    expert testimony.

15          Q.     I thought I just heard you say  
16    that these position statements are not  
17    typically supported by "Here's the study  
18    we relied on." Isn't that what you said?

19          A.     Well, no. In the -- in the  
20    actual document that they publish, they  
21    make -- they make reference to things  
22    like that.

23                     What I meant to say, I suppose,

1 is that -- that I've reviewed the current  
2 literature, particularly in the last  
3 three to five years, that's germane to  
4 the subject of gender affirmation in  
5 pediatric patients and adolescents, and  
6 I -- and I find that the science is weak,  
7 so --

8 Q. But because you have no  
9 firsthand knowledge of how any of these  
10 associations came out with these position  
11 statements, you do not know to what  
12 extent it may have taken that literature  
13 into account before adopting these  
14 position statements; right?

15 MR. KNEPPER: Objection.

16 A. I can only say that if they gave  
17 full force to the scientific literature  
18 that is used to support their position, I  
19 find the scientific literature weak,  
20 yeah.

21 Q. This Brandt case involves a  
22 state law that prohibits doctors in  
23 Arkansas from providing gender-affirming

1 medical treatment to anyone under  
2 eighteen; correct?

3 A. Yes.

4 Q. You yourself support these kind  
5 of state law bans; right?

6 MR. KNEPPER: Objection, form,  
7 scope.

8 A. I do support a control over  
9 these kinds of therapies, yes, I do.

10 Q. Well, not -- not just control,  
11 because Arkansas says it will criminally  
12 prosecute doctors that do it; right?

13 A. Right.

14 MR. KNEPPER: Objection to form,  
15 scope.

16 Q. And you think that's a good  
17 idea; right?

18 A. I do.

19 MR. KNEPPER: Objection to form,  
20 scope.

21 Q. You think that other states  
22 outside of Arkansas should be passing  
23 similar bans; right?

1                   MR. KNEPPER:   Objection, form,  
2                   scope.

3           A.       Actually, what I would prefer to  
4           see is the -- is the professional  
5           societies recommend against these sorts  
6           of things, yes. That would be my  
7           preference. I would rather that the  
8           State did not step in and manage the care  
9           of people who are suffering. I'd rather  
10          the State stayed out of it. But short of  
11          that, I suppose that's the -- the  
12          fallback position is to recourse through  
13          the law.

14                   It would seem to me that  
15          professional organizations should be  
16          managing these issues, and practitioners  
17          ultimately should be responsible, as was  
18          found in the -- in the -- the case in  
19          Great Britain at the Tavistock Portman  
20          Institute when the Court came back and  
21          reviewed the find -- the ruling there and  
22          declared that primacy should be given to  
23          the decision-making of doctors rather

1       than the Courts stepping in as -- as  
2       managers of medical care.

3               And I feel the same way. I  
4       don't think that the State should have to  
5       do this. But -- given that -- given that  
6       things are moving at the pace they are.

7       Q.     Are you aware that state  
8       legislators in Utah have proposed a  
9       similar ban as Arkansas for  
10      gender-affirming medical treatment for  
11      minors?

12      A.     Yes.

13              MR. KNEPPER:  Objection to form,  
14      scope.

15      Q.     You had involvement with those  
16      legislative efforts in Utah, didn't you?

17      A.     I think I made some  
18      recommendations to them. Yes, I did.

19      Q.     Yeah. Because now I hear you  
20      saying you prefer the professional  
21      organizations handle it. But the fact is  
22      you have actively lobbied to get these  
23      kind of bans passed in other states,



1 haven't you?

2 A. Yes, I have.

3 MR. KNEPPER: Objection to form,  
4 scope.

5 A. Yes, I have.

6 Q. I'm going to introduce another  
7 exhibit. Let me know when you have it,  
8 Doctor.

9 (Exhibit 5 was marked for identification  
10 and is attached.)

11 A. I have it.

12 Q. Exhibit 5 is a document titled:  
13 "Transgender 'Transition' Procedures  
14 Performed on Minors. Answers to  
15 Questions and Information for Joint  
16 Interim Committee," dated June 10th,  
17 2021. Do you see that?

18 A. I do.

19 Q. It says, "Submitted by Rep Rex  
20 P. Shipp," S-H-I-P-P. Do you know who  
21 that is?

22 A. I don't know him personally, but  
23 I -- I see he's a representative from

1 Utah apparently.

2 Q. Have you ever communicated with  
3 Mr. Shipp and his staff?

4 A. I may have and don't recall.

5 Q. Why do you say you may have?

6 A. I have a lot of correspondence  
7 with people who ask a lot of questions  
8 who are involved in this -- in this  
9 issue, and I don't have a great memory  
10 for names sometimes. But I know I was in  
11 communication at some level with people  
12 in Utah, but I don't recall exactly the  
13 nature of that conversation, or that  
14 interchange.

15 Q. Go to page 16.

16 A. Sixteen?

17 Q. One six.

18 A. One six. Okay.

19 Q. Toward the bottom of the page,  
20 it says, "We express appreciation to  
21 these noted professionals who contributed  
22 to this report." Do you see that?

23 A. I do.

1 Q. Go to page 17.

2 A. Okay.

3 Q. The bottom of the page says,  
4 "Patrick Lappert, M.D."

5 A. Yes.

6 Q. That's you; right?

7 A. Yes.

8 Q. So at some point earlier this  
9 year, you were providing information to  
10 the Utah State Legislature to support the  
11 potential enactment of a ban on  
12 gender-affirming healthcare for minors;  
13 right?

14 MR. KNEPPER: Objection, form.

15 A. Yes.

16 Q. Look at the fourth name from the  
17 bottom on page 17.

18 A. Fourth name -- I'm sorry?

19 Q. Fourth name from the bottom.

20 A. Paul Hruz. Yes.

21 Q. That's the same Dr. Hruz who's  
22 an expert in this case; right?

23 A. Yes.

1           Q.     Go to page 18.   The second name  
2     from the top is Stephen B. Levine M.D.;  
3     right?

4           A.     Yes.

5           Q.     Same Dr. Levine who is an expert  
6     in this case; right?

7           A.     Yes.   I think so, yes.

8           Q.     And the next name is Paul  
9     McHugh, M.D.; right?

10          A.     Yes.

11          Q.     The same Dr. McHugh who is an  
12     expert in this case; right?

13          A.     Yes.

14          Q.     All four of you were providing  
15     information to the Utah State Legislature  
16     to support this potential ban; right?

17               MR. KNEPPER:   Objection to form.

18          A.     Yes.

19          Q.     How did you get involved with  
20     providing this information to the Utah  
21     State Legislature?

22          A.     I don't recall.   My -- my  
23     suspicion is I may have been contacted by

1 e-mail or some other such thing. In  
2 fact, I'm fairly confident it was an  
3 e-mail request for assistance, probably.

4 Q. Do you remember who the e-mail  
5 was from?

6 A. I do not.

7 Q. Do you remember who at the Utah  
8 State Legislature or anyone affiliated  
9 with them you were communicating with in  
10 this respect?

11 A. I don't remember, no.

12 Q. All right. Let's see what you  
13 were telling the state legislature in  
14 this report. Go to page 5. See there's  
15 a section near the top titled "Sex  
16 reassignment surgeries"?

17 A. Yes.

18 Q. There's some language in quotes  
19 -- in quotes and italicized. Do you see  
20 that?

21 A. I do.

22 Q. And the first portion of the  
23 paragraph says: '"Sex reassignment

1 surgery' is a massive misrepresentation  
2 of what these operations actually do.  
3 You can't change a person's sex. All  
4 that is happening is that the patient is  
5 undergoing an intentional mutilation in  
6 order to create a counterfeit appearance  
7 of the other sex."

8 Do you see that?

9 A. I do.

10 Q. And underneath, it says,  
11 "Patrick Lappert, M.D." Right?

12 A. Yes.

13 Q. These are your words, Dr.  
14 Lappert; right?

15 A. Yes.

16 Q. You consider gender reassignment  
17 surgery to be an intentional mutilation;  
18 right?

19 A. I do. Absolutely.

20 MR. KNEPPER: Form.

21 Q. And calling gender reassignment  
22 surgery, quote, intentional mutilation,  
23 is that commonly accepted terminology in

1       this field, Doctor?

2           A.     I expect not.

3           Q.     And then you say that when a  
4       patient undergoes gender reassignment  
5       surgery, all that is happening is, quote,  
6       a counterfeit appearance of the other  
7       sex; right?

8           A.     Yes.

9           Q.     This phrase, "counterfeit  
10      appearance," do you think that's an  
11      appropriate term for a doctor to use?

12          A.     Absolutely.

13          Q.     And you stand by these words;  
14      right?

15          A.     I do.

16          Q.     All right. So, we've talked  
17      about Arkansas, we've talked about Utah.  
18      Now, I know there is currently a number  
19      of other states that are considering  
20      passing similar bans. Outside of Utah,  
21      have you done any work whatsoever in  
22      connection with these potential bans in  
23      other states?

1                   MR. KNEPPER:  Objection, form,  
2       scope.

3           A.     I have.

4           Q.     Which states?

5           A.     Alabama, Texas.

6           Q.     What else?

7           A.     Texas.  I don't know if there  
8       were any in the Northwest or not.  I  
9       think that's all of them.  I may be  
10      wrong, but I think that's all.  Alabama  
11      and Texas I would just add to your list.

12          Q.     Okay.

13          A.     There may been something in  
14      Arizona.  I'm not certain about Arizona  
15      as well, but --

16          Q.     Now let me introduce another  
17      exhibit.  Okay.  Let me know when you get  
18      this one.

19      (Exhibit 6 was marked for identification  
20      and is attached.)

21          A.     I've got it.

22          Q.     All right.  This article is  
23      titled, "Alabama bill that would



1 criminalize treatment for transgender  
2 minors headed to full Alabama Senate."  
3 You see that?

4 A. I do.

5 Q. Alabama, your home state, was  
6 considering a ban very similar to  
7 Arkansas just this year; correct?

8 A. Actually over the last couple of  
9 years.

10 Q. Okay. The first paragraph says,  
11 "The Alabama Senate Health Committee on  
12 Wednesday approved a bill that would  
13 outlaw puberty-blocking medications and  
14 gender-affirming care for minors,  
15 giving" -- "giving it a favorable report  
16 in an 11-2 vote." You see that?

17 A. I do.

18 Q. Then it says, "An Alabama House  
19 committee heard testimony in a public  
20 hearing on a companion bill, but the  
21 committee did not vote on the" -- "on the  
22 measure." You see that?

23 A. I do.

1           Q.     You testified in support of this  
2 bill; right?

3           A.     Yes, sir.

4           Q.     Go to page 2.

5           A.     Okay.

6           Q.     Look at the second paragraph  
7 from the bottom.

8           A.     Second from the bottom. Yes.

9           Q.     It says, "Dr. Patrick Lappert, a  
10 Decatur plastic surgeon, spoke in favor  
11 of the bill."

12                     That's you; right?

13          A.     That's right.

14          Q.     Go to page 3.

15          A.     Okay.

16          Q.     And look at the third paragraph.  
17 It says that you've "spoken against the  
18 use of medicine and surgery for  
19 transgender people as a Catholic deacon  
20 in his local diocese." See that?

21          A.     Yes.

22          Q.     You don't deny that you've  
23 spoken against the use of medical and

1 surgical treatment for transgender people  
2 in your position as a Catholic deacon;  
3 right?

4 A. That's correct, I do not.

5 Q. All right. Focus on the last  
6 sentence of this third paragraph. It  
7 says that when a committee member  
8 questioned your medical expertise on this  
9 issue, you said that you would not treat  
10 a person for gender dysphoria and would  
11 instead refer them to a qualified mental  
12 health professional. You see that?

13 A. Yes.

14 Q. At this hearing, someone on the  
15 committee was questioning your medical  
16 expertise to offer these opinions; right?

17 MR. KNEPPER: Objection, form.

18 A. I don't remember that detail,  
19 but I think so, yeah. I think the  
20 objection they raised was that I don't do  
21 these treatments, how could I know.

22 Q. You're not a psychiatrist;  
23 right?

1           A.     No.

2           Q.     You do not have specialized  
3 training or expertise in diagnosing  
4 mental health conditions; right?

5           A.     I have limited -- limited  
6 training.   Yes.

7           Q.     And when you say "limited  
8 training," what does that mean?

9           A.     Well, in the training of plastic  
10 surgeons, we are -- we are required --  
11 because we offer aesthetic surgery, we  
12 get some training in issues,  
13 psychological/psychiatric issues relating  
14 to people who will seek to modify their  
15 bodies in order to achieve a sense of  
16 peace or a sense of improvement in their  
17 lives.   And it's imperative that a  
18 plastic surgeon be able to recognize  
19 persons who are suffering from  
20 psychiatric problems because plastic  
21 surgery -- to offer them plastic surgery  
22 to modify their bodies is in the category  
23 of malpractice, not to mention that very

1       often, dissatisfied patients will -- will  
2       make life very difficult for the  
3       practitioner, if not threaten them with  
4       physical harm.

5               I would refer you to an article  
6       by -- although we haven't offered it up,  
7       -- a friend of mine, Dr. Mark Gorney, who  
8       was one of the -- one of the grand old  
9       men of plastic surgery, started the  
10      Physicians Company to manage physician  
11      liability and risk and had -- he  
12      discovered that there's an  
13      overrepresentation of -- of violence  
14      against physicians by aesthetic patients  
15      committing violence against plastic  
16      surgeons. That's just one of the  
17      motivators.

18             But nonetheless, the issue of  
19      body dysmorphic disorder is part of our  
20      training, persons who are seeking a  
21      remedy to their interior woundedness or  
22      their psychological disturbances by  
23      changing their outward opinion. And body

1       dysmorphic disorder is a  
2       well-characterized psychiatric diagnosis  
3       that impinges greatly upon plastic  
4       surgery precisely because aesthetic  
5       surgery -- even in its name, you can tell  
6       that aesthetic surgery is surgery aimed  
7       at the aesthetic, the feelings, esthesia,  
8       the feelings that a patient has about  
9       themselves, about their life. So it's  
10      incumbent upon plastic surgeons to know  
11      about these things, and so we get trained  
12      in those matters.

13               So again, I have very limited  
14      psychiatric/psychological knowledge, but  
15      I do know that that subset of patients  
16      should be referred for psychological help  
17      rather than offered surgery. Not to  
18      mention the fact that such patients can't  
19      even give informed consent because of  
20      their psychological disturbances.

21      Q.     All right. You're talking about  
22      patients who have body dysmorphic  
23      disorder; right?

1           A.     That's right.

2           Q.     When did you last receive  
3 training in how to diagnose someone with  
4 body dysmorphic disorder?

5           A.     I guess it's ongoing training  
6 when one's in the -- in the practice of  
7 plastic surgery. But I had originally in  
8 my residency and then on an ongoing basis  
9 I think at conferences through the years.

10                  Formal training in it, I -- I  
11 don't recall beyond my residency. All I  
12 do is try to keep abreast of the  
13 literature.

14           Q.     Yeah. So, let's take that in  
15 steps. Outside of -- when was your  
16 residency in plastic surgery, Doctor?

17           A.     '92 to '94.

18           Q.     Right. Past '94, you have not  
19 received formal training in how to  
20 diagnose someone with body dysmorphic  
21 disorder; right?

22           A.     There may have been some CME  
23 credits at a conference in there

1        somewhere or remote learning. I don't  
2        recall.

3            Q.     But sitting here, you can't  
4        recall any of those specifically; right?

5            A.     I cannot, no.

6            Q.     What are the diagnostic criteria  
7        for body dysmorphic disorder?

8            A.     Well --

9            Q.     Do you know that sitting here  
10       today?

11          A.     Yes. So, a person with body  
12       dysmorphic disorder, the diagnostic  
13       criteria is the -- is the patient who  
14       presents with evidence of a psychological  
15       disturbance. In review of their history  
16       and physical examination, you may see  
17       evidence of a history of substance abuse,  
18       maybe evidence of some self-harm,  
19       evidence of social isolation in their  
20       intake forms, that sort of thing. That  
21       would raise the concern.

22                  The second would be the person  
23       who attaches tremendous potential benefit



1 of, psychologically, the -- the quality  
2 of the -- sort of a transformative power  
3 of cosmetic surgery.

4 And then the third criteria  
5 would be that they -- they see something  
6 that you don't see. They see a defect  
7 that you don't see. And that's probably  
8 the key diagnostic criteria. For  
9 example, a man who presents seeking a  
10 modification to his nose who has evidence  
11 of living a life of social isolation who  
12 is adamant that by changing his -- the  
13 appearance of his nose, he will -- he  
14 will have a much better life. And  
15 hearing that, of course, the alarm bells  
16 go off and then examining the patient and  
17 seeing that there's no objectively  
18 definable deformity, only a normal  
19 variation that one would expect to see on  
20 a man's face.

21 Those are all red flags. And --  
22 and based upon that, it is -- it  
23 is definitely the -- has been

1 historically the recommendation of the  
2 likes of Dr. Mark Gorney and other  
3 leaders in the American Society of  
4 Plastic Surgery to not offer surgery, but  
5 rather to offer referral for  
6 psychiatric/psychological support and  
7 evaluation.

8 Q. These diag- -- these diagnostic  
9 criteria that you mentioned, where do  
10 they come from?

11 A. They -- I think you can find  
12 much of that in the DSM book, if -- if --  
13 if that's the route you want to go. You  
14 find it in the literature. There are --  
15 there are references in the scientific  
16 literature about it dating back to I  
17 think the 1920s. I included some of  
18 those, I think, in my discussion, if not  
19 on this one, in the Arkansas case.

20 But -- but there have been  
21 papers published through the years that  
22 describe the condition and make  
23 recommendations about care, and again,

1       going all the way back even to textbooks  
2       in plastic surgery and -- and of course,  
3       the residency training that speaks about  
4       that as well.

5           Q.     So for diagnosing someone with  
6       body dysmorphic disorder, you would rely  
7       on the DSM-5; right?

8           A.     I wouldn't rely on it, no.   No.  
9       I would rely on my -- my clinical  
10      experience more than anything else there.

11          Q.     Well, you just rattled off three  
12      or four guidelines that I think I heard  
13      you say come from the DSM-5; right?

14                  MR. KNEPPER:   Objection, form.

15          A.     Well, they're -- they don't come  
16      from the DSM-5 but are described in the  
17      DSM-5, yeah.

18          Q.     So when I asked you --

19          A.     And 4 -- actually, DSM-4 has a  
20      clearer description, I think, than DSM-5.

21          Q.     So when I asked you what  
22      criteria you would use to diagnose  
23      someone with body dysmorphic disorder,

1 the source you went to was the DSM;  
2 right?

3 A. No. The source I went to was my  
4 training and the -- and the papers that  
5 relate to it. I think it's just been  
6 subsequently characterized in the DSM.  
7 And it's a ready -- it's a volume that's  
8 readily accessible to people. The  
9 language is readily accessible, so people  
10 who are seeking information about that,  
11 they can go there for it or they can go  
12 to the articles, if they like. Yes.

13 Q. Outside of whatever training you  
14 had on diagnosing someone with body  
15 dysmorphic disorder, you do not have  
16 specialist training or expertise in  
17 diagnosing other mental health  
18 conditions; fair?

19 MR. KNEPPER: Objection, form.

20 A. Let's see. Well, there's -- I  
21 guess there are subcategories of -- of  
22 body dysmorphic disorder, like  
23 recognizing the anorexic patient, of

1 course, who presents for body  
2 modification. That -- that's a fairly  
3 readily and obvious one.

4 But no, I'm not a -- I'm not  
5 formally trained in psychiatry or  
6 psychology.

7 Q. You do not have -- you do not  
8 hold yourself out as an expert in  
9 diagnosing mental health conditions  
10 outside, potentially, of body dysmorphic  
11 disorder; right?

12 A. Correct.

13 Q. You do not have specialist  
14 training or expertise in treating mental  
15 health conditions; right?

16 A. No.

17 Q. You would refer that person to a  
18 qualified mental health professional;  
19 right?

20 A. I would. I would.

21 Q. Because you yourself are not a  
22 qualified mental health professional;  
23 correct?

1           A.     Correct.

2           Q.     All right.  You've also  
3 published an op-ed in May of this year  
4 supporting this Alabama ban; correct?

5           A.     Yes.

6           Q.     And you said that Alabama  
7 legislators should enact this ban because  
8 they have a duty to protect the  
9 vulnerable population of gender-confused  
10 children.  Does that sound familiar?

11          A.     Yes.

12          Q.     So again, earlier you said you  
13 had a preference for professional  
14 societies dealing with this, but you're  
15 out there publishing op-eds calling on  
16 state legislatures to pass these bans;  
17 right?

18                 MR. KNEPPER:  Objection, form.

19          A.     Right.  Yes, sir.

20          Q.     All right.  How about Texas?  
21 Tell me what work you've done supporting  
22 this kind of a ban in Texas?

23          A.     It's been similar.  I've been in

1 communication with -- I can't remember if  
2 they're on the legislative side or on the  
3 justice side. I don't remember exactly  
4 where they fit into the -- the government  
5 of Texas, but I've corresponded with them  
6 and offered them information and advice.

7 Q. Was it similar information to  
8 what we've seen in that Utah packet?

9 A. I'm sorry, sir?

10 Q. Was it information similar to  
11 what we've seen in that Utah legislation  
12 packet?

13 MR. KNEPPER: Objection, form.

14 A. Right. The substance -- the  
15 substance of the issue at hand is the  
16 same wherever you find it. It's this  
17 contest between those who -- who promote  
18 gender-affirming care versus those who  
19 promote, in the case of children, for  
20 example, watchful waiting and  
21 psychological support and cognitive  
22 behavioral therapy and those things, yes.  
23 It's the same battle wherever you find it

1       because it's the same problem, the same  
2       science, the same language. All of it's  
3       the same.

4           Q.     So earlier, we saw that in  
5       addition to you, Dr. Hruz and Dr. Levine  
6       and Dr. McHugh were also involved with  
7       those Utah legislative efforts; right?

8           MR. KNEPPER:   Objection, form.

9           A.     I -- I don't know their  
10      involvement in -- in Texas. I'm -- I'm  
11      not aware.

12          Q.     Yeah. Do you know whether any  
13      of them have been involved with any of  
14      these efforts in any other state?

15          A.     I don't. I don't know.

16          Q.     Okay. Fair to say that you have  
17      some strong personal opinions on whether  
18      doctors should be providing  
19      gender-affirming treatment to minors?

20          MR. KNEPPER:   Objection to form.

21          A.     Very fair to -- very fair to  
22      say, yes.

23          MR. TISHYEVICH:   Let's go off



1 the record.

2 THE VIDEOGRAPHER: This is the  
3 end of Media Unit 1. We are off the  
4 record at 9:33 a.m.

5 (Break taken.)

6 THE VIDEOGRAPHER: This is the  
7 beginning of Media Unit No. 4. We are on  
8 the record at 9:44 a.m.

9 Q. (By Mr. Tishyevich) Doctor,  
10 you're familiar with an organization  
11 called Alliance Defending Freedom, ADF;  
12 right?

13 A. Yes.

14 Q. How are you familiar with the  
15 ADF?

16 A. I was invited down there for a  
17 conference on the subject of transgender.  
18 I was an invited presenter, I should say.  
19 They asked me to come and speak from a  
20 plastic surgeon's perspective on how I  
21 view the current state of transgender  
22 medicine and surgery.

23 Q. Those were -- those were the

1 meetings in Arizona? Is that right?

2 MR. KNEPPER: Objection.

3 A. Yes.

4 Q. Who invited you?

5 A. I don't remember who the  
6 particular name was. I -- I don't recall  
7 who the -- the particular person, the one  
8 that sent me the invitation.

9 Q. Was it --

10 A. It may have been -- it may have  
11 been Gary McCaleb, I want to say. I'm  
12 not positive about that, though.

13 Q. You -- you anticipated my  
14 question.

15 A. Okay.

16 Q. To your knowledge, what's the  
17 view that the FDA takes on providing  
18 healthcare treatment to patients with  
19 gender dysphoria?

20 A. The position of the FDA?

21 Q. The ADF.

22 A. Oh, the ADF. They -- let's see.  
23 So, the sense I get is that the ADF takes

1       a -- the opinion that the present state  
2       of transgender medicine and surgery is  
3       not in the interest of the patients or  
4       the families.

5           Q.     The ADF has moral objections to  
6       doctors performing this kind of surgery  
7       and treatment; right?

8           MR. KNEPPER:   Objection, form,  
9       scope.

10          A.     I would -- I would characterize  
11       the ADF's position as more than just a  
12       moral objection.  It's both moral and  
13       objective scientific objections.

14                 So the -- the -- the sense I got  
15       from that conference was that most of the  
16       invited speakers came to speak about --  
17       for example, Dr. Hruz was there, and he  
18       spoke about endocrinology and the  
19       endocrinol- -- endocrinologic basis for  
20       sex/gender.  And he spoke about the  
21       effects of -- the endocrinological  
22       effects, the objective changes that are  
23       caused by, for example, puberty-blocking

1 cross-sex hormones.

2 I was -- there was also another  
3 speaker there, I think, on the subject  
4 of -- from the family medicine  
5 perspective, the overall effects on the  
6 health of the child, developmental  
7 issues. There was a presenter on the  
8 objective psychological issues.

9 And then, I presented on the  
10 realities of the surgery. They wanted me  
11 to speak about the technical details of  
12 transgender surgery, kind of the  
13 evolution of the process of transitioning  
14 surgery, and the -- and to give them a  
15 summary of the state of the science on  
16 it.

17 So I would characterize the ADF  
18 as interested in both the moral -- the  
19 moral issues and the objective, and they  
20 impinge upon one another. Clearly, to do  
21 something that is not in the -- in the  
22 objective benefit of the patient is a  
23 moral problem.

1 Did I answer your question?

2 Q. That's helpful, yeah.

3 The ADF is not a professional  
4 scientific organization; right?

5 A. Not to my knowledge, no.

6 MR. KNEPPER: Objection to form,  
7 scope.

8 Q. They're a legal organization;  
9 right?

10 A. Yes. That's my understanding.

11 Q. ADF is engaged with bringing  
12 lawsuits that do things like challenge  
13 schools' rights to -- to have transgender  
14 persons on their teams; right?

15 MR. KNEPPER: Objection, form,  
16 scope.

17 A. I don't know the scope, the full  
18 scope of their efforts, but yeah, they're  
19 one of I guess several legal  
20 organizations that are -- that are  
21 approaching these matters, as are you,  
22 for example.

23 Q. All right. Let's talk about

1       these meetings in more detail. So, how  
2       many -- strike that.

3               You've been to two meetings  
4       organized by ADF?

5       A.     That's my recoll- -- yeah, two  
6       meetings. I think that's right.

7       Q.     All right. Let's start with the  
8       first one. This was in 2017?

9       A.     That sounds about right, yeah.

10      Q.     What --

11      A.     I think it was 2017, yeah.

12      Q.     What month roughly?

13      A.     I don't remember now.

14      Q.     Do you know how they came to  
15      invite you to that first meeting?

16      A.     I do not.

17      Q.     Before that meeting, you had not  
18      published anything about gender  
19      dysphoria, had you?

20      A.     No.

21      Q.     Before that meeting, you had not  
22      published anything about the risks of use  
23      of hormone blockers in minors; right?

1           A.     No.    I've given -- I gave some  
2           -- some -- I think they may have heard of  
3           me not through publications, but through  
4           public speaking.

5           Q.     How long have you been doing  
6           public speaking on the issues related to  
7           gender dysphoria?

8           A.     Since 2014.

9           Q.     Let's start with the first  
10          meeting.   So, Dr. Hruz was also present  
11          at that meeting?

12          A.     Yes.

13          Q.     Was Dr. Levine present at that  
14          meeting?

15          A.     I don't think I've ever met Dr.  
16          Levine, so I don't -- he couldn't have  
17          been there because I would have  
18          remembered meeting him, and I don't  
19          remember ever having met him.

20          Q.     How about Dr. McHugh?

21          A.     No.    I would have remembered  
22          him.    He's a very famous person.

23          Q.     How many people were present at

1       this first meeting?

2           A.     Perhaps ten.   I'm not certain.

3           Q.     Outside of you and Dr. Hruz, who  
4       else do you remember being at that first  
5       meeting?

6           A.     I remember meeting a Dr. Andre  
7       Van Mol.   I believe he was at that  
8       meeting.   There was a pediatric  
9       endocrinologist there by the name of  
10      Quentin Van Meter.   I think he was there.

11                There was a -- there was an  
12      expert in scientific data and scientific  
13      data analysis, medical record data  
14      analysis from UC-San Francisco.   I don't  
15      believe he was a physician.   I think he  
16      was a -- had a doctorate in science.   And  
17      he was a -- he was actually a  
18      detransitioner.   So he was giving not  
19      only his knowledge of the medical  
20      literature, he was just an incredible  
21      resource and reference for medical  
22      literature.   You could just about ask him  
23      anything.   But he was also there, I



1 think, to speak from a personal  
2 perspective as well, being a  
3 detransitioner.

4 There was another detransitioner  
5 there who I don't remember their name,  
6 but they were there to speak. I think  
7 they were also an educator as well. I'm  
8 not positive about that.

9 So it's kind of vague for me,  
10 but I -- but definitely Paul Hruz stands  
11 out because we had a very good  
12 conversation there.

13 Q. What was the format? Were there  
14 presentations, a round table discussion?  
15 How did the conversations go?

16 A. There was some introductory  
17 remarks, and then -- and then each --  
18 each sort of specialist gave a  
19 presentation. I think I gave an  
20 hour-long presentation. And there were  
21 others like mine on those other subjects  
22 we talked about.

23 Q. Did you use slides as part of

1       that presentation?

2           A.     I usually do, yes, although I  
3       don't know what I've done with that slide  
4       deck.   I don't keep them very long.  They  
5       sort of morph all the time.

6           Q.     Do you think you might have an  
7       electronic copy of that slide deck  
8       somewhere?

9           A.     I don't.

10          Q.     At a very high level, what was  
11       the -- what were you trying to convey  
12       through your presentation to that group?  
13       Let me ask it a different way.  Were --  
14       was your presentation broadly similar to  
15       the opinions that you're offering in this  
16       case and in the Brandt case?

17               MR. KNEPPER:  Objection, form.

18          A.     Well, by the -- by "broadly  
19       similar," do you mean the subject matter  
20       or the nature of my opinion or the  
21       evidence used to support my opinion?

22          Q.     All right.  Give me a high-level  
23       summary of what your presentation was at

1       that first meeting.

2           A.     It was a --

3                   MR. KNEPPER:   Objection, form,  
4       scope.

5           A.     -- a summary, a summary of the  
6       present state of transgender medicine and  
7       surgery, a review of the scientific  
8       literature used to support the treatments  
9       that are being offered, a review of the  
10      long-term outcomes of treatment that are  
11      being offered, with particular attention  
12      to the European literature, which is more  
13      reliable. I sort of -- I compared the  
14      American literature to the European  
15      literature because that's one of the  
16      great problems we're having in this  
17      issue. And it was already evident in  
18      2017 that there was a great disparity  
19      between the American literature and the  
20      European literature in terms of the  
21      quality of the scientific evidence that's  
22      being used to support the interventions.

23                   So that was -- really at the

1 heart of the presentation was what's the  
2 state of the science and where is the  
3 reliable science coming from and what is  
4 it -- what is it showing us, so. But  
5 they also -- the audience wanted to have  
6 an understanding of what these plastic  
7 surgery interventions were. So there was  
8 an extensive discussion of the  
9 particulars of the surgeries, the details  
10 about the surgeries, the typical outcomes  
11 of the surgeries, so.

12 Q. I want to -- strike that.

13 One of the topics of discussion  
14 at that meeting was about the need to  
15 have expert witnesses for litigation;  
16 right?

17 MR. KNEPPER: Objection, form,  
18 scope.

19 A. I remember -- I remember a  
20 fairly long discussion about the poverty  
21 of people who are willing to testify  
22 because of the risk that they take in  
23 testifying. That was a -- that was a

1       fairly long discussion. And the  
2       difficulty that that -- that people have  
3       in finding expert witnesses because of  
4       the risks they place themselves in, in  
5       testifying.

6           Q.     And people at that meeting were  
7       asked whether they would be willing to  
8       participate as expert witnesses; right?

9           A.     Yes.

10          Q.     Before that meeting, you had  
11       never testified as an expert witness?

12          A.     Before this moment, I never  
13       testified as an expert witness.

14          Q.     Who made the introductory  
15       remarks at the beginning of this meeting?

16               MR. KNEPPER:   Objection, form,  
17       scope.

18          A.     I'm trying to remember. It was  
19       a -- it was an attorney whose first name  
20       is Jeff, and I'm trying to remember what  
21       his last name was. But he seemed to be  
22       the -- the -- kind of the emcee, if you  
23       will. Yeah, Jeff. I'll see if, in the

1 course of our conversation today, the  
2 name will pop in. This is the difficulty  
3 I have with remembering names. They'll  
4 just pop in at a moment's notice.

5 But it was -- yeah, it was an  
6 attorney who gave the overall scope of  
7 why -- why we were there, to discuss this  
8 issue, to see what -- what the -- what  
9 the science is showing to see where --  
10 what the -- the moral aspects of good  
11 science versus bad science and issues  
12 like that, yeah.

13 Q. Aside from you and Dr. Hruz, do  
14 you recall anyone else expressing an  
15 interest at that conference about serving  
16 as an expert witness?

17 MR. KNEPPER: Objection, form,  
18 scope.

19 A. You mean someone expressing just  
20 generally about having expert witnesses?

21 Q. No. Other participants saying,  
22 "I might consider being an expert witness  
23 in one of these cases."

1           A.     I don't recall. I don't, no.

2           Q.     Okay. All right. So then there  
3 was a second meeting also in Arizona;  
4 right?

5           A.     Right.

6           Q.     And that was also in 2017?

7           A.     I don't remember the date of  
8 that as well -- either, no.

9           Q.     What was the purpose of that  
10 second meeting?

11          A.     I think it was similar, although  
12 it may have been a little bit more  
13 refined. There was not as much  
14 discussion of the really foundational  
15 science as more a review, I think, of --  
16 you know, I -- I guess it was similar in  
17 terms of format. I think there were more  
18 -- more people there who were speaking  
19 from personal experience.

20                 So I think the most important  
21 thing I recall from that meeting was that  
22 -- that there was a mother -- actually, a  
23 couple of family members of persons who

1 experienced cross-sex self-identification  
2 who have gone through various -- various  
3 phases of transitioning. And they were  
4 giving sort of a personal experience,  
5 trying to describe to us what they went  
6 through as a family, what they went  
7 through with their children. And that's  
8 what -- so that was the difference  
9 between the first and the second meeting.  
10 I think it was more of a personal thing.  
11 It had the science as well, but I think  
12 it had more of a personal side to it as  
13 well.

14 Q. How many people do you think  
15 attended -- attended that second meeting?

16 A. I'm trying to think how full the  
17 room was. I think it was probably  
18 comparable maybe, a dozen perhaps. I'm  
19 not sure.

20 Q. Who do you remember being there  
21 by name?

22 A. I think that may have been when  
23 I met Dr. Cretella. I can't remember if



1 I met her at the first meeting or the  
2 second meeting.

3 Oh, also at that second meeting,  
4 there was a plastic surgeon. I can't  
5 remember his last name. I was -- I  
6 remember being very encouraged to meet  
7 another plastic surgeon who saw this as  
8 an issue. And I do remember that he had  
9 been the chairman -- this speaks to the  
10 issue of fear about testifying. He had  
11 been the chairman of a major plastic  
12 surgery department in a large Midwest  
13 university, had built that program for  
14 many years, had run one of the most  
15 successful residency training programs.  
16 And he had been fired because he had  
17 objections to the transgender services  
18 that the hospital administration -- or  
19 the university administration wanted to  
20 introduce. And I thought it was a very  
21 heartbreaking story to see that a man had  
22 lost his entire career over his  
23 professional opinion. I don't remember

1 his last name, but I do know that I met  
2 him at that second meeting.

3 Q. Do you remember his first name?

4 A. I don't.

5 Q. Do you remember which center he  
6 was affiliated with?

7 A. I believe he was from the Ohio  
8 State University. But I haven't seen or  
9 heard from him since. He has just  
10 disappeared. I tried to reach out to  
11 him, I recall, because, again, there's  
12 not a lot of plastic surgeons who are  
13 willing to speak on this matter. And --  
14 but I haven't heard from him since.

15 Q. Did participants at the second  
16 meeting make presenta- -- make  
17 presentations as well?

18 MR. KNEPPER: Objection, form,  
19 scope.

20 A. I -- I don't -- yeah, I think it  
21 was more limited presentations, briefer,  
22 sort of reviews sort of thing. But it  
23 wasn't -- it didn't have the formality of

1 the first meeting, as I recall. Again,  
2 it's -- it's a little bit murky four  
3 years on.

4 Q. Yeah. I'm just asking for your  
5 best recollection. That's fine.

6 A. Sure. Okay.

7 Q. Do you remember giving a  
8 presentation at that second meeting?

9 A. I believe I did.

10 Q. How long do you think that  
11 meeting lasted, roughly?

12 MR. KNEPPER: Objection, form,  
13 scope.

14 A. Well, I remember it -- we went  
15 through a full morning, a light lunch,  
16 and perhaps into the very early  
17 afternoon.

18 Q. And you mentioned that there was  
19 some personal testimony from parents,  
20 families. What portion of the meeting  
21 was that, roughly?

22 A. What -- what portion?

23 MR. KNEPPER: Objection, form,

1 scope.

2 Q. What portion, yes.

3 A. I would be guessing that perhaps  
4 a third of the meeting was -- was that.

5 Q. Okay. After these meetings in  
6 2017, have you continued to stay in touch  
7 with the ADF?

8 MR. KNEPPER: Objection, form,  
9 scope.

10 A. I think perhaps, you know, one  
11 or two e-mail exchanges, but nothing --  
12 nothing substantive. I haven't really  
13 heard anything from them. I think I got  
14 a -- no. Well, I can't -- I can't recall  
15 anything other than maybe a thank-you  
16 e-mail or hope you're doing well kind of  
17 thing, but nothing substantive, no.

18 Q. How did you come to get involved  
19 with being an expert in this case?

20 A. I was contacted by Mr. Knepper.

21 Q. Okay.

22 A. Actually, I was contacted by his  
23 staff. He didn't call me himself, but

1 his -- someone on his staff called me and  
2 asked --

3 Q. I understand.

4 A. -- if I would be available.  
5 Yeah.

6 Q. How did you come to get involved  
7 with the Brandt case in Arkansas?

8 MR. KNEPPER: Objection, form,  
9 scope.

10 A. I think it may have been  
11 similar. I don't recall the particulars,  
12 but I -- someone on -- on the legal  
13 counsel side contacted me. I don't  
14 remember who it was.

15 Q. Okay. Let me shift gears a bit.  
16 You know what the American Society of  
17 Plastic Surgeons is; right?

18 A. Of course.

19 Q. Are you a current member?

20 A. No. I -- I let my membership  
21 lapse years ago, yeah.

22 Q. When --

23 A. About two years ago, I would

1 say. Maybe two years ago, yeah.

2 Q. Why did you decide to let your  
3 membership lapse?

4 A. Well, in order to be a member of  
5 the American Society of Plastic Surgeons,  
6 you have to be board-certified. And so  
7 since I declined continuing board  
8 certification for the reasons I explained  
9 to you, then my membership -- you know,  
10 over time, when my subscriptions and  
11 membership fees lapsed, so did my  
12 membership. And I think that would have  
13 been in 2019.

14 Q. I understand.

15 A. Yeah.

16 Q. Is it -- is an active board  
17 certification in plastic surgery a  
18 prerequisite to being in the American  
19 Society of Plastic Surgeons?

20 A. I seem to remember that when I  
21 -- back in the '90s after my residency,  
22 there's a -- there's a membership for --  
23 for board-eligible. It's not the full

1 membership, but then when you get  
2 board-certified, then you get full  
3 membership and the rights to use the logo  
4 and all that sort of stuff, so. Yeah, as  
5 I recall. It's been a long time since I  
6 read the bylaws. That would have been  
7 back in '95, I think, that I read those  
8 things.

9 Q. Yeah. When did you first join  
10 the ASPS?

11 A. I think I joined as a student  
12 member when I was in my residency. I  
13 want to say it was probably like '92 or  
14 '93, somewhere in there.

15 Q. So you were in the ASPS roughly  
16 '92 --

17 A. I think, yeah.

18 Q. -- to 2017?

19 A. I think, yeah. As I recall --  
20 again, it's a little bit murky, but as I  
21 recall, there's sort of a provisional  
22 membership for residents in training.  
23 You sort of get a discounted rate on all

1 of the expensive things, and the -- and  
2 access to the White Journal, as it's  
3 called. And then -- and then I -- as I  
4 recall, you don't get the full membership  
5 until you've been board-certified, which  
6 happened for me, as you know, in '97.

7 Q. Okay. But you were part of the  
8 ASPS for a long time; right?

9 A. Yes. Going to meetings.

10 Q. You consider the ASPS to be a  
11 reputable organization; right?

12 MR. KNEPPER: Objection, form.

13 A. Yeah. Well, for the most part,  
14 yeah. Certainly, the members, virtually  
15 most of the members I've ever known are  
16 reputable. And there are some things  
17 that the ASPS has done through the years  
18 that -- that I've had difficulty with  
19 and -- but they're certainly the  
20 organization in American plastic surgery.

21 Q. Yeah. I think one statistic I  
22 heard is 93 or so percent of all plastic  
23 surgeons are part of the ASPS.



1           A.     Yeah.

2           Q.     Right?

3           A.     That -- that number wouldn't  
4     surprise -- I would have thought even  
5     higher, actually, but yeah.

6           Q.     Do you think the ASPS would  
7     encourage its members to perform  
8     surgeries that are not medically  
9     necessary?

10           MR. KNEPPER:   Objection, form.

11           A.     Well, the -- as a -- as an  
12     organization, they don't encourage  
13     particular surgeries, but they may  
14     support them with their scientific  
15     presentations, their conferences, and  
16     that sort of thing.

17                     For example, three or four years  
18     ago, I went to a meeting of the  
19     California Society of Plastic Surgery,  
20     which is -- I think it has sort of a  
21     subsidiary relationship with the ASPS.  
22     And at that conference, among other  
23     things -- I went there because that's one

1 of the -- the areas of the country where  
2 I trained and I had hoped to see some  
3 friends there. But -- but for example,  
4 in that conference I went to a lot of  
5 great presentations, but the last day was  
6 devoted almost entirely to transgender  
7 surgery.

8 And so if you're asking me do I  
9 -- how do I feel about that, well, I have  
10 great difficulty with a professional  
11 organization that would support or  
12 promote those sorts of interventions  
13 knowing what I know about the scientific  
14 underpinnings of those medical and  
15 surgical procedures. And I had many  
16 conversations at that conference on the  
17 subject with persons who were providing  
18 the services, and I didn't find their  
19 answers particularly satisfactory. So  
20 that would be an example.

21 I can't give you carte blanche  
22 that everything that the Society says and  
23 does is to my liking. I would say

1       probably most of what they say and do is  
2       very much to my liking. But on this  
3       matter, I have -- I have a great  
4       difficulty. And it's one of the reasons  
5       that I -- I -- yeah.

6           Q.     It's one of -- one of the  
7       reasons that you what?

8           A.     That I -- that I don't have a  
9       lot of heartache about stepping away from  
10      the ASPS.

11          Q.     Do you think the AS- -- ASPS  
12      advocates in favor of surgical procedures  
13      that are not medically necessary?

14          A.     I think that would be probably  
15      an overreaching statement. I wouldn't  
16      say that. I would say that perhaps  
17      they're mute on some of the -- some of  
18      the procedures that their members  
19      perform, and they certainly have their  
20      eyes and ears open for new things. And  
21      so when members come forward to make  
22      presentations about particular new  
23      therapies and new approaches, as they

1       should, the ASPS is open to those things.  
2       So for many years, transgender surgery  
3       has been in that category.

4               I remember when I was a -- even  
5       when I was a general surgeon and I was  
6       looking for residency programs to train  
7       in, I was considering UVA. And I saw  
8       that -- that Milton Edgerton, one of the  
9       great names in plastic surgery was at UVA  
10      doing transgender surgery, both at UVA  
11      and at Johns Hopkins. And I remember  
12      thinking, well, I'm -- I really need --  
13      it struck me as an unusual operation, and  
14      I -- I started doing some research into  
15      it.

16             And I remember starting to think  
17      about the issue of transgender surgery  
18      back in the -- what would have been 1991,  
19      1990, 1991. And -- and through the  
20      years, the ASPS has made room for that  
21      intervention, those therapies, in their  
22      conferences, in their dialogues, in their  
23      publications. And I've reviewed all that

1 stuff as it has come along. And I think  
2 now being twenty, nearly thirty years on  
3 since I first started looking at it and  
4 they're still just sort of at that stage  
5 of -- of putting it out there, although  
6 now they're offering more extensive  
7 training conferences on how to do those  
8 procedures, and they're now encouraging  
9 that it be included in residency  
10 programs, and so -- yeah.

11 Q. Do you know what position the  
12 ASPS takes on whether gender-affirming  
13 surgery is medically necessary?

14 A. I think that position has  
15 changed, and now they're -- they're  
16 speaking positively about it.

17 Q. Yeah. Your own professional  
18 organization, or at least your former  
19 organization, takes the position that  
20 gender-affirming surgery is medically  
21 necessary; right?

22 MR. KNEPPER: Objection, form.

23 A. Yeah. As I -- as I said before,

1       this is one of the reasons why I don't  
2       have a lot of heartache about having  
3       withdrawn my membership. Yeah.

4           Q.     Now let me introduce another  
5       exhibit. Let me know when you have it,  
6       Doctor.

7       (Exhibit 7 was marked for identification  
8       and is attached.)

9           A.     Okay. Okay. I've got it.

10          Q.     The top of the page says,  
11       "American Society of Plastic Surgeons."  
12       Right?

13          A.     Yes.

14          Q.     You see this document is dated  
15       February 25, 2021; right?

16          A.     Yes.

17          Q.     This is after all the studies  
18       that you cite in your report; right?

19          A.     Where does that say that? I'm  
20       sorry, you're at a particular paragraph?

21          Q.     No. The date of this --

22          A.     Oh, I see. Oh, the date is  
23       after this --

1 Q. Yeah.

2 A. Yes. Well, February 25th, yes,  
3 2021.

4 Q. Yeah. This is -- this is dated  
5 after all of the studies that you cite in  
6 your report; correct?

7 A. I don't -- yeah, I don't  
8 remember off the top of my head any  
9 studies that were dated after. There may  
10 have been an April study in there, but  
11 okay.

12 Q. The first sentence says, "Policy  
13 around transgender care has recently  
14 gained considerable attention amid a  
15 growing trend of legislation carrying  
16 serious professional, financial or  
17 criminal penalties for the provision of  
18 gender affirmation care." You see that?

19 A. I do.

20 Q. Now, this reference to a growing  
21 trend of legislation, that's talking  
22 about legislation like the Arkansas ban  
23 and the Utah ban and the Alabama ban that

1 we talked about earlier; right?

2 A. Right.

3 MR. KNEPPER: Objection, form.

4 Q. Go to page 2. Look at the  
5 second paragraph. It says that "Less  
6 than three months into 2021, 11 pieces of  
7 legislation attempting to criminalize  
8 gender affirmation therapies have been  
9 introduced in 10 states." See that?

10 A. I do.

11 Q. And then there's a list of  
12 states; right?

13 A. Yes.

14 Q. So we talked about Utah and  
15 Alabama and Texas before. Looking at  
16 this list, does that refresh your  
17 recollection whether you've worked on  
18 these kind of legislative efforts in any  
19 other states?

20 A. I think -- I think, yeah, my  
21 answer has not changed. I think I've  
22 only been involved in Alabama, Texas, and  
23 Utah. I don't remember anything from



1 Oklahoma, New Hampshire, Montana, or  
2 Missouri or Mississippi. I don't recall  
3 any other states in that list, no.

4 Q. Okay. All right. Now let's  
5 look at what position the ASPS takes on  
6 whether gender-affirming treatment is  
7 medically necessary. Go to page 3. The  
8 first sentence says, "ASPS firmly  
9 believes that plastic surgery services  
10 can help gender dysphoria patients align  
11 their bodies with whom they know  
12 themselves to be and improve their  
13 overall mental health and well-being."  
14 Do you see that?

15 A. I do.

16 Q. The ASPS, your own professional  
17 organization, does not agree with your  
18 opinions that gender-affirming surgery is  
19 medically inappropriate; right?

20 MR. KNEPPER: Objection, form.

21 A. Let me just read that. Give me  
22 just a moment to look at that. Okay.

23 Yeah. This is a very --

1 language used by the other professional  
2 organizations, and essentially, the  
3 language takes the position that surgical  
4 intervention for a subjective problem is  
5 medically indicated. And that's the  
6 difficulty that I'm having here, is that  
7 in this document the ASPS does not --  
8 does not provide medical scientific  
9 support. They essentially admit that the  
10 surgery is for help with a psychological  
11 problem of perception on the part of the  
12 patient. So essentially what -- what the  
13 ASPS firmly believes in is the use of  
14 surgery to manage a psychological  
15 problem. And -- and this is -- this is  
16 consonant with the -- with the -- the  
17 consensus opinions that were offered by  
18 the other professional organizations that  
19 you listed earlier.

20 Q. The AS- -- ASPS does not agree  
21 with your opinions that gender-affirming  
22 surgery is experimental; correct?

23 MR. KNEPPER: Objection, form.

1           A.     They don't -- let's see, do they  
2     say anything about experimental in here?  
3     No, they don't.    So yeah, I would agree.

4           Q.     Do you agree?   Yeah.

5           A.     I would agree, yeah, sure.

6           Q.     Look at the last sentence.   It  
7     says, "ASPS will continue its efforts to  
8     advocate across state legislatures for  
9     full access to medically necessary  
10    transition care."   Do you see that?

11          A.     Yeah.   I don't find that  
12    statement at all surprising.   No.

13          Q.     Yeah.

14          A.     I do see that, yeah.   Not  
15    surprising.   This is legislative --

16          Q.     The ASPS --

17          A.     -- legislative advocacy by the  
18    ASPS.

19          Q.     The ASPS considers transition  
20    care to be medically necessary; right?

21                 MR. KNEPPER:   Objection, form.

22          A.     Again, that returns -- returns  
23    to that -- that inherent and

1 contradictory statement of medical  
2 necessity for a subjective condition.  
3 And the statement is consistent with what  
4 -- yeah. Exactly, yeah.

5 Q. It's fair to say that the  
6 opinions that you and Dr. Hruz and Dr.  
7 Levine are offering in this case are very  
8 different than the position that the ASPS  
9 has adopted on whether gender-affirming  
10 surgery is medically necessary; right?

11 MR. KNEPPER: Objection, form.

12 A. Absolutely correct.

13 Q. In fact, let me show you how  
14 strongly the ASPS feels about this issue.  
15 Let me introduce another exhibit. Okay.  
16 Let me know when you -- when you receive  
17 it.

18 MR. KNEPPER: Dmitriy, I -- I  
19 will tell you, it seems to be moving more  
20 slowly than normal. I don't know if  
21 you're seeing the same thing on your end.

22 MR. TISHYEVICH: I am.

23 A. So yeah, I have this document.

1 Again from the ASPS? Is that the one?  
2 February 25th?

3 Q. No. It should be -- it's a  
4 one-page document. I think it just says  
5 ASPS in your folder.

6 A. Exhibit 7?

7 MR. TISHYEVICH: Let me -- let's  
8 go off the record for a minute.

9 MR. KNEPPER: Sure.

10 THE VIDEOGRAPHER: We are off  
11 the record at 10:19 a.m.

12 (Break taken.)

13 THE VIDEOGRAPHER: We are back  
14 on the record at 10:21 a.m.

15 Q. (By Mr. Tishyevich) All right.  
16 Doctor, before the break, we were talking  
17 about the ASPS and the position they take  
18 on the medical necessity of  
19 gender-affirming surgery. You recall  
20 that?

21 A. Yes.

22 Q. All right. This is a document  
23 from the ASPS titled "2021 State Policy

1 Priorities." Do you see that?

2 (Exhibit 8 was marked for identification  
3 and is attached.)

4 A. Yes.

5 Q. Last sentence of the first  
6 paragraph says, "To ensure that our  
7 health care system is effective and  
8 efficient, ASPS will focus its state  
9 advocacy efforts on," and then there's a  
10 list. Do you see that?

11 A. Yes.

12 Q. And there's three sections:  
13 "Core Priorities," "High Priorities," and  
14 "Other Priorities." You see that?

15 A. Yes.

16 Q. Go to the "High Priorities"  
17 section.

18 A. Okay.

19 Q. The last bullet says, "Opposing  
20 attempts to criminalize gender  
21 confirmation." Do you see that?

22 A. I do.

23 Q. And you understand what this

1 bullet means; right?

2 A. I do.

3 MR. KNEPPER: Objection to form.

4 Q. One of the ASPS's high  
5 priorities for this year is to oppose  
6 legislation like the Arkansas ban and the  
7 Utah ban and the Alabama ban that you are  
8 supporting; right?

9 A. Apparently so, yes.

10 MR. KNEPPER: Objection, form,  
11 scope.

12 Q. The sense that I got from  
13 reading your report, Doctor, is that it's  
14 supposedly generally accepted that  
15 gender-affirming surgical treatment is  
16 experimental and should not be performed  
17 on anyone; right? That's what you think?

18 MR. KNEPPER: Objection, scope,  
19 form.

20 A. Right. My opinion -- my opinion  
21 in that matter is based on the -- on the  
22 world literature rather than advocacy  
23 statements by a professional

1 organization. That's right.

2 Q. You are suggesting, in fact,  
3 that doctors who do these surgeries  
4 should be investigated for unethical  
5 behavior and potential misconduct; right?

6 MR. KNEPPER: Objection, form.

7 A. I -- yes, I do.

8 Q. And you do not think it's  
9 relevant to mention that your own  
10 professional society takes a view that is  
11 contrary to the opinions that you're  
12 offering in this case; right?

13 A. I'm not sure I understood your  
14 question, sir.

15 Q. Yeah. When you talk about how  
16 these doctors should be investigated for  
17 misconduct, you don't think it's relevant  
18 that your own professional society takes  
19 a completely contrary view?

20 MR. KNEPPER: Objection, form.

21 A. Well, I think I would -- I would  
22 characterize my concern and -- and  
23 possibly recommendation of investigation,



1 I was discussing, I think, consent  
2 procedures and getting informed consent.  
3 I don't think -- yeah, so -- so I think  
4 the object- -- the concerns I raised had  
5 to do with the off-label use of drugs in  
6 irreversible treatments, the -- the  
7 problem of obtaining consent from  
8 emotionally compromised people who are  
9 threatening suicide. Those were the  
10 issues that I raised in terms of, you  
11 know, investigation kind of things, or  
12 examination would be a better term,  
13 examination of -- of how a  
14 physician/surgeon conducts their  
15 practice, so.

16 Q. Go -- go back to your report.

17 A. Okay.

18 Q. Go to page 15. You with me?

19 A. Yes, sir.

20 Q. Look at the second sentence in  
21 the bottom paragraph. You say, "Basing  
22 life changing surgeries that damage and  
23 destroy the natural functions of

1 perfectly healthy organs on nothing more  
2 than the unverified self-reports  
3 (conversations) of often disturbed  
4 patients as part of untested, unproven,  
5 experimental 'treatments' that are  
6 'supported' by a methodo-" --  
7 "methodologically defective research base  
8 when competent reviews have called such  
9 research 'low quality' evidence and noted  
10 the 'lack of any randomized clinical  
11 trials' -- should be properly  
12 investigated as unethical, misconduct and  
13 an abuse of a vulnerable patient  
14 population."

15 Right? That's your opinion?

16 A. Yes, sir. And I stand by that.

17 Q. You know that today there's  
18 thousands of plastic surgeons that are  
19 performing these surgeries; right?

20 MR. KNEPPER: Objection, form,  
21 scope.

22 A. I don't know the number of  
23 plastic surgeons who do these surgeries.

1 Q. Hundreds?

2 A. I'm -- I'm sure the number is  
3 large. I don't know what the number is.  
4 Yes.

5 Q. And you think all of those  
6 doctors are out there committing  
7 misconduct? Is that really what you  
8 think?

9 A. Well, I think that -- that their  
10 knowledge might affect their  
11 decision-making. So if somebody is going  
12 through a residency training program that  
13 -- that is teaching these things and they  
14 grow up in that world -- let me give you  
15 an example.

16 When I was a surgeon in training  
17 in general surgery, the -- the most  
18 coveted surgical experience would be, as  
19 a chief resident, to do ulcer surgery.  
20 At the time, we thought that ulcers were  
21 caused by neurologic problems affecting  
22 the stomach. And so some of the most  
23 complex abdominal surgeries were ulcer

1       surgeries, and some of the greatest names  
2       in general surgery were given to those  
3       operations. Subsequent to my residency  
4       training, perhaps five years later, it  
5       was found to be a medical condition  
6       treatable with antibiotics and antacids.  
7       Nobody does ulcer surgery any longer.

8               I would put -- I would put  
9       transgender surgery in the same category.  
10      Well-meaning persons who are interested  
11      in the care of people who are suffering,  
12      in this case, transgender persons who are  
13      suffering, well-meaning physicians and  
14      surgeons are offering them the best care  
15      that they've learned in their training.  
16      But I -- I would expect that when the  
17      science shows that to be not the case,  
18      that those same doctors will abandon it.  
19      And I think we're at the same stage now.  
20      We're at an inflection point in plastic  
21      surgery where in the last three years  
22      things have changed radically.

23              If you had asked that question

1 five, seven years ago, it would have been  
2 up for grabs. But things have changed  
3 radically with the flood of credible  
4 scientific evidence pouring in from  
5 Europe to now -- if -- if five years from  
6 now, having seen that information,  
7 surgeons persist in doing transgender  
8 surgery, then I would -- then I would  
9 have real issues with that, as I would  
10 with a -- with a general surgeon offering  
11 a Billroth II ulcer operation today when  
12 you could give the patient erythromycin  
13 and some -- and some Zantac. You see  
14 where I'm going.

15 So we're at a -- we're at a  
16 tipping point in the world of plastic  
17 surgery right now, and the last three  
18 years have changed everything, because  
19 the very, very well-supported -- see, the  
20 problem is quality of evidence. Plastic  
21 surgeons in America are operating with  
22 scientific evidence that even the  
23 American Society of Plastic Surgery

1 characterizes as level 5 evidence,  
2 basically, the -- the professional  
3 opinions based on personal experience.  
4 This is entry-level science for a  
5 particular therapy or a particular  
6 intervention.

7 To raise to level 4, you would  
8 have to have the same collected cases  
9 with -- with before and after tests of  
10 the patient. We haven't gotten to that  
11 level yet. There are no long-term  
12 longitudinal studies in the American  
13 literature. It's all in the European  
14 literature, and the bulk of it in the  
15 last three years.

16 So the question is a difficult  
17 one to answer. As simply as saying that  
18 all of these people are immoral, I'm not  
19 saying that at all. I'm saying that  
20 they're doing the best that they know how  
21 according to the training that they've  
22 received for people that they very much  
23 care for and are hoping to do good by.

1 But the -- but the world is changing  
2 rapidly now, and we've reached a stage  
3 now where it's such a controversy that  
4 this is -- this is -- this is why I've  
5 become so publicly vocal about it,  
6 because the controversy is now raging.  
7 It's no longer: "Maybe so. Milton  
8 Edgerton, interesting guy. You know, the  
9 surgery at UVA, the surgery at Johns  
10 Hopkins, let's get a look at that kind of  
11 thing." We've gone beyond that now, and  
12 just in the last three years.

13 So I -- the people who do these  
14 surgeries are not right out of residency  
15 training. These are people who have --  
16 you know, who have been in the -- in the  
17 business for a number of years now, and  
18 they're relying on what they learned and  
19 doing the best that they can. But as I  
20 say, the science is changing everything,  
21 so.

22 MR. TISHYEVICH: With respect,  
23 I'm going to strike that answer as not

1 responsive.

2 Q. Here's the -- here's --

3 MR. KNEPPER: No.

4 Q. -- the question that I'd like  
5 you to answer.

6 MR. KNEPPER: Go ahead.

7 Q. Here's the question that I'd  
8 like you to answer. Is it your expert  
9 opinion that the surgeons that are today  
10 performing gender-affirming surgical  
11 procedures are committing or potentially  
12 committing misconduct, yes or no?

13 MR. KNEPPER: Objection, form,  
14 scope, asked and answered. Dmitriy, you  
15 asked him. He gave you a --

16 MR. TISHYEVICH: I don't need  
17 the speaking objections. I do not need  
18 the speaking objections.

19 Q. Answer my question, Doctor.

20 MR. KNEPPER: He gave you a  
21 thoughtful answer.

22 A. Okay. If you could ask me the  
23 question again, I want to be sure that



1 I -- I answer it as succinctly as I can.

2 Q. Is it your expert opinion that  
3 the surgeons that are performing  
4 gender-affirming surgical procedures  
5 today are potentially committing  
6 professional misconduct, yes or no?

7 MR. KNEPPER: Objection, form.

8 A. I would -- I would say, only to  
9 the extent that they're familiar with the  
10 more recent literature would make them  
11 sort of culpable, if you will. Not --  
12 not being aware of that literature, I  
13 would not accuse them of such a thing.

14 Q. All right. Let me introduce  
15 another exhibit. Let me know when you  
16 get this one, Doctor, Exhibit 9.  
17 (Exhibit 9 was marked for identification  
18 and is attached.)

19 A. All right. The first page of  
20 my -- well, that's the CV, I guess. My  
21 CV, yes.

22 Q. This is a copy of your CV;  
23 right?

1           A.     Yeah.    Yes.

2           Q.     You prepared this?

3           A.     Well, it was prepared for me by  
4     -- I gave -- I gave the factual input for  
5     it, but I didn't prepare it myself, let's  
6     say.

7           Q.     Top of the page says, "Board  
8     Certified in Surgery and Plastic Surgery"  
9     again; right?

10          A.     Right.   Same mistake, yeah.

11          Q.     We agree that's not consistent  
12     with guidance from the American Board of  
13     Surgery, American Plastic Board of  
14     Surgery; correct?

15                 MR. KNEPPER:   Objection, form.

16          A.     Yes.

17          Q.     Go to page 3, the bottom of the  
18     page.   It says, "Publications - Peer  
19     Reviewed Medical Journals."   You see  
20     that?

21          A.     I do.

22          Q.     And then through page 4, it  
23     lists six publications; right?

1           A.     Right.

2           Q.     In your professional career,  
3     you've published six articles in  
4     peer-reviewed medical journals; right?

5           A.     Right.

6           Q.     First one was in 1997; right?

7           A.     '87.    Yes.

8           Q.     Most recent one was in 1998;  
9     correct?

10          A.     Correct.

11          Q.     That's 23 years ago; right?

12          A.     Right.

13          Q.     You have not published any  
14     original research in peer-reviewed  
15     literature within the last 23 years;  
16     correct?

17          A.     Correct.

18          Q.     All right.  Let's go through  
19     these in reverse order.  All right.  Most  
20     recent one from '98 is titled "Treatment  
21     of an isolated outer table frontal sinus  
22     fracture using endoscopic reduction and  
23     fixation."  Right?

1           A.     Yes.

2           Q.     That publication doesn't relate  
3           to gender-affirming surgery or to gender  
4           dysphoria; correct?

5           A.     Tangentially, it would relate to  
6           it. And I would say this about it. It  
7           was one of the first, if not the first,  
8           paper demonstrating the use of endoscopic  
9           technique to operate on facial bones of  
10          the forehead and the use of internal  
11          fixation devices for modification or  
12          repair of the forehead. Those are the  
13          same techniques that are now used by  
14          transgender surgeons who are offering top  
15          surgery. For example, for feminization  
16          of a masculine brow ridge, they use  
17          endoscopic technique, which is described  
18          in this paper that came out 23 years ago  
19          and was written by myself and another  
20          Navy surgeon.

21          Q.     Understood.

22          A.     Yeah.

23          Q.     The -- the patient in this

1 publication was not treated for face --  
2 for gender dysphoria obviously; right?

3 A. No. She was a sweet pizza maker  
4 who had slipped in the kitchen and struck  
5 her head on a stainless steel table and  
6 had a -- had a displaced fracture of her  
7 forehead. But no, she was -- not to my  
8 knowledge. I don't know if she was or  
9 not, but to my knowledge, she was not.

10 Q. Next one going backwards is from  
11 1996, and it's titled, "Scarless Fetal  
12 Skin Repair: 'Unborn Patients' and 'Fetal  
13 Material.'" Do you see that?

14 A. I do.

15 Q. All right. That doesn't relate  
16 to gender-affirming surgery or to gender  
17 dysphoria, I take it?

18 A. It -- it actually refers to all  
19 forms of surgery and particularly,  
20 ethical decision-making. So I would say  
21 that it's -- it's a -- it's a fairly  
22 broad paper that talks about how we treat  
23 other human persons. So transgender

1 surgery is all about how we treat other  
2 human persons. That's what that paper is  
3 about and how -- how some surgeons are  
4 likely -- or possibly physicians and  
5 surgeons could characterize someone as  
6 less than human, which is a -- which is a  
7 danger that transgender persons  
8 experience when they're seeking care.  
9 And so I would say that in a very  
10 tangential way, it does. It does impinge  
11 upon the field of transgender medicine  
12 precisely for the reason that transgender  
13 persons suffer oftentimes from being  
14 treated as -- as someone who is less than  
15 human.

16 Q. Aside from that very tangential  
17 angle, this paper does not specifically  
18 relate to gender-affirming surgery or  
19 gender dysphoria; correct?

20 A. No, it does not.

21 Q. And the next one before that is  
22 in 1995. Do you see that?

23 A. I do.

1           Q.     You're listed as the third  
2 author in this one; right?

3           A.     Yes, sir.

4           Q.     Because you're not the lead  
5 author; right?

6           A.     No. The attending surgeon is  
7 always the lead author, and I was a  
8 resident. I was a resident at that time,  
9 yeah.

10          Q.     Understood. This one's titled  
11 "Delayed development of an ectopic  
12 frontal sinus mucocoele after pediatric  
13 cranial trauma."

14          A.     Mucocoele, yes. Mucocoele.

15          Q.     Thank you. This publication  
16 doesn't relate to gender-affirming  
17 surgery or gender dysphoria; correct?

18          A.     Not directly, no.

19          Q.     Okay. Next one before that is  
20 titled "Patch Esophagoplasty"?

21          A.     Very good.

22          Q.     And that's repair or  
23 reconstruction of the esophagus; right?

1           A.     Yes.

2           Q.     Does this relate to  
3 gender-affirming surgery or gender  
4 dysphoria?

5           A.     No.

6           Q.     Next one before that is titled  
7 "Modified Skin Incisions for Mastectomy:  
8 The Need for Plastic Surgical Input in  
9 Preoperative Planning." Do you see that?

10          A.     I do.

11          Q.     And finally, your oldest  
12 publication is from 1987, titled  
13 "Peritoneal Fluid in Human Acute  
14 Pancreatitis." Do you see that?

15          A.     Yes.

16          Q.     Does that relate to  
17 gender-affirming surgery or gender  
18 dysphoria?

19          A.     It does not. By the way,  
20 that -- that second to the last article,  
21 your pattern of questions, I wondered if  
22 you overlooked asking the same question  
23 on that paper.



1           Q.     No. I want to ask you more  
2 specific questions about that one, so  
3 we'll spend --

4           A.     Oh, okay.

5           Q.     -- more time on that one.

6           A.     Good. Good. Very good. All  
7 right.

8           Q.     Don't worry.

9           A.     Yeah. "Peritoneal Fluid in  
10 Acute Pancreatitis" was a research paper,  
11 animal model, and review of the  
12 literature. Yeah.

13          Q.     Okay. You agree there's a  
14 difference between a scientific article  
15 that reports original research versus a  
16 letter to the editor that's published in  
17 a scientific journal?

18                 MR. KNEPPER: Objection, form.

19          A.     Yes.

20          Q.     Some of your publications listed  
21 here are just letters to editors; right?

22          A.     Yes.

23          Q.     Why is it that your CV doesn't

1 identify those as letters as opposed to  
2 original research?

3 A. I didn't -- that didn't occur to  
4 me to do that. Do we generally list them  
5 separately? I don't know. I just put  
6 all my publications there.

7 Q. So we can look at them, but for  
8 example, the scarless fetal skin repair,  
9 that's a letter to the editor; right?

10 A. Right.

11 Q. And so is the 1993 publication  
12 on patch esophagoplasty; right?

13 A. Right.

14 Q. So out of the six publications  
15 that you list in your CV, at least two of  
16 them are letters to editors rather than  
17 original research; fair?

18 MR. KNEPPER: Objection, form.

19 A. Right. Yes.

20 Q. Okay. Let's talk about your  
21 experience treating transgender patients.  
22 You retired from the military in 2002;  
23 correct?

1           A.     Correct.

2           Q.     In 2002, the U.S. military  
3           certainly was not providing any  
4           gender-affirming treatment to anyone in  
5           the military; right?

6           A.     That's correct.

7           Q.     Or to veterans; right?

8           A.     Correct.

9           Q.     In fact, at that time, there was  
10          a policy not to provide gender-affirming  
11          treatment to active military or to  
12          veterans; correct?

13               MR. KNEPPER:  Objection, form,  
14          scope.

15          A.     Correct.

16          Q.     So during your career in the  
17          military, you did not provide any  
18          gender-affirming treatment to any  
19          patients; correct?

20          A.     Correct.

21          Q.     All right.  Let's focus on your  
22          practice after you left the military in  
23          2002.  You currently run the Lappert Skin

1 Care clinic; right?

2 A. That's correct.

3 Q. How long have you operated that  
4 clinic?

5 A. One year.

6 Q. Did you operate any clinics  
7 before opening this one?

8 A. Yes.

9 Q. What was that one?

10 A. That was my plastic surgery  
11 office called Lappert Plastic Surgery in  
12 Madison, Alabama. And before that, it  
13 was under the same name but located in  
14 Decatur, Alabama. And before that, it  
15 was in Scottsbluff, Nebraska, same name.

16 Q. How long did you run the Lappert  
17 Plastic Surgery clinic?

18 A. The Madison office was for 15  
19 years. I'm sorry. The Madison office  
20 was for ten years. My -- my mistake.  
21 Ten years at the Madison office, five  
22 years at the Decatur office, and three  
23 years at the Scottsbluff office.

1           Q.     So, let me just make sure I have  
2 my timing here. So you've had the  
3 Lappert Skin Care clinic for a year,  
4 since 2020?

5           A.     Right.

6           Q.     And then the Lappert Plastic  
7 Surgery ten years in Madison, so roughly  
8 2010 to 2020?

9           A.     That's right.

10          Q.     And then five years before that  
11 in Decatur, 2005 --

12          A.     Right.

13          Q.     -- to 2010, roughly?

14          A.     Right.

15          Q.     And then --

16          A.     Scottsbluff was from 2002  
17 through two -- through 2005. That was  
18 where I went when I retired out of the  
19 Navy.

20          Q.     Your -- your skin clinic  
21 currently does treatments like Botox,  
22 light therapy, laser hair removal; right?

23          A.     Right. Laser tattoo removal,

1 injectables, just skin consultations for  
2 skin problems like rosacea, acne, that  
3 sort of thing. That's right.

4 Q. Were you performing similar  
5 treatments at the Lappert Plastic Surgery  
6 clinic?

7 A. Yes. All I've done is I've just  
8 suspend -- I just retired from active  
9 surgical practice. I had an operatory in  
10 my office in Madison as well as in  
11 Decatur previously, so I would do both  
12 hospital-based surgeries as well as  
13 clinic-based, office-based procedures.

14 Q. So for example, light therapy  
15 services, you've offered that for  
16 ten-plus years, I take it?

17 A. I believe we got that instrument  
18 in 2006.

19 Q. How about Botox? Have you been  
20 offering that for more than ten years?

21 A. Yes.

22 Q. Have you done forehead  
23 injections for more than ten years?

1           A.     With Botox?

2           Q.     Yes.

3           A.     Yes.

4           Q.     How about crow's feet? Is that  
5 the right term?

6           A.     Yes.

7           Q.     More than -- more than ten  
8 years?

9           A.     Yes.

10          Q.     When was the last time you've  
11 performed a surgical procedure?

12          A.     Well, as I said, I retired from  
13 surgery in August of 2020, so it was -- I  
14 think I was doing some last procedures in  
15 that same month, perhaps July, somewhere  
16 in there.

17          Q.     And in 2020, roughly how many  
18 surgical procedures do you think you've  
19 performed?

20          A.     From January to July?

21          Q.     Yes.

22          A.     Let's see. Seven months.

23          Perhaps -- I don't know. Maybe eighty,

1 something 80 to 100, I'm guessing. I  
2 don't know.

3 Q. And give me examples of common  
4 surgeries you would have performed in  
5 2020.

6 A. Well, among the most common ones  
7 that we did in the -- in the office were  
8 autologous fat grafting for recon- -- for  
9 rejuvenation of the face, autologous fat  
10 grafting for breast augmentation,  
11 ultrasound -- I'm sorry -- laser  
12 lipoplasty for body contouring, and then  
13 many in-office surgical procedures for  
14 skin cancer and skin cancer  
15 reconstruction, particularly of the face  
16 and the extremities.

17 And then on the hospital side, I  
18 would be guessing how many, but it was  
19 common for me to do breast reductions and  
20 abdominoplasties, little local flap  
21 reconstructions in the hospital for  
22 younger patients who needed anesthesia,  
23 reconstruction -- little reconstructive



1 flaps for trauma or for cancer.

2 I had a working relationship  
3 with a dermatologist who did a lot of  
4 what's called Mohs surgery for removal of  
5 cancers. He would send me his patients  
6 if they -- if they were cancers that  
7 involved the face. I would do those  
8 reconstructive surgeries.

9 Yeah, that was probably -- I was  
10 definitely throttling back in my last  
11 year. I didn't take on a lot of complex  
12 cases, so.

13 Q. Okay.

14 A. Because I needed -- you need  
15 follow-up, and so limited.

16 Q. I understand. Let's go back to  
17 your report. Go to page 4.

18 A. Okay.

19 Q. Okay. Five lines down, you see  
20 the sentence starting with, "In my  
21 private practice"?

22 A. Yes.

23 Q. Okay. Let's break this down.

1        So you reference treated skin  
2        pathologies. What skin pathologies are  
3        you referring to here?

4        A. Skin can- -- well, surgically or  
5        medically, we're talking two different  
6        categories, but. So I'm consulted on --  
7        on a lot of nonsurgical skin pathologies.  
8        But as far as surgical skin pathologies,  
9        that would include various forms of  
10       malignancy and then benign growths and  
11       things that are either aesthetically or  
12       -- aesthetically problematic or  
13       suspicious in appearance, so both proven  
14       cancers and things that are suspicious of  
15       cancers. So those would be the skin  
16       conditions. The medical --

17       Q. Yeah. Well --

18       A. -- skin conditions -- I'm sorry?

19       Q. Yeah. That's all right. I'm  
20       asking more specifically.

21       A. Okay.

22       Q. Because here, you write, "I've  
23       had occasion to treat many

1 self-identified transgender patients for  
2 skin pathologies related to their use of  
3 high dose sex steroids."

4 A. Yeah.

5 Q. So focusing specifically on that  
6 patient population.

7 A. Okay.

8 Q. So, what skin pathologies are  
9 you referring to here with respect to  
10 transgender patients?

11 A. Well, I've had a few patients  
12 who've come in evidencing, you know,  
13 acneiform conditions of the facial skin.  
14 And so helping people manage acne is a  
15 common thing that I do, and a variety of  
16 interventions including, you know, the  
17 light therapy, but more -- more properly,  
18 the use of medications and -- and  
19 sometimes laser therapy to manage  
20 scarring. But in those particular cases  
21 of the trans-identified people, it's  
22 mostly just ordinary management of acne.  
23 And it's usually the same patients who

1       come to see me about facial hair removal  
2       with laser. I have a couple of patients  
3       in that category, people who are  
4       transitioning and who are seeking laser  
5       removal of hair from their faces.

6           Q.     And you said this is a few  
7       patients. How many transgender patients  
8       would you estimate you've treated for  
9       skin pathologies related to steroids?

10          A.     Related to -- to sex steroids?

11          Q.     Yes.

12          A.     Oh, I don't know. Probably less  
13       than half a dozen.

14          Q.     Okay. The acne you're referring  
15       to, it's essentially a side effect from  
16       the steroids; right?

17          A.     It's a common side effect of --  
18       of -- yeah. Particularly androgen is the  
19       most common.

20          Q.     So this -- and so you're  
21       treating patients with gender dysphoria  
22       after they have already decided to follow  
23       a certain course of treatment and started

1 taking sex steroids; right?

2 A. Right. Yeah.

3 Q. Okay. And then you say you've  
4 done laser therapies for management of  
5 facial hair of also the transgender  
6 population?

7 A. That's right.

8 Q. Right?

9 A. That's right.

10 Q. And is that also in about half a  
11 dozen patients? Or what's you're  
12 estimate?

13 A. Yeah. It's not a huge number.

14 Q. Okay. And finally, you say  
15 you've done breast reversal surgeries for  
16 detransitioning patients. On how many  
17 patients have you performed -- strike  
18 that.

19 On how many detransitioning  
20 patients have you performed the surgery?

21 A. Two.

22 Q. Two. All right. It's not a  
23 commonly performed procedure for you;

1 fair?

2 MR. KNEPPER: Objection, form.

3 A. Yeah, no. They -- they started  
4 coming to me in that last year of  
5 practice, so. Yeah, that -- it's not  
6 a -- yeah, it's not a -- it was never a  
7 common procedure for me. I did a lot of,  
8 you know, implant removals and stuff  
9 through my years. It's the same  
10 operation. And I've done a lot of  
11 gynecomastectomy surgeries. That's also  
12 the same operation. But in terms of as  
13 it's applied to a trans- -- a  
14 transitioned person who wants to revert  
15 back to male presentation, very limited  
16 experience. But even though it's the  
17 same operation, I have only done it for  
18 two people.

19 Q. And you said both of those  
20 patients were in 2020?

21 A. I believe so, yeah. One of them  
22 may have been in 2019. I'm not positive  
23 about that.

1           Q.     Before 2019 or 2020, you had  
2     never had a detransitioning patient come  
3     to you to obtain breast reversal surgery;  
4     fair?

5           A.     I think that's correct, yeah.  
6     I'm just trying to think if there was  
7     any, but I can't -- I can't recall any  
8     other.

9           Q.     Okay. Are you aware that modern  
10    gender affirmation programs typically  
11    have a multidisciplinary team of  
12    healthcare providers?

13          A.     Yes.

14               MR. KNEPPER: Objection, form.

15          Q.     And they usually involve mental  
16    health specialists; right?

17          A.     Yes.

18               MR. KNEPPER: Objection, form.

19          Q.     Endocrinologists?

20          A.     Yes, that's my understanding.

21          Q.     And oftentimes plastic surgeons  
22    if the patient wants to go that route;  
23    right?

1           A.     Right.  That's -- that's my  
2     understanding, yes.

3           Q.     You personally have never been  
4     part of this kind of a multidisciplinary  
5     team for any patient with gender  
6     dysphoria; correct?

7           A.     No.  I have always -- I have  
8     always turned away personal -- for per-  
9     -- well, my understanding of those  
10    procedures has caused me to reject  
11    offering them to my patients because I  
12    don't see them as beneficial.  So  
13    clearly, I wouldn't want to participate  
14    in a multidisciplinary team that's  
15    offering therapies that I consider to be  
16    incorrect treatments for a condition that  
17    deserves our care, so.

18          Q.     All right.

19          A.     If you want, I can give you a  
20    shorter answer.  No.

21          Q.     Yeah, let's -- you personally  
22    have never treated a single patient for  
23    gender dysphoria; correct?



1           A.     I have never treated a patient  
2     with gender dysphoria surgically.

3           Q.     Okay.

4           A.     Other than the detransitioner.  
5     I -- I suspect they were still suffering  
6     from dysphoria even though they were  
7     detransitioning, but I didn't treat them  
8     with surgery to -- per se for that  
9     condition the way the transgender teams  
10    do.   Yeah.

11          Q.     When you were providing laser  
12    hair removal to trans women, is that  
13    providing gender-affirming care?

14               MR. KNEPPER:   Objection, form.

15          A.     I don't get into the affirmation  
16    side of the treatment.   I'm simply  
17    providing a service to -- to people who  
18    -- who I want to have as friends.  
19    Believe it or not, it's true.   I -- I  
20    don't turn anyone away whose -- whose  
21    request is -- is within the scope of what  
22    I consider moral practice of medicine and  
23    surgery, so.

1           Q.     So earlier, I asked you, you  
2 personally have never treated a single  
3 patient for gender dysphoria, and I think  
4 you said not surgically. Let me ask more  
5 broadly. Not limited to surgery, you  
6 have never treated a single patient for  
7 their gender dysphoria symptoms; correct?

8           A.     Well, I guess if -- if you were  
9 to look at laser facial hair removal and  
10 consider that in the -- in the spectrum  
11 of care, certainly that's -- that's --  
12 that's clinic care that's probably  
13 improving the emotional life of the  
14 patient because they're seeking to  
15 present as women. So in that sense, I  
16 have, yeah.

17          Q.     Nothing outside of laser hair  
18 removal?

19          A.     No.

20          Q.     You personally have never --

21          A.     Well, and -- and acne. Because  
22 clearly, that's a problem. But in terms  
23 of their -- the trajectory of their

1 transition, acne doesn't enter into it.  
2 But certainly laser hair removal, yeah.

3 Q. You personally have never sat in  
4 any meetings between a provider and a  
5 patient where the doctor was trying to  
6 diagnose whether the patient has gender  
7 dysphoria; correct?

8 A. Correct.

9 Q. You have never sat in any  
10 meetings between a provider and a patient  
11 discussing their potential treatment  
12 options for gender dysphoria; correct?

13 A. No.

14 Q. All right. You're not an  
15 endocrinologist; right?

16 A. Correct.

17 Q. You're not a psychiatrist;  
18 right?

19 A. Correct.

20 Q. You're not a licensed mental  
21 healthcare provider of any kind; right?

22 A. Correct.

23 Q. In your professional day-to-day

1 practice, you do not diagnose mental  
2 health conditions of any kind; right?

3 MR. KNEPPER: Objection, form.

4 A. With the exception of what we  
5 discussed earlier about body dysmorphic  
6 disorder and gender -- gender identity as  
7 a subcategory of body dysmorphic  
8 disorder, no, I would say I don't.

9 Q. Okay. If some patient thinks  
10 that they may have depression or anxiety,  
11 you would expect that patient to go to a  
12 mental health professional, not to you;  
13 right?

14 A. That's my expectation. But  
15 again, many depressed people come to  
16 plastic surgeons seeking a remedy for  
17 their depression thinking that their  
18 appearance is the cause of their  
19 depression. And it's my duty as a  
20 plastic surgeon to recognize those  
21 patients and -- and send them to the  
22 psychologist, psychiatrist, rather than  
23 offering them surgical care, yeah, so.

1           Q.     Yeah. I'm asking a slightly  
2 different question.

3           A.     Okay.

4           Q.     If a -- if a patient, for some  
5 reason, came to you and asked you to  
6 diagnose them with depression or anxiety,  
7 I assume you would refer them to a train  
8 -- trained mental health professional;  
9 right?

10          A.     Yes.

11          Q.     Because doctors should not be  
12 diagnosing patients with mental health  
13 conditions if they do not have training  
14 in how to diagnose mental health  
15 conditions; right?

16                 MR. KNEPPER: Objection, form.

17          A.     Well, I wouldn't say that,  
18 because for example, as a -- as a -- as a  
19 surgeon, as a plastic surgeon, we do have  
20 to make diagnoses outside of our  
21 specialty in order to get people to the  
22 right specialist. So to an extent, you  
23 have to make that diagnosis.

1           So for example, as a resident in  
2           training, I diagnosed an endocrinological  
3           disease and probably saved a woman's life  
4           because she was in a psych ward, and --  
5           and -- and the doctors had a question  
6           about her -- a lump in her neck. She had  
7           been on the psych ward for weeks, and I  
8           diagnosed a hyperfunctioning thyroid  
9           nodule. I didn't confirm that diagnosis.  
10          I sent her to an endocrinologist. But I  
11          made the initial diagnosis of  
12          hyperfunctioning thyroid nodule, and --  
13          and ultimately, I did her thyroidectomy.  
14          But that's an example.

15                You have to understand pathology  
16                outside your specialty because you don't  
17                know why the patient is going to present  
18                to you, and you have to be ready to start  
19                the process that gets them to the  
20                specialist, so you have to have a working  
21                knowledge of the problems.

22                Q.     Yeah, that's exactly the point.  
23                Even for that one example, you still send

1       this patient to a trained endocrinologist  
2       to confirm the diagnosis; right?

3           A.     Right.   And then they sent them  
4       back to me to give them definitive care.

5           Q.     Yeah.   And that's what you would  
6       do for any patient that presents to you  
7       with a mental health condition; right?  
8       You would train -- you would send them to  
9       someone who is -- who is trained in how  
10      to diagnose mental health conditions;  
11      right?

12                   MR. KNEPPER:   Objection, form.

13           A.     Yes.

14           Q.     You're not trained in providing  
15      psychotherapy counseling; right?

16           A.     Right.

17           Q.     You've never provided  
18      counseling, psychotherapy counseling to  
19      children or adolescents with gender  
20      dysphoria; right?

21           A.     Right.

22           Q.     You've never provided  
23      psychotherapy counseling to adults who

1 have gender dysphoria; right?

2 A. Right.

3 Q. You do not have the professional  
4 training to provide psychotherapy  
5 counseling to adults who have gender  
6 dysphoria; right?

7 MR. KNEPPER: Objection, form.

8 A. Correct.

9 Q. Or to children or adolescents  
10 with gender dysphoria; right?

11 MR. KNEPPER: Objection, form.

12 A. Correct.

13 Q. Go to page -- back to your --  
14 strike that.

15 Back to your report on page 4,  
16 in this paragraph 9, about six lines  
17 down, you say, "I have consulted with  
18 families with children who are  
19 experiencing gender discordance." Do you  
20 see that?

21 A. Yes.

22 Q. Describe these consultations for  
23 me at a high level.



1           A.     Basically, it was families that  
2           wanted to understand what -- the nature  
3           of plastic surgery sort of in the future  
4           for their children. These were -- these  
5           were personal encounters rather than in  
6           the office, but fairly lengthy at times,  
7           talking to families about -- they wanted  
8           to understand what was being offered to  
9           their children. They wanted to  
10          understand the nature of -- or what the  
11          future would look like for their  
12          children. They wanted to get some idea  
13          of -- basically, they wanted to hear sort  
14          of a fuller explanation of the -- of the  
15          medical and surgical side of things. So  
16          I wasn't giving them psychiatric  
17          counseling, but basically offering them  
18          my experience as a plastic surgeon,  
19          wanting to know what the surgery's about,  
20          what the -- the hormone therapy that  
21          precedes the surgery's about, that sort  
22          of thing.

23          Q.     How many of these consultations

1 have you done, would you estimate?

2 A. Perhaps five or six, maybe more.  
3 Maybe -- yeah, five or six would be a  
4 fair number, I think.

5 Q. Over what years?

6 A. Perhaps the last three.

7 Q. Do you know how these parents  
8 know to reach out to you for these  
9 consultations?

10 A. It's -- I think maybe some of  
11 them were -- having heard about my public  
12 presentations at various venues. People  
13 hear about this plastic surgeon in  
14 Decatur who's raising objections, I  
15 guess. I don't know the particular  
16 details about how a particular patient  
17 might have come to me. I just -- I just  
18 always make myself available when people  
19 are anxious for their children and  
20 they're looking for an understanding of  
21 what transgender is about.

22 Q. What's the typical advice that  
23 you give to parents of children or

1 adolescents who are considering starting  
2 puberty blockers?

3 A. Well, my advice on that score is  
4 based on the -- on the world literature,  
5 that the desistance rate for their child,  
6 if they don't give them puberty blockers,  
7 the likelihood is that by the time they  
8 reach mid-adolescence, they have an 80  
9 percent likelihood of desisting in their  
10 cross-sex self-identification. And if  
11 you follow them into young adulthood,  
12 that percentage will be in the 90s.

13 But essentially, I recommend  
14 that they slow everything down, and I  
15 recommend against the use of puberty  
16 blockade because it's experimental and  
17 because the likelihood is very high -- in  
18 fact, if I had any medical procedure that  
19 gave me 90-plus percent success rate, I  
20 would consider that a great victory.  
21 So -- so that's -- that's what I speak to  
22 them about.

23 That -- that desistance data is

1 a very important thing for parents to  
2 understand. And very often, the patient  
3 -- the parents are experiencing  
4 tremendous pressure from the people  
5 they've seen in consultation, a  
6 tremendous pressure. And usually, the  
7 parents are very distressed about what  
8 they're hearing, particularly the -- the  
9 fear of suicide and self-harm.

10 Q. Yeah.

11 A. So --

12 Q. You encourage -- yeah, no, I got  
13 it. You encourage patients of children  
14 who -- or adolescents who experience  
15 gender dysphoria not to start them on  
16 puberty-blocking drugs; fair?

17 MR. KNEPPER: Objection, form.

18 A. Yeah, I discourage the use of  
19 puberty blockade for anything other than  
20 precocious puberty or other  
21 endocrinopathies.

22 Q. And you also discourage them  
23 from pursuing surgical procedures for

1 gender dysphoria; correct?

2 MR. KNEPPER: Objection, form.

3 A. Correct.

4 Q. When you do these consultations,  
5 do you talk just to the parents or to the  
6 children as well?

7 A. Both, yeah. I like to meet the  
8 children and -- and -- and get to know  
9 them, yeah.

10 Q. And do you convey the same  
11 message to the children? Don't start  
12 puberty blockers; don't start -- don't do  
13 any surgical procedures?

14 MR. KNEPPER: Objection.

15 A. I -- I generally don't -- I'm  
16 sorry. I generally don't speak about the  
17 details of therapy to children. I speak  
18 to their parents.

19 Q. How many children do you think  
20 you have consulted with specifically?

21 A. On this -- on this issue?

22 Q. Yes.

23 A. As I say, maybe six. I often --

1       well, yeah, I would say six is a good  
2       number.

3           Q.     Do you know how many of them  
4       went on to start hormone-blocking  
5       therapy, if any?

6           A.     I don't. I don't know the  
7       answer to that question. Yeah, I don't.

8           Q.     Do you know how many of them, if  
9       any, went on to start cross-sex hormone  
10      therapy?

11          A.     I don't know the answer to that  
12      question, no.

13          Q.     You don't know how many of them  
14      went on to do any kind of surgical  
15      gender-affirming procedures?

16          A.     No.

17          Q.     You haven't done any follow-up  
18      with any of these families that you've  
19      consulted?

20          A.     As I say, this was an informal  
21      thing, so. Yeah. So no, I -- I haven't  
22      followed up long-term. This has -- as I  
23      say, this has happened over the last

1 perhaps three years. And so the general  
2 course of events there is -- is typically  
3 longer than that, so. But I have not  
4 seen -- well, I have seen one -- one  
5 child twice, actually, with the parents.  
6 And actually -- okay. So -- so perhaps  
7 she would be an exception.

8 She was sort of headed in the  
9 direction of seeking puberty blockade.  
10 And then in our meetings, she has sort of  
11 given that up. She was under a lot of  
12 pressure at school, you know, being  
13 pressured by boys because she was  
14 starting to develop secondary sex  
15 characteristics, and she developed a  
16 tremendous anxiety about it. And someone  
17 had told her that -- that if she went  
18 through transition care, that that would  
19 be avoided. And I had a conversation  
20 with her parents, I had a conversation  
21 with her, and essentially just encouraged  
22 her to slow down and sort of examine her  
23 other options. And I think within about

1       seven months, she came back to me, and  
2       she's not even thinking along those lines  
3       any longer. In fact, now she's talking  
4       about what high school she wants to go  
5       to, so.

6           Q.     Okay. So this is one child who  
7       was considering, or whose parents were  
8       considering starting puberty-blocking,  
9       but after consultation with you, decided  
10      not to; right?

11          A.     I think that she -- yeah.

12                 MR. KNEPPER: Objection to form.

13                 MR. TISHYEVICH: Okay. All  
14      right off the record.

15                 THE VIDEOGRAPHER: This is the  
16      end of Media Unit No. 2. We are off the  
17      record at 11:06 a.m.

18                         (Break taken.)

19                 THE VIDEOGRAPHER: This is the  
20      beginning of Media Unit No. 3. We are on  
21      the record at 11:16 a.m.

22           Q.     (By Mr. Tishyevich) Doctor, you  
23      know what facial feminization surgery is;



1 right?

2 A. Yes, I do.

3 Q. You have never performed facial  
4 feminization surgery for any transgender  
5 patient; correct?

6 A. Correct.

7 Q. You know what facial  
8 masculinization surgery is?

9 A. Yes.

10 Q. You have never performed that  
11 for any transgender patient; correct?

12 A. Correct.

13 Q. Do you know what transfeminine  
14 top surgery is?

15 A. Yes.

16 Q. You have never performed that on  
17 a transgender patient?

18 A. No.

19 Q. How about a chest reconstruction  
20 surgery? Have you performed that on a  
21 transgender patient?

22 A. No.

23 Q. You have never performed a

1       vaginoplasty for a transgender patient?

2           A.     No.

3           Q.     You have never performed a  
4       metoidioplasty for any transgender  
5       patient?

6           A.     No.

7           Q.     You've never performed what's  
8       colloquially known as bottom surgery for  
9       any transgender patient; correct?

10          A.     Correct.

11          Q.     Fair to say you've never  
12       performed any kind of gender-affirming  
13       surgery in transgender patients; right?

14          A.     Correct.

15          Q.     And fair to say you don't have  
16       recent and substantive experience in  
17       performing gender-affirming -- -affirming  
18       surgery for transgender patients;  
19       correct?

20               MR. KNEPPER:    Form.

21          A.     I have -- I have substantive  
22       experience with all the actual -- the  
23       nature of the particular operations but

1       never performed for transgender patients  
2       to transition them, no. But the  
3       operations themselves as used in  
4       reconstruction, I have considerable  
5       experience with.

6           Q.     We talked earlier about the  
7       American Society of Plastic Surgeons.  
8       You recall that?

9           A.     I do.

10          Q.     You know that the ASPS has a  
11       code of ethics?

12          A.     Yes.

13          Q.     And you know that members are  
14       required to comply with the code of  
15       ethics; right?

16          A.     Yes.

17          Q.     And I know you're not a member  
18       now, but you were a member of the ASPS  
19       for a considerable amount of time; right?

20          A.     Yes.

21          Q.     And I assume during that time,  
22       you followed the ASPS code of ethics;  
23       right?

1           A.     To my knowledge, I never  
2     violated it.   Yes.

3           Q.     When was the last time you  
4     reviewed it?

5           A.     I'm sorry, did I lose the sound  
6     here?

7           Q.     When was the last time you  
8     reviewed the ASPS code of ethics?

9           A.     Oh, gosh.   Years ago.   Years  
10    ago.

11          Q.     Let me introduce an exhibit.  
12                  Let me ask you this first.   Are  
13    you aware that the ASPS code of ethics  
14    had some specific rules for members who  
15    provide expert testimony?

16          A.     Yes.

17          Q.     Okay.   You didn't review those  
18    provisions before you formed your expert  
19    opinions in this case?

20          A.     No.

21          Q.     Sitting here today, do you know  
22    if your opinions in this case are in  
23    compliance with what the ASPS code of

1 ethics says about members who provide  
2 expert testimony?

3 A. I'm not aware that I've violated  
4 them in any way, yeah.

5 Q. Let me introduce an exhibit.  
6 Okay. Let me know when you have it.  
7 (Exhibit 10 was marked for identification  
8 and is attached.)

9 A. Okay.

10 Q. It's still opening on my end.  
11 Okay. So, Exhibit 10 is the  
12 Code of Ethics of the American Society of  
13 Plastic Surgeons. You see that?

14 A. I do.

15 Q. The bottom left corner says,  
16 "Updated September 25, 2017." See that?

17 A. I do.

18 Q. That's when you were still an  
19 active member of the ASPS; right?

20 A. Yeah, that's right.

21 Q. Go to page 4.

22 A. I think I'm on page 4 here.  
23 They're not numbered. Oh, here we are,

1       yes.

2           Q.     Or I'm sorry, page 6.

3           A.     Page 6.

4           Q.     Section IV.

5           A.     Section IV, yes.

6           Q.     Section IV is "Expert  
7     Testimony"; right?

8           A.     Yes.

9           Q.     I want to focus you on the last  
10    two sentences of this first paragraph.  
11    It says, "Members whose testimony,  
12    including testimony as to credentials or  
13    qualifications, is false, deceptive, or  
14    misleading may be subject to disciplinary  
15    action, including expulsion." You see  
16    that?

17          A.     Yes.

18          Q.     The next sentence says, "Further  
19    to help limit false, deceptive and/or  
20    mislead" -- "misleading testimony,  
21    Members serving as expert witnesses  
22    must," and then there's a list of  
23    requirements. You see that?

1           A.     I do.

2           Q.     Okay.   So "must" means this is a  
3           mandatory rule, not an optional  
4           suggestion; right?

5                     MR. KNEPPER:   Objection, form.

6           A.     I expect that's what it means,  
7           yes.

8           Q.     All right.   Let's look at these  
9           rules.   Number 1 says that members  
10          serving as expert witnesses must "Have  
11          recent and substantive experience (as  
12          defined in the Glossary of the Code) in  
13          the area in which they testify,  
14          including, without limitation, experience  
15          in the relevant subspecialty or the  
16          particular procedure performed on the  
17          plaintiff."

18                    Do you see that?

19          A.     I do.

20          Q.     All right.   Without looking at  
21          the glossary, do you know, sitting here  
22          today, how the glossary defines "recent  
23          and substantive experience"?

1           A.     I don't.

2           Q.     Okay.   Why don't we look at that  
3 definition together.   Go to page 8.

4           A.     Okay.

5           Q.     See there's subsection F?

6           A.     Yes.

7           Q.     All right.   Read that definition  
8 to yourself, and tell me when you're  
9 done.

10          A.     Okay.

11                   (Witness reviews document.)

12          A.     Okay.

13          Q.     To be able to provide expert  
14 testimony -- well, strike that.

15                   Let me focus you on the very  
16 last part of this definition.   Okay.   To  
17 be able to provide expert testimony about  
18 a particular surgical procedure, the ASPS  
19 Code of Ethics requires a surgeon to have  
20 performed a specific procedure in  
21 question within three years of being  
22 retained as an expert witness; correct?

23          A.     That's what it says, yes, sir.



1 MR. KNEPPER: Objection, form.

2 Q. All right. Now, as we've just  
3 discussed, you personally have not  
4 performed any kind of facial  
5 masculinization surgery in the last three  
6 years; correct?

7 MR. KNEPPER: Objection, form.

8 A. Correct.

9 Q. Any kind of facial feminization  
10 surgery; right?

11 A. Correct.

12 MR. KNEPPER: Objection, form.

13 Q. Vaginoplasty; right?

14 MR. KNEPPER: Objection, form.

15 A. Correct.

16 Q. Metoidioplasty; right?

17 MR. KNEPPER: Objection to form.

18 A. Correct.

19 Q. You personally have not  
20 performed any kind of gender-affirming  
21 surgical procedure on a transgender  
22 patient in the last three years; correct?

23 MR. KNEPPER: Objection, form.

1           A.     I have never performed such  
2     procedures.

3           Q.     All right. Well, given that you  
4     have not ever personally performed any  
5     kind of surgical procedures in the last  
6     three years, I take it you're not  
7     offering expert opinions on any of these  
8     surgeries because doing so would be  
9     inconsistent with the ASPS code of  
10    ethics; right?

11               MR. KNEPPER: Objection, form.

12           A.     Well, so the ethics that informs  
13    my opinion here is I don't derive from  
14    the ASPS, nor am I subject to their --  
15    their -- what's the word I'm looking  
16    for -- their sanctions, I guess, would be  
17    the correct word. The expert opinion I  
18    offer here is not on -- on complications  
19    of an operation that might enter into a  
20    litigation. In terms of the -- you know,  
21    I guess the -- the question at hand here  
22    is transition surgery, the bigger  
23    picture. I certainly make record of --

1 of the known complications as available  
2 in the literature. And in my testimony,  
3 I did a literature review on the  
4 complications of particular surgeries.

5 But I don't do these operations  
6 for a reason, and the reason I don't do  
7 these operations is ethical based on my  
8 knowledge of the science. I don't derive  
9 my ethical decision-making from the ASPS,  
10 and this is one of the reasons why,  
11 again, I have no heartburn about having  
12 withdrawn my membership. I have great  
13 issue with -- with the idea that a  
14 professional organization would encourage  
15 or sanction these operations given the  
16 world literature.

17 Q. Your opinion -- your -- strike  
18 that.

19 Your expert report does offer  
20 some opinion, or purports to offer some  
21 opinions about surgical risks of some of  
22 these gender-affirming surgical  
23 procedures, does it not?

1           A.     Yes.   Based on my -- my  
2           experience in microvascular surgery, on  
3           flap reconstruction of the perineum, for  
4           example, flap reconstruction of the chest  
5           or the -- or the genital area in  
6           treatment for traumatic injuries and  
7           things.   So the operations themselves,  
8           I'm quite familiar with.   I'm quite  
9           familiar with the complications that are  
10          peculiar to free flap or local flap  
11          reconstructions.

12                 But as far as doing those  
13          operations for gender transitioning, I --  
14          I don't do those operations.   But the  
15          complications are the same: flap loss,  
16          flap necrosis, urinary fistulas.   All of  
17          those things I have -- I have experience  
18          with in managing trauma, in managing  
19          cancer, in managing infectious  
20          destruction of the genital area.   But  
21          I've never done the operation for  
22          transgender per se, correct.

23          Q.     And because you've never done

1 any of those procedures on transgender  
2 patients, can we agree that offering  
3 those opinions is inconsistent with the  
4 ASPS Code of Ethics?

5 MR. KNEPPER: Objection, form.

6 A. I would not agree with that.

7 Q. Does it bother you that you  
8 might be in violation of the Code of  
9 Ethics by offering these opinions?

10 MR. KNEPPER: Objection.

11 A. No. Not in the least.

12 Q. Do you think that a judge might  
13 be troubled by the fact that your  
14 professional organization, former  
15 professional organization, says you  
16 shouldn't be allowed -- you shouldn't be  
17 offering these kind of opinions?

18 MR. KNEPPER: Objection, form.

19 A. Yeah, I find -- I find the --  
20 the whole situation troubling, and I  
21 would hope that the judge would be  
22 troubled by it, yes.

23 Q. Okay. Yeah, no, I mean, I'm

1 asking a much more specific question.  
2 The judge is going to be asked to find  
3 whether your testimony is reliable. Do  
4 you think the judge might have some  
5 concerns if she -- if they were to  
6 conclude that the testimony you're  
7 offering in this case is not allowed  
8 under the code of ethics of the ASPS?

9 MR. KNEPPER: Objection, form.

10 A. I -- I -- I haven't thought  
11 about it.

12 Q. And you haven't thought about it  
13 because before today, you didn't know  
14 whether or not your testimony complies  
15 with the ASPS Code of Ethics; right?

16 MR. KNEPPER: Objection, form.

17 A. I was not -- I was not concerned  
18 with the ASPS Code of Ethics, for reasons  
19 we've discussed earlier.

20 Q. Did you know that -- did you  
21 know that the ASPS Code of Ethics  
22 prohibits members from offering expert  
23 testimony on topics in which they do not

1 have recent and substantive experience?

2 MR. KNEPPER: Objection, form.

3 A. Could you -- can you -- I want  
4 to make sure I answer your question and  
5 not something else. Could you offer me  
6 that question again, please?

7 Q. Before I showed you this code of  
8 ethics at your deposition today, were you  
9 aware that the ASPS Code of Ethics  
10 prohibits members from offering expert  
11 opinions on topics on which they do not  
12 have recent and substantive experience?

13 MR. KNEPPER: Objection, form.

14 A. Actually, I dreaded that such a  
15 -- such a fact would come to light. I  
16 have not read the -- the ethics code in  
17 recent years, as I said earlier. But  
18 I -- I have dreaded this evolution in the  
19 ethics of my former professional society,  
20 that they would consider transgender  
21 surgery the way they do.

22 I -- other -- aside from that, I  
23 was not concerned that I might be

1       violating the ethics of the society  
2       because in all my previous life, I have  
3       never violated the ethics of the society.  
4       And I don't -- at present, I don't  
5       consider my testimony to be a violation  
6       of this policy that we've read together.

7           Q.     I understand. All right. Let's  
8       switch gears. You know what the WPATH  
9       is? The World Professional Association  
10      for Transgender Health?

11          A.     Yes.

12               MR. TISHYEVICH: And for the  
13      court reporter, it's W-P-A-T-H, all  
14      capital.

15          Q.     All right. You know that the  
16      WPATH publishes standards of care for the  
17      health of transgender people; right?

18          A.     They have a publication that  
19      they call the standards of care, yes.

20          Q.     And are you aware that they've  
21      been publishing those standards since  
22      1979?

23          A.     Yes.



1           Q.     The latest publicly available  
2     standard of care is Version 7; correct?

3           A.     Correct.

4           Q.     And that was published in 2012;  
5     right?

6           A.     That's right.

7           Q.     All right. Before you wrote  
8     your report, did you sit down and review  
9     the Standards of Care, Version 7 that  
10    you're criticizing?

11          A.     Yes, I did.

12          Q.     All right. You yourself are not  
13    part of the WPATH; correct?

14          A.     No, I am not.

15          Q.     You've never been part of the  
16    WPATH; right?

17          A.     I would never be part of the  
18    WPATH.

19          Q.     You've never advised the WPATH  
20    in any capacity; right?

21          A.     They've never asked my opinion.  
22    No.

23          Q.     You've never advised the WPATH

1 in any capacity; correct?

2 A. I have not.

3 Q. You personally have not been  
4 involved with the development of WPATH's  
5 Standards of Care, Version 7; correct?

6 A. Correct.

7 Q. You don't know what year the  
8 WPATH started working on Version 7;  
9 right?

10 A. My understanding was it was in  
11 2007, but I could be wrong. I think it  
12 was 2007. I think it was a five-year  
13 process, but I could be wrong on that.

14 Q. You don't know for sure?

15 A. I don't know for sure.

16 Q. You don't know how many  
17 different work groups at the WPATH were  
18 involved with working on Version 7;  
19 correct?

20 MR. KNEPPER: Objection, form.

21 A. In reading the -- the  
22 introduction to the document, the number  
23 nine pops into my mind, but I can't swear

1 to that.

2 Q. Okay. You don't know what kind  
3 of scientific literature the WPATH  
4 conducted as part of drafting Version 7;  
5 right?

6 A. As far as naming the particular  
7 papers that they may have reviewed, I  
8 can't do that for you because those  
9 are -- that happens in closed committee.  
10 I -- all I can say to you is my -- based  
11 upon my reading of the product and the  
12 verbiage that it's used, my suspicion is  
13 that it's pretty heavily weighted towards  
14 the American literature and -- and does  
15 not bring in particular document -- well,  
16 being that it was published in 2012, the  
17 big inflection point in 2011 probably  
18 wasn't available to the committee when  
19 they were writing that document.

20 So given that the document is  
21 already out of date and it's -- and the  
22 subsequent WPATH 8, no one knows when  
23 it's going to come out, yeah, it's --

1       it's almost -- it's almost irrelevant  
2       because of the change in the literature  
3       that happened since it was published, so.  
4       In particular, the 2011 article by  
5       Dhejne, Cecilia Dhejne, and -- and others  
6       that kind of changed the view of the  
7       scientific evidence.

8               So yeah, it's an out-of-date  
9       document by the standards of what are  
10      called standards of care. It's not a  
11      standards of care document. It's a --  
12      it's a treatment guideline document is  
13      really what it is, and it's a poorly  
14      supported treatment guideline at that,  
15      so -- gosh, I wandered off.

16             Did I -- did I answer your  
17      question?

18             Q.     Yeah, you anticipated my  
19      objection.

20             MR. TISHYEVICH:   Which, again,  
21      I'll move to strike most of that as  
22      nonresponsive.

23             Q.     Because here's my question.   You

1 don't personally know what kind of  
2 scientific literature the WPATH conducted  
3 as part of drafting Version 7; correct?

4 MR. KNEPPER: Objection, form.

5 A. No. Again, a closed session, so  
6 I don't know what documents they used.

7 Q. You don't know what kind of  
8 outside experts the WPATH may have  
9 consulted in drafting Version 7; right?

10 A. No.

11 Q. You don't know what kind of peer  
12 review the WPATH may have conducted as  
13 part of developing Version 7; right?

14 MR. KNEPPER: Objection, form.

15 A. No.

16 Q. You don't know what kind of  
17 public comments the WPATH may have  
18 solicited as part of developing Version  
19 7.

20 MR. KNEPPER: Objection, form.

21 Q. Right?

22 A. No.

23 Q. You don't know how many

1 different drafts the Version 7 went  
2 through before it was finalized; right?

3 A. No.

4 Q. You don't know how many  
5 different meetings or conferences the  
6 WPATH had to discuss the development of  
7 Version 7; right?

8 A. Correct.

9 Q. You have no idea what may have  
10 gone on during those meetings or  
11 conferences; correct?

12 MR. KNEPPER: Objection, form.

13 A. No. I was not a part of the  
14 conferences that produced the product.

15 Q. Yeah, you are not an expert in  
16 how Version 7 of the WPATH was developed;  
17 right?

18 A. Correct.

19 Q. And we can go through all these  
20 questions again individually for Version  
21 8, but maybe we can shortcut this.

22 A. Well, no one knows what's in  
23 Version 8 except the people who are in

1 the committee. It's a -- it's a  
2 privileged document. There's no one in  
3 plastic surgery who knows it apart from  
4 the people who serve as members of the  
5 WPATH, so that would be the case.

6 Q. Okay.

7 A. It's a -- it -- yeah.

8 Q. So just so we have it on the  
9 record, you don't hold yourself out as an  
10 expert on how Version 8 of the WPATH  
11 Standards of Care are currently being  
12 developed; fair?

13 A. Fair.

14 Q. Okay. We talked earlier about  
15 the DSM; right?

16 A. Yes.

17 Q. In your day-to-day practice, you  
18 don't use the DSM-5; correct?

19 A. No.

20 Q. But you do know the DSM-5 is  
21 widely used by psychiatrists; correct?

22 A. Yes.

23 Q. The DSM-5 was published in 2013;

1 correct?

2 A. I don't know the publication  
3 date, but it sounds about right.

4 Q. Do you know that it was  
5 developed by the American Psychiatric  
6 Association?

7 A. Yes.

8 Q. You're not a member of the APA;  
9 right?

10 A. Correct.

11 Q. You personally have not been  
12 involved with the development of DSM-5;  
13 right?

14 A. No.

15 Q. You don't know how many  
16 different working groups were involved  
17 with developing the DSM-5; right?

18 MR. KNEPPER: Objection, form.

19 A. Correct.

20 Q. You don't know how many  
21 different members those working groups  
22 had; right?

23 MR. KNEPPER: Objection, form.



1           A.     No.

2           Q.     Or how they were selected;  
3     right?

4                     MR. KNEPPER:   Objection, form.

5           A.     Correct.

6           Q.     You don't know how many  
7     different authors contributed to the  
8     development of DSM-5; correct?

9           A.     Correct.

10                    MR. KNEPPER:   Objection, form.

11           Q.     You don't know what kind of  
12     scientific literature review was done by  
13     different work groups as part of  
14     developing the DSM-5; correct?

15                    MR. KNEPPER:   Objection, form.

16           A.     Correct.

17           Q.     You don't know what kind of  
18     public comments the APA may have  
19     solicited in developing the DSM-5;  
20     correct?

21                    MR. KNEPPER:   Objection, form.

22           A.     Correct.

23           Q.     You don't know how many

1 different drafts the DSM-5 went through  
2 before it was finalized; correct?

3 MR. KNEPPER: Objection, form.

4 A. Correct.

5 Q. You don't know how many  
6 different meetings or conferences or  
7 telephonic conferences the working groups  
8 had to discuss the development of the  
9 DSM-5; right?

10 MR. KNEPPER: Objection, form.

11 A. Right.

12 Q. You have no idea what was  
13 discussed during any of those meetings;  
14 right?

15 A. Right.

16 Q. Let me ask you specifically  
17 about the Sexual and Gender Identity  
18 Disorders Work Group. First of all,  
19 before today, did you know that the APA  
20 had a Sexual and Gender Identity  
21 Disorders Work Group as part of the  
22 development of the DSM-5?

23 MR. KNEPPER: Objection, form.

1           A.     Yes.

2           Q.     Do you know how many members  
3 were in that work group?

4           A.     No.

5           Q.     You don't know --

6                   MR. KNEPPER:  Objection.

7           Q.     -- how those members were  
8 selected; right?

9                   MR. KNEPPER:  Objection to form.

10          A.     Correct.

11          Q.     You don't know their expertise;  
12 right?

13          A.     Correct.

14          Q.     You do not have expert firsthand  
15 knowledge of how the DSM-5 was developed;  
16 fair?

17                   MR. KNEPPER:  Objection, form.

18          A.     Fair.

19          Q.     Are you aware that the DSM-4  
20 used the term "gender identity disorder"  
21 instead of "gender dysphoria"?

22          A.     Yes.

23          Q.     Do you know the reason for that

1 change?

2 A. From DSM-4 to DSM-5?

3 Q. Yes.

4 A. Yes.

5 Q. What's the reason?

6 A. In reading the literature and  
7 reading the reports of perhaps people who  
8 served on the committee, because I don't  
9 know how else you would be privy to this  
10 information, there was a desire on the  
11 part of the APA to de-pathologize the  
12 condition, and they wanted to use  
13 terminology that didn't sound like  
14 medical diagnoses. It was the opinion of  
15 the members of that committee that --  
16 that transgenderism is only a diagnostic  
17 issue from the standpoint of the  
18 discomfort or the sorrow that the patient  
19 feels rather than any underlying  
20 pathology. So the -- the desire was to  
21 move those -- the diagnosis to change the  
22 language of diagnosis to de-pathologize  
23 it. But the problem that the committee

1 faces is that having done that, there's  
2 no mechanism for providing the services  
3 that they felt that the patients needed,  
4 so there had to be a diagnose -- a  
5 diagnostic code in order to get  
6 thirty-part -- third-party payers to pay.  
7 So it's a de-pathologize but maintain a  
8 diagnostic -- diagnostic code. That's my  
9 understanding of it.

10 Again, I wasn't there. But  
11 again, reading the writings of people who  
12 could only have gleaned it from having  
13 been present because it's closed session,  
14 that's my understanding.

15 Q. Understood. All right. Do you  
16 know what the Endo- -- Endocrine Society  
17 guidelines for treatment of  
18 gender-dysphoric or gender-incongruent  
19 persons are?

20 A. Do I know what they are?

21 Q. Yeah.

22 A. Yes.

23 Q. Do you know when they were

1 initially published?

2 A. No.

3 Q. Do you know when they were last  
4 revised?

5 A. I think it was just a couple of  
6 years ago, but I don't know the exact  
7 date.

8 Q. If I tell you it's 2017, does  
9 that sound right?

10 A. That wouldn't -- it wouldn't  
11 surprise me if that were true. I -- just  
12 within the last couple of years. I think  
13 theirs are current, and the expectation  
14 is that these standards of care or  
15 treatment guidelines will have a  
16 five-year revision. So given that  
17 they're current, they couldn't be any  
18 older than, say, 2017. So I suspect that  
19 -- yeah.

20 Q. All right. Did you review the  
21 latest available version of those  
22 Endocrine Society guidelines before  
23 forming your opinions in this case?

1           A.     Yes.    I have read them, yes.

2           Q.     Okay.  You yourself are not part  
3 of the Endocrine Society; right?

4           A.     Correct.

5           Q.     Have never been part of that  
6 society; right?

7           A.     Correct.

8           Q.     You've never advised the  
9 Endocrine Society in any capacity;  
10 correct?

11          A.     Correct.

12          Q.     You personally were not involved  
13 with the development of these original  
14 guidelines; correct?

15          A.     That's correct.

16          Q.     Not personally involved with the  
17 development of the updated guidelines in  
18 2017; right?

19          A.     Correct.

20          Q.     Do you know how many people at  
21 the Endocrine Society were involved with  
22 those 2017 updates?

23          A.     I do not know that number.

1           Q.     And you don't know how they were  
2     selected to work on the 2017 updates;  
3     correct?

4           A.     Correct.

5           Q.     You personally don't know what  
6     kind of scientific literature review the  
7     Endocrine Society conducted in developing  
8     those updates; correct?

9           MR. KNEPPER:   Objection to form.

10          A.     Correct.

11          Q.     You don't know what kind of  
12     outside experts they may have used;  
13     right?

14          A.     What kind of outside experts?   I  
15     would imagine they were all  
16     endocrinologists.   Or are you asking did  
17     they have plastic surgeon input or --

18          Q.     Do you know specifically whether  
19     the Endocrine Society used any outside  
20     experts in updating the -- in  
21     implementing the 2017 updates?

22          A.     Well --

23          MR. KNEPPER:   Objection, form.



1           A.     I can only infer that they  
2     would, because such -- such statements,  
3     in order to be valid, demand review by  
4     outside parties to -- to obviate  
5     conflicts of interest, whether financial  
6     or professional. Those are all issues  
7     when generating standards of care, so of  
8     necessity, they would have had to have  
9     had outside experts to come in, yes.

10          Q.     Okay. Do you know what kind of  
11     public comments the Endocrine Society may  
12     have solicited as part of developing the  
13     2017 updates?

14          A.     I don't.

15                 MR. KNEPPER: Objection to form.

16          Q.     You don't know how many  
17     different drafts there were of those 2017  
18     updates before they were finalized;  
19     right?

20          A.     No.

21                 MR. KNEPPER: Objection to form.

22          A.     No, I don't.

23          Q.     Again, you haven't been to any

1 meetings or conferences or telephonic  
2 conferences where those 2017 updates were  
3 discussed, where the development of those  
4 2017 updates was discussed; correct?

5 MR. KNEPPER: Objection to form.

6 A. Correct.

7 Q. You don't know what went on  
8 during those meetings or conferences;  
9 right?

10 MR. KNEPPER: Objection, form.

11 A. I do not.

12 Q. You -- you're not an expert in  
13 how the Endocrine Society developed the  
14 original 2009 guidelines for treating  
15 gender dysphoria; correct?

16 MR. KNEPPER: Objection to form.

17 A. That's not -- that's not my area  
18 of expertise. That's correct.

19 Q. Right. And you're also not an  
20 expert in how the Endocrine Society then  
21 developed the 2017 updates back to those  
22 guidelines; correct?

23 A. Correct.

1           Q.     Okay. All right. Now let's  
2 talk about puberty-blocking agents. What  
3 puberty blocker drugs are you aware of by  
4 name?

5           A.     Well, Lupron is probably the  
6 most widely used one. They're -- they're  
7 all gonadotropin-releasing hormone  
8 agonists. They come by a variety of  
9 trade names. But gonadotropin-releasing  
10 hormone is the generic -- I'm sorry, the  
11 generic name for the drug that may appear  
12 under a variety of, you know, proprietary  
13 names, Lupron being the most commonly  
14 used.

15          Q.     You've never prescribed Lupron;  
16 right?

17          A.     No, I have never. No.

18          Q.     You have never prescribed any  
19 puberty-blocking drugs of any kind;  
20 right?

21          A.     No. That's not my area of  
22 expertise.

23          Q.     Right. Have you ever looked at

1 the package -- strike that.

2 You know what a package insert  
3 is; right?

4 A. Yes.

5 Q. Have you ever looked at a  
6 package insert for Lupron?

7 A. Some time ago, but yes, I have.

8 Q. Okay. How recently do you  
9 think?

10 A. Gosh, it's probably more than  
11 four or five years ago. I think probably  
12 when I first started go -- you know,  
13 looking into this more carefully back in  
14 2014. It was probably that long ago.

15 Q. Do you know what Vantas is?  
16 V-A-N-T-A-S.

17 A. Oh, I've read that somewhere  
18 before. Let's see. Is it -- it's the  
19 adverse events reporting -- is that what  
20 I -- I don't --

21 Q. It's a type of drug.

22 A. Oh.

23 Q. So no, that doesn't sound

1 familiar?

2 A. It does not sound familiar, no.

3 Q. How about Triptodur?

4 T-R-I-P-T-O-D-U-R.

5 A. That sounds like a trade name

6 I'm not familiar with.

7 Q. Okay. Fensolvil?

8 F-E-N-S-O-L-V-I-L.

9 A. That sounds like a trade name

10 I'm not familiar with.

11 Q. Trelstar? T-R-E-L-S-T-A-R.

12 A. Same.

13 Q. All right. You're not an expert  
14 in the different types of prescription  
15 drugs that are used as puberty-blocking  
16 agents; fair?

17 A. I do not consider myself an  
18 expert in that area, no. I rely on  
19 experts.

20 Q. All right. You know that  
21 puberty blockers are typically prescribed  
22 by endocrinologists; right?

23 A. Yes. Pediatricians and

1       endocrinologists, yes.

2           Q.     Right.  You have no specialized  
3     training or expertise in endocrinology;  
4     correct?

5           A.     Correct.

6           Q.     You don't hold yourself out as  
7     an expert in endocrinology; correct?

8           A.     No, I do not.

9           Q.     You're not planning on offering  
10    any expert opinions in endocrinology in  
11    this case because that's outside your  
12    scope of expertise; right?

13          A.     Yes.

14               MR. KNEPPER:  Objection to form.

15          Q.     All right.  Earlier, you said  
16    you have never prescribed  
17    puberty-blocking agents to anyone, so I  
18    take it you have no experience, no  
19    firsthand experience with advising your  
20    patients about potential risks and  
21    benefits of puberty blockers; right?

22               MR. KNEPPER:  Objection, form.

23          A.     Well, I have talked to patients

1 -- well, families, really, about the  
2 risks of puberty blockers in -- in early  
3 puberty and into adolescence. I have  
4 because I've reviewed the literature and  
5 I've spoken with experts in the area.  
6 And so, is that the question --

7 Q. Yeah.

8 A. -- you're asking, have I spoken  
9 to anybody? Yeah, I have. I -- I have,  
10 again, knowing that -- for example, that  
11 the drug Lupron, as an example, is -- is  
12 -- is not cleared by the FDA for  
13 application. It's an off-label use when  
14 using it in the diagnosed condition of  
15 gender dysphoria. So I know that it's an  
16 off-label application of the drug, and I  
17 know what the effects of the drug are.  
18 But nobody knows what the effects of the  
19 drug are on otherwise normal children,  
20 and that's pretty much all I'd relate to  
21 the families on the -- on that subject.

22 I don't offer myself as an  
23 endocrinologist, but I offer myself as a

1       concerned physician who has spoken with  
2       the specialists and read the package  
3       insert.   Yes.

4           Q.     You think off-label use is  
5       improper; right?   That's the sense I got  
6       from reading your report.

7                   MR. KNEPPER:   Objection, form.

8           A.     Off-label use in certain  
9       situations.   So I use -- I use -- I have  
10      applied drugs' off-label use many times.  
11      But what the -- what the practitioner has  
12      to do is weigh the risk/benefit equation  
13      there and what is the expected goal and  
14      what are the likely risks.

15                   For example, I used Botox long  
16      ago in the treatment of -- of  
17      hyperhidrosis before the company that  
18      produces it got FDA clearance to use it  
19      that way.   The risk, very, very low risk;  
20      the potential benefit, very, very high.  
21      But in this case, we're talking about  
22      very significant risks for an unproven  
23      benefit.   So that's an example of how you



1 have to weigh off-label use.

2 And the FDA understands that,  
3 and they don't go after off-label use  
4 unless there's significant risk. And  
5 even then, they might not yet spring into  
6 action. It's a pretty slow-moving  
7 organization.

8 Q. All right. We'll come back to  
9 that.

10 A. Okay.

11 Q. You never sat in on any  
12 appointment where an endocrinologist  
13 prescribed a puberty-blocking drug to a  
14 patient; correct?

15 A. I have never.

16 MR. KNEPPER: Objection, form.

17 Q. You personally don't know what  
18 endocrinologists typically tell their  
19 patients about risks and benefits of  
20 puberty blockers; right?

21 MR. KNEPPER: Objection, form.

22 A. Only what I have read in the  
23 record. For example, the plaintiffs'

1 records, I -- I -- I believe I have read  
2 that -- that kind of consultation, yeah.  
3 But I -- but I wasn't present in the  
4 room, if that's what your question is.

5 Q. Yeah. You don't know what was  
6 actually communicated to the patient;  
7 correct?

8 A. Only what was entered in the  
9 record, yeah, the medical record.

10 Q. And just as a more -- outside of  
11 these plaintiffs, as a more general  
12 matter, you don't personally know what  
13 endocrinologists tell their patients  
14 about potential risks and benefits of  
15 puberty blockers because you're not  
16 present on those prescribing decisions;  
17 right?

18 MR. KNEPPER: Objection, form.

19 A. Well, if -- I assume that they  
20 follow the same sort of process that  
21 every other medical professional does  
22 when getting consent for -- for therapies  
23 of various kinds. And so to offer

1 informed consent to a -- in this case,  
2 perhaps a family, parents, that informed  
3 consent would have to include -- in order  
4 to be valid, it would have to include the  
5 potential risks that are enumerated in  
6 the package insert. And then they would  
7 also, in certain cases, have to enumerate  
8 risks that may not be in the package  
9 insert but may be expected given the --  
10 the particular case of their child or the  
11 particular patient.

12 So we all have to follow that  
13 same general standard, and so to that  
14 extent, I have some knowledge of what  
15 they would be saying. But the particular  
16 words or the particular things they may  
17 have emphasized, I have no -- no personal  
18 knowledge of.

19 Q. Your general expectation is that  
20 before a doctor prescribes the drugs,  
21 they will at least inform the patients of  
22 the risks as specifically enumerated in  
23 the drug labeling; right?

1           A.     Among other things, yes.

2           Q.     And the doctor may also go  
3     beyond the labeling and advise them of  
4     potential risks even though they're not  
5     specifically disclosed in the drug  
6     labeling; right?

7           A.     Yes.    Because there -- there are  
8     circumstances wherein the underlying  
9     conditions of the patient may -- may  
10    cause particular risks in particular  
11    areas, so that's right.

12                 So there's the general  
13    precautions that are included in the  
14    package insert, but they usually tend to  
15    be exhaustive.    They -- they list in the  
16    package inserts even remote  
17    possibilities, so.    But most physicians  
18    can't drill down into those details with  
19    a patient.    You don't want to overwhelm  
20    the patient and their family with those  
21    minute details.    You want to talk about  
22    the major risks and then the risks that  
23    are peculiar to the patient because of

1       their underlying condition. And that's  
2       generally what everybody does.

3           Q.     Yeah.

4           A.     Although, again, I'm not present  
5       in every office on every occasion, but  
6       that's generally how we're trained to  
7       conduct a consent.

8           Q.     Do you know -- are you aware  
9       that patients who are prescribed  
10      puberty-blocking agents are typically  
11      monitored through blood tests and lab  
12      work?

13                  MR. KNEPPER:  Objection, form.

14          A.     It -- I don't -- I'm not  
15      familiar in all cases to what extent  
16      they're monitored. My hope is that  
17      they're being monitored. I would expect  
18      that they're being monitored.

19          Q.     Yeah. And you don't have  
20      experience with monitoring patients who  
21      undergoing treatment with puberty  
22      blockers; right?

23          A.     No.

1 Q. And you don't have experience  
2 with reviewing blood work, labs, what's  
3 normal, what's not, anything in that  
4 field; right?

5 MR. KNEPPER: Objection to form.

6 A. Oh, no, I am familiar with  
7 reviewing labs and interpreting  
8 laboratory data --

9 Q. Sorry.

10 A. -- as it pertains -- yeah.

11 Q. Sorry. Let me make -- make my  
12 question more specific. I'm still  
13 talking about patients who are treated  
14 with puberty-blocking agents.

15 A. Okay.

16 Q. For those patients in  
17 particular, you don't have experience  
18 with reviewing their blood work, labs to  
19 see -- to check their hormone levels and  
20 see if any adjustments are needed; right?

21 MR. KNEPPER: Objection, form.

22 A. No. I have some familiarity  
23 with the interpretation of hormone levels

1 in endocrinology. As a -- as a general  
2 surgeon and a critical care doctor, these  
3 issues were very important to me for a  
4 number of years. So I'm familiar with  
5 that, although I haven't monitored  
6 patients receiving puberty blockers or  
7 cross-sex hormones per se. So generally,  
8 I am familiar with -- with that and the  
9 ramifications of endocrinopathies, again,  
10 because I had considerable experience  
11 with management of critical care patients  
12 and -- yeah.

13 Q. Yeah. My question is more  
14 specific.

15 A. Okay.

16 Q. You personally have not  
17 monitored blood work from patients who  
18 are undergoing puberty-blocking agents;  
19 right?

20 A. Correct.

21 Q. Okay. And you mentioned  
22 cross-sex hormones. You know what those  
23 are; right?

1           A.     Yes.

2           Q.     For transgender women, estrogen  
3           is a hormone that's typically prescribed;  
4           right?

5           A.     Yes.

6           Q.     For transgender men,  
7           testosterone is the hormone that's  
8           typically prescribed; right?

9           A.     Right.

10          Q.     You've never prescribed  
11          cross-sex hormones for treatment of  
12          gender dysphoria to anyone; correct?

13          A.     Correct.

14          Q.     You have no firsthand experience  
15          with advising your patients about  
16          potential risks and benefits of cross-sex  
17          hormones when used for treatment of  
18          gender dysphoria; correct?

19          A.     Correct.

20          Q.     You personally don't know what  
21          doctors who do prescribe estrogen or  
22          testosterone to their patients for gender  
23          dysphoria tell those patients about the



1 risks and benefits of that treatment;  
2 correct?

3 MR. KNEPPER: Objection, form.

4 A. I would answer that question as  
5 we did earlier, that my expectation would  
6 be that they would cover the -- the risks  
7 and benefits of that -- of that  
8 particular therapy and that the  
9 exploration of potential risks would  
10 include the major points that are  
11 contained in the package insert and  
12 whatever particular risks that the  
13 patient may have because of their  
14 underlying conditions, medical conditions  
15 that may impinge upon them. That would  
16 be my expectation.

17 Q. Okay. So for testosterone and  
18 estrogen when used to treat gender  
19 dysphoria, you would generally expect  
20 doctors to at least give the warning  
21 about -- that's in the labeling and  
22 potentially give additional warnings  
23 outside of that as well; fair?

1 MR. KNEPPER: Objection to form.

2 A. That would be my -- that would  
3 be my expectation.

4 Q. All right. We started talking  
5 about off-label use, so let's circle back  
6 to that. So in your report, you  
7 criticize Dr. Brown and Dr. Schechter for  
8 not disclosing that the FDA has not  
9 approved these hormones for treatment of  
10 gender dysphoria. Do you recall that?

11 A. Yes. My testimony, yes, I do  
12 recall that.

13 Q. All right. Off-label use is  
14 when a doctor prescribes a drug outside  
15 of its FDA-approved indication; correct?

16 A. Correct.

17 Q. And we touched earlier on  
18 whether it's proper or improper to  
19 prescribe drugs on an off-label basis.  
20 There are circumstances where it is  
21 appropriate to prescribe a drug on an  
22 off-label basis; correct?

23 A. Yes.

1           Q.     It's a case-by-case decision;  
2     right?

3                     MR. KNEPPER:   Objection, form.

4           A.     Yes.

5           Q.     It's a case-by-case decision  
6     that's made between the doctor and their  
7     patient; right?

8                     MR. KNEPPER:   Objection, form.

9           A.     Right.

10          Q.     You're not expressing the  
11     opinion that doctors should not be  
12     prescribing drugs on an off-label basis  
13     ever; right?

14          A.     I'm expressing the opinion that  
15     -- that drugs that have massive potential  
16     side effects should not be off-label  
17     prescribed unless those risks warrant --  
18     I mean, those risks are warranted given  
19     the underlying condition of the patient  
20     and that the patient is being treated as  
21     a -- as a -- as a trial or an  
22     experimental patient with ethics  
23     monitoring and all the rest of it that

1 attends.

2 The reason why off-label use is  
3 problematic is because it doesn't have a  
4 body of proven scientific evidence that  
5 the FDA has made use of in order to -- to  
6 warrant the use of the drug. So if  
7 you're going to go off label, again, the  
8 risks have to be low. If the condition  
9 you're treating makes -- makes the risks  
10 high, then that's where you have to get  
11 into ethics panels and experimental  
12 trials and things like that. I think  
13 that's at the heart of this issue.

14 We're dealing with a condition  
15 where the application of these drugs is  
16 not proven and the risks are very high,  
17 and that's where my concern lay.

18 Q. Do you think that off-label use  
19 of prescription drugs is, by definition,  
20 investigational?

21 A. To the extent that very often  
22 the -- the use of -- the off-label use of  
23 drugs begins on the basis of anecdotal

1 reports. So anecdotal reports, again,  
2 are categorized as level 5 evidence. And  
3 -- and so when those reports are  
4 published and -- and the risks are seen  
5 as low, then other physicians may begin  
6 the off-label use of those drugs.

7 But generally, one wants to  
8 progress to a more definitive scientific  
9 evidence, like level 4 evidence where  
10 there's a pre-application test, the use  
11 of the drug, and a post-application test,  
12 or level 3 where you're looking at  
13 longitudinal data to confirm not only the  
14 safety but the efficacy of the  
15 application of the drug.

16 In the case of the use of  
17 puberty blockade and cross-sex hormones,  
18 it doesn't exist beyond level 5 evidence  
19 even though the treatment has now been  
20 going on off-label for more than a  
21 decade, if not approaching twenty years.

22 Q. All right. You mentioned  
23 doctors are prescribing on an off-label

1 basis after there's case reports. It  
2 does happen that doctors prescribe drugs  
3 on an off-label basis based on nothing  
4 more than case reports; right?

5 A. That's how it always begins,  
6 yeah.

7 Q. Yeah. The FDA doesn't say  
8 that's not permissible, do they?

9 A. No, they don't.

10 Q. Okay.

11 A. I don't know. I don't know what  
12 the FDA -- if there's a published policy  
13 about that. I would suspect not, given  
14 the history in my lifetime of people  
15 off-label using, for example, asthma  
16 medications for the treatment of breast  
17 implant encapsulation, that kind of  
18 stuff. That's an example of a very  
19 benign drug being used off-label to treat  
20 a surgical condition of breast implant  
21 encapsulation. So that's my personal  
22 experience. I suspect there isn't an FDA  
23 policy that utterly prohibits it. I

1 would agree, yeah.

2 Q. Okay. The FDA is the federal  
3 agency that regulates prescription drugs;  
4 correct?

5 A. Food and drugs, yes.

6 Q. And they decide whether a  
7 particular drug can be marketed for a  
8 particular indication; correct?

9 A. Right.

10 MR. KNEPPER: Form.

11 Q. And one of the areas of  
12 oversight the FDA has is the safety of  
13 prescription drugs; right?

14 A. Right.

15 Q. Before forming your opinions in  
16 this case, did you investigate what  
17 position the FDA takes on off-label use  
18 of drugs?

19 A. No, I did not.

20 Q. Sitting here today, do you know  
21 what that position is?

22 A. I do not, no.

23 Q. Do you know whether the expert

1       opinions you're expressing about  
2       off-label use of drugs are consistent or  
3       inconsistent with what the -- what the  
4       FDA has said about off-label use?

5               MR. KNEPPER:  Objection, form.

6               A.     I remember when the controversy  
7       about the use of Singulair in breast  
8       implant capsules came up.  That was  
9       discussed at an ASPS meeting and then  
10      some articles that came out.  And I think  
11      I recall from those -- either the  
12      conference or the article that the FDA  
13      takes a permissive attitude where risk is  
14      low.

15              Q.     You think the FDA only allows  
16      off-label use of prescription drugs when  
17      the risk is low?

18              A.     I don't know that for a fact.

19              Q.     All right.

20              A.     I would -- I would hope.  I  
21      would hope low risk/high benefit.  So --  
22      so again, it's an equation, it's not just  
23      a one-sided thing.  So it isn't just the



1 risk but also the potential benefits.  
2 And the potential benefits have to be  
3 very high. The higher the risk is, the  
4 higher the benefit has to be. And that's  
5 kind of a general principle of the  
6 medical care. You know, before all else,  
7 do no harm. That's what informs all  
8 medical care, and I would hope that's  
9 what informs the FDA policy, whatever  
10 that may be.

11 Q. Okay. Well, let's look at the  
12 policy.

13 A. Okay.

14 Q. I'm going to introduce another  
15 exhibit. Okay. This is going to be  
16 Exhibit 11. Let me know when you have  
17 it.

18 (Exhibit 11 was marked for identification  
19 and is attached.)

20 A. Okay.

21 Q. Have you ever seen this document  
22 before?

23 A. I have not.

1           Q.     Do you know what the Federal  
2 Register is?

3           A.     It's a -- it's a federal list of  
4 regulations pertaining to things like  
5 this.

6           Q.     Yeah. It's the  
7 official publication --

8           A.     Federal code.

9           Q.     -- of federal rules, proposed  
10 rules, and notices for federal agencies;  
11 right?

12          A.     Yeah. Right.

13          Q.     I see this is dated at the top  
14 November 18, 1994. See that?

15          A.     Yes.

16          Q.     Page 1, middle column, see it  
17 says, "Agency: Food and Drug  
18 Administration, HHS"?

19          A.     Let's see. "Agency: Food and  
20 Drug Administration, HHS." Yes.

21          Q.     It says, "Action." It says,  
22 "Notice; request for comments." Do you  
23 see that?

1           A.     Yes.

2           Q.     All right.  Go to page 2.

3           A.     Okay.

4           Q.     In the column all the way to the  
5 right, you see there's a section II, and  
6 it's titled, "FDA Policy on Promotion of  
7 Unapproved Uses."  Do you see that?

8           A.     I do.

9           Q.     All right.  The first paragraph  
10 says, "Over a decade ago, the FDA Drug  
11 Bulletin informed the medical community  
12 that 'once a [drug] product had been  
13 approved for marketing, a physician may  
14 prescribe it for uses or in treatment  
15 regimens of patient populations that are  
16 not included in approved labeling.'"  Do  
17 you see that?

18          A.     I do.

19          Q.     What do you understand that to  
20 mean?

21          A.     That --

22                   MR. KNEPPER:  Objection.

23          A.     I apply that to mean that --

1       that the -- that the FDA does not -- does  
2       not intend to weigh in on off-label use,  
3       you know, without restriction, I guess.  
4       The sense I get of it is that they're --  
5       they're declining to prohibit the  
6       off-label use in -- in other patients at  
7       this time, I would -- I would guess. I  
8       suppose that if they started to see  
9       complications, they might weigh in. This  
10      has been the history, for example, with  
11      nausea medicines and things like that  
12      that created problems after use.

13       Q.     At that time at least, the FDA  
14      was telling the medical community that  
15      doctors may prescribe drugs for uses  
16      outside of FDA-approved indications;  
17      correct?

18       A.     Yes. I would say that --

19              MR. KNEPPER: Objection, form.

20       A.     -- in 1994, the FDA declined to  
21      -- to -- I don't know what they've done  
22      subsequently. I -- but -- but in 1994,  
23      they -- they -- off-label use was not

1 prohibited.

2 Q. Well, actually --

3 A. They finally --

4 Q. Sorry, finish.

5 A. No, go ahead.

6 Q. Well, you see this actually  
7 says, "The publication further stated,"  
8 and then there's a quote. And after the  
9 quote, there's a Footnote 4.

10 Before we get to that, do you  
11 see it says -- it cites to the FDA Drug  
12 Bulletin from 1982.

13 A. Right.

14 Q. Right?

15 A. Right.

16 Q. So that original guidance came  
17 from a 1982 FDA position; right?

18 A. Right.

19 MR. KNEPPER: Objection, form.

20 Q. And you say that you read this  
21 and you don't think that the FDA has  
22 taken a position, but let's see what else  
23 that quote says. You see the quoted

1 language starting with "The publication  
2 further stated"? Do you see that?

3 A. That starts with the word  
4 "unapproved"?

5 Q. Yeah. It says, "'unapproved'  
6 or, more precisely, 'unlabeled' uses may  
7 be appropriate and rational in certain  
8 circumstances, and may, in fact reflect  
9 approaches to drug therapy that have been  
10 extensively reported in medical  
11 literature." Do you see that?

12 A. I do.

13 Q. You understand what that means;  
14 right?

15 MR. KNEPPER: Objection to form.

16 A. Yes. Yes.

17 Q. Off-label use -- strike that.

18 The FDA has recognized as early  
19 as 1982 that off-label use may be based  
20 on medical literature, not published  
21 indications; right?

22 A. Right.

23 Q. And then it says, "Valid new

1       uses for drugs already on the market are  
2       often first discovered through  
3       serendipitous observations and  
4       therapeutic innovations, subsequently  
5       confirmed by well-planned and executed  
6       clinical investigations." Right?

7           A.     Yeah. That's -- that's kind of  
8       a -- just a restating of what I related  
9       to you about, for example, the use of  
10      Botox and hyperhidrosis, as I have done.  
11      Yeah, I would totally agree with that.

12          Q.     And then it says, "The agency  
13      and its representatives have restated  
14      this policy on numerous occasions." Do  
15      you see that?

16          A.     I do.

17          Q.     Do you understand that for  
18      decades, for three decades at least, the  
19      FDA has taken the position that  
20      physicians are allowed to prescribe drugs  
21      on an off-label basis?

22                  MR. KNEPPER: Objection, form.

23          A.     Yes.

1           Q.     Your report doesn't acknowledge  
2     this longstanding position from the FDA,  
3     does it?

4           A.     My report does not -- no, it  
5     does not.

6           Q.     And I mean, I know I just heard  
7     you say, well, maybe this is from the  
8     '80s. Let me show you what the FDA says  
9     today.

10          A.     Okay.

11          Q.     I'm going to introduce another  
12     exhibit. This is Exhibit 12. Let me  
13     know when you get it.  
14     (Exhibit 12 was marked for identification  
15     and is attached.)

16          A.     Okay. All right. I've got it.

17          Q.     All right. You see that this is  
18     a printout from fda.gov, the official  
19     website of the FDA; right?

20          A.     Right.

21          Q.     The title is "Understanding  
22     Unapproved Use of Approved Drugs 'Off  
23     Label.'" Right?



1           A.     Right.

2           Q.     Go to page 2.

3           A.     Okay.

4           Q.     Toward the bottom, it says in  
5     bold, "Why might an approved drug be used  
6     for an unapproved use?" Do you see that?

7           A.     I do.

8           Q.     Then it says, "From the FDA  
9     perspective, once the FDA approves a  
10    drug, healthcare providers generally may  
11    prescribe the drug for an unapproved use  
12    when they judge that it is medically  
13    appropriate for their patient." Do you  
14    see that?

15          A.     I do.

16          Q.     And then skipping one sentence,  
17    it says, "One reason is that there"  
18    may -- "might not be an approved drug to  
19    treat your disease or medical condition."  
20    Right?

21          A.     Right.

22          Q.     So the FDA -- the position that  
23    the FDA takes is off-label use may be

1 medically appropriate for patients;  
2 right?

3 A. Right.

4 Q. That's a position they've taken  
5 for thirty years plus; right?

6 A. Right.

7 MR. KNEPPER: Objection, form.

8 Q. All right. And we talked  
9 earlier about, you know, is off-label use  
10 experimental or investigational. Before  
11 forming those opinions, did you look to  
12 see what the FDA says on that point?

13 A. How the FDA classifies  
14 experimental or investigational?

15 Q. Do you know what position the  
16 FDA takes on whether off-label use is  
17 considered investigational?

18 A. I don't know what their official  
19 position is, no.

20 Q. All right. Let's look at that.  
21 All right. This is going to be Exhibit  
22 13. Let me know when you have it.

23 (Exhibit 13 was marked for identification

1 and is attached.)

2 A. I have it.

3 Q. This is a guidance document from  
4 the FDA from 1998. Generally, are you  
5 aware that the FDA issues guidance  
6 documents?

7 A. Generally, yes, I am aware.

8 Q. Have you ever seen an FDA  
9 guidance document before today?

10 A. I've heard them referred to, but  
11 I've never read one, no.

12 Q. Okay. All right. Well, this  
13 one's titled "'Off-Label' and  
14 Investigational Use of Marketed Drugs,  
15 Biologics, and Medical Devices." You see  
16 that?

17 A. I do.

18 Q. Okay. All right. The first  
19 paragraph, second sentence says, "If  
20 physicians use a product for an  
21 indication not in the approved labeling,  
22 they have the responsibility to be well  
23 informed about the product, to base its

1 use on firm scientific rationale and on  
2 sound medical evidence, and to maintain  
3 records of the product's use and  
4 effects." You see that?

5 A. I do.

6 Q. All right. The next sentence  
7 says, "Use of a marketed product in this  
8 manner when the intent is the 'practice  
9 of medicine' does not require the  
10 submission of an Investigational New Drug  
11 Application, Investigational Device  
12 Exemption or review by an Institutional  
13 Review Board." Do you see that?

14 A. I do.

15 Q. I understand that what this is  
16 saying, according to the FDA, when a  
17 doctor prescribes a drug on an off-label  
18 basis, that is not necessarily an  
19 investigational use of that drug; right?

20 MR. KNEPPER: Objection, form.

21 A. I would disagree, because as it  
22 says there, when they're -- when they're  
23 prescribing in that manner, they have a

1       responsibility not only to be informed  
2       about the product but to do the  
3       recordkeeping of its effects, which is  
4       really the initial phase of  
5       investigation. So in a sense, they are  
6       -- they are part of the investigative  
7       process now because a new application of  
8       the medication has been proposed, and  
9       safety and efficacy have -- have to be  
10      documented in some measure.

11               So the FDA is giving you room to  
12      broaden the application of the drug, but  
13      they're also placing upon you the burden  
14      of documenting so that its effects and  
15      benefits can be characterized because  
16      that's being -- obviously, it's being  
17      investigated. That's the point of their  
18      wanting the recordkeeping, so --

19           Q.     Do you know what the  
20      Institutional Review Board is?

21           A.     Yes.

22           Q.     Clinical trials have to be  
23      cleared by IR- -- IRBs; right?

1           A.     Right.

2           Q.     And this says you don't actually  
3     have to apply for approval by an IRB when  
4     you're prescribing a drug on an off-label  
5     basis; right?

6                     MR. KNEPPER:   Objection, form.

7           A.     It says that it's not of  
8     necessity, so they're not making a  
9     blanket requirement.   I would imagine  
10    that that might be modified in particular  
11    cases.

12          Q.     Yeah.   Because this is saying  
13    that when you're prescribing a drug on an  
14    off-label basis, that doesn't mean you're  
15    starting up a clinical trial; right?

16          A.     It doesn't necessarily mean  
17    you're starting a clinical trial, that's  
18    right.   It doesn't exclude the necessity  
19    for a clinical trial.   It just says  
20    you're not necessarily starting a  
21    clinical trial.

22          Q.     Yeah.   And when this says --  
23    when it says doctors should maintain

1 records of the product's use and effects,  
2 it's not telling them that they're  
3 enrolling their patients in a clinical  
4 trial by starting -- by prescribing a  
5 drug on an off-label basis; right?

6 MR. KNEPPER: Objection, form.

7 A. Right. But what it -- what it  
8 probably is inferring is that if they  
9 start seeing complications, then the  
10 further application of the drug in that  
11 circumstance might be required -- might  
12 require an IRB. So yeah. So it's --  
13 what they're saying is it doesn't require  
14 an IRB of necessity. It does require  
15 recordkeeping. And I would expect that  
16 if they were to see complications,  
17 problems, lack of efficacy, that -- and  
18 the desire for its continued use might  
19 require an IRB. In fact, I would -- I  
20 would hope it would require an IRB.  
21 Yeah.

22 Q. Yeah. A clinical trial down the  
23 line is a "this might be nice to have,"

1 but it's not a requirement for a doctor  
2 to prescribe a drug on an off-label use  
3 basis. That's what this says; right?

4 MR. KNEPPER: Objection, form.

5 A. That's what that says, yeah.

6 Q. Yeah. You don't cite this  
7 guidance in your report obviously; right?

8 A. I don't think it's --

9 MR. KNEPPER: Objection, form.

10 A. I don't think it's germane to my  
11 report. No.

12 Q. All right. You've also offered  
13 opinions on whether it's proper to  
14 prescribe drugs on an off-label basis to  
15 children and adolescents; right?

16 A. I've only offered it in the case  
17 of this particular therapy. I haven't  
18 offered it generally, only in the case of  
19 puberty blockade and cross-sex hormones  
20 for the purposes of transitioning a child  
21 to the appearance of the other sex.  
22 That's all I've offered it as an opinion.

23 Q. All right. Do you know what the



1 American Pediatrics Association is?

2 A. Yes.

3 Q. Before forming your opinions,  
4 did you look to see what the APA says  
5 about off-label use of drugs in children  
6 and adolescents?

7 A. No.

8 Q. Sitting here today, you don't  
9 know the APA's position on this -- on  
10 this topic; correct?

11 MR. KNEPPER: Objection, form.

12 A. Correct.

13 Q. Let's look at that next. Okay.  
14 This is going to be Exhibit 14, and let  
15 me know when you have it.  
16 (Exhibit 14 was marked for identification  
17 and is attached.)

18 A. Okay. I have it.

19 Q. You understand this is a policy  
20 statement from the APA?

21 A. I'm reading it now. I see that  
22 it is a policy statement from the  
23 American Academy of Pediatrics.

1           Q.     It's a policy statement  
2     entitled, "Off-Label Use of Drugs in  
3     Children."    Right?

4           A.     Yes.    Yes.

5           Q.     Look at the introduction section  
6     toward the bottom of the page.

7           A.     Okay.

8           Q.     It says that, "The purpose of  
9     this statement is to further define and  
10    discuss the status of off-label use of  
11    medic- -- medications in children."   And  
12    then it talks about a publication of a  
13    2002 statement.   You see that?

14          A.     Yes.

15          Q.     All right.   So the FDA -- APA  
16    has taken a position on off-label use of  
17    drugs in children since at least 2002;  
18    right?

19                 MR. KNEPPER:   Objection, form.

20          A.     I'm reading it now.   It appears  
21    to be that, yeah.

22          Q.     All right.   Look at the abstract  
23    towards the top.

1           A.     Okay.

2           Q.     Second sentence says, "However,  
3     off-label drug use remains an important  
4     public health issue for infants,"  
5     childrens, and" -- "children, and  
6     adolescents, because an overwhelming  
7     number of drugs still have no information  
8     in the labeling for use in pediatrics."  
9     Do you see that?

10          A.     I do.

11          Q.     Okay. And then it says, "The  
12     purpose of off-label use is to benefit  
13     the individual patient." Right?

14          A.     Yes.

15          Q.     And then it says, "Practitioners  
16     use their professional judgment to  
17     determine these uses." Correct?

18          A.     Yes.

19          Q.     And then it says, "As such, the  
20     term 'off-label' does not imply an  
21     improper, illegal, contraindicated, or  
22     investigational use." Right?

23          A.     That's what it says there, yes.

1           Q.     Yeah.   The APA also takes the  
2           position that off-label use does not  
3           imply investigational use; correct?

4                   MR. KNEPPER:   Objection to form.

5           A.     It does not de facto imply  
6           off-label use, that's right, yeah.   It  
7           does not imply, right.

8           Q.     And it does not imply that  
9           off-label use is de facto improper or  
10          illegal or contraindicated; right?

11          A.     Right.

12                  MR. KNEPPER:   Objection, form.

13          Q.     All right.   Go to page 2.

14          A.     Okay.

15          Q.     Look at the left column, the  
16          very bottom paragraph.

17          A.     Okay.

18          Q.     It says:   "The absence of  
19          labeling for a specific age group or for  
20          a specific disorder does not necessarily  
21          mean that the drug's use is improper for  
22          that age or disorder.   Rather, it only  
23          means that the evidence required by law

1 to allow inclusion in the label has not  
2 been approved by the FDA. Additionally,  
3 in no way does a lack of labeling signify  
4 that therapy is unsupported by clinical  
5 experience or data in children."

6 Do you see that?

7 A. I do.

8 Q. This is the APA recognizing that  
9 even in the absence of FDA approval for a  
10 particular indication, that use may still  
11 be supported by clinical experience and  
12 data; right?

13 MR. KNEPPER: Objection, form.

14 A. Yeah. I would -- I would say  
15 also that the APA recognizes that -- that  
16 there's a poverty of evidence. The  
17 poverty of evidence is one of the  
18 characteristics of off-label use. And  
19 that's -- that's what the nature of my  
20 expert opinion was about, that the  
21 poverty of evidence is what makes the  
22 off-label use an issue, and in this case,  
23 poverty of evidence for off-label use in

1 a situation where the harms -- potential  
2 harms are great. That's what the concern  
3 was, not -- obviously, I use -- I've  
4 off-label used drugs in my own practice,  
5 as I said before.

6 I don't have an objection  
7 without qualification that -- that the  
8 off-label use of drugs is somehow a  
9 crime. I'm saying that in this  
10 particular instance of this particular  
11 application, that the off-label use tells  
12 us that there's a poverty of scientific  
13 evidence to support its application that  
14 way. Clearly, there's anecdotal reports;  
15 otherwise, doctors wouldn't be using it.  
16 But there's a poverty of evidence, and  
17 what we're dealing with here is not a  
18 potential trivial complication but  
19 potentially permanently life-altering  
20 complications.

21 That was the issue that I was  
22 addressing in my concern about the  
23 off-label use, that there's a standard

1 of -- of caution that's required when you  
2 go off-label. And that caution isn't  
3 being demonstrated by the -- for the  
4 persons who are prescribing or applying  
5 these drugs in this way. That was my  
6 concern.

7 Q. All right. You think that  
8 before these drugs are to be prescribed,  
9 they should first be supported by results  
10 from clinical trials; right?

11 MR. KNEPPER: Objection, form.

12 A. That's the beginning.

13 Q. That's the beginning.

14 A. Yeah.

15 Q. The absolute minimum to  
16 prescribe these drugs; right?

17 MR. KNEPPER: Objection, form.

18 A. Well, no. No, I -- I didn't say  
19 that. As I said, it begins with  
20 anecdotal evidence, not clinical trials.  
21 So somebody somewhere sees an effect. As  
22 it said in that FDA document, it's  
23 oftentimes serendipitous. A clinician

1 will see an effect, and then -- and then  
2 they'll, based on that, they'll hopefully  
3 check out the potential risks to the  
4 patient and then begin that off-label  
5 use.

6 So it begins actually with  
7 anecdotal reports, maybe case  
8 collections, maybe a number of providers'  
9 case collections, maybe it's a -- it's  
10 a -- it's an institutional experience.  
11 But that leads to clinical trials and the  
12 IRB and all the rest of it. So that's  
13 just the beginning of it.

14 Q. It may be appropriate for a  
15 doctor to prescribe a drug on an  
16 off-label basis without having the  
17 results from a clinical trial; correct?

18 A. Yeah, I would -- I would hope  
19 that after thirty years of doing this,  
20 that we would beyond -- be beyond  
21 institutional or personal experience,  
22 that those trials would have already been  
23 done. This isn't -- we're not just at



1 the beginning of puberty blockade and  
2 cross-sex hormones. We're well into this  
3 now, to the point where the European  
4 literature is now vehemently rejecting  
5 that.

6 That's -- these things have  
7 changed. In the last three years, it's  
8 all changed. With respect to this  
9 off-label application of puberty blockade  
10 and cross-sex hormones, it's changed  
11 utterly. So these general statements  
12 about off-label use are important to  
13 understand, certainly, when you see a  
14 serendipitous result and you consider  
15 applying the drug. But we are so far  
16 beyond that at this point in the history  
17 of transgender therapy, this is where  
18 we're concerned. We're concerned with  
19 the continued off-label use, the  
20 continued absence of clinical trials. We  
21 should have been beyond that years ago.  
22 And this is what the European literature  
23 is now showing us, that the application

1 of those drugs by -- which is approved by  
2 the APA, is now being rejected by the  
3 medical services in Great Britain, in  
4 Sweden, in Finland, in Holland. And this  
5 is where we as American providers have to  
6 get.

7 Q. All right. We'll -- we'll  
8 definitely come back to those --

9 A. Okay.

10 Q. -- studies. I promise.

11 A. Okay.

12 Q. Let's finish this document  
13 first, though. All right. Go to page 3.  
14 All right.

15 A. Okay.

16 Q. Look at the left column.

17 A. Okay.

18 Q. It says: "Therapeutic  
19 decision-making should always be guided  
20 by the best available evidence and the  
21 importance of the benefit for the  
22 individual patient. Practitioners are in  
23 agreement regarding the importance of

1 practicing evidence-based medicine.  
2 However, for the pediatric population,  
3 gold standard clinical trials are often  
4 not available, so practitioners must rely  
5 on either less definitive information,  
6 such as expert opinion for the age group  
7 that they are treating, or use evidence  
8 from a different population to guide  
9 practice."

10 You see that?

11 A. I do. And I would agree with  
12 that, that particularly in pediatric  
13 patients, the clinical trial approach  
14 oftentimes is -- is not available because  
15 of the nature of the condition and so on.  
16 But in the -- in this case, there's a --  
17 it's not an all or none, it's got to be  
18 clinical trials or -- or nothing.

19 There's longitudinal  
20 population-based studies, long-term  
21 results seen in a population that has  
22 matured through this therapy, and looking  
23 at, you know, cohort studies

1       longitudinally, cohort study, which is --  
2       which is an alternative when -- when the  
3       clinical trial is not available to you  
4       for ethical reasons. Like you wouldn't  
5       do sham surgery on somebody. That would  
6       be ethically untenable. But you can look  
7       at population-based studies where you  
8       have a cohort to compare. And that's --  
9       that's where we should be. That's where  
10      the European literature is now.

11               So I would agree with that  
12      statement that -- that the APA is making  
13      there, but I would qualify it by saying  
14      that there's an alternative available  
15      that brings you to a higher level of  
16      evidence that may in fact bring it to  
17      on-label use if they were to bother to do  
18      it.

19           Q.     The APA recognizes that for the  
20      pediatric population in particular,  
21      results from clinical trials are often  
22      not available; right?

23           A.     Right.

1           Q.     And the answer in those  
2           situations is not to stop prescribing  
3           these drugs altogether; right?

4                     MR. KNEPPER:   Objection, form.

5           A.     Yeah.   The "altogether" would be  
6           the qualifier there because there are  
7           some circumstances where it would be -- I  
8           mean, it wouldn't be good to stop its  
9           prescription, but there would be others  
10          that you would have to examine more  
11          carefully because of the risk issue.

12          Q.     Yeah.   Instead, what the APA  
13          says is that when clinical trial results  
14          are not available, doctors have to rely  
15          on less definitive -- definitive  
16          information; right?

17          A.     That's what -- that's all you  
18          have.   That's right.

19          Q.     Yeah.   The APA says it may be  
20          appropriate for doctors to prescribe  
21          drugs to pediatric patients on an  
22          off-label basis even when that use is not  
23          supported by randomized clinical trials;

1 correct?

2 A. Right.

3 Q. Because the reality is that for  
4 a lot of conditions, in the pediatric  
5 population, there are no randomized  
6 clinical trial results available; right?

7 MR. KNEPPER: Objection, form.

8 A. Again, so you're holding out  
9 randomized clinical trial, or they're  
10 holding out randomized clinical trial as  
11 the only alternative to the lowest form  
12 of evidence. And I -- I agree that  
13 randomized clinical trial are not always  
14 available, and we have to have recourse  
15 to perhaps lesser but nonetheless more  
16 convincing forms of evidence to fall back  
17 on rather than falling back to the lowest  
18 form of evidence as is the case today  
19 with the application of these drugs.

20 Q. All right. Look at the last  
21 paragraph in the left column of this  
22 page.

23 A. Okay.

1           Q.     It says: "In most situations,  
2     off-label use of medications is neither  
3     experimentation nor research. The  
4     administration of an approved drug for a  
5     use that is not approved by the FDA is  
6     not considered research and does not  
7     warrant special consent or review if it  
8     is deemed to be in the individual  
9     patient's best interest." Do you see  
10    that?

11           A.     I do.

12           Q.     If the physician deems an  
13     off-label use to be in the individual  
14     patient's best interest, that's not  
15     experimental use, according to the APA;  
16     right?

17                   MR. KNEPPER: Object to the  
18     form.

19           A.     Well, according to the --  
20     according to the APA, in most situations.

21           Q.     Yeah.

22           A.     So in that statement, it  
23     acknowledges that there are some

1 situations where that would be  
2 considered. That's the implication in  
3 that statement. So "most" is the  
4 qualifier, implying that there are  
5 situations where it would be considered  
6 experimental.

7 Q. Okay.

8 A. And that's what we propose in  
9 our expert testimony, is that this is one  
10 of those situations. This is  
11 experimental use.

12 MR. TISHYEVICH: Now let's go  
13 off the record.

14 THE VIDEOGRAPHER: This is the  
15 end of Media Unit No. 3. We are off the  
16 record at 12:30 p.m.

17 (Break taken.)

18 THE VIDEOGRAPHER: This is the  
19 start of Media Unit No. 4. We are on the  
20 record at 1:21 p.m.

21 Q. (By Mr. Tishyevich) All right,  
22 Doctor. You know you're still under  
23 oath; right?



1           A.     Yes.

2           Q.     Before lunch, we were talking  
3     about off-label use of prescription  
4     drugs. Do you know how common or  
5     uncommon off-label use of prescription  
6     drugs is in the overall population?

7           A.     I'm not familiar with that  
8     number, no.

9           Q.     All right. You don't know if  
10    it's 5 percent or 10 percent or 50  
11    percent of all drugs are prescribed off  
12    label; right?

13          A.     I have no idea.

14          Q.     How about pediatrics  
15    specifically? Do you know how common or  
16    uncommon off-label use is in the  
17    pediatric population?

18          A.     I do not.

19          Q.     Let me introduce an exhibit.

20                 MR. KNEPPER: One second.

21                 Dr. Lappert?

22                 THE WITNESS: Yes.

23                 MR. KNEPPER: Your camera has

1 moved accidentally, yeah.

2 THE WITNESS: It just allows me  
3 to look at the bottom of the other screen  
4 here so I can look at the exhibits.

5 MR. KNEPPER: Okay. I think  
6 just for the video recording, we want to  
7 make sure that the camera stays on your  
8 face.

9 THE WITNESS: I'll go like this,  
10 then.

11 MR. KNEPPER: Perfect.

12 Q. (By Mr. Tishyevich) So this is  
13 going to be Exhibit 15. Let me know when  
14 you have it.

15 (Exhibit 15 was marked for identification  
16 and is attached.)

17 A. All right. I have it.

18 Q. All right. This is a study from  
19 2019 by Dr. Yackey, Y-A-C-K-E-Y, titled  
20 "Off-label Medication Prescribing  
21 Patterns in Pediatrics: An Update." Do  
22 you see that?

23 A. I do.

1           Q.     All right.   And the objective is  
2     "To describe the frequency of off-label  
3     drug use in 2014 as defined by the  
4     FDA-approved age ranges in patients 18 or  
5     under 18 years of age."   Do you see that?

6           A.     I do.

7           Q.     All right.   Look at "Methods."  
8     Do you see that section?

9           A.     I do.

10          Q.     It says, "This is a  
11     retrospective cohort study of an  
12     administrative database containing  
13     inpatient resource use data from January  
14     1, 2014, to December 31, 2014."   And do  
15     you see that?

16          A.     I do.

17          Q.     Look at the "Results" section.

18          A.     Okay.

19          Q.     The first sentence says, "At  
20     least 1 drug was prescribed off-label in  
21     779,270 of 2,773,770 (28.1%) patient  
22     visits during the study period."   Do you  
23     see that?

1           A.     I do.

2           Q.     And skipping a sentence, then it  
3           says: "Off-label usage of certain  
4           medications differed between care  
5           settings. Rates of off-label medication  
6           use were higher in observational (45.5%),  
7           inpatient (53.9%), and ambulatory (54.2%)  
8           settings." Do you see that?

9           A.     I do.

10          Q.     All right. The study concluded  
11          after reviewing 2.7 patient visits that  
12          overall, 28.1 percent of patients were  
13          prescribed an off-label -- prescribed a  
14          drug on an off-label basis; right?

15          A.     Right.

16          Q.     And depending on the setting,  
17          off-label prescriptions in the pediatrics  
18          context can be as high as 45 to 54  
19          percent; right?

20          A.     That's what the study shows.

21          Q.     All right. The reality is that  
22          prescribing drugs to children and  
23          adolescents on an off-label basis is a

1       fairly common practice; right?

2               MR. KNEPPER:  Objection to form.

3           A.     It appears to be, yes.

4           Q.     You did not know this before you  
5       formed your expert opinions?

6           A.     I knew that it was more common  
7       in children than in adults, and I knew  
8       that it was, you know, fairly common,  
9       having -- having prescribed off-label  
10      myself to children, that it's -- it's  
11      probably fairly common.  I didn't know  
12      the exact numbers, though, until now.

13          Q.     Okay.

14          A.     Again, my -- my expert opinion  
15      about this is not about does it happen.  
16      It's about the particular case of the  
17      transgendered person receiving an  
18      off-label use of a -- of a fairly  
19      problematic drug in light of the recently  
20      changing evidence about its efficacy.  So  
21      the issue of off-label use that I  
22      presented was not about are drugs  
23      prescribed off-label.  The issue was

1       these particular drugs in these  
2       particular patients off-label in light of  
3       the recent change in the world literature  
4       about the risk/benefits of doing those  
5       things. And the evidence now is that  
6       that whole position about puberty  
7       blockade and cross-sex hormones, it's  
8       falling apart in the last three years,  
9       and there's a -- there's a growing wave  
10      of evidence that says do not do this.  
11      And in fact, that's where the Court  
12      stepped in in Great Britain, and it's  
13      where the Karolinska Institute stepped  
14      in.

15               It's not that it's off-label  
16      use. It's that it's particularly  
17      problematic in the case of these drugs in  
18      these suffering patients. That's what my  
19      expert opinion was about. It was not  
20      about drug policy. It was about these  
21      patients, these problems, these drugs.  
22      And the fact is that when you off-label  
23      use, the responsibility falls much more

1 heavily on the provider. When the FDA  
2 approves it, the responsibility falls to  
3 the shoulders of the approving authority.  
4 But if you're going off-label, it's on  
5 you as the provider to be certain that  
6 you're doing good to the patient. And up  
7 until the last three years, the evidence  
8 wasn't there. Now it's there. The  
9 continued use of the drugs in this way  
10 has become very problematic, and that's  
11 -- that's what my expert opinion was  
12 about, not about drug policy, but about  
13 these drugs, these patients.

14 Q. Doctor, there's actually no  
15 question pending, so I'm going to ask  
16 that you stick with listening to my  
17 questions and then answering them instead  
18 of making speeches. Okay?

19 All right. You -- we talked  
20 earlier about the Botox injections that  
21 you've done; right?

22 A. Yes.

23 Q. You told me you've been doing

1       Botox injections in the forehead for over  
2       ten years; right?

3           A.     Correct.

4           Q.     You've told me that you've been  
5       doing Botox injections for crow's feet  
6       for over ten years; right?

7           A.     Yes.

8           Q.     Do you know when the FDA first  
9       approved Botox for the use of treating  
10      forehead wrinkles?

11          A.     Let's see. I recall that it was  
12      when I was the chief of plastics at  
13      Portsmouth, Virginia, because we had been  
14      using it for dystonias and things like  
15      that in children. And it got approved  
16      for cosmetic use I'm going to say before  
17      we moved to the new hospital, so it had  
18      to have been around ninety- -- I want to  
19      say '97, somewhere in there. I'm just  
20      ballparking it here.

21          Q.     So when you were using Botox to  
22      do forehead injections, you think that  
23      was an on-label FDA approved use for the



1 last ten years; right?

2 A. Yeah. When used in the  
3 corrugator and procerus muscles, that's  
4 the on-label use for cosmetic botulinum  
5 toxin.

6 Q. Let me introduce another  
7 exhibit. All right. This is going to be  
8 Exhibit 16, and let me know when you have  
9 it.

10 (Exhibit 16 was marked for identification  
11 and is attached.)

12 A. All right. I have it.

13 Q. Top right corner, you see it  
14 says, "Food and Drug Administration"?

15 A. Yes.

16 Q. Below that, do you see it says,  
17 "Supplement Approval"?

18 A. Yes.

19 Q. You know what this is?

20 A. It looks to be a -- a letter  
21 from the FDA to the Allergan corporation,  
22 to a particular Ph.D. there who is the  
23 director of regulatory affairs. And it's

1 a supplemental -- I guess it's an  
2 amendment. I haven't read it. Can I  
3 have a moment to read it?

4 Q. I'll -- I'll point you to it.  
5 Don't worry.

6 A. All right.

7 Q. Allergan is a manufacturer of  
8 Botox; right?

9 A. Allergan, yes, uh-huh.

10 Q. Go to page 3.

11 A. Okay.

12 Q. And you see there's a signature  
13 line, and under that, it says,  
14 "10/02/2017"?

15 A. Correct.

16 Q. You understand this was issued  
17 on October 2, 2017; right?

18 A. That's -- that's what the  
19 document appears to show, yeah.

20 Q. Go back to the first page.

21 A. Okay.

22 Q. First paragraph says, "Dear Dr.  
23 Richmond: Please refer to your

1 Supplemental Biologics License  
2 Application, dated and received December  
3 2, 2016." Do you see that?

4 A. I do.

5 Q. The next paragraph says, "This  
6 Prior Approval supplemental biologics  
7 application proposes an additional  
8 indication for the temporary improvement  
9 in the appearance of moderate to severe  
10 forehead lines associated with frontalis  
11 muscle activity."

12 A. Right.

13 Q. Do you see that?

14 A. I do.

15 Q. All right. Then the next  
16 section says, "Approval & Labeling."  
17 Right?

18 A. Yes.

19 Q. It says, "We have completed our  
20 review of this supplemental application,  
21 as amended. It is approved, effective on  
22 the date of this letter, for use as  
23 recommended in the enclosed, agreed-upon

1 labeling text." Do you see that?

2 A. I do.

3 Q. All right. You understand that  
4 Botox was not an FDA-approved treatment  
5 for improvement in moderate to severe  
6 forehead lines until October 3, 2017 --

7 MR. KNEPPER: Objection --

8 Q. -- right?

9 MR. KNEPPER: -- to form.

10 A. The sense I get of your question  
11 is that you -- you're conflating the  
12 injection of corrugator and procerus  
13 muscles with the injection of the  
14 frontalis muscles. I consider all those  
15 muscle groups to be forehead muscles  
16 because they all animate the brow. The  
17 approval of Botox for the corrugator and  
18 frontalis -- I mean, corrugator and  
19 procerus muscle that goes way back is, I  
20 thought, what you were -- you were asking  
21 me about with ten years application to  
22 the forehead. So yeah. So I consider  
23 the -- the corrugator and procerus

1 muscles (indicating) forehead muscles.  
2 Maybe others would call them glabellar,  
3 but glabellar is the lesser-included  
4 category. So yeah.

5 So I was aware of the broadened  
6 application, and I was aware that for  
7 most of the time it's been on the market,  
8 it has been limited, the approval been  
9 limited to the corrugator and procerus.  
10 And the frontalis marginal radicularis  
11 was considered off-label use, as was its  
12 use in hyperhidrosis, like we talked  
13 about earlier. Yeah.

14 Q. You have prescribed Botox  
15 cosmetic -- or strike that.

16 You have used Botox for  
17 treatment of moderate to severe forehead  
18 lines associated with frontalis muscle  
19 activity before October 3, 2017; correct?

20 A. Yes.

21 MR. KNEPPER: Objection to form.

22 A. Absolutely.

23 Q. It's an off-label use; right?

1           A.     As we've talked about before,  
2     yes, I've -- I've used it off-label.

3           Q.     And do you know when Botox  
4     received this indication for treatment of  
5     crow lines?

6           A.     I'm sorry.   Of?

7           Q.     Treatment of crow lines.

8           A.     Crow lines?

9           Q.     Yes.

10          A.     Oh, crow's feet (indicating).

11          Q.     Sorry, crow's feet.

12          A.     Yeah.   Yeah.   I don't know -- I  
13     don't know the exact date of that.   I  
14     just know that it's been broadened.

15          Q.     All right.   Before -- strike  
16     that.

17                 Before you first started using  
18     Botox on an off-label basis, did you do a  
19     literature search to see if there was a  
20     randomized, double-blinded controlled  
21     trial to demonstrate that this forehead  
22     use was safe and effective?

23          A.     No.

1 MR. KNEPPER: Objection, form.

2 Q. So you were using it without  
3 having any idea if there was randomized  
4 controlled clinical trials to demonstrate  
5 the safety and effectiveness of that use;  
6 correct?

7 MR. KNEPPER: Objection, form.

8 A. So the question is, was I using  
9 it in other than the on-label purposes  
10 before the approval was handed down by --  
11 to the -- by the FDA?

12 Q. No. I already heard the answer  
13 to that question.

14 A. Oh, okay.

15 Q. I'm asking you a different  
16 question.

17 A. Okay.

18 Q. At the time you were using  
19 Botox on --

20 A. Oh.

21 Q. -- an off-label basis --

22 A. Right.

23 Q. -- you were doing that without

1       having results from a randomized  
2       controlled trial to demonstrate that this  
3       off-label use was safe and effective;  
4       correct?

5           A.     Correct.   Correct.

6                   MR. KNEPPER:   Objection, form.

7           Q.     The same is true for respective  
8       cohort studies; right?

9           A.     Correct.

10          Q.     The same is true for case  
11       control studies; right?

12                  MR. KNEPPER:   Objection, form.

13          A.     Right.   And that's an example of  
14       what we were talking about earlier where  
15       a low-risk application begins with  
16       anecdotal experience, shared anecdotal  
17       experience, and -- and the literature  
18       that comes later leading to the  
19       controlled trial that the Allergan  
20       company may have done and it's then  
21       subsequently approved by the FDA.   That's  
22       right.   So this would fit into that  
23       category.



1           Q.     All right.  Let's talk more  
2     about randomized controlled trials  
3     outside of Botox.  If I call them RCTs  
4     for short, you'll know what I'm referring  
5     to; right?

6           A.     Yes.

7           Q.     An RCT typically involves two  
8     groups, an experiment group and a control  
9     group; right?

10          A.     Yes.

11          Q.     RCTs are typically  
12     double-blinded; right?

13          A.     Well, in most cases.  But when  
14     you're talking about things where there's  
15     going to be an outward change in the  
16     patient, it's -- it's difficult to blind  
17     such studies.  You're essentially just --  
18     for example, you couldn't have a  
19     double-blinded study of a surgical  
20     procedure, or you couldn't have a  
21     double-blinded study of a -- of a medical  
22     intervention where there's outward change  
23     to the patient that would be evident to

1 both the experimenter and the subject.

2 So yeah.

3 Q. Yeah. So -- yeah, we'll get to  
4 that in a minute. Let me ask just some  
5 more general questions first.

6 A. Okay.

7 Q. Because I want to figure out  
8 your experience with RCTs. You  
9 personally have never been the lead  
10 investigator for an RCT; correct?

11 A. That's correct.

12 Q. You personally -- strike that.  
13 Have you ever been involved with  
14 an RCT?

15 A. Yes. When I was a resident at  
16 the University of California-San  
17 Francisco working on the neurosurgical  
18 trauma unit, we were doing a randomized  
19 controlled trial of the medical  
20 management of elevated intracranial  
21 pressure, and I was -- because I was part  
22 of the team, I was responsible for  
23 gathering data in the critical care unit

1 and -- and working with the investigators  
2 ensuring the integrity of the data. So I  
3 was not the lead investigator, obviously.  
4 I was just one of the participants as one  
5 of the treating physicians.

6 Q. The only time you worked on a  
7 randomized controlled trial was during  
8 your surgery res- -- general surgery  
9 residency; correct?

10 MR. KNEPPER: Objection, form.

11 A. I'm trying to think if there  
12 were other instances here. At UC-Davis  
13 -- I'm trying to think. Give me just a  
14 moment. I just want to --

15 Q. Sure.

16 A. -- make sure I'm not missing any  
17 more. I think that's the only one where  
18 it was a randomized blinded study.  
19 That's right, yeah.

20 Q. And that residency was '87  
21 through '91?

22 A. That's right.

23 Q. Okay. You've never published

1       any articles in peer-reviewed journals  
2       about RCTs; correct?

3           A.     That's correct.

4           Q.     You've personally never designed  
5       an RCT; correct?

6           A.     That's correct.

7           Q.     You don't hold yourself out as  
8       an expert in RCT design; right?

9                   MR. KNEPPER:  Objection, form.

10          A.     Well, I would qualify that  
11       answer by saying that part of my training  
12       involves me being able to understand and  
13       review published literature on the  
14       subject even though I'm not the  
15       investigator because of my training as a  
16       plastic and reconstructive surgeon, as a  
17       general surgeon.  As just a physician in  
18       general, we're trained on how to  
19       interpret the validity or the veracity of  
20       the medical literature, including how to  
21       interpret the randomized controlled trial  
22       and -- and understand its validity, which  
23       is -- what I'm testifying about is not my

1       personal experience. It's my opinion of  
2       the validity of the scientific data. So  
3       I -- so it's not that I -- that I can't  
4       express an opinion on it. It's just that  
5       I haven't personally conducted one, but I  
6       have been trained on how to interpret  
7       them.

8           Q.     I understand that distinction  
9       you're making.

10          A.     Thank you.

11          Q.     But when it comes to designing  
12       RCT, you're not an expert in that aspect  
13       of RCT?

14                 MR. KNEPPER:   Objection, form.

15          A.     Well, again, part of the  
16       evaluation of a randomized controlled  
17       trial is to evaluate how the study was  
18       designed. That's one of the criteria  
19       used for understanding the validity of a  
20       published document like a RCT. So you  
21       always look at -- that's why it's such an  
22       essential part of a -- of a RCT  
23       publication is you look at the materials

1       and methods and you look at the study  
2       design, and that's where, really, your  
3       analysis begins if you're trying to  
4       interpret the data. Did they design the  
5       study properly? Does it have the power  
6       of discrimination of what they claim that  
7       it has? And then you look at the actual  
8       results, and it's on -- it's on your  
9       shoulders as the -- as the professional,  
10      whether you're a -- you know, a  
11      researcher or somebody who's seeking to  
12      apply it in his practice, you're  
13      responsible for interpreting the data  
14      quite apart from their interpretation of  
15      it.

16                So an example of that would be  
17      the Branström study, where they --  
18      they -- they generated a good -- a  
19      reasonable study design, but they  
20      misinterpreted the data, and that's what  
21      caused the retraction of the Branström  
22      study, is that all the other people who  
23      were not RCT investigators, but they were

1 all physicians, endocrinologists,  
2 pediatricians, they looked at the data  
3 and said, "You've misinterpreted the  
4 study."

5 And that's really what we're  
6 talking about here. There are those who  
7 perform the study, and then there's us  
8 who have to live with it, and we have to  
9 be able to understand what they're --  
10 what they're purporting to. So we have  
11 to interpret the data even before reading  
12 their conclusions.

13 Q. Do you know what the CONSORT  
14 criteria are? C-O-N-S-O-R-T.

15 A. I've read it sometime before. I  
16 can't -- I can't -- I can't quote it for  
17 you, but it's -- it's germane to the  
18 study design process? I'm not sure.

19 Q. Okay. Can you describe for me  
20 what the CONSORT criteria are in general  
21 terms?

22 A. I cannot.

23 Q. All right. How about cohort

1 studies? You've personally never  
2 designed a cohort study; correct?

3 A. No, I have not.

4 Q. You've personally never been an  
5 investigator in a cohort study; correct?

6 A. Well, so -- so, that experience  
7 at -- at UC-San Francisco was a -- well,  
8 so are you asking -- by cohort study, are  
9 you talking about like a retrospective  
10 study of a -- of a population cohort? Is  
11 that what you're asking me about?

12 Q. Prospective or retrospective,  
13 either -- either/or.

14 A. I haven't designed any of those  
15 studies, no.

16 Q. Okay. And outside the one  
17 experience in your residency, have you  
18 ever been involved with any prospective  
19 or retrospective cohort study?

20 A. No.

21 Q. And how about case-control  
22 studies? Have you ever personally  
23 designed a case-control study?



1           A.     No, I have not.

2           Q.     Have you ever been an  
3 investigator in a case-control study?

4           A.     I'm just trying to think if the  
5 -- if the head trauma investigation would  
6 fit the category of a case control. It  
7 was a randomized study. It had its own  
8 internal controls. So I guess I've  
9 assisted in that investigation, but only  
10 as a -- as a provider and a -- and a data  
11 gatherer.

12          Q.     Outside of that one experience,  
13 you have not been involved with any  
14 prospective or retrospective cohort  
15 study; right?

16          A.     No.

17          Q.     Or a case-control study? Excuse  
18 me.

19                 Okay. Let's go back to your  
20 report, Exhibit 1, and go to page 13.

21          A.     Okay. Okay.

22          Q.     You see there's a header that  
23 says in capital letters, "Anecdotal

1 Patient Stories Are Not Data." Do you  
2 see that?

3 A. I do.

4 Q. And you write, "Drs Schechter  
5 and Brown also failed to disclose and  
6 properly discuss that Anecdotal Data  
7 unverified patient reports without  
8 control groups, randomized trials, or  
9 other scientific protections for the  
10 integrity of the medical system -- are  
11 not reliable science." Do you see that?

12 A. I do.

13 Q. And then you reference personal  
14 patient stories, and you say, "This is  
15 unreliable Anecdotal Data and it is not  
16 credible, scientific information." Do  
17 you see that.

18 A. I do.

19 Q. All right. You think that case  
20 reports are anecdotal evidence; right?

21 A. Yeah, they're --

22 MR. KNEPPER: Objection.

23 THE WITNESS: I'm sorry?

1 MR. KNEPPER: Objection, form.

2 Go ahead.

3 THE WITNESS: I'm sorry.

4 A. Yeah. And so anecdotal data is  
5 personal experience of a -- of a  
6 practitioner, for example. So -- so a  
7 surgeon reporting on five cases that he  
8 did would be considered anecdotal  
9 reporting, or case reports and things  
10 like that, yeah. That's anecdotal,  
11 personal experience, a personal exper- --

12 Q. And you think --

13 A. I'm sorry?

14 Q. Go ahead. Sorry.

15 A. Personal experience as distinct  
16 from more stringent scientific evidence  
17 like a longitudinal study or a cohort  
18 study or something like that. Or even --  
19 even personal experience with pre- and  
20 posttreatment testing rises to a higher  
21 level than anecdotal. So you can base --  
22 you can base scientific evidence on that  
23 next level, which would be anecdotal

1       experience elevated to the next level by  
2       pretreatment and posttreatment testing.  
3       This is -- this is from the guidance that  
4       the American Society of Plastic Surgery  
5       puts out.

6               So depending on the -- depending  
7       on the type of study, if it's a -- if  
8       it's a therapeutic study or a diagnostic  
9       study or a prognostic study, depending on  
10      what you're looking at, if -- if you --  
11      if you take it to that next level with  
12      pre- and posttreatment testing with a  
13      validated scientific instrument, you  
14      know, a validated study even of  
15      subjective reporting from the  
16      psychiatric/psychological side of things,  
17      that has more validity than the anecdotal  
18      reports of a practitioner or even an  
19      institution.

20       Q.     Do you think that a case report  
21      that doesn't have this before and after  
22      comparator that you describe is  
23      essentially worthless from the --

1           A.     No.

2           Q.     -- scientific perspective?

3           A.     No, no. Not worthless. Not  
4 worthless, but it's what's considered in  
5 the -- in the -- in plastic surgery  
6 circles, certainly, it's considered the  
7 lowest form of evidence. So for a number  
8 of years now, the American Society of  
9 Plastic Surgery has insisted that  
10 publications -- if you're going to  
11 publish a case series, for example, that  
12 they have to be a sequential -- you can't  
13 pick the cases you're reporting on. It  
14 has to be a sequential series of  
15 patients, and you have to declare in the  
16 publication, in your -- in your article,  
17 the level of evidence that you're  
18 presenting.

19                 So if -- if it's merely a --  
20 case reports, that would be level 5  
21 evidence. If you added to that a review  
22 of the literature with a -- you know, a  
23 definitive review of the literature

1 looking at the -- at where the weight of  
2 evidence lies, then you raise it to the  
3 next level. But we're -- we're now  
4 required when we're publishing in -- in  
5 the ASPS journal, for example, to state  
6 in the -- in the document level of  
7 evidence. So a case report is not zero  
8 scientific evidence. It's level 5  
9 evidence. It's the lowest form of -- of  
10 evidence is what it is.

11 Q. You personally would not rely on  
12 a level 5 case report to decide if a  
13 surgical technique is effective?

14 A. It would be the beginning of my  
15 interest in a particular technique. As a  
16 surgeon, we tend to be very conservative,  
17 and we call upon our personal experience  
18 very much and certainly upon our  
19 training. So if somebody proposes  
20 something radically new and all they have  
21 to support it is level 5 evidence,  
22 generally -- there's a saying that I  
23 learned in training is never be the first

1 or -- first one to do a procedure or the  
2 last one to do a procedure.

3 And so, yeah, you know, surgeons  
4 tend to not jump in early on -- on  
5 low-quality evidence. We tend to be  
6 conservative about it. And I would  
7 number myself among them.

8 Q. All right. Let me ask the flip  
9 side.

10 A. Okay.

11 Q. Do you think it's necessary for  
12 a surgical procedure to be supported by  
13 results from a level 5 RCT before it can  
14 be considered effective?

15 A. No.

16 MR. KNEPPER: Objection to form.

17 A. That would -- that would be one  
18 of those circumstances where what is the  
19 risk to the patient and -- and what's the  
20 potential benefit to the patient.  
21 That's -- that's what kind of would drive  
22 my decision to act on a level 5 case  
23 report, offering something like that to

1       one of my patients.

2           Q.     Do you think that a surgical  
3       procedure has to be supported by a level  
4       2 controlled study before that surgical  
5       procedure can be considered  
6       nonexperimental?

7           A.     Not necessarily. It would  
8       depend on what is -- what is -- what is  
9       at risk here. Certainly, we're much more  
10      willing to -- to proceed with -- with  
11      techniques and procedures that aren't  
12      hugely supported if there's great risk to  
13      the patient of not doing anything. So  
14      level of risk and what is at stake kind  
15      of drives that and -- and yeah.

16                   Did I answer that question? Is  
17      that what you were asking?

18           Q.     Yeah. It's basically a  
19      case-by-case decision; right?

20                   MR. KNEPPER: Objection, form.

21           A.     Well, I wouldn't say case by  
22      case. I would say, you know, you're  
23      relying on -- on -- on a lifetime of



1       experience possibly, and you're relying  
2       also on -- on conversations with your  
3       peers, your colleagues, what is their  
4       experience in the area and how much of a  
5       risk are you going to subject to the  
6       patient -- subject the patient to in  
7       order to achieve a result. The greater  
8       the risk, the greater the expectation of  
9       a defined scientifically supported  
10      outcome.

11               So in the case -- in the issue  
12      at hand here, great risk of doing, for  
13      example, a transition surgery, because  
14      you're talking about permanent  
15      sterilization, irreversible  
16      sterilization, or the removal of the  
17      breasts, permanent and irreversible loss  
18      of the breasts, that's a huge stake, a  
19      huge risk to the patient that the -- the  
20      expected outcomes have to be consummately  
21      much larger in order to justify something  
22      like that if you don't have scientific  
23      support. If you're at low levels of

1       scientific evidence, then clearly, you  
2       have an obligation to the patient not to  
3       -- not to try something risky if you  
4       don't have extensive and very valid  
5       scientific -- and that's where we are  
6       now. We're at very low-level evidence  
7       for these things. That's kind of why  
8       we're here today.

9       Q.     I guess I'm asking a more  
10      specific question. You're not taking the  
11      position that in order to be considered  
12      nonexperimental, a particular surgical  
13      procedure has to be supported by at least  
14      level 1 or level 2 evidence; right?

15             MR. KNEPPER:  Objection, form.

16      A.     Oh, okay. So you're asking me  
17      the definition of experimental. Is  
18      that -- do I understand you correctly?

19      Q.     Sure.

20      A.     Yes. Am I saying that something  
21      is nonexperimental once it reaches level  
22      2 evidence or higher and not before?

23      Q.     Correct.

1           A.     I'm not saying that, no.

2           Q.     Okay.   How about level 3?   Are  
3     you taking the position -- strike that.

4                   Are you expressing the opinion  
5     that a surgical procedure can only be  
6     considered not experimental if it reaches  
7     evidence level 3?

8           A.     Well, it's getting closer.   So  
9     when you're -- when you're at level 3,  
10    you're talking about a retrospective  
11    study with a cohort.   And if we were  
12    talking about some simple technique of  
13    reconstructing, say, a wound on the face  
14    for cancer therapy, then I certainly  
15    wouldn't wait to try a new technique.   If  
16    it promised to get a better result, I  
17    wouldn't wait until I got to level 3  
18    evidence.

19                   But if you're talking about a  
20    very drastic operation where I'm  
21    amputating healthy parts, then yeah, I'm  
22    going to want to go at least to level 3  
23    before I consider that, because again,

1       you're talk about tremendous risk to the  
2       patient, permanently life-altering  
3       changes. You better have very strong  
4       evidence that you're doing the patient  
5       good because you're doing the patient a  
6       great harm by, you know, removing their,  
7       genitals, permanently sterilizing them,  
8       removing their breasts. So again, it's  
9       -- it's not a case by case, but let's --  
10      let's say broad categories of -- of  
11      techniques or surgery.

12                If you're talking about  
13      something small like reconstructing a  
14      facial defect, then yeah, you don't need  
15      to get to level 3. But if you're talking  
16      about something large and permanently  
17      life-altering, then at least level 3.

18           Q.     All right. We talked earlier a  
19      while ago about some of the surgical  
20      procedure you performed, and I think one  
21      of the things you mentioned was breast  
22      reductions.

23           A.     Yes.

1 Q. Right?

2 A. Yes.

3 Q. You've done those; right?

4 A. I have done so many of those.

5 Q. All right. You've done breast  
6 reduction surgery without having the  
7 results from a randomized controlled  
8 clinical trial; right?

9 A. I believe the -- the bulk of the  
10 evidence in the therapeutic benefit of  
11 breast reduction is primarily given to us  
12 by a long-term longitudinal cohort study  
13 that we actually get from the insurance  
14 industry. Because when you do breast  
15 reduction surgery, one of the key issues  
16 in a breast reduction is, is it going to  
17 be efficacious in curing an orthopedic  
18 problem. So if you're talking about  
19 breast reduction surgery as a quote,  
20 unquote reconstructive procedure, then  
21 really, it's being applied to an  
22 orthopedic condition.

23 And the insurance companies have

1 a wealth of evidence about, for example,  
2 the weight of the specimen that has to be  
3 submitted in order to have a hope of  
4 relieving the orthopedic complaint of  
5 neck, back, and shoulder pain.

6 So -- and vir- -- and I can tell  
7 you categorically, because I'm very  
8 fastidious about this, that all of the  
9 breast reduction operations that I've  
10 ever done for the orthopedic condition of  
11 neck, back, and shoulder pain have met  
12 the criteria based upon this long-term  
13 longitudinal cohort study that the  
14 insurance companies have been running  
15 since back in the '80s at least.

16 Q. All right. Doctor, again, I  
17 need you to listen to my questions. I  
18 didn't ask about cohort studies. I asked  
19 about randomized clinical trial.

20 A. Oh.

21 Q. You have done -- you have done  
22 breast reductions without having results  
23 from a randomized controlled clinical

1 trial?

2 A. Oh, forgive me. I -- I  
3 misunderstood the question, then. No.  
4 The -- I have not, no. The industry --  
5 the plastic surgery community does not  
6 rely on a randomized trial for the -- the  
7 operation to be merited. That's correct.

8 Q. Right. Nobody in this industry  
9 waits for results from a randomized  
10 controlled trial before determining that  
11 a particular surgical procedure is  
12 nonexperimental; right?

13 MR. KNEPPER: Objection, form.

14 A. Well, this gets back to what we  
15 were talking about before, what the --  
16 what the level of evidence is, what's at  
17 risk, and what are the potential  
18 benefits. So in the case of breast  
19 reduction surgery, yes, we have not  
20 relied on randomized controlled trials  
21 because there was such an abundance of  
22 level 3 evidence to justify the  
23 procedure. And so -- and level 3

1 evidence is sufficient to answer the  
2 question, is this experimental or not?  
3 This procedure doesn't rise to the level  
4 of level 2 or level 1 in order to be  
5 justified. I believe there have been --  
6 well, no, I can't say categorically, so I  
7 won't.

8 So yeah, to answer your  
9 question, breast reduction does not rely  
10 on randomized trials. It relies on level  
11 3 evidence.

12 Q. All right. Let's take it out of  
13 the realm of breast reduction in  
14 particular.

15 A. Okay.

16 Q. It is not uncommon for plastic  
17 surgeons to perform procedures that are  
18 not supported by results from an RCT;  
19 correct?

20 MR. KNEPPER: Objection, form.

21 A. As a general principle, plastic  
22 surgeons are perhaps more innovative than  
23 other surgeons, so we're inclined to try



1 new techniques. And then, of course, you  
2 have to exercise some significant  
3 prudential judgment about what risk are  
4 you placing the patient in before you get  
5 experimental with them. Yeah. So yes,  
6 we -- we do that all -- we're innovators,  
7 as -- as a general principle.

8 Q. And as a general principle,  
9 plastic surgeons will often commonly  
10 perform procedures that are not supported  
11 by level 2 evidence; correct?

12 MR. KNEPPER: Objection, form.

13 A. Yes.

14 Q. And as innovators, plastic  
15 surgeons will often perform surgical  
16 procedures that are not level 3 evidence;  
17 right?

18 MR. KNEPPER: Objection, form.

19 A. Yeah. They -- if you're talking  
20 about small like technical improvements  
21 in -- in low-risk procedures, then yeah,  
22 we -- we do that very commonly.

23 Q. Okay. You know what the

1       Plastics and Reconstructive Surgery  
2       journal is; right?

3           A.     Yes.

4           Q.     It's the official publication of  
5       the ASPS; correct?

6           A.     Correct.

7           Q.     It's a peer-reviewed medical  
8       journal; right?

9           A.     Correct.

10          Q.     It's published monthly; right?

11          A.     And plus supplements as well and  
12       online.    Yes, sir.

13          Q.     One purpose of that journal is  
14       to educate members about new surgical  
15       techniques; right?

16          A.     Yes.

17          Q.     Would you agree that the journal  
18       is the premier peer-reviewed source for  
19       current information on reconstructive and  
20       cosmetic surgery?

21          A.     I would.

22          Q.     All right.   Are you -- I know  
23       that you're no longer a member.   Are you

1 still subscribing to the journal?

2 A. No, I'm not. It's a -- it's for  
3 members that you get the journal, so  
4 yeah. That's what my subscription relied  
5 on, so -- all those years.

6 Q. I understand. So not -- you  
7 haven't had access to it since 2018?

8 A. Well, I -- no, I go online, and  
9 I'll pay for access to particular  
10 articles. So yeah. So it's not that  
11 I've lost contact with it, it's just that  
12 I do literature searches, and if an ASPS  
13 citation comes up, I'll pay to look at  
14 it.

15 Q. I understand. Sitting here  
16 today, what percent of publications in  
17 that journal do you think consist of  
18 results from RCTs?

19 MR. KNEPPER: Objection, scope,  
20 form.

21 A. Yeah, I'm -- I'm not sure I  
22 could hazard a guess even.

23 Q. Ballpark, do you think it's 10

1       percent?   50 percent?

2           A.     Of their published articles that  
3       are randomized controlled trials?

4           Q.     Yes.

5                   MR. KNEPPER:   Objection to form,  
6       scope.

7           A.     Gosh, I'm going to guess it's  
8       probably somewhere -- probably less than  
9       10 percent.

10          Q.     How about cohort studies?   If  
11       you had to estimate, what percentage of  
12       publications in that journal do you think  
13       consist of results from cohort studies?

14                   MR. KNEPPER:   Objection, form.

15          A.     Again, just ballparking here  
16       after, you know, 35 years of reading that  
17       article -- that journal for 35 years, I  
18       would say that -- I don't -- I may be  
19       guessing, but 15 percent maybe are -- are  
20       cohorts that are usually single-center  
21       studies.   There's a lot of those in  
22       the -- in the White Journal.   There'll be  
23       a single-center cohort study of -- of

1       some operation or technique, and they'll  
2       usually report it as three or four  
3       surgeons at a single center reporting a  
4       -- a longitudinal cohort of, say, breast  
5       cancer reconstructions with implants  
6       versus breast reconstruction with  
7       autologous flaps and comparing  
8       satisfaction surveys and things like  
9       that. So I'm going to ballpark it at 15  
10      percent, but I don't know. I don't know  
11      for a fact.

12       Q.     Let me introduce an exhibit. So  
13      this will be Exhibit 17, and let me know  
14      when you get it.

15      (Exhibit 17 was marked for identification  
16      and is attached.)

17       A.     Okay. All right. I have it.

18       Q.     All right. This is a study from  
19      2019 by Sugrue, S-U-G-R-U-E, titled  
20      "Levels of Evidence in Plastic and  
21      Reconstructive Surgery Research." See  
22      that?

23       A.     I do.

1           Q.     All right.  See there's a  
2     "Summary" box on the first page?

3           A.     Yes.

4           Q.     The third sentence says, "The  
5     aim of this study is to determine if the  
6     quality of evidence in plastic surgery  
7     research has improved over the past 10  
8     years.  Systematic review of research  
9     published in *Plastics and Reconstructive*  
10    *Surgery* journal over the years, 10-year  
11    period (2008, 2013, 2018), was  
12    performed."  Do you see that?

13          A.     I do.

14          Q.     Now, you understand what this  
15    study was trying to accomplish; right?

16          A.     Yeah.  They were measuring the  
17    level of success that the American  
18    Society of Plastic Surgery was having  
19    after having applied those criteria we  
20    talked about earlier, the -- this  
21    requirement of reporting levels of  
22    evidence, seeking the clarity on levels  
23    of evidence.  And so I expect -- I

1 haven't read this -- this article before,  
2 but I guess that's what they're looking  
3 at, is how successful have we been as a  
4 professional society in publishing --

5 Q. Yeah.

6 A. -- these things.

7 Q. And this references the levels  
8 of evidence, LOE, metric; right?

9 A. Yes.

10 Q. And that's the same metric that  
11 you referenced earlier, levels 1 through  
12 5; right?

13 A. Right. Well, the levels 1  
14 through 5 that I referenced includes  
15 the -- sort of the subcategorizing,  
16 depending on if it's a therapeutic trial  
17 or a -- or a trial of risk or things like  
18 that. So the -- the document that the  
19 ASPS published some years ago includes  
20 risk studies and diagnostic studies, but  
21 they're all ranked 1 through 5. That's  
22 right.

23 Q. And you see a couple of

1 sentences down, it says 884 studies were  
2 included in the final analysis. You see  
3 that?

4 A. Yes, I do.

5 Q. Okay. Go to page 2.

6 A. Okay.

7 Q. You see there's a Table 1?

8 A. Yes, I do.

9 Q. Table 1 is "Percentage of Each  
10 Level of Evidence Published per Year."  
11 Do you see that?

12 A. I do.

13 Q. And there's columns for 2008,  
14 2013, and 2018; right?

15 A. Yes.

16 Q. All right. Let's start with  
17 level 1, and that's randomized control  
18 trials or metaanalyses of those trials;  
19 right?

20 A. Right.

21 Q. In 2018, only 2.1 percent of all  
22 publications in the journal were level 1  
23 evidence; right?



1           A.     That's right.

2           Q.     And in 2008 and 2013, those  
3 percentages were 0.3 and 1.7 percent  
4 respectively; correct?

5           A.     Correct.

6           Q.     Not very common for the journal  
7 to report on results of RCTs, according  
8 to this summary; right?

9                   MR. KNEPPER:   Objection, form.

10          A.     Yeah.   And it even goes along  
11 with what -- my ballpark earlier, so I'm  
12 surprised -- yes, it was less than 10  
13 percent were -- were level 1 evidence and  
14 somewhere around -- yeah, so those  
15 numbers are consistent.   But yeah.

16                   And the other thing to note  
17 about it is that they appear to have been  
18 successful in choosing what they publish  
19 to support higher levels of evidence.   So  
20 I guess they're to be commended for  
21 having done this, yeah.

22          Q.     Okay.   All right.   Then level 2  
23 are -- level 2 evidence includes

1 prospective cohort or comparative  
2 studies; right?

3 A. Yes.

4 Q. With controls; right?

5 A. Yeah. There's a level of  
6 randomization that -- that's there as  
7 well --

8 Q. Okay.

9 A. -- in those prospective studies.  
10 That's right.

11 Q. And for that level 2 evidence,  
12 only 13.6 percent of all publications in  
13 the journal in 2018 consisted of that  
14 evidence; right?

15 A. Yes. That's what it says there,  
16 yes.

17 Q. All right. Level of evidence 4  
18 is case series with a pre- or posttest or  
19 only posttest; right?

20 A. Right.

21 Q. And in 2018, those amounted to  
22 41.7 percent of all publications; right?

23 A. Right. It looks as though more

1 of those level 4 have been shifted up  
2 into level 3, given that the level 5 has  
3 declined. So it looks like they're  
4 pushing more of the level 4 up into level  
5 5. Yeah.

6 Q. Yeah. Much of the research on  
7 which your field relies doesn't consist  
8 of results from RCTs or controlled cohort  
9 studies; right?

10 A. Well, I wouldn't --

11 MR. KNEPPER: Objection, form.

12 A. I wouldn't say that based on  
13 this. I would say that much of the  
14 published research in this journal is of  
15 that -- of what you described, relying on  
16 RCTs and so on.

17 This is a -- this is not a  
18 document about what the profession is  
19 doing. This is a document about what  
20 this journal is publishing. And what  
21 they're publishing is more papers of  
22 higher value, for which they're to be  
23 commended. So this says nothing about

1        what people are investigating. This says  
2        about -- this says something about what  
3        this journal is publishing.

4            Q.     Well, this is the journal for  
5        the ASPS; right?

6            A.     Right. With limited space for  
7        publication. So they're being,  
8        apparently, more selective about what  
9        they'll publish, that it's not just that  
10       well, this is the chief of plastic  
11       surgery at NYU, so we're going to publish  
12       his paper. It's the chief of plastic  
13       surgery has a level 2 case. Let's --  
14       let's present -- let's publish that one.  
15       I think that's what this is telling us,  
16       that they're being more fastidious about  
17       what they publish, whereas before, they  
18       might have been more -- well, less  
19       selective, let's say.

20           Q.     Have you ever been involved with  
21        selecting articles to be published in  
22        this journal?

23           A.     I've never been involved in --

1 in journal publication staff or -- no, I  
2 have not.

3 Q. You don't know the process by  
4 which they select what article to  
5 publish; right?

6 MR. KNEPPER: Objection, form.

7 A. I have some idea, but I'm --  
8 it's not my -- my area of professional  
9 expertise.

10 Q. Yeah.

11 A. I merely read the journal, and  
12 have for approaching forty years now.

13 Q. Look at Table 2.

14 A. Okay.

15 Q. And look at the column under  
16 2018.

17 A. Yes.

18 Q. The first two rows, "Systematic  
19 review/meta analysis" and "Randomized  
20 control trials," account for 3.2 plus 3.8  
21 percent of all publications of the  
22 journal in 2018. Correct?

23 A. Right.

1 MR. KNEPPER: Objection.

2 Q. Case series account for 26.3  
3 percent; right?

4 A. Right.

5 Q. Okay. Go to page 3 of this  
6 exhibit.

7 A. Okay. I'm there.

8 Q. All right. First full  
9 paragraph, first sentence says, "Case  
10 series are the backbone of surgical  
11 research." Do you see that?

12 A. I do.

13 Q. You don't disagree that case  
14 series can be helpful scientific  
15 evidence; right?

16 A. No. As I -- as I testified  
17 before, this is the beginning of  
18 research. It always begins with perhaps  
19 a serendipitous discovery, then to case  
20 reports, then to case series, single --  
21 single-provider case series or multiple  
22 providers in a -- in a -- an institution.  
23 But that's the beginning of surgical

1 research, yeah. That's how it always  
2 begins.

3 Q. Well, it's a beginning, but  
4 sometimes it's also the end; right?  
5 Because look at the third sentence. It  
6 says: "The absence of a control group  
7 justifiably ranks this design at the  
8 lower end of the evidence pyramid.  
9 Despite this, case series are vital.  
10 They may be the only feasible and ethical  
11 study methodology obtainable, as seen  
12 with craniofacial surgery." You see  
13 that?

14 A. Yeah. And to that -- to that  
15 particular point, so I've got extensive  
16 experience with craniofacial surgery, and  
17 -- and it's -- this is one of those  
18 procedures where the outward change to  
19 the child can't be blinded. You cannot  
20 blind the investigator because,  
21 obviously, he's doing the surgery, and  
22 you can't blind the patient or the family  
23 to it because the results are quite

1 obvious. And that's what they're saying  
2 here. And obviously, they're not saying  
3 that it's never useful or is never  
4 necessary. They're saying that in many  
5 cases, you don't need to rise to that  
6 level because you have evident benefit to  
7 the patient and the risk is not only  
8 manageable but -- but sufficiently low to  
9 warrant the application of a particular  
10 technique.

11 So that was certainly the case,  
12 for example, when we introduced external  
13 fixation devices for advancement of the  
14 mid face in certain congenital  
15 deformities. Nobody had done a  
16 randomized trial because you can't.  
17 You've got this hardware sitting on the  
18 patient's face. So -- but yet, the --  
19 the luminaries in craniofacial surgery  
20 were able to demonstrate through a case  
21 series that this was a valid technique,  
22 and then the rest of us adopted it. So  
23 that's an example of how plastic surgery



1       works.

2               Now, if the patient was at risk  
3       of death because this technique was being  
4       applied or if the patient was at risk of  
5       permanent life-altering changes that  
6       couldn't be reversed, then yeah, you  
7       would have to proceed with much greater  
8       caution, and you may be looking at  
9       finding some way, longitudinal  
10      study-wise, to -- to quantify the benefit  
11      of using your technique over using  
12      established techniques.

13       Q.     There are some areas in plastic  
14      surgery and reconstructive surgery where  
15      case series are basically as good as it  
16      gets in terms of scientific evidence;  
17      right?

18             MR. KNEPPER:   Objection, form.

19       A.     Yeah.   I suppose in the newer --  
20      at the newer end of techniques, that's  
21      all you got for now until the technique  
22      has been applied over a sufficiently long  
23      time that you can look at a retrospective

1 cohort.

2           So for example, in the case of  
3 gender transitioning surgery, the -- the  
4 -- the surgeons have been at it now for  
5 several decades. And we should be  
6 already at the level of level 3 evidence,  
7 but -- but we're not.

8           Q. Well, you --

9           A. So I wouldn't put that in the  
10 category of -- you're talking there about  
11 a high-risk procedure that has a long  
12 track record that can be examined. And  
13 -- and clearly, the examination of that  
14 technique in the last three years, give  
15 or take, has -- has shown us that that  
16 this is in the category of those  
17 operations that demand higher levels of  
18 evidence than a case series, whether it's  
19 single provider, single institution, or  
20 even single nation. You've got to --  
21 you've got to look at the data now and --  
22 and prove that you are doing something  
23 good for the patient.

1           And quite frankly, it hasn't  
2       been proven in the -- in the American  
3       literature. Certainly, WPATH hasn't  
4       proven that. But in the European  
5       literature, they're looking at it and  
6       saying, gosh, you know, the -- the  
7       Swedish study shows us that if you only  
8       follow patients for five years at the  
9       most, you're not even going to see the  
10      long-term effect of what you did to them.  
11      And if you look at them eight years and  
12      beyond, you'll see that you haven't  
13      solved the suicidality, the self-harm,  
14      the incarceration, psychiatric diagnosis  
15      admissions, and things like that.

16           So -- so yeah, as far as what  
17      we're talking about today, yeah, there's  
18      a whole spectrum of what's acceptable  
19      levels of evidence for a particular  
20      procedure. The higher the risk, the  
21      higher the level of evidence is demanded.  
22      And sometimes you have to wait to get to  
23      that level of evidence if you're dealing

1 with something potentially  
2 life-threatening.

3 Like certainly, the providers  
4 were fully justified in considering this  
5 because of the high suicide rate of  
6 transgender patients. Case series,  
7 totally valid reason given that the life  
8 of the patient is at risk here, totally  
9 valid to go with a case series as the  
10 evidence by which you're consenting the  
11 patient to surgery. But we're now beyond  
12 that. We're now beyond that. We're at  
13 -- we're now -- the ethics demands that  
14 we look at higher levels of evidence  
15 because of the long-term risk to the  
16 patient and the fact that the long-term  
17 evidence doesn't support the indication  
18 for surgery, which is lower suicide rate,  
19 lower self-harm, lower drug abuse.  
20 That's really what we're talking about  
21 here.

22 Q. I have some other questions.  
23 You agree that -- strike that.

1                   Do you agree that it is not  
2                   possible to perform RCTs for some  
3                   surgical procedure because you can't  
4                   blind the patient or the investigator to  
5                   what the procedure is?

6           A.     Absolutely agree, yeah.

7           Q.     So, let's take phalloplasty;  
8                   right?

9           A.     Okay.   Yeah.

10          Q.     When a surgeon performs a  
11                   phalloplasty on a patient, both the  
12                   surgeon and the patient are going to know  
13                   that the procedure was done; right?

14          A.     Yes.

15          Q.     It's not possible to have a RCT  
16                   for phalloplasty because you can't blind  
17                   the participant or the investigator;  
18                   right?

19          A.     Yeah.   That's typical of most  
20                   surgical interventions.   The only  
21                   exception to that would be intraabdominal  
22                   or intrathoracic surgeries or even  
23                   intracranial surgeries.   And -- and

1       that's considered sham surgery, which is  
2       considered malpractice and ethical  
3       violation of professional standards. So  
4       you can pretty much rule out most all  
5       surgical procedures from the randomized  
6       control trial category. Correct.

7           Q.     And we agree that the same would  
8       apply to metoidioplasty, for example;  
9       right?

10          A.     Yes.

11          Q.     To all types of, again,  
12       colloquially known as bottom surgery;  
13       right?

14          A.     Correct.

15          Q.     All right. Let's take  
16       puberty-blocking hormones.

17          A.     Okay.

18          Q.     When patients with gender  
19       dysphoria treatment start  
20       puberty-blocking hormones, they're not  
21       going to undergo puberty, basically;  
22       right?

23          A.     Well, that's the intended use,

1       that's correct.

2           Q.     So there's going to be  
3       observable physical effects of the  
4       hormones that will be apparent to the  
5       patient; right?

6           A.     Yes.   Within a year, that child  
7       is going to look much smaller than his  
8       peers.   He's going to be developmentally  
9       delayed psychologically,  
10      neurophysiologically.   His -- his  
11      movements are not going to be as -- his  
12      coordination is going to be less matured.  
13      His higher executive functions will be  
14      impaired.   So it will be very obvious  
15      that this child is now different from his  
16      peers.   So I would agree with you; you  
17      couldn't find a way to blind such a study  
18      because the evidence of effect is so  
19      obvious within the first year that  
20      everyone would know that they're taking  
21      the -- the puberty-blocking  
22      gonadotropin-releasing hormone agonist.

23           Q.     We agree that -- we agree that

1       it's not possible to do an RCT for  
2       puberty-blocking hormones because of  
3       these apparent physical effects; right?

4               MR. KNEPPER:  Objection, form.

5           A.     I -- I would agree, yes.

6           Q.     Okay.  Let's take cross-sex  
7       hormones.

8           A.     And the -- the last question you  
9       asked me, did you qualify that as you  
10      couldn't do a double-blinded study using  
11      puberty-blocking drugs in self-identified  
12      transgender children?

13          Q.     Yes.

14          A.     Yeah.  Because if you're  
15      applying the drug to other conditions  
16      like precocious puberty, it -- it may be  
17      possible.  It may be possible to -- I  
18      don't know.  I'd have to think about that  
19      but -- okay.  Sorry.

20          Q.     Let's take cross-sex hormones.

21          A.     Okay.

22          Q.     When somebody -- someone is  
23      treated with estrogen or testosterone for



1 gender dysphoria, there are also going to  
2 be physical effects from those  
3 treatments; correct?

4 A. Yes. Given that sex hormones  
5 have such a profound effect on every body  
6 system, then it's going to be impossible  
7 to conceal the fact that the person is on  
8 sex hormones because every -- every  
9 function of the body is affected by sex  
10 hormone levels, particularly at the age  
11 of early adolescence.

12 Q. And given these visible physical  
13 effects, it's not possible to design a  
14 double-blind RCT for cross-sex hormones  
15 for gender dysphoria; correct?

16 A. It would probably be an invalid  
17 study, yes.

18 Q. All right. Let's go back to  
19 your -- actually, you know what? I'm  
20 going to move to a different area. It's  
21 been about an hour. Let's take a quick  
22 break.

23 MR. TISHYEVICH: Off the record.

1 THE VIDEOGRAPHER: This is the  
2 end of Media Unit No. 4. We are off the  
3 record at 2:16 p.m.

4 (Break taken.)

5 THE VIDEOGRAPHER: This is the  
6 beginning of Media Unit No. 5. We are on  
7 the record at 2:24 p.m.

8 Q. (By Mr. Tishyevich) Let's go  
9 back to your report, Exhibit 1.

10 A. Okay.

11 Q. Go to page 21.

12 A. Twenty-one. Okay.

13 Q. And you see there's a paragraph  
14 starting with, "Failure to discuss the  
15 failure to conduct"?

16 A. Yes.

17 Q. Okay. So in the second line,  
18 you reference the "unknown number and  
19 percentage of patients who drop out of  
20 transitioning or reverse the process  
21 parentheses (Detransitioners)."

22 A. Right.

23 Q. You see that?

1           A.     I do.

2           Q.     All right.  You agree that the  
3           number and percentage of patients with  
4           gender dysphoria who drop out of  
5           transitioning or who reverse the process  
6           is currently unknown; right?

7           A.     Well, it depends on if you're  
8           asking that question about the general  
9           population or in a particular study.  So  
10          in particular studies, that number is  
11          known, but in the general population,  
12          it's an unknown.

13          Q.     Yeah.

14          A.     And the reason -- the reason  
15          it's unknown in the general population is  
16          because the people doing the research  
17          aren't following those patients.  That's  
18          why we don't know.

19          Q.     In the overall population, the  
20          number and percentage of patients who  
21          drop out of transitioning or reverse the  
22          process is unknown; agree?

23          A.     Yeah.  I would agree that's

1 unknown, yeah.

2 Q. All right. Given that,  
3 obviously, you're not offering any expert  
4 opinions on what that number or  
5 percentage is in the general population;  
6 right?

7 A. Yeah, I don't -- I don't think  
8 it's possible for anyone to break out the  
9 difference, for example, between somebody  
10 who isn't followed up because they've  
11 detransitioned or somebody who isn't  
12 followed up because they've taken their  
13 own life. We have no way of knowing  
14 because nobody's following up.

15 Q. All right. Look toward the  
16 bottom of this page 21. You cite a case  
17 series from I believe it's Djordjevic,  
18 D-J-O-R-D-J-E-V-I-C. Do you see that?

19 A. I do.

20 Q. And you say, "More dramatically,  
21 a surgical group prominently active in  
22 the SRS field has published a report on a  
23 series of seven male-to-female patients

1        requesting surgery to transform their  
2        surgically constructed female genitalia  
3        back to their original male form."

4        Right?

5            A.     I see that, yes.

6            Q.     Okay. Now, this article was not  
7        an RCT, obviously; right?

8            A.     Right, right.

9            Q.     It was not a cohort study;  
10       right?

11          A.     No. This would be a case -- a  
12       case series.

13          Q.     Yeah. The lowest level of  
14       evidence; right?

15          A.     No. Actually, the lowest level  
16       of evidence would be sort of single  
17       patient -- well, it's sort of somewhere  
18       between 4 and 5, I suppose. I'd have to  
19       look at the article again to see what the  
20       -- what the denominator is, but --

21          Q.     Yeah. Well, generally, you  
22       think that anecdotal patient stories like  
23       these are not reliable scientific

1 information; right?

2 MR. KNEPPER: Objection, form.

3 A. No. They're the first clue to a  
4 problem or the first clue to a solution.  
5 That's exactly right. So that -- that  
6 sort of points to the controversial  
7 nature of these therapies, is that -- is  
8 that we don't have the answer. We can't  
9 explain why these detransitioners weren't  
10 predicted preoperatively because we don't  
11 have a test instrument to figure that  
12 out.

13 So when you see a series like  
14 this -- this is what we talked about  
15 earlier, about the -- the history of  
16 progression of levels of evidence. You  
17 start out with reports like this. This  
18 leads to further research. And I'm just  
19 trying to remember, when I read the  
20 article, where that study was done. I  
21 don't have it in front -- I'm just trying  
22 to remember what -- what country that was  
23 done in.

1           Q.     Yeah.  I'll -- I'll show it to  
2     you.

3           A.     Okay.

4           Q.     Hold on.  Let me introduce it.

5           A.     Thank you.

6           Q.     You did read these -- this  
7     article in full before you cited it;  
8     right?

9           A.     Yeah.  That -- it was -- it was  
10    probably about seven months ago, but yes,  
11    I did.

12          Q.     Sure.

13                 THE COURT REPORTER:  I didn't  
14    hear anything.  So it's just --

15                 THE WITNESS:  Okay.

16                 THE COURT REPORTER:  We're  
17    losing it in Zoom.  Thank you.

18                 THE WITNESS:  Forgive me.  I'm  
19    sorry.

20                 THE COURT REPORTER:  No, that's  
21    okay.  It's awkward.

22          Q.     (By Mr. Tishyevich) Okay.  This  
23    is going to be Exhibit 18, and let me

1 know when you have it.

2 (Exhibit 18 was marked for identification  
3 and is attached.)

4 A. Okay. Okay. Yeah, there it is.  
5 Yes. Yeah, right. Okay. It's coming  
6 back to me now. And this was published  
7 out of the -- Amsterdam. That's right.  
8 Okay. All right. Yeah.

9 Q. All right. Let me ask you --  
10 strike that.

11 Bottom of the page, there's a  
12 section titled "Introduction." You see  
13 that?

14 A. The bottom of the first page?

15 Q. Yes.

16 A. Yes, I see that.

17 Q. Look at -- look to the column on  
18 the right.

19 A. Okay.

20 Q. The last sentence says, "In  
21 general, most researchers have reported  
22 their patients are extremely satisfied  
23 overall with their surgical outcomes,



1 with a low rate of complications." You  
2 see that?

3 (Witness reviews document.)

4 A. Right. I see -- I do see that,  
5 yes.

6 Q. Then it cites three footnotes, 5  
7 through 7; right?

8 A. Right.

9 Q. You don't acknowledge this  
10 portion of the article in your report;  
11 right?

12 A. Well, it is in the discussion, I  
13 think. Well, actually, probably maybe in  
14 the summary of the -- of the medical  
15 evidence. The -- I would put this in the  
16 category of subjective reporting and  
17 short -- subjective reporting and short  
18 follow-up. Right. That's what --

19 Q. Well, you --

20 A. I'm sorry. Go ahead.

21 Q. No, no, go ahead.

22 A. So I think the reason I included  
23 this was to show that there are -- you

1 know, that there's a growing pool of  
2 patients who are returning for reversal  
3 surgery. I don't think I discussed in  
4 this part of my report -- yeah. I'm just  
5 talking about increasingly visible  
6 community and patient -- increasing  
7 number of patients requesting reversal  
8 surgery. And as an example of that,  
9 again, going to a single-center case  
10 collection as an example, early evidence,  
11 we're starting to see this now as numbers  
12 of patients who have surgically  
13 transitioned increases, the numbers of  
14 patients who regret is going to increase,  
15 particularly in light of what these  
16 authors speak about here.

17 Let me see if I -- yeah. So in  
18 the second sentence of the abstract in  
19 the introduction, it says, "However,  
20 misdiagnosed patients sometimes regret  
21 their decisions." And one of the reasons  
22 for including this article is the fact  
23 that misdiagnosis is not measured. The

1 world literature doesn't present error  
2 rates. This would be what I would  
3 consider an error rate, that an erroneous  
4 diagnosis was acted upon surgically,  
5 leading to this complication of regret  
6 and a -- and a desire for reversal.  
7 Yeah.

8 Q. Your expert testimony is that  
9 there's no data available on the  
10 percentage of people who have received  
11 treatment for gender dysphoria who  
12 experience regret?

13 A. Yeah. It's very, very low --  
14 low-level evidence right now. It's  
15 basically we're in the -- we're in the  
16 case collection study, whereas actually  
17 in the -- well, that's not regret. But  
18 -- but perhaps in the category of  
19 misdiagnosis would be the -- the reports  
20 out of Sweden, certainly the -- yeah, so  
21 beginning with the Swede -- Swedish  
22 studies by Cecilia Dhejne and others that  
23 shows us a lack of efficacy. Whether or

1 not the patient presented for reversal is  
2 definitely an unknown number, definitely.

3 Q. All right. That study doesn't  
4 quantify anything about patient regret;  
5 right?

6 A. The Swedish study does not. It  
7 quantifies lack of -- of effect from the  
8 surgical interventions. Lack of benefit,  
9 I should say.

10 Q. Go to page -- PDF page 7 of this  
11 document and look at the Conclusions --

12 A. Okay.

13 Q. -- section.

14 A. All right. Let's see that page.  
15 Conclusions. Okay. I'm there.

16 Q. The first sentence says, "The  
17 vast majority of properly diagnosed  
18 transsexual patients are satisfied with  
19 their decision to undergo SRS, with only  
20 a few coming to regret it." Right?

21 A. Right. So this -- the other  
22 reason why this study is useful to our  
23 conversation is that this is the same

1 language and the same metrics that's used  
2 to describe the success of cosmetic  
3 surgery. They don't include in here,  
4 apart from the regret number that they're  
5 actually publishing here -- not number  
6 but the examples, I should say. They  
7 don't include in their -- in their  
8 conclusions any statement about objective  
9 quantifiable benefit from the surgery.  
10 They talk about subjective reporting.

11 So this is an example of a -- of  
12 a peer-reviewed journal article that  
13 measures the efficacy of this surgery  
14 based solely upon a satisfaction survey  
15 of patients who have returned for  
16 follow-up, so this would be an example of  
17 that. Yes, sir.

18 Q. Do you know what metric was used  
19 to measure satisfaction or  
20 nonsatisfaction in these studies?

21 A. I'd have to reread the -- the  
22 methods and materials here, but I  
23 would -- I would guess it was one of the

1 approved instruments for measuring  
2 satisfaction. There are a variety of  
3 test instruments used for -- in  
4 satisfaction surveys, particularly in the  
5 world of plastic surgery.

6 Let's see. They used the --  
7 these are the kind of things I don't keep  
8 in my long-term memory here for a  
9 particular article. Okay.

10 (Witness reviews document.)

11 A. Okay. There's the outcomes  
12 measures. Forgive me for eating up your  
13 time.

14 Q. Let me -- let help you, Doctor.  
15 Go to page --

16 A. Okay. There it is.

17 Q. -- PDF page 5.

18 A. Yeah. Fif- -- yeah.

19 Q. Yeah.

20 A. Fifteen, right.

21 Q. Question on the page --

22 A. So there's a -- there's a test  
23 instrument there. Right.

1           Q.     Yeah.  There's a test instrument  
2     that measures things like erectile  
3     function, sexual desire, orgasmic  
4     function, intercourse satisfaction, and  
5     overall satisfaction; right?

6           A.     Right.

7           Q.     They don't just ask the patient,  
8     "Hey, are you happy with the surgery?"  
9     There's five criteria that are applied;  
10    right?

11          A.     Right.

12          Q.     This is an approved instrument  
13    for measuring this type of satisfaction  
14    for surgery; right?

15               MR. KNEPPER:  Objection, form.

16          A.     This is -- this is -- yeah, it's  
17    definitely a valuable instrument for  
18    measuring things, but none of them are  
19    the -- are the indication for surgery,  
20    which is things like reduced suicidality,  
21    reduced self-harm, reduced alcohol use,  
22    all of those other things which are --  
23    which are the reason, the indication for

1 the operation. So you generally try to  
2 match the surgical procedure with the  
3 indication for the surgery.

4 They're measuring things that  
5 weren't involved in the indications for  
6 surgery. They didn't get, you know,  
7 reconstructive surgical approval so that  
8 they could achieve erections, for  
9 example. This was approved because of  
10 the risk of self-harm, suicide, those  
11 sorts of things. Yeah. But none of  
12 those are measured. They -- it is -- it  
13 is they do have objective measures, and  
14 this is one of the -- one of the values  
15 of this study. But I don't think they  
16 report the complication rate in this  
17 study, as I recall.

18 Q. This -- this study specifically  
19 did not purport to seek out anything  
20 about suicidality or mortality or other  
21 adverse outcomes of that nature; right?

22 A. Let's see. I'm trying to  
23 remember in their introduction.



1 (Witness reviews document.)

2 A. Yeah. I think their indications  
3 used language that was more consistent  
4 with -- with aesthetic, aesthetic surgery  
5 rather than the reconstructive language.  
6 So yeah.

7 (Witness reviews document.)

8 A. Yeah. So --

9 Q. Yeah. Here's --

10 A. Yeah, I would --

11 Q. Here's what I find interesting,  
12 Doctor.

13 A. Okay.

14 Q. Your report cites this one case  
15 series of seven patients to make the  
16 point that there's this regret occurring  
17 without even mentioning that there's  
18 multiple case series that say the vast  
19 majority of these patients end up being  
20 satisfied with this type of surgery?

21 A. No. I don't think --

22 Q. You don't think that's  
23 appropriate to mention?

1           A.     No.   I -- actually, what I  
2     present these examples to show, that --  
3     that the literature in support of these  
4     surgeries is characterized by very short  
5     follow-up and subjective reporting.   So  
6     this is an example of some objective  
7     reporting, mostly subjective reporting.  
8     And most of the articles, for example,  
9     that you just asked me about involve  
10    subjective reporting and short follow-up.  
11    That's right, yeah.

12          Q.     All right.

13          A.     And in this case, you also --  
14    I'm -- I'm pleased that they reported  
15    that one, two, three, four, five, six,  
16    seven -- so nearly half of their patients  
17    had a surgical complication of a urethral  
18    fistula, and if you have a urethral  
19    fistula and you have a malleable  
20    prosthesis, probably they went on to  
21    remove the prosthesis as well.   But  
22    that's -- I mean, I -- props for this --  
23    this team that they reported their

1 complications.

2 Q. Where -- what page is the  
3 complications portion you're looking at?

4 A. That's on -- just before you get  
5 -- the last page before the -- the same  
6 page as the conclusions. There's a table  
7 at the top, and they have the seven  
8 patients, and you can see -- what's also  
9 interesting here, too, is -- is that if  
10 you look at the period after sex  
11 reassignment surgery, that the -- that  
12 the dissatisfaction level really kicks in  
13 when you're beyond eight years.

14 Actually, if you look at even six years  
15 beyond.

16 Initially, there's no patients  
17 reporting dissatisfaction at anything  
18 less than five years, and so this is  
19 actually further evidence of the -- of  
20 the inadequacy of the -- the papers that  
21 are in the literature right now which  
22 have follow-ups that are typically two to  
23 three years. So none of these patients

1 would have been seen, with most of the  
2 literature that supports these  
3 techniques, as a way to, you know, avoid  
4 -- avoid dissatisfaction or -- or  
5 suicidality or drug use or anything else  
6 like that. So that's an interesting -- I  
7 hadn't noticed that before, but yeah.

8 Q. Yeah. Are you reading Table 1  
9 to say that these complications like  
10 urethral fistula and stricture were from  
11 the original surgery?

12 A. Well, I'm -- I'm merely --

13 Q. Or is it from the reversal  
14 surgery that was being done later?

15 A. So they're talking here about  
16 flaps. They're talking about  
17 complications from the -- the -- the  
18 surgeries. Yeah. So this --

19 Q. Yeah. This is --

20 A. They're speaking about urethral  
21 fistulas and strictures are the main  
22 problem after total phalloplasty. So  
23 that's the construct of the counterfeit

1       phallus because of insufficient vascular  
2       supply. I also discuss that in my  
3       complications section. These are  
4       characteristic complications of these  
5       free flaps, radial forearm free flaps,  
6       and you see those complications here.  
7       And you even see them later in -- in the  
8       case, so. Some of them are step  
9       procedures. In fact, all of them are.

10       Q. All right. Let me -- let me  
11       show you another study.

12       A. Okay.

13       Q. Let me reintroduce this with an  
14       exhibit -- exhibit stamp. Give me a  
15       second. All right. I'm reintroducing  
16       this as Exhibit 20. Let me know when you  
17       have it.

18       (Exhibit 20 was marked for identification  
19       and is attached.)

20       A. I just got Exhibit 19. Is there  
21       another? There's a 20 to follow?

22       Q. It -- it should load  
23       momentarily. Yeah.

1           A.     Oh, I'm sorry.

2                   MR. KNEPPER:   Are 19 and 20 the  
3     same, just one's missing the little  
4     stamp?

5                   MR. TISHYEVICH:   Correct.

6                   THE WITNESS:   Okay.   I'll just  
7     go to 20, then, when it comes in.

8           Q.     Okay.   This is a study titled  
9     "The Amsterdam Cohort of Gender Dysphoria  
10    Study (1972-2015): Trends in Prevalence,  
11    Treatment, and Regrets."   Do you see  
12    that?

13          A.     I do.

14          Q.     And then it's by an author,  
15    let's say Wiepjes, W-I-E-P-J-E-S.

16          A.     Yeah.

17          Q.     Right?

18          A.     I agree.

19          Q.     Have you seen this study before?

20          A.     I'm trying to gloss it to see if  
21    I've read this before.   I -- I may have.  
22    Give me just a moment, if that's okay.

23          Q.     Sure.

1 (Witness reviews document.)

2 A. Yeah, this looks familiar.

3 Q. I don't think I saw this in your  
4 report, but tell me if you remember  
5 otherwise.

6 (Witness reviews document.)

7 A. Yeah, no. I remember this being  
8 evidence of the growing population of  
9 self-reported transgender patients,  
10 and it's a retro- --

11 Q. Okay. Let me --

12 A. -- retrospective trial. Yeah.

13 Q. Yeah. Let's go through this.

14 A. Retrospective study, I should  
15 say.

16 Q. All right. You see the  
17 "Abstract" section on the first page?

18 A. I do.

19 Q. See the "Results" section?

20 A. I do.

21 Q. It says, "6,793 people (4,432  
22 birth-assigned male, 2,361 birth-assigned  
23 female) visited our gender identity

1 clinic from 1972 through 2015." See  
2 that?

3 A. I do.

4 Q. All right. So you understand  
5 that as part of this study, the authors  
6 reviewed medical records of 6,793 people  
7 who visited this gender identity clinic  
8 from 1972 to 2015; right?

9 A. I do.

10 Q. All right. And you see the  
11 "Strengths and Limitations" section?

12 A. Yes, I do.

13 Q. And you understand that this  
14 Dutch gender identity clinic treats more  
15 than 95 percent of the transgender  
16 population in the Netherlands; right?

17 A. Right.

18 Q. Pretty comprehensive study;  
19 right?

20 MR. KNEPPER: Objection, form.

21 A. As of 2015, yes. So it's a  
22 7-year-old study, and it's -- it's  
23 certainly large in numbers, that's for



1       sure. So it's a retrospective chart  
2       review of patients visiting the -- the  
3       center in the Netherlands, and it's -- it  
4       concludes in 2015.

5           Q.     This is certainly a better study  
6       than that seven series case report that  
7       you cited in your report; right?

8           A.     It's a different type of study.  
9       Yes, it is. Right.

10          Q.     Yeah. This study reports on  
11       6,793 people, whereas the case series on  
12       which you rely has seven what you call  
13       anecdotes; right?

14          A.     I wouldn't say I relied on that  
15       study. I merely presented it as an  
16       example of -- of reporting on transgender  
17       regret. I didn't present it as a study  
18       that I relied all my opinions on.  
19       Certainly, there's other study types and  
20       other studies in the literature that --  
21       that one might rely more heavily on.

22          Q.     Well, let the --

23          A.     A retro- -- a retrospective

1 chart review, for example, might be more  
2 useful.

3 Q. Yeah.

4 A. But not -- not definitive. And  
5 again, we've got to examine the fact that  
6 we're looking at old data here.

7 Q. Well, let's see what this  
8 30-year retrospective review found. Look  
9 at the "Results" section.

10 A. Scroll down. Okay.

11 Q. Look at the last two sentences.  
12 "The percentage of people who underwent  
13 gonadectomy within 5 years after starting  
14 HT remained stable over time" --

15 A. Right.

16 Q. -- "(74.7% of transwomen and  
17 83.8% of transmen). Only 0.6% of  
18 transwomen and 0.3% percent of transmen  
19 who underwent gonadectomy were identified  
20 as experiencing regret." Do you see  
21 that?

22 A. I do. And that has caused me to  
23 want to look back and see -- okay. So

1       they started with the 6,800, roughly, and  
2       they report on 6,000 -- 7,000 almost.

3       Okay. And clinic. Okay. And increase.

4               So I'm just trying to see if  
5       they reported the average follow-up.  
6       They're reporting when they underwent  
7       gonadectomy after starting hormone  
8       therapy, but they don't report the length  
9       of follow-up, which is one of the key  
10      reporting points there, because regret,  
11      as we talked about earlier, is a -- tends  
12      to be a function of time postsurgically.  
13      So, let's just scroll down because it's  
14      been a long time since I looked at this  
15      article. Transwomen, transmen total  
16      underwent gonadectomy.

17             Yeah. As I recall, they don't  
18      report average follow-up time. Every  
19      five-year cohort. So they're looking --  
20      they -- they did look at when they  
21      entered the system. Prevalence and  
22      treatment. Confidence interval.

23             Yeah, as I -- yes. So I think

1       that's -- this is coming back to me now.  
2       I think they didn't report the average  
3       follow-up or the -- let's see if I'm  
4       missing something here. Age for each  
5       year, so they did break them out in age  
6       that they -- they entered the -- the  
7       process, the years during which they  
8       entered the process, age groups. And  
9       yeah, I think that's -- that was one of  
10      the -- one of the issues.

11               And this is -- consonant with --  
12      with a lot of the literature, is they  
13      don't report the follow-up interval. And  
14      that's what the Swedish study is showing  
15      us, that if -- if you don't have a handle  
16      on the length of follow-up after sex  
17      reassignment surgery, then you don't have  
18      a -- you don't have any way to fully  
19      understand the issue of lack of efficacy  
20      or regret.

21               If you're asking the questions  
22      is the surgery effective in correcting  
23      the most calamitous problems that a

1 transgender person has, which is  
2 suicidality, self-harm, and all those  
3 things that we talked about earlier, then  
4 you have to look at the interval  
5 postsurgery in order to have a full  
6 understanding of the efficacy of the  
7 procedure. And as I recall now, looking  
8 it over again, this study does not report  
9 on the follow-up period. The median age  
10 at first visit was younger, 25. Yeah.  
11 So they talk about age. They talk about  
12 the years in which they were cared for,  
13 but they don't talk about the length of  
14 the follow-up interval, so.

15 Q. All right. Let me move on --

16 A. Okay.

17 Q. -- to save time.

18 A. All right.

19 Q. Go to page 4 and where it says  
20 "Regret."

21 A. Okay.

22 Q. You with me?

23 A. I am.

1           Q.     Third sentence says -- fourth  
2           sentence says, "Reasons for regret were  
3           divided into social regret, true regret,  
4           or feeling non-binary." You see that?

5           A.     I do.

6           Q.     And social regret -- strike  
7           that.

8                     It says, "Transwomen who were  
9           classified as having social regret still  
10          identified as women, but reported reasons  
11          such as 'ignored by surroundings' or 'the  
12          loss of relatives is a large sacrifice'  
13          for returning to the male role." Do you  
14          see that?

15          A.     I do.

16          Q.     All right. So some of the  
17          persons who are being counted as  
18          experiencing regret in the study did not  
19          experience regret in the sense of they're  
20          realizing they're not transgender; right?

21          A.     Realizing they're not  
22          transgender? I'm -- I'm trying to  
23          understand your question here. So you're

1 -- you're pointing me to the -- social  
2 regret, true regret, feeling non-binary  
3 is what's stated here.

4 "Transwomen who were classified  
5 as having social regret still identified  
6 as women, but reported reasons such as  
7 'ignored by surroundings' or 'the loss of  
8 relatives is a large sacrifice' for  
9 returning to the male role."

10 Okay. Yeah. So -- so it's --  
11 it's reporting without quantifying the  
12 reasons for regret and the -- basically  
13 all of them, subjective reporting again,  
14 so -- okay.

15 Q. Well -- well, let's go to page  
16 6.

17 A. That's the next page, isn't it?  
18 Am I on the right page?

19 Q. On page 6, it has a large  
20 vertical table on the left side.

21 A. Okay. There we are.

22 Q. And you may want to rotate it so  
23 that you can see that table 6.

1           A.     When I got -- let's see.

2           There's a way to do that, isn't there?

3           THE COURT REPORTER:   Yeah.   If  
4           you put your cursor over the document, a  
5           black rectangle will come up at the  
6           bottom.

7           THE WITNESS:   I see it now.

8           Yes.

9           THE COURT REPORTER:   There you  
10          go.

11          THE WITNESS:   All right.   There  
12          we are.

13          Q.     Table 4 is titled  
14          "Characteristics of people with regret."

15          A.     Okay.

16          Q.     According to this table, out of  
17          6,793 patients who received treatment, 14  
18          of them reported regret of any type;  
19          right?

20          A.     Okay.

21          Q.     And all the way on the right,  
22          you see there's a "Reason for regret"  
23          column; right?



1           A.     Right.

2           Q.     And you're welcome to count it,  
3     but by my count, only 7 of those 14  
4     reported, quote, unquote, true regret;  
5     right?

6           A.     Yeah.   And what's interesting  
7     about that is that those are the same  
8     criteria that were used to seek  
9     transgender surgery to solve their  
10    interior problems.   So many patients will  
11    present for care because they feel  
12    socially isolated and because they have,  
13    you know, issues of -- well, for example,  
14    being non-binary and so on, those --  
15    those -- like social acceptance and  
16    feeling non-binary is among the  
17    indications for the procedure.   So it's  
18    interesting to note also that time after  
19    surgery, the regretters seem to favor --  
20    postsurgical, you start to see them,  
21    what, maybe 50 to 90 months out and a lot  
22    of them, years -- ten years out.   Yeah.  
23    So that -- that speaks to what we talked

1       about earlier, that you see these regrets  
2       and these problems beyond five years.

3           Q.     All right.  Whatever criticism  
4       you have of the methodology, what the  
5       study reports is -- are rates of regret  
6       that are below 1 percent; right?

7           MR. KNEPPER:  Objection, form.

8           A.     Yeah.  Again, so as we talked  
9       about earlier, that's the problem with  
10      this study, is that -- is that the -- the  
11      denominator is a much larger number than  
12      these 14 patients, and they don't address  
13      the length of follow-up out of which they  
14      extracted these 14 patients.  So it makes  
15      it difficult to interpret the study, and  
16      the claim that it's a small number is  
17      hard to support by their own evidence  
18      because they didn't follow them long  
19      enough.  As their own data shows, you got  
20      to follow them longer to see the regret  
21      in most patients.  And they don't tell us  
22      what that number is.

23          Q.     Are you aware that there are

1 studies on patient regret outside of the  
2 treatment for gender dysphoria?

3 A. Am I aware of -- of transgender  
4 transition regret outside of --

5 Q. No. I'm going to ask -- I'm  
6 going to ask this again.

7 A. I'm sorry.

8 Q. Are you aware there are studies  
9 on rates of patient regret outside of  
10 surgical treatment for gender dysphoria?

11 A. Yes. Absolutely, yeah. So --

12 Q. Okay.

13 A. One of the -- one of the most  
14 important --

15 Q. Okay. Let me ask -- yeah,  
16 Doctor, let's -- this is going to be a  
17 long day. Just listen to my questions.

18 Did you do a literature search  
19 to find out what the average rates of  
20 patient regret are for other surgical  
21 procedures compared to surgical treatment  
22 for gender dysphoria?

23 A. I did not.

1           Q.     Do you know if those rates are  
2           higher, lower, or about the same as the  
3           rates of regret for surgical treatment  
4           for gender dysphoria?

5           A.     I would say there's no way of  
6           knowing because we don't have the -- the  
7           rate of regret in transgender regretters.  
8           We don't have that number, so there's no  
9           way to compare or to know which is the  
10          higher number.

11          Q.     Okay.

12          A.     Like we talked about earlier, we  
13          don't have this number.

14          Q.     Well, this one study I just  
15          showed you showed a finding of 0.3  
16          percent to 0.6 percent; right?

17          A.     Right. And I -- and as I said,  
18          this is -- this is -- it's difficult to  
19          use this to compare to other regret cases  
20          because of the poor quality of this  
21          study. So I can't use this to compare it  
22          to the other studies on regret because  
23          this is not -- not useful to that end. I

1 mean, it's useful in seeing that 14 -- 14  
2 regretters had these complications, 14  
3 regretters had these -- these  
4 explanations for their regret.

5 And so it's kind of like a case  
6 collection, and retrospective reviews of  
7 -- of patient records are helpful in  
8 getting a sense of the size of the  
9 problem. Certainly, this study shows us  
10 that there's an increasing patient pool  
11 of people who self-identify as  
12 transgender. So in that regard, this  
13 publication is very useful. But in terms  
14 of comparing the regret rate based on  
15 this paper, I'd say this paper is  
16 useless.

17 Q. Okay. Open Exhibit 21.

18 (Exhibit 21 was marked for identification  
19 and is attached.)

20 A. Okay.

21 Q. Let me know when you have it.

22 A. Okay.

23 Q. All right. This is a

1 publication from 2017 by Wilson,  
2 W-I-L-S-O-N, titled "Regret in Surgical  
3 Decision Making: a Systematic Review of  
4 Patient and Physician Perspectives." See  
5 that?

6 A. I do.

7 Q. All right. Look at the  
8 abstract. You with me?

9 A. I'm -- I'm looking -- I'm just  
10 reading it now.

11 Q. The third sentence says, "We  
12 performed a systematic review of the  
13 literature focused on patient and  
14 physician regret in the surgical  
15 setting." See that?

16 A. I do.

17 Q. Now look at "Results." See  
18 that?

19 A. I'm there now, yes.

20 Q. It says, "Of 889 studies  
21 identified, 73 patient studies and 6  
22 physician studies met inclusion  
23 criteria." Do you see that?

1           A.     I'm reading it now, yes.

2           Q.     I understand this is a  
3           systematic review of 73 patient studies  
4           and 6 physician studies on regret and  
5           surgical decision-making; right?

6           A.     That's what it says here, yes.

7           Q.     Then the third sentence of  
8           "Results" says, "Interestingly  
9           self-reported patient regret was  
10          relatively uncommon with an average  
11          prevalence across studies of 14.4%."  
12          Right?

13          A.     Right.

14          Q.     And then "Conclusion" says,  
15          "Self-reported decisional regret was  
16          present in about 1 in 7 surgical  
17          patients." You see that?

18          A.     I do.

19          Q.     All right. So according to this  
20          systematic review, one out of seven  
21          surgical patients, on average, report  
22          having decisional regret; correct?

23                 MR. KNEPPER: Objection, form.

1           A.     Right.   So actually, I would go  
2     a little deeper than that.   The first  
3     thing to note about this study -- and  
4     again, this is my first reading of it, so  
5     I'm on the fly here.

6                     The first thing to note about it  
7     is that they looked at nearly 900  
8     studies, of which only 73 qualified as  
9     having sufficient validity to include in  
10    their study.   So this -- this speaks to a  
11    problem in the literature.   I'd have to  
12    read lower to see what particular -- if  
13    they even examined what kind of surgeries  
14    were performed, because regret can happen  
15    for a number of reasons, including  
16    postsurgical complications and so on,  
17    types of surgery.

18          Q.     We don't need --

19          A.     Yeah.

20          Q.     We don't need to dig into this  
21    too deeply.   But, I mean, you don't  
22    dispute that regret is not uncommon for  
23    patients who have any kind of surgical



1 procedure; right?

2 MR. KNEPPER: Objection to form.

3 A. No. You know, there's --  
4 there's -- it's such a life-changing  
5 event that the potential for regret is  
6 very high, so that's why you have to be  
7 careful in consenting the patient.

8 Q. Okay. Let me -- let's go back  
9 to your report.

10 A. Okay.

11 Q. Because I hear you criticizing  
12 all this evidence, and I want to see the  
13 stuff that you're relying on. Go to page  
14 22.

15 A. All right.

16 Q. All right. About halfway down  
17 this paragraph, you say, "As reported by  
18 one author in 2021, 60,000 testimonies of  
19 personal de-transition can be found on  
20 the Internet."

21 A. Yeah, that's a typo. That's a  
22 typo. That should have been 16, not 60.

23 Q. Okay. Well, I think it's more

1       than that.

2           A.     Okay.

3           Q.     So we'll look at this in a  
4       second.

5           A.     Sure, sure.

6           Q.     And you cited this article from  
7       Pablo Exposito-Campos.

8           A.     Yes.

9           Q.     E-X-P-O-S-I-T-O, dash,  
10       C-A-M-P-O-S. Right? That's what you  
11       rely on; right?

12          A.     Not relying. I'm basically just  
13       putting that out there as an example of a  
14       growing number of patients regretting  
15       transitioning, yeah.

16          Q.     Well, no. What you say in your  
17       report is that according to this  
18       publication, you can find 60,000 -- or  
19       let's call it 16,000 testimonies of  
20       personal de-transition on the Internet;  
21       right? That's the point you're making?

22          A.     Sixteen thousand, right. Yeah.

23          Q.     Let's look at what that article

1       actually says.

2           A.     Okay.

3           Q.     Okay. This is going to be  
4       Exhibit 22. And let me know when you get  
5       it.

6           A.     Doesn't seem to be coming  
7       through.

8           Q.     Yeah, it may be stuck on my end.  
9       Okay. Just went through, so you should  
10      see it shortly.

11      (Exhibit 22 was marked for identification  
12      and is attached.)

13          A.     There it is. Okay. Right.

14          Q.     All right. This is the article  
15      that you're citing in your report; right?

16          A.     Uh-huh.

17          Q.     All right. So before we get  
18      there, you know that what this author was  
19      talking about was a Reddit website;  
20      right?

21          A.     Yeah. That was -- that was  
22      their data source, yeah. Right.

23          Q.     Reddit is not a peer-reviewed

1 publication, obviously; right?

2 A. Clearly.

3 MR. KNEPPER: Objection.

4 A. Yeah.

5 Q. Right?

6 A. Yes. It's not a peer-reviewed.

7 Q. It's a social website that  
8 anyone can access; right?

9 A. Right. Correct.

10 Q. Anyone can post -- can register  
11 an account on Reddit and post whatever  
12 they want; right?

13 A. Right.

14 Q. A post on Reddit is not  
15 something that you would consider  
16 reliable scientific evidence, I assume;  
17 right?

18 A. Yeah, no.

19 MR. KNEPPER: Objection, form.

20 A. I would -- I would put that as  
21 self-reporting anecdotal-level evidence,  
22 that's right. So it's -- it's not  
23 definitive, but it's suggestive of an

1 area in need of examination. And that's  
2 the reason I include it here, is not as  
3 definitive evidence of a particular level  
4 of problem but the -- the presence of a  
5 problem that needs to be addressed. So  
6 the substance of my testimony there where  
7 I call this study up is to show that  
8 there's a growing body of patients, as we  
9 talked about earlier, a growing body of  
10 patients who regret their transition and  
11 are seeking reversal. So that's what  
12 this is about.

13 It's not a quantification of the  
14 phenomenon. It's not a level 3 evidence  
15 of the phenomenon. It's a level 5,  
16 self-reported, anecdotal stuff that --  
17 that is basically just calling us to look  
18 more carefully at what promises to be a  
19 controversial area of medical care. So  
20 this is just part -- part of the  
21 controversy is what we're looking at  
22 here. We're not looking at a definitive  
23 scientific document, so.

1           Q.     It's not even level 5 because at  
2     least a case report that's published in a  
3     peer-reviewed journal has someone looking  
4     at that case report to figure out if it's  
5     a real thing; right?

6           A.     Right.

7           MR. KNEPPER:   Objection, form.

8           A.     What we have here is a clinical  
9     psychologist who's looking at something  
10    going on online, and the clinical  
11    psychologist is -- is reporting this,  
12    that's right.

13          Q.     Go to page 4 of this article.

14          A.     One, two, three, four.   Okay.

15          Q.     See there's a second paragraph  
16    under "Further clarifications"?

17          A.     Yes, I do.

18          Q.     All right.   And it references  
19    this Reddit/detrans subreddit; right?

20          A.     Right.

21          Q.     And it says it's "a subreddit  
22    for detransitioners to share their  
23    experiences with more than 16,000

1 members."

2 A. That's correct.

3 Q. Right?

4 A. Uh-huh.

5 Q. Then it says, "one can find  
6 several stories of people who call their  
7 transgender status into question." You  
8 see that?

9 A. Right.

10 Q. All right. This author is not  
11 saying that there's 16,000 separate  
12 testimonies of people tran- --  
13 detransitioning on that subreddit; right?

14 A. I think the author is saying  
15 that there's a pool of 16,000 people  
16 among whom are evidence of regret or  
17 cessation of transition. That's what --  
18 I think that's what the author's saying.

19 Q. Well, let's be more specific,  
20 because what he actually says is "one can  
21 find several stories." Right?

22 A. Right.

23 Q. There's a very big difference

1       between, quote, several stories and  
2       16,000 stories of detransitioning; right?

3       A.     I think what the author is  
4       saying is that -- that there are -- let's  
5       see. Subreddit -- detran- --  
6       experiences -- more than 16- -- one can  
7       find several stories of a particular kind  
8       of transgender -- persons who call their  
9       transgender status into question after  
10      stopping transition.

11             So the several stories have to  
12      do with people who call their transgender  
13      status into question. Not people who  
14      regret the surgery, but these are people  
15      who regret the diagnosis. So he's  
16      talking about several stories of  
17      regretters of the diagnosis. It doesn't  
18      speak about regretters of the transition.  
19      He doesn't address that in that.

20      Q.     All right. A bunch of posts on  
21      a social website is not scientifically  
22      reliable evidence to show the number of  
23      different people who actually



1        detransition; right, Doctor?

2                MR. KNEPPER:    Form.

3                A.        Yeah.    As we said before, we  
4        have no way of -- at present, of knowing  
5        the number of people.

6                Q.        Okay.    Go back to your report.

7                A.        Okay.

8                Q.        Go to page 40.

9                A.        All right.    Okay.

10              Q.        All right.    Your first paragraph  
11        at the top of this page says, "A  
12        currently unknown percent-" --  
13        "percentage and number of patients  
14        reporting gender dysphoria are being  
15        manipulated by a -- peer group, social  
16        media, YouTube role modeling, and/or  
17        parental -- social contagion and social  
18        pressure processes."    Right?

19              A.        That's right.

20              Q.        I take it you're not aware of  
21        any peer-reviewed studies that quantifies  
22        the number of people with gender  
23        dysphoria that are being, quote, unquote,

1 manipulated by social contagion or social  
2 pressure; right?

3 A. Again, as I said before, we  
4 don't know the numbers because that's not  
5 -- it's not adequately reported in the  
6 literature. But what we do know is that  
7 the social -- Lisa Littman's article, for  
8 example, in 2017 shows us that there's a  
9 significant factor in this new  
10 demographic of self-reported transgender  
11 patients, the new demographic being  
12 adolescent to young adult females without  
13 prior history of gender dysphoria or  
14 gender discordance suddenly reporting  
15 transgender self-identification.

16 And -- and what it shows us,  
17 what Lisa -- Lisa Littman's publication  
18 from Brown University shows us is that  
19 underlying these outbreaks is peer group  
20 networks of people online, peer groups  
21 online, social media, a modeled speech, a  
22 rehearsed speech, and -- and these --  
23 these sudden outbreaks of -- of

1 self-identified transgender patients.

2           So we know it's there, but we  
3 can't quantify it yet. It's just it's --  
4 but it's -- we have at present no other  
5 explanation for why the demographic of  
6 self-reported transgender patients has  
7 suddenly shifted from virtually all young  
8 boys to 50 to 60 percent of the new cases  
9 being adolescent to young adult females.  
10 And that's -- that's what we're -- what  
11 we're talking about here. This just  
12 speaks to the controversial nature of  
13 this -- medical and surgical  
14 interventions is that we don't even  
15 understand the origin of that phenomenon.  
16 And -- and what that Littman article  
17 shows us is precisely these things: that  
18 there's an element of social contagion,  
19 that there's peer pressure, there's  
20 rehearsed speech, online networks that  
21 cause these outbreaks of these new kind  
22 of patients, adolescent young adult  
23 females who previously had no

1 self-reporting of trans- -- cross-sex  
2 self-identification.

3 MR. TISHYEVICH: This is not  
4 responsive to my question, and I move to  
5 strike it.

6 Q. Here's my question, Doctor. You  
7 are not aware of any peer-reviewed study  
8 that quantifies the number of people with  
9 gender dysphoria who are being  
10 manipulated by social contagion or social  
11 pressure; correct?

12 A. No. We're at the -- we're at  
13 the level of level 4/5 evidence now.  
14 Lisa Littman's article is a level 5,  
15 possibly 4. A level 5. So --

16 Q. It's not a -- you're also not  
17 aware of any peer-reviewed study that  
18 quantifies the percentage of people with  
19 gender dysphoria who are being  
20 manipulated by social contagion or social  
21 pressure; correct?

22 A. No. That's part of the -- part  
23 of the problem with the literature.

1 Exactly right.

2 Q. Yeah.

3 A. Exactly right.

4 Q. Given this lack of reliable  
5 studies, do you agree that this  
6 phenomenon of social contagion is  
7 currently hypothetical?

8 MR. KNEPPER: Objection, form.

9 A. I would not agree with that.  
10 It's not hypothetical.

11 Q. Do you -- did you read the  
12 response from Lisa -- from Littman to the  
13 criticisms to that article?

14 A. I did. And -- and I also noted  
15 that the -- the -- the organization under  
16 which she published that article put  
17 considerable pressure on her. But she  
18 can't retract her data. She can retract  
19 her conclusions, but she can't retract  
20 her data, and she can't retract the  
21 findings in the paper itself that show  
22 the rehearsed speech, that show the  
23 networks that are involved, that showed

1 the -- the character of the -- the  
2 rehearsed speech, like, you know, if  
3 you're talking to the psychologist, tell  
4 them you've been thinking about suicide;  
5 if you're talking to the endocrinologist,  
6 tell them you feel better now that you're  
7 started on T, that sort of stuff. So --  
8 so it's not hypothetical, it's actual.

9 The -- the size of the  
10 phenomenon can only be compared to the  
11 change in the demographic. Why are 60  
12 percent of patients fitting into that  
13 category suddenly, whereas before, only  
14 20 percent of patients were females?

15 Q. Do you remember --

16 A. That's what --

17 Q. Okay. Do you remember the part  
18 of the correction from Ms. Littman where  
19 she said that this is a  
20 hypothesis-generating article?

21 A. Hypothesis as to -- as to  
22 mechanism of -- of action, and some of  
23 the hypotheses are what's listed there:

1 social network peer -- media -- I'm  
2 sorry -- peer pressure, social media,  
3 role modeling, social contagion. So she  
4 admits that is a -- it is not understood.  
5 She admits that those phenomena are  
6 there, but it -- at present, we're  
7 hypothesizing about the actual cause.  
8 And this speaks again to the  
9 controversial nature of even the  
10 diagnosis, much less the treatment.

11 Q. Go back to your report.

12 A. Okay.

13 Q. Page 40.

14 A. I'm there.

15 Q. Toward the bottom, you say, in  
16 capital letters, "Not Generally  
17 Accepted." You see that?

18 A. I do.

19 Q. And you say, "Affirmation  
20 medical treatments -- hormones and  
21 surgery -- for gender dysphoria and  
22 transitioning have not been accepted by  
23 the relevant scientific communities." Do

1       you see that?

2           A.     I do.

3           Q.     It's your expert opinion that  
4       it's generally accepted that puberty  
5       blockers are not medically necessary;  
6       right?

7           A.     No.

8                   MR. KNEPPER:  Objection, form.

9           A.     I would say puberty blockers in  
10      the setting of a self-identified  
11      transgender is not medically necessary,  
12      but puberty blockers are often medically  
13      necessary, just not in that particular  
14      patient population.

15          Q.     Is it also your expert opinion  
16      that it's generally accepted that hormone  
17      treatment for gender dysphoria is not  
18      medically necessary?

19          A.     Well, the scientific evidence  
20      now shows that it is -- is not useful.  
21      That's what I said --

22          Q.     Answer my question.  Is it your  
23      expert opinion that it's generally



1       accepted that hormone treatment for  
2       gender dysphoria is not medically  
3       necessary?

4           A.     Yes.

5           Q.     Is it also your expert opinion  
6       that it's generally accepted that  
7       gender-affirming surgery for gender  
8       dysphoria is not medically necessary?

9           A.     Yes. I would say so, yeah. I  
10       can't put a number on it, but yeah.

11          Q.     All right. Let me -- let me  
12       show you another document. Okay. Let me  
13       introduce this. Okay. This is going to  
14       be Exhibit 23. And let me know when you  
15       get it.

16       (Exhibit 23 was marked for identification  
17       and is attached.)

18          A.     Okay. All right. I'm there.

19          Q.     Okay. Top of the page says,  
20       "BlueCross BlueShield of North Carolina."  
21       Right?

22          A.     Correct.

23          Q.     You know what Blue Cross and

1 Blue Shield is; right?

2 A. Right.

3 Q. It's a healthcare insurer;  
4 right?

5 A. Yes.

6 Q. Are you aware that Blue Cross  
7 Blue Shield is the largest private  
8 insurer in the state of North Carolina?

9 A. I am now.

10 MR. KNEPPER: Objection, form.

11 Q. All right. This document is  
12 titled "Corporate Medical Policy,"  
13 "Gender Affirmation Surgery and Hormone  
14 Therapy." Right?

15 A. Right.

16 Q. Do you know what this is?

17 A. Do I know what what is?

18 Q. Do you know what this document  
19 is?

20 A. It appears to be an insurance  
21 company document concerning the coverage  
22 of certain services. I would have to  
23 read it to know what it is specifically,

1 but I think it's probably a policy  
2 statement about what is covered and what  
3 is not covered and what the diagnostic  
4 criteria are.

5 Q. Yeah.

6 A. What the policy of the company  
7 is. Yeah. So, shall I read it or?

8 Q. I'll walk you through it.

9 A. Okay.

10 Q. You see it says "Last Review"  
11 near the top?

12 A. Right.

13 Q. It's 3/2021. That's March 2021;  
14 right?

15 A. Yes.

16 Q. All right. You understand this  
17 policy was a -- strike that.

18 In your report, you cite a  
19 number of articles that you say Dr. Brown  
20 and Dr. Schechter overlooked, like a  
21 bunch of 2020 articles; right?

22 A. Right.

23 Q. You understand this was

1 published -- updated after all those  
2 studies that you cited were published;  
3 right?

4 A. It appears to be.

5 Q. Okay. Go to page 7. You see it  
6 says "Scientific Background and Reference  
7 Sources"?

8 A. Right.

9 Q. You understand this section of  
10 the policy provides some of the  
11 scientific background on which the policy  
12 is based; right?

13 A. I see that, yes.

14 Q. And if you go to page -- the  
15 next page, page 8, you see there's a  
16 bunch of references to Specialty Matched  
17 Consultant Advisory Panel; right?

18 A. I see that, yeah.

19 Q. And there's some references to  
20 sen- -- Senior Medical Director reviews;  
21 right?

22 A. I see that, yeah, from 2016.

23 Q. Yeah. Well, if you keep

1       looking, there's a bunch from 2020;  
2       right?

3           A.     I see medical director review in  
4       2020.   Yes, I do.   I see that.

5           Q.     And then including a medical  
6       director review in March 2021; right?

7           A.     I see it.   That's probably what  
8       generated this document.   Am I right?

9           Q.     Yeah.   Good guess.   Now,  
10      obviously --

11          A.     That's why they pay me the big  
12      bucks.   Sorry.

13          Q.     Obviously, you had no  
14      involvement with the development of this  
15      policy from BlueCross BlueShield of North  
16      Carolina; right?

17          A.     Correct.

18          Q.     You have no idea how BlueCross  
19      BlueShield of North Carolina came to  
20      decide what gender affirmation surgeries  
21      or hormone therapy they're going to cover  
22      or not; right?

23          A.     Wrong.   I -- I have now some

1 idea of what they used because you've  
2 listed -- or they've listed the  
3 scientific background and reference  
4 sources for coming to their company  
5 policy. And what I would point you to is  
6 the fact that every one of the documents,  
7 the scientific documents that support  
8 their decision-making, I think the most  
9 recent one is 2014. You've got some that  
10 go back to the year 2000. So you've got  
11 21-year-old DSM-4 characterizations.  
12 You've got 2001 Harry Benjamin Gender  
13 Dysphoria Association publications. The  
14 most recent thing is a -- is a -- well,  
15 that's actually an advisory panel. So  
16 the most recent medical article is the  
17 Cohen-Kettenis Hembree article from 2016.  
18 So what's used to support a March 2021  
19 document is essentially six-year-old  
20 information. And as we talked about  
21 earlier, it hasn't -- it's changed a lot.  
22 It's changed a lot since then.

23 The fact that Blue Cross Blue

1       Shield is slow off the mark would be  
2       troublesome to the shareholders, I  
3       suppose. But as far as what I'm here to  
4       talk about, the scientific basis for  
5       this, the scientific basis is old data.

6       Q. Doctor, you don't know whether  
7       this is an exhaustive list of every  
8       scientific resource that Blue Cross Blue  
9       Shield considered in making the March  
10      2021 update; right? You have no idea?

11           MR. KNEPPER: Objection, form.

12      A. I can only go by what they've  
13      disclosed.

14      Q. Right.

15      A. And what they've disclosed --  
16      which I would assume they would be  
17      leading with their best information  
18      rather than their worst -- I would call  
19      that -- the scientific support of low  
20      quality because of the -- the  
21      better-quality data that's now available  
22      in the last three years.

23      Q. You don't know personally

1       whether Blue Cross Blue Shield considered  
2       any of the articles that you've cited  
3       when they're making this policy change in  
4       2021; right? You don't know that?

5           A.     I have no way of knowing how --

6           Q.     Yeah.

7           A.     -- that committee worked. I  
8       only -- I only assume that they would  
9       have put out their best scientific  
10      support rather than their weakest.

11          Q.     Yeah. Bottom of this page, by  
12      the way, see there's a section that says,  
13      "Policy Implementation/Update  
14      Information"?

15          A.     Yes, I see that.

16          Q.     And it says, "7/19/11" --

17          A.     Yeah.

18          Q.     -- "New policy developed."  
19      Right?

20          A.     Right.

21          Q.     You understand that Blue Cross  
22      Blue Shield has had some form of this  
23      policy for gender affirmation surgery



1       since July 2011?

2               MR. KNEPPER:   Objection, form.

3               A.     I can see that they have had a  
4       policy, according to their own reporting,  
5       since July of 2011.

6               Q.     All right.   So, let's look at  
7       what Blue Cross Blue -- Blue Cross Blue  
8       Shield thinks about whether these  
9       procedures are medically necessary.   Go  
10      to page 5.

11              A.     Let's see.   So we're at page 8.  
12      We're going up to page 5?   Okay.   Okay.

13              Q.     Give me a second.   Actually, let  
14      me start you on page 1.   You see there's  
15      a description of -- let me know when you  
16      get there.

17              A.     I'm there.

18              Q.     Okay.   Now, the beginning says,  
19      "Gender Dysphoria is the formal diagnosis  
20      used by professionals to describe persons  
21      who experience significant gender  
22      dysphoria (discontent with their  
23      biological sex and/or birth gender)."

1 Right?

2 A. Yes, I see that.

3 Q. All right. You understand what  
4 this policy is addressing; right?

5 A. Yeah. It's addressing a  
6 psychiatric classification, not medically  
7 classified as a medical illness. So  
8 they're -- yeah.

9 Q. Okay. Go to page 2.

10 A. Can you give me just a moment to  
11 reread that sentence for just a second.

12 (Witness reviews document.)

13 A. Okay. Yeah. So that's  
14 boilerplate. I'm sorry. Sorry for  
15 slowing you down here.

16 Q. That's fine. Go to page 2.

17 A. Okay.

18 Q. Top of the page says, "Policy."  
19 Right?

20 A. Correct.

21 Q. And it says, "Services for  
22 gender affirmation surgery and hormone  
23 therapy may be considered medically

1       necessary when the criteria below are  
2       met."   You see that?

3           A.     Right.   So that's -- that's  
4       language that insurance companies use.  
5       If you're not in the category of medical  
6       necessity, there's no insurance coverage.  
7       So whether or not one could classify it  
8       as a medical diagnosis is not at issue.  
9       What's at issue is, is the insurance  
10      company going to cover this -- this  
11      benefit.

12          Q.     Yeah.   Because insurers  
13      typically are not in the business of  
14      covering services that are not medically  
15      necessary; right?

16          A.     No.   I wouldn't --

17                  MR. KNEPPER:   Objection, form.

18          A.     -- characterize it that way.

19                  THE WITNESS:   I'm sorry.

20          A.     I wouldn't characterize it that  
21      way.   Insurance companies are in the  
22      business of -- certainly, they're in the  
23      business of -- of paying for covered

1       benefits. But that's the problem with  
2       the insurance industry, is their primary  
3       fiduciary duty is to their investors.  
4       And so the question of coverage has more  
5       to do with are we going to make an  
6       insurance policy that earns us money or  
7       are we going to be paying for something  
8       and not seeing the money. Okay? Does  
9       that make sense?

10       Q. Doctor, you --

11       A. I think that's what -- that's  
12       what this language here is talking about  
13       is -- is medical necessity is the  
14       language that's used when an insurance  
15       company will cover. They will not cover  
16       cosmetic surgery, but they're -- they're  
17       proposing to cover transgender surgery  
18       beginning by attempting to define it as a  
19       medical diagnosis. That's what's at  
20       stake here is.

21       Q. No. What -- what this policy  
22       says is that when certain criteria are  
23       met --

1           A.     Right.

2           Q.     -- gender affirmation surgery  
3           and hormone therapy may be considered  
4           medically necessary; right? That's what  
5           it says in black and white.

6                     MR. KNEPPER: Objection, form.

7           A.     Yeah, again, so medically  
8           necessary from the standpoint of an  
9           insurance company is if you meet these  
10          criteria, we'll pay for it; if you don't  
11          meet these criteria, we won't pay for it.  
12          That's -- that's --

13          Q.     Right. And the difference is  
14          whether the surgery is considered to be  
15          medically necessary or not; right?

16                     MR. KNEPPER: Objection, form.

17          A.     Well, again, so medically  
18          necessary in this case is has the  
19          insurance company decided that they're  
20          going to cover this benefit. It says  
21          nothing about the scientific support for  
22          the efficacy of the procedure. They  
23          haven't said anything in that about it.

1       They've just called it medically  
2       necessary.

3           Q.     All right.   Let's -- let's go  
4       off the record.

5           A.     Okay.

6                   THE VIDEOGRAPHER:   This is the  
7       end of Media Unit No. 5.   We are off the  
8       record at 3:25 p.m.

9                           (Break taken.)

10                   THE VIDEOGRAPHER:   This is the  
11       beginning of Media Unit No. 6.   We are on  
12       the record at 3:36 p.m.

13           Q.     (By Mr. Tishyevich) All right.  
14       I'm going to introduce another exhibit,  
15       Doctor.

16           A.     Okay.

17           Q.     It's being slow on my end.   Bear  
18       with me.   Okay.   This will be Exhibit 24.  
19       Let me know when you have it.

20       (Exhibit 24 was marked for identification  
21       and is attached.)

22           A.     I will.   Okay.   I've got it.

23           Q.     Okay.   You've seen this study

1 before; right?

2 A. Yes, I have.

3 Q. How do you pronounce the lead  
4 author's name?

5 A. That's the subject of great  
6 debate, but I think it's Dhejne or -- I  
7 think it's Dhejne, Cecilia Dhejne, but  
8 I -- I -- I'm not -- I'm not a  
9 Swissophone.

10 Q. I'll use Dhejne as well.

11 A. Okay.

12 MR. TISHYEVICH: And for the  
13 court reporter, it's D-H-E-J-N-E.

14 Q. Okay. This is a study from  
15 2011; right?

16 A. Yes.

17 Q. And you cited this study in  
18 several places in your report --

19 A. I do.

20 Q. -- right?

21 And one of the points for which  
22 you cite this study is to say that  
23 Swedish patients who underwent

1 gender-affirming surgery had a 19.1 times  
2 greater suicide rate than the control  
3 group; right?

4 A. Yeah. The hazard ratio for --  
5 well, for all reassigned persons is 19.1,  
6 and they further break out the -- that  
7 into subgroups of female-to-male and  
8 male-to-female.

9 Q. Yeah. And you understand how  
10 the control group in this study was  
11 defined; right?

12 A. Yes.

13 Q. The control group did not  
14 consist of patients with gender dysphoria  
15 who did not undergo gender-affirming  
16 surgery; correct?

17 A. Correct.

18 Q. The control group consisted of  
19 patients without gender dysphoria; right?

20 A. Yeah. That's kind of the point  
21 of the -- of the research, yes. That's  
22 right.

23 Q. Yeah. What this Dhejne study



1 compared was the suicide rate for  
2 patients who underwent gender-affirming  
3 surgery against the general Swedish  
4 population; right?

5 A. Right.

6 Q. And you know there's many  
7 studies that find that patients with  
8 gender dysphoria, as a population, have a  
9 higher risk of suicide compared to the  
10 general population; right?

11 A. Very much accepted fact, yes.

12 Q. Yeah. All right. We'll go to  
13 page 7.

14 A. Let's see here.

15 Q. You see there's a "Strengths and  
16 limitations of the study" section?

17 A. Two, three, four, five, six,  
18 seven. Yes, I'm there.

19 Q. All right. Look at the third  
20 full paragraph in that column.

21 A. Okay.

22 Q. All right. Second sentence  
23 says: "The caveat with this design is

1       that transsexual persons before sex  
2       reassignment might differ from healthy  
3       controls (although this bias can be  
4       statistically corrected for by adjusting  
5       for baseline differences). It is  
6       therefore important to note that the  
7       current study is only informative with  
8       respect to transsexual persons health  
9       after sex reassignment; no inferences can  
10      be drawn as to the effectiveness of sex  
11      reassignment as a treatment for  
12      transsexualism."

13                You see that?

14           A.     Right. Yeah.

15           Q.     Then it says: "In other words,  
16      the results should not be interpreted  
17      such as sex reassignment per se increases  
18      morbidity and mortality. Things might  
19      have been even worse without sex  
20      reassignment." Correct?

21           A.     Yeah. It's -- the -- let's see.  
22      The -- yeah, so -- and I don't think I  
23      ever make the claim that the surgery

1 increases the risk of morbidity and  
2 mortality. Yeah, I -- I would agree with  
3 that.

4 Q. Yeah, no --

5 A. But I would -- I would also  
6 wonder on what basis they -- there's  
7 nothing to support that it might have  
8 been worse either. It's for the same  
9 reason.

10 Q. Yeah. This study does not  
11 support the conclusion that sex  
12 reassignment surgery by itself increases  
13 risk of suicide; correct?

14 A. That's what they -- they say,  
15 yes.

16 Q. And they also say that this  
17 study does not support the conclusion  
18 that surgical procedure for gender  
19 dysphoria by themselves increase risk of  
20 morbidities other than suicide; right?

21 A. Right.

22 Q. Okay. All right. Let me -- you  
23 mentioned that -- in your report the 2020

1 Finland guidelines. You recall that?

2 A. I do.

3 Q. Let me ask you a couple of  
4 questions on those.

5 A. Okay.

6 Q. So I'll introduce another  
7 exhibit. This will be Exhibit 25, and  
8 let me know when you get it.

9 (Exhibit 25 was marked for identification  
10 and is attached.)

11 A. Okay.

12 Q. Let me ask you before we get  
13 into this, look at page 46 of your  
14 report.

15 A. Okay.

16 Q. Near the top, there's a "2020 -  
17 Finland" reference. You see that?

18 A. I see that, yeah.

19 Q. You say, "This new Finnish  
20 guidance prioritizes psychological  
21 therapy over treatment with hormones or  
22 surgery and suggests different care plans  
23 for early-onset vs late-onset childhood

1 gender dysphoria." You see that?

2 A. I do.

3 Q. And then you say in the last  
4 sentence, "The Finland National  
5 Guidelines appear quite contrary to the  
6 opinions of Drs Brown and Schechter and  
7 WPATH." Do you see that?

8 A. I do.

9 Q. Is it your opinion that the  
10 WPATH guidelines recommend that children  
11 who experience gender dysphoria should  
12 transition to a different gender role?

13 MR. KNEPPER: Objection, form.

14 A. No. I would say that the WPATH  
15 guidelines essentially leaves us with  
16 affirmation care only, that it does -- it  
17 does, you know, recom- -- recommend all  
18 of the psychological support but all of  
19 it in support of transition. I would say  
20 that. Yeah.

21 Q. Yeah. The WPATH guidelines do  
22 not recommend that children with gender  
23 dysphoria automatically be put on puberty

1 blockers; right?

2 A. They don't make that  
3 recommendation, no. They don't state  
4 that recommendation, no.

5 Q. Yeah. Let's look at what they  
6 actually say.

7 A. Okay.

8 Q. I'm going to introduce one more  
9 exhibit.

10 A. So we're going to leave the  
11 Finland article for now and go to --

12 Q. Yeah. We'll come back to it. I  
13 want to show you the WPATH --

14 A. Okay.

15 Q. -- Standards of Care Version 7  
16 first.

17 A. Uh-huh.

18 Q. All right. This will be Exhibit  
19 26. Let me know when you have it.  
20 (Exhibit 26 was marked for identification  
21 and is attached.)

22 A. Okay.

23 Q. This is a larger file, so this

1       may take an extra minute or so.

2           A.     Okay. I've got it.

3           Q.     Okay. These are the WPATH  
4 Standards of Care Version 7; right?

5           A.     Yes.

6           Q.     Turn to page 23.

7           A.     Okay.

8           Q.     All right. There's a section  
9 titled "Social Transition in Early  
10 Childhood." You see that?

11          A.     I must be on the wrong page.  
12 Did you say page 23?

13          Q.     It's PDF page 23, which is going  
14 to be page 17 in the standards.

15          A.     Oh, I'm sorry. Okay. Let's go  
16 back, then. Page 17. Okay. I'm there.  
17 Right. "Social Transition in Early  
18 Childhood."

19          Q.     All right. It says: "Some  
20 children state that they want to make a  
21 social transition to a different gender  
22 role long before puberty. For some  
23 children, this may reflect an expression

1 of their gender identity. For others,  
2 this could be motivated by other forces."

3 You see that?

4 A. I do.

5 Q. And then a couple of sentences  
6 down, it says: "This is a controversial  
7 issue, and divergent views are held by  
8 health professionals. The current  
9 evidence base is insufficient to predict  
10 the long-term outcomes of completing a  
11 gender role transition during early  
12 childhood." You see that?

13 A. I do.

14 Q. All right. The WPATH Standards  
15 of Care Version 7 is not making any  
16 clinical recommendations encouraging  
17 children in early childhood to go through  
18 gender transition roles; correct?

19 A. Yeah, I would -- yes. I would  
20 add to that that they're also not  
21 offering any clinical guidance on how to  
22 distinguish who might or who might not be  
23 suitable for transition. Right.



1 Q. Do you know whether that's  
2 explored somewhere else in this Standards  
3 of Care Version 7?

4 A. Yeah. I think it's discussed.

5 Q. Okay.

6 A. But -- but it's -- but I --  
7 yeah. So what's -- what's important, I  
8 think, in what you cite here is that the  
9 current evidence base is insufficient to  
10 predict the long-term outcome. Yes.

11 Q. Okay. Go to the next page.

12 A. Okay.

13 Q. Page 18, PDF page 24.

14 A. Okay.

15 Q. There's a section titled  
16 "Physical Interventions for Adolescents."

17 A. Right.

18 Q. Right?

19 A. Yes.

20 Q. You understand that adolescents  
21 are different than children; right?

22 MR. KNEPPER: Objection, form.

23 A. Well, yeah. So, adolescents are

1       treated in pediatric clinics, but they're  
2       different from prepubertal children, yes.

3       Q.     Yeah. This section does not  
4       provide any clinical recommendations for  
5       hormone therapy in prepubescent children;  
6       right?

7       A.     Let's see. I've just got to  
8       refresh my memory here on the verbiage.

9             (Witness reviews document.)

10      A.     Yeah. So it -- it addresses the  
11      important issue of gender fluidity in  
12      adolescents, potential for shift to  
13      conformity and -- that may not persist.  
14      Yeah. Right.

15      Q.     Okay. And this section also  
16      does not provide any clin- -- clinical  
17      recommendations for surgical intervention  
18      in prepubescent children; right?

19      A.     This section doesn't address  
20      prepubescent children. It addresses  
21      adolescents.

22      Q.     Yeah, exactly. And you don't  
23      know of any other section in these

1 Standards of Care Version 7 that provide  
2 those guidelines for prepubescent  
3 children; right?

4 A. No.

5 Q. Okay. Go to the next page, PDF  
6 page 25, page 19 in the document.

7 A. Okay.

8 Q. And you see there's a section  
9 that says, "Criteria for  
10 Puberty-Suppressing Hormones"?

11 A. Yes.

12 Q. It says, "In order for  
13 adolescents to receive  
14 puberty-suppressing hormones, the  
15 following minimum criteria must be met."  
16 You see that?

17 A. Yes.

18 Q. And then there's four items;  
19 right?

20 A. Yes.

21 Q. Number 4 says, "The adolescent  
22 has given informed consent and,  
23 particularly when the adolescent has not

1       reached the age of medical consent, the  
2       parents or other caretakers or guardians  
3       have consented to the treatment and are  
4       involved in supporting the adolescents  
5       throughout the treatment process."

6                You see that?

7           A.     Yeah. That -- in fact, that was  
8       one of the most troubling things I read  
9       when I reviewed this whole document from  
10      the WPATH guidelines, is that -- yeah,  
11      that using those words in the same  
12      sentence, an adolescent giving informed  
13      consent, is a -- is a non sequitur  
14      because I -- I don't think -- in all my  
15      years of practice as a surgeon, which  
16      amounts to greater than 35, the idea of  
17      obtaining consent from an adolescent was  
18      never accepted by the surgical community  
19      or the medical community, to my  
20      understanding.

21          Q.     Well, this also talks about  
22      getting informed consent from the parents  
23      or other caretakers or guardians; right?

1           A.     Yeah.   So in their role  
2     supporting the adolescent's decision.   It  
3     doesn't say -- yeah.   So the parents or  
4     other caregivers have consented in  
5     support.   Right.

6           Q.     Yeah.   What the guidelines  
7     contemplate is that it's not just the  
8     adolescent that's going to give an  
9     informed consent, it's also the parents  
10    or other caretakers or guardians; right?

11          A.     Yeah.   But again, that's the  
12    problem I have with it, because that's --  
13    the introductory sentence has -- has no  
14    meaning -- or the introductory part of  
15    the one sentence has no meaning.   If the  
16    beginning point of the process is  
17    adolescent consent, that's -- that's not  
18    an ethical thing to do because --

19          Q.     Yeah.

20          A.     -- because an adolescent can't  
21    grasp -- they don't have enough executive  
22    function or development, particularly if  
23    they have been through a period of

1       puberty suppression before they begin the  
2       period of cross-sex hormones, that it's  
3       -- it's already quite evident that these  
4       patients, these children do not have  
5       enough -- and it's just known in society  
6       at large that adolescent children don't  
7       have the capacity for long-term reckoning  
8       of things like risk and outcomes and  
9       neither do they have the executive  
10      capacity in their brains to make an  
11      informed consent decision. So that part  
12      of it is meaningless to me. Yeah.

13       Q.     Yeah. But you understand  
14      there's two components to this  
15      requirement; one is informed consent by  
16      the adolescent, and two is informed  
17      consent by parents or other caretakers or  
18      guardians. Right?

19       A.     Yes.

20       Q.     Okay.

21       A.     That's what it says.

22       Q.     All right. Let's now go back to  
23      the Finland guidelines. It's Exhibit 25.

1           A.     Okay.

2           Q.     And go to PDF page 9 which has  
3     Section 8, "Summary" -- "Summary of the  
4     Recommendations." Let me know when you  
5     get there.

6           A.     Okay.

7           Q.     All right. This page provides  
8     recommendations for treatment of minors  
9     with gender dysphoria in Finland; right?

10          A.     Yes.

11          Q.     All right. Look at number 2 at  
12     the bottom.

13          A.     At the bottom. Okay. Okay.

14          Q.     All right. So it starts with,  
15     "If a child is diagnosed prior to the  
16     onset of puberty with a persistent  
17     experience of identifying as the other  
18     sex and shows symptoms of gender-related  
19     anxiety, which increases in severity in  
20     puberty." You see that?

21          A.     Yes, I do.

22          Q.     All right. And then next  
23     sentence says, "Based on these

1        assessments, puberty suppression  
2        treatment may be initiated on a  
3        case-by-case basis after careful  
4        consideration and appropriate diagnostic  
5        examinations if the medical indications  
6        for the treatment are present and there  
7        are no contraindications."

8                    Do you see that?

9            A.     I do.

10          Q.     All right. You understand that  
11        these Finland guidelines do not  
12        categorically prohibit the use of  
13        puberty-blocking agents in minors;  
14        correct?

15                   MR. KNEPPER: Objection, form.

16          A.     Right. They don't  
17        categorically, but what they do is they  
18        express uncertainty about the data that  
19        -- that's been used to support the use of  
20        those drugs in children.

21          Q.     Yeah. But -- but despite that  
22        data, what the guidelines recognize is  
23        that puberty-blocking treatment may still



1 be initiated for some minor patients in  
2 certain circumstances.

3 A. Right.

4 Q. Right?

5 A. Agree.

6 MR. KNEPPER: Objection, form.

7 Q. All right. Let's go back to  
8 your report. Go to page 46.

9 A. I'm there.

10 Q. So in your discussion of these  
11 Finland guidelines, you cite something  
12 called -- it's a website,  
13 genderreport.ca.

14 A. Correct.

15 Q. Do you see that?

16 A. I do.

17 Q. And I saw at least two other  
18 references to this source in your report.  
19 All right. This is -- genderreport is  
20 not a peer-reviewed publication, Doctor;  
21 right?

22 A. No. It's a data collection  
23 site. Yeah.

1 Q. It's a data collection site?

2 A. I think that's what the -- so,  
3 let me just review what I wrote here.

4 (Witness reviews document.)

5 A. All right. Okay. Yeah. Okay.  
6 Yeah, no. I agree they're not  
7 peer-reviewed to my knowledge, no.

8 Q. It's a blog; right?

9 A. Right. It's on -- it's online,  
10 exactly.

11 Q. Blogs are not generally  
12 considered reliable scientific evidence,  
13 I take it. Right?

14 MR. KNEPPER: Objection, form.

15 A. No, they're not.

16 Q. Okay. Do you know who started  
17 this genderreport blog?

18 A. I do not.

19 Q. Do you know this person was a  
20 doctor?

21 A. I don't know the person, no.

22 Q. You don't know they're a  
23 scientist?

1           A.     I'm sorry?

2           Q.     You don't know whether they're a  
3     scientist; right?

4           A.     I don't know.

5           Q.     Did you know that this blog was  
6     started by a parent who was upset that  
7     her daughter was told in school that  
8     girls are not real and who filed a  
9     lawsuit about it?

10           MR. KNEPPER:   Objection, form.

11           A.     I did not know those details,  
12     no.

13           Q.     Assuming that's true, do you  
14     think this is an unbiased, objective  
15     resource?

16           MR. KNEPPER:   Objection to form.

17           A.     I -- I don't know.   I don't know  
18     the answer to that question.

19           Q.     Do other experts in your field  
20     rely on blogs like this one to support  
21     their opinions?

22           MR. KNEPPER:   Objection, form.

23           A.     And I don't, and neither did I

1       rely on this as sole support for my  
2       opinion. This -- again, this is just  
3       evidence of -- of controversy that exists  
4       out in the literature, or that exists out  
5       in the -- in the greater world, I should  
6       say, in this case because this is not  
7       medical literature, but in the wider  
8       world.

9       Q.     Well, as I read this, your page  
10      46, you're -- you're citing this gender  
11      report for your analysis of the 2020  
12      Finland guidelines.

13           MR. KNEPPER:   Objection, form.

14      Q.     Right?

15      A.     I think I'm using the Finland  
16      guidelines as a standalone and just  
17      referencing this gender report as  
18      evidence of events in Finland rather than  
19      scientific support for the conclusions of  
20      the Finland review.

21      Q.     Okay. Another article you cite  
22      is the Carmichael 2021 study.

23      A.     Right.

1           Q.     Let's look at that one. I'll  
2     introduce it as Exhibit 27. Let me know  
3     when you have that.  
4     (Exhibit 27 was marked for identification  
5     and is attached.)

6           A.     Okay. Okay. I have it.

7           Q.     Okay. This is titled,  
8     "Short-Term outcomes of pubertal  
9     suppression in a selected cohort of 12 to  
10    15 year old young people with persistent  
11    gender dysphoria in the UK."

12          A.     Right.

13          Q.     Right?

14          A.     Yeah.

15          Q.     All right. Look at the -- on  
16    page 1, you see there's an abstract?

17          A.     Yes.

18          Q.     Under "Methods," it says, "We  
19    undertook an uncontrolled prospective  
20    observational study." Right? Do you see  
21    that?

22          A.     Right.

23          Q.     All right. This is not a

1 randomly controlled clinical trial;  
2 right?

3 A. Right.

4 Q. Not a cohort study --

5 A. Right.

6 Q. -- right?

7 A. Right.

8 Q. There's no control group; right?

9 A. Correct.

10 Q. You don't mention any of that in  
11 your report even though you spend a lot  
12 of time discussing the limitations of  
13 other studies. Why is that?

14 MR. KNEPPER: Objection, form.

15 A. I -- we include this to one to  
16 show the raging controversy in the world  
17 of transgender medicine, and this is an  
18 example of that, the -- the evidence of  
19 uncertain result or no result, no change  
20 from baseline effect.

21 Let's see. Let me just review  
22 because I've reviewed so many of these  
23 articles lately.

1 (Witness reviews document.)

2 A. Right. Yeah. So -- yeah. So  
3 that's right. So they were unable to  
4 quantify benefit or harm from puberty  
5 suppression.

6 Q. Go to page 21. See there's a  
7 "Strength and Limitations" section?

8 A. I see it. Yes, I do.

9 Q. The second sentence says: "The  
10 study size and uncontrolled design were  
11 key limitations. The small sample size  
12 limited our ability to identify small  
13 changes in outcomes. This was an  
14 uncontrolled observational study and thus  
15 cannot infer causality." See that?

16 A. I do.

17 Q. Again, you don't acknowledge any  
18 of these limitations in your report;  
19 right?

20 MR. KNEPPER: Objection, form.

21 A. Right. I believe I made  
22 reference to this in terms of it's  
23 evidence of -- of controversy in the

1 literature, that they could not see a  
2 benefit from it. So again, at lower  
3 levels of evidence, evidence of benefit  
4 would suggest further study. This shows  
5 that further study is needed because, at  
6 the observational level, you don't see  
7 effect.

8 Q. All right. Another study -- not  
9 a study, a review that you cite is this  
10 Cochrane 2020 --

11 A. Yes.

12 Q. -- review; right?

13 A. Right.

14 MR. TISHYEVICH: And for the  
15 court reporter, that's C-O-C-H-R-A-N-E.

16 Q. I'm going to introduce that one  
17 next.

18 A. Okay.

19 Q. All right. I'm introducing this  
20 as Exhibit 28, and let me know when you  
21 get it.

22 (Exhibit 28 was marked for identification  
23 and is attached.)



1           A.     I will.    Okay.

2           Q.     Okay.   This is from the Cochrane  
3     Library.   This is the review that you  
4     cite in your report; right?

5           A.     Right.

6           Q.     Go to page 2.

7           A.     Okay.

8           Q.     All right.   You see there's the  
9     section titled, "Authors' Conclusions"?

10          A.     Okay.   Yes, I do.

11          Q.     All right.   Toward the end, do  
12     you see it says, "We will include  
13     non-controlled cohort studies in the next  
14     iteration of this review, as our review  
15     has shown that such studies provide the  
16     highest quality evidence currently  
17     available in the field."   You see that?

18          A.     Yes, I do.

19          Q.     All right.   So the Cochrane  
20     review is not saying they're just going  
21     to ignore all those studies going  
22     forward; right?

23          A.     Right.

1 MR. KNEPPER: Objection, form.

2 Q. They rec- -- they recognize that  
3 those noncontrolled studies currently  
4 represent the best available evidence;  
5 right?

6 MR. KNEPPER: Objection, form.

7 A. Well, yeah. Before they say  
8 best available evidence, they speak about  
9 the level of the evidence now. And  
10 what's -- what's interesting about this  
11 Cochrane review, because it's a worldwide  
12 review of the literature on the subject  
13 of cross-sex hormones and hormone  
14 blockade in transwomen, is that they  
15 found over a thousand references, and by  
16 the time they got through qualifying  
17 those references for suitability, they  
18 got down to thirteen studies. And when  
19 they fully screened the text, they got  
20 down to a single study. And that's --  
21 that's kind of characteristic of -- of  
22 the data used to support hormonal  
23 transitioning.

1                   And so yeah, they -- they have  
2                   to -- they have to backpedal in order to  
3                   get any data because what they have in  
4                   hand now is -- is not supportive of -- of  
5                   the use of cross-sex hormones in  
6                   transwomen, so.

7               Q.     All right.   Let me introduce  
8                   another exhibit.

9                   MR. TISHYEVICH:   Can we go off  
10                  the record?

11                  THE VIDEOGRAPHER:   We are off  
12                  the record at 4:07 p.m.

13                               (Break taken.)

14                  THE VIDEOGRAPHER:   We are back  
15                  on the record at 4:20 p.m.

16               Q.     (By Mr. Tishyevich) All right.  
17                   Doctor, let me ask you about what  
18                   experience you have with the individual  
19                   plaintiffs in this case specifically.

20                               You personally did not meet with  
21                   any of the plaintiffs in this case;  
22                   correct?

23               A.     No.   I did a review of their

1 charts and nothing more. Yeah.

2 Q. All right. You've personally  
3 never spoken with any of the plaintiffs;  
4 correct?

5 A. I have not.

6 Q. You obviously were not present  
7 in any meetings that any of these  
8 plaintiffs may have had with their mental  
9 health professionals; right?

10 A. I was not.

11 Q. And you don't know specifically  
12 what was said or not said during those  
13 meetings; correct?

14 A. The only information I have  
15 about those meetings was what's entered  
16 in the medical record that was given to  
17 me to review.

18 Q. Yeah. You were also not present  
19 in any meetings any of the plaintiffs may  
20 have had with their endocrinologists;  
21 right?

22 A. Correct.

23 Q. And outside of reading medical

1 records, you don't know what was said or  
2 not said during those meetings; correct?

3 A. Correct.

4 Q. And finally, for plaintiffs who  
5 had undergone surgical procedures, you  
6 were also not present in any meetings  
7 between these plaintiffs and their  
8 surgeons; correct?

9 A. Correct.

10 Q. And outside of medical records,  
11 again, you don't know what was said or  
12 not said during those meetings; correct?

13 A. Correct.

14 Q. Okay. You should see a new  
15 exhibit pop up, Exhibit 29.

16 A. Okay.

17 (Exhibit 29 was marked for identification  
18 and is attached.)

19 Q. And if you can go to PDF page  
20 54.

21 A. PDF page 54. Okay.

22 Q. First of all, you understand  
23 what this document is; right?

1           A.     I didn't get to see the header  
2     on it. I haven't seen this before, I  
3     don't think.

4           Q.     Oh, feel free -- yeah, feel free  
5     to go back to the first page if you want  
6     to.

7           A.     Okay.

8                     (Witness reviews document.)

9           Q.     All right. This is the --

10          A.     Okay. Okay. So it's --

11          Q.     Yeah.

12          A.     -- a benefits booklet for the  
13     State health plan. Is that right?

14          Q.     For North Carolina, right.

15          A.     Yes. The teachers union --  
16     teachers and employ- -- and State  
17     employees, right. Okay.

18          Q.     You know what a benefit plan is;  
19     right?

20          A.     Yes, uh-huh.

21          Q.     At a high level, it sets out  
22     what the insurer is going to cover or not  
23     cover; right?

1           A.     Correct.

2           Q.     Among other things.   Okay.   And  
3           earlier, we talked about medical  
4           necessity.   You recall that?

5           A.     Yes.

6           Q.     All right.   Go to -- now go back  
7           to PDF page 54 of this plan.

8           A.     Okay.   I'm there.

9           Q.     You see at the top, it says,  
10          "What is not Covered?"   And it's a list  
11          of items?

12          A.     Am I on the right page?   I'm  
13          on -- on PDF page 54?

14          Q.     Yeah.

15          A.     That's the -- the -- oh, I'm  
16          sorry.

17          Q.     Plan page 46, so that's --

18          A.     Plan page 46.   Let me back up  
19          real quickly here.   Sorry.   Okay.   I'm  
20          there.

21          Q.     At the top or near the top, it  
22          says, "What is not Covered?"   You see  
23          that?

1           A.     I do.

2           Q.     There's a list of items  
3           alphabetically. See that?

4           A.     Yes.

5           Q.     And under M, it says, "Services  
6           or supplies deemed not medically  
7           necessary." "Medically necessary" is in  
8           bold; right?

9           A.     Right.

10          Q.     All right. Let's look at that  
11          definition. Go to PDF page 89, which is  
12          page 81 of the plan.

13          A.     Okay.

14          Q.     All right. At the bottom, you  
15          see there's a definition of "Medically  
16          Necessary (or Medical Necessity"; right?

17          A.     Yes.

18          Q.     And it says, "those covered  
19          services or supplies that are: a)  
20          Provided for the diagnosis, treatment,  
21          cure, or relief of a health condition,  
22          illness, injury, or disease; and, except  
23          for clinical trials as described under



1       this health benefit plan, not for  
2       experimental, investigational, or  
3       cosmetic purposes." Right?

4           A.     Okay.

5           Q.     I understand that as part of  
6       determining what the benefit plan is  
7       going to consider medically necessary,  
8       whether or not the treatment is  
9       experimental is one of the factors;  
10      right?

11          A.     As would be defined -- so all of  
12      the definitions here are determined by  
13      the insurance provider. So they've  
14      defined these listed necessities as  
15      covered under their plan, yes.

16          Q.     Yeah. So under this definition,  
17      if a treatment is experimental, it is  
18      likely not going to be covered under the  
19      plan; right?

20          A.     Right. According to their  
21      definition, it doesn't appear they would  
22      cover experimental surgery or cosmetic  
23      surgery.

1           Q.     Conversely, if a treatment is  
2     not experimental, it may be covered by  
3     the plan in some circumstances; right?

4           A.     It would seem --

5                     MR. KNEPPER:   Objection, form.

6           Q.     Yeah.   And I showed you earlier  
7     a policy from BlueCross BlueShield of  
8     North Carolina from March 2021 that says  
9     that gender-affirming hormone and  
10    surgical treatment is considered  
11    medically necessary; right?

12                    MR. KNEPPER:   Objection, form.

13          A.     Yeah, no.   As we talked about  
14    before, these are definitions formulated  
15    by the insurance company to define  
16    coverage, not medical definitions in  
17    terms of medical care.   This is strictly  
18    coverage by insurance.   Yeah.

19          Q.     Well, one of the factors that  
20    goes into that consideration is whether  
21    or not that treatment in question is  
22    experimental; right?

23                    MR. KNEPPER:   Objection, form.

1           A.     Right.   The plan excludes  
2     experimental or investigational or  
3     cosmetic procedures.

4           Q.     Okay.   All right.   We're talking  
5     about BlueCross BlueShield of North  
6     Carolina.   Let me ask you about another  
7     insurer, Aetna, A-E-T-N-A.   You've heard  
8     of Aetna; right?

9           A.     Yes.

10          Q.     Are you aware that Aetna is one  
11     of the five largest health insurance --  
12     insurers in the U.S.?

13          A.     It would not surprise me to  
14     learn that.

15                 MR. KNEPPER:   Form.

16          Q.     Do you have any idea whether  
17     Aetna considers gender-affirming surgery  
18     and hormone therapy to be medically  
19     necessary?

20                 MR. KNEPPER:   Objection, form,  
21     scope.

22          Q.     Would it surprise you if Aetna  
23     --

1                   THE COURT REPORTER: I'm sorry.  
2 I didn't hear the answer over the  
3 objection.

4                   THE WITNESS: I haven't answered  
5 yet.

6                   THE COURT REPORTER: Okay.

7                   THE WITNESS: Sorry.

8           A.     So as to the size of Aetna or  
9 the -- that they cover --

10          Q.     Yeah, let me just ask -- I'll  
11 ask the question again.

12          A.     Okay.

13          Q.     Do you have any idea whether  
14 Aetna considers gender-affirming surgery  
15 and hormone therapy to be medically  
16 necessary?

17                 MR. KNEPPER: Objection, form,  
18 scope.

19          A.     I don't.

20          Q.     Well, let me show you. I'm  
21 going to introduce another exhibit.  
22 Okay. This is going to be Exhibit 30.  
23 Let me know when you have it.

1 (Exhibit 30 was marked for identification  
2 and is attached.)

3 A. Okay. All right. I have it.

4 Q. All right. This is a policy  
5 from Aetna titled "Gender Affirming  
6 Surgery." You see that?

7 A. I do.

8 Q. You see there's a "Policy  
9 History" on the right?

10 A. Yes.

11 Q. Under "Last Review," it says  
12 January 12th, 2021; right?

13 A. Yes.

14 Q. So you understand this was  
15 revised within this year; right?

16 A. Yes.

17 Q. And under Policy, it says,  
18 "Aetna considers gender affirming surgery  
19 medically necessary when all of the  
20 following criteria are met." Right?

21 A. Right.

22 MR. KNEPPER: Form.

23 Q. All right. So according to this

1 policy, in Aetna's view, gender-affirming  
2 surgery is medically necessary, therefore  
3 nonexperimental; right?

4 MR. KNEPPER: Objection, form.

5 A. Yeah, Aetna's definition of what  
6 is medically necessary appears to allow  
7 for gender-affirming surgery.

8 Q. Okay. Go to page 3.

9 A. Okay.

10 Q. Look at the bottom of the page.

11 A. Okay.

12 Q. The second to the last paragraph  
13 says, "Aetna considers  
14 gonadotropin-releasing hormone medically  
15 necessary to suppress puberty in trans  
16 identified adolescents if they meet World  
17 Professional Association for Transgender  
18 Health (WPATH) criteria." Do you see  
19 that?

20 A. I do.

21 Q. Okay. According to Aetna,  
22 puberty-blocking hormones are medically  
23 necessary to suppress puberty in

1 trans-identified adolescents if they meet  
2 the WPATH criteria; right?

3 MR. KNEPPER: Objection, form.

4 A. That -- that's what it states  
5 there, yes.

6 Q. By the way, look at the next  
7 paragraph. See it says, "Aetna considers  
8 reversal of gender affirming surgery for  
9 gender dysphoria not medically  
10 necessary."

11 MR. KNEPPER: Objection.

12 Q. Do you see that?

13 A. I do.

14 Q. Okay. We talked about Blue  
15 Cross Blue Shield, talked about Aetna.  
16 Do you know what Cigna is?

17 A. Yeah. It's one of the largest  
18 health insurance providers.

19 Q. Do you know what position Cigna  
20 takes on whether gender dysphoria  
21 treatment is medically necessary?

22 MR. KNEPPER: Objection, form,  
23 scope.

1 A. I have not read their policies.

2 Q. You don't know; right?

3 A. Correct.

4 Q. Let me show you that policy.

5 A. Okay.

6 Q. All right. This is going to be  
7 Exhibit 31. Let me know when you have  
8 it.

9 (Exhibit 31 was marked for identification  
10 and is attached.)

11 A. Okay. Okay. I have it.

12 Q. All right. This is a Cigna  
13 medical coverage policy titled "Treatment  
14 of Gender Dysphoria." Do you see that?

15 A. Yes, I do.

16 Q. On the right top, it says  
17 "Effective Date," May 18th, 2021; right?

18 A. Yes.

19 Q. Also recently updated; right?

20 A. Yes.

21 Q. Go to page 2. Under "Coverage  
22 Policy," look at the third paragraph in  
23 bold. It says, "Medically necessary



1 treatment for an individual with gender  
2 dysphoria may include any of the  
3 following services, when services are  
4 available in the benefit plan." Do you  
5 see that?

6 A. I do.

7 Q. All right. And then there's  
8 five different bullets of different  
9 categories of services; right?

10 A. One, two, three, four, five.  
11 Yes.

12 Q. Number two is "Hormonal therapy,  
13 including but not limited to androgens,  
14 anti-androgens, Gn-" -- "GnRH analogues,  
15 estrogens, and progestins." Right?

16 A. Yes.

17 Q. That's a medically necessary  
18 benefit in Cigna's view; right?

19 MR. KNEPPER: Objection, form.

20 A. It is a -- medically necessary  
21 as defined by a insurance company for  
22 purposes of a policy.

23 Q. Yeah.

1           A.     Yes.

2           Q.     And the last bullet point says,  
3     "Gender reassignment and related surgery  
4     (see below)."   Do you see that?

5           A.     I do.

6           Q.     According to this policy, in  
7     Cigna's view, gender reassignment and  
8     related surgery is a medically necessary  
9     service; right?

10           MR. KNEPPER:   Objection, form.

11           A.     Again, so -- so the insurance  
12     company makes a distinction between  
13     medically necessary, meaning things that  
14     they will cover, versus not medically  
15     necessary, meaning things they won't  
16     cover.   It's not based on an actual  
17     medical diagnosis but a -- a managerial  
18     diagnosis, because if it's not medically  
19     necessary, it's not covered by insurance.  
20     So if they choose to cover it, they will  
21     call that medically necessary.   And  
22     that's what they're detailing here, what  
23     they will cover and what they won't

1 cover.

2 Q. Okay.

3 A. And they call what they will  
4 cover medically necessary.

5 Q. Let me show you one last policy.  
6 Do you know -- strike that.

7 You know what UnitedHealthcare  
8 is; right?

9 A. Yes, I do.

10 Q. It's another health insurer;  
11 right?

12 A. Yes.

13 Q. They're the largest health  
14 insurer in the country; right?

15 A. I don't know that for a fact.  
16 I'll assume if you're telling me so.

17 Q. All right. Well, do you have  
18 any idea whether United considers  
19 gender-affirming surgery and hormone  
20 treatment to be medically necessary for  
21 gender dysphoria?

22 A. I have a dawning suspicion that  
23 they do.

1           Q.     Yeah. I think you can probably  
2 tell where this is heading at this point;  
3 right?

4           A.     Sure. The insurance industry  
5 likes these services.

6           Q.     Let me introduce this next  
7 exhibit. This is going to be Exhibit 32.  
8 All right at the top it says, "United  
9 Healthcare." You see that?  
10 (Exhibit 32 was marked for identification  
11 and is attached.)

12          A.     I don't have it yet.

13          Q.     Oh, I apologize.

14          A.     That's okay.

15          Q.     Let me know when.

16          A.     Okay. Yes.

17          Q.     All right. Top right says  
18 "United Healthcare" -- "Healthcare  
19 Commercial Medical Policy." Right?

20          A.     Yes.

21          Q.     Under that, it says, "Gender  
22 Dysphoria Treatment." Right?

23          A.     Yes.

1           Q.     See there's an effective date of  
2     April 1, 2021; right?

3           A.     Yes.

4           Q.     Also fairly recently updated;  
5     right?

6           A.     Yes.

7           Q.     Okay. And then you see there's  
8     a bunch of bullet points setting forth  
9     criteria for the services on page 1;  
10    right?

11          A.     Yeah. Yes.

12          Q.     Then go to page 2.

13          A.     Okay.

14          Q.     And the first full paragraph  
15    says, "When the above criteria are met,  
16    the following surgical procedures to  
17    treat Gender Dysphoria are medically  
18    necessary and covered as a proven  
19    benefit." Do you see that?

20          A.     I do.

21          Q.     Okay. So United also covers --  
22    also considers this treatment to be  
23    medically necessary; right?

1 MR. KNEPPER: Objection to form.

2 A. Yeah, again, so the interesting  
3 thing about this that I'm just reading --  
4 because, again, this is the first time  
5 I've seen this -- is that the same policy  
6 declares that the policy does not apply  
7 to individuals with objectively ambiguous  
8 genitalia or disorders of sexual  
9 development. So that's an example of the  
10 insurance company choosing what to call  
11 medically necessary based upon an  
12 insurance definition rather than a  
13 medical definition. Because under, you  
14 know, plastic surgical/general medical  
15 wisdom, ambiguous genitalia and disorders  
16 of sexual development are objective  
17 medical surgical -- well, medical  
18 conditions, at least, that would be  
19 covered -- would be considered medically  
20 necessary to treat, you know, because  
21 disorders of sexual development can  
22 include emergencies like adrenal  
23 hyperplasia. So that's a -- you've given

1 an example of how insurance companies  
2 make their own definitions for the sake  
3 of distinguishing what they will cover  
4 and what they will not cover.

5 Q. Go to page 9.

6 A. Okay.

7 Q. You see there's a section toward  
8 the bottom that says, "Benefit  
9 Considerations"?

10 A. Yes.

11 Q. Third paragraph says, "Unless  
12 otherwise specified, if a plan covers  
13 treatment for Gender Dysphoria, coverage  
14 includes psychotherapy, cross-sex hormone  
15 therapy, puberty suppressing medications  
16 and laboratory testing to monitor the  
17 safety of hormone therapy." Do you see  
18 that?

19 A. I do.

20 Q. You understand that United  
21 considers not just surgery but all these  
22 other services, including cross-sex  
23 hormone therapy and puberty suppressing

1 medications, to be medic- -- medically  
2 necessary for the treatment of gender  
3 dysphoria; right?

4 MR. KNEPPER: Objection, form,  
5 scope.

6 A. Yeah, again, the same -- same  
7 issues of definition. So they -- they  
8 can define it any way they choose for the  
9 sake of the business of insuring people,  
10 yeah. So they -- they definitely have  
11 defined all of the services associated  
12 with gender dysphoria as covered  
13 benefits.

14 Q. And not just as covered  
15 benefits, as medically necessary; right?

16 A. Again --

17 MR. KNEPPER: Objection, form  
18 and scope.

19 A. Again, they use -- the use of  
20 the word "medically necessary" is defined  
21 by the insurance company to distinguish  
22 covered benefits from not covered  
23 benefits, and it's not based in medical



1 evidence of efficacy or anything else.  
2 It's just an internal definition for the  
3 sake of their business model.

4 Q. You think that insurers do not  
5 look at scientific literature in deciding  
6 whether or not to cover something?

7 MR. KNEPPER: Objection, form.

8 Q. Is that really what you think?

9 A. Your -- your first example that  
10 we've gone through is a -- is an example  
11 of the level of literature they've been  
12 using, and that example showed that the  
13 most recent paper that they used to  
14 support it was 2016. So in my mind, it's  
15 in doubt. I don't know for a fact what  
16 this particular policy used as  
17 references. All I have is what you've  
18 shown me on that particular policy. And  
19 the evidence there was they're not  
20 current in the -- in the literature. But  
21 they're still doing good business,  
22 apparently, because they continue even  
23 after reviewing.

1 Q. Okay. Go to page 10.

2 A. Okay. All right.

3 Q. See there's a section at the  
4 bottom that says, "Clinical Evidence"?

5 A. Yes.

6 Q. Do you know what that means?

7 A. Yes, I do.

8 Q. You see then the first thing  
9 that's said -- cited is a study from 2019  
10 and the second thing is a study from  
11 2019, the third thing is a study from  
12 2019. You see that?

13 A. I do.

14 MR. KNEPPER: Objection, form.

15 Q. Do you under- -- do you  
16 understand what this section represents?

17 MR. KNEPPER: Objection, form.

18 A. Permit me to just look at the  
19 particular names and the particular cited  
20 articles, if I could.

21 (Witness reviews document.)

22 A. Sorry. I just wanted to see if  
23 there were any -- and then they go to --

1       okay.   Okay.   Could I ask you to ask your  
2       question again?   I'm sorry to have to do  
3       that.   I just wanted to see what you were  
4       referring to.

5           Q.     Yeah.   You understand that this  
6       "Clinical Evidence" section provides an  
7       overview of some of the scientific  
8       evidence on which United based its  
9       policy; right?

10           MR. KNEPPER:   Objection, form.

11           A.     Yes.   They -- they have listed  
12       some of the scientific evidence available  
13       in the literature.

14           Q.     Including studies as recently as  
15       2019 --

16           A.     Yes.

17           Q.     -- right?

18           A.     Right.

19           Q.     And because you weren't involved  
20       with writing this policy or updating for  
21       United, you don't know what else they may  
22       have considered outside of this policy;  
23       right?

1           A.     I have no way of knowing what  
2           they would have considered. That's  
3           right.

4           Q.     Okay. All right. Let's shift  
5           gears a little bit. You've heard the  
6           term "Christian anthropology." Right?

7           A.     Yes, I have.

8           Q.     You've used that term yourself;  
9           right?

10          A.     Yes, I have.

11          Q.     The view that Christian  
12          anthropology takes is that the -- a  
13          person's sex assigned at birth is  
14          intrinsic and unchangeable; correct?

15          A.     No.

16                 MR. KNEPPER: Objection, form,  
17          scope.

18          A.     I would not say that.

19          Q.     What would you -- how would you  
20          describe it?

21          A.     Well, your use of the term "sex  
22          assigned at birth" is not -- is not  
23          contained within Christian anthropology.

1 Q. Let me try this --

2 A. By the -- by the way, I don't --  
3 I don't use definitions in Christian  
4 anthropology to confect my expert  
5 opinion. My opinion is based in the  
6 scientific literature, my review of that  
7 literature, and my 30-plus years'  
8 experience as a reconstructive surgeon.

9 Q. I understand. The view that  
10 Christian -- to use your words, the view  
11 that Christian anthropology takes is that  
12 a person's biologic sex is intrinsic and  
13 unchangeable; right?

14 A. Yes.

15 MR. KNEPPER: Objection, form,  
16 scope.

17 Q. You think that people with  
18 gender dysphoria should be welcomed, but  
19 they should be told that they're  
20 biological sex cannot be changed; right?

21 MR. KNEPPER: Objection, form,  
22 scope.

23 A. Yeah. So, persons who

1 self-identify as transgender are to be  
2 welcomed and are to be cared for because  
3 they suffer greatly, and they -- they  
4 deserve, in justice -- they deserve, out  
5 of justice, I should say, our -- our care  
6 and support. But that care and support  
7 must always be rooted in the truth of the  
8 nature of the human person, the nature of  
9 the biology that informs our  
10 understanding of that, because that has  
11 to drive our medical and surgical  
12 decision-making.

13 So that's why my -- my expert  
14 opinion is based in the objective  
15 scientific evidence. I don't make  
16 reference to my -- any faith statements  
17 when I'm -- when I'm developing my expert  
18 opinion on transgender medicine and  
19 surgery.

20 Q. In your expert report, you refer  
21 to plaintiff Julie -- Dr. Julie McKeown;  
22 right?

23 A. Could you walk me to where I

1 speak about her?

2 Q. Yeah. Go to -- go to page 54 of  
3 your report.

4 A. Fifty-four. Thank you.

5 MR. TISHYEVICH: And the  
6 spelling is M-C-K-E-O-W-N.

7 A. Fifty-four. Okay. I'm there.

8 Q. Give me a second. Yeah. This  
9 is -- this is you discussing one of the  
10 plaintiffs; right?

11 A. Yes. Yes. I'm on page 53, 54.

12 Q. Yeah. And the second full  
13 paragraph on page 54, you refer to Dr.  
14 McKeown as a he; right?

15 (Witness reviews document.)

16 A. Am I looking at the right -- oh,  
17 yes. Okay. I'm sorry. Right at the  
18 very beginning. Yes.

19 Q. Page 48 of your report, this is  
20 you discussing minor plaintiff CB; right?

21 A. Right.

22 Q. And you refer to minor plaintiff  
23 as a she; right?

1 A. Correct.

2 Q. Go to page 51.

3 A. Fifty-one?

4 Q. Five one.

5 A. Okay. All right.

6 Q. This is you talking about  
7 plaintiff Connor Thonen-Fleck; right?

8 A. Let me go to the preceding page  
9 because I've got to see where the names  
10 -- oh, I only used the initials. Yes.  
11 CT-F, yes.

12 Q. It's T-H-O-N-E-N, dash,  
13 F-L-E-C-K. And you refer to him as a  
14 she; right?

15 A. Yes.

16 Q. Now, you personally do not  
17 believe that a person's sex assigned at  
18 birth can ever be changed?

19 MR. KNEPPER: Objection.

20 Q. Sorry, let me -- let me use your  
21 terms. You personally do not believe  
22 that a person's biological sex can ever  
23 be changed; right?



1 MR. KNEPPER: Objection, form.

2 A. A person's biological sex can  
3 never be changed, yes.

4 Q. Do you know what the term  
5 "misgendering" is?

6 A. It's a -- it's a political term,  
7 yes. It's a political, cultural term, I  
8 should say. Political, cultural term.

9 Q. Misgendering means referring to  
10 a person in a way that doesn't align with  
11 their gender; right?

12 MR. KNEPPER: Objection, form.

13 A. In -- within their hearing, I  
14 could see a problem with that. But from  
15 the standpoint of offering medical  
16 evidence, I'm obliged to honor objective  
17 biological realities when I speak about  
18 an examination of their medical record.

19 There's so many things at stake  
20 relating to the sex of the patient that  
21 impinge upon the effects of drugs, the  
22 effects of time, the effects of hormones  
23 that I -- I cannot incorrectly report the

1 sex of the patient when I'm talking about  
2 objective medical care.

3 Now, speaking with the patients  
4 themselves, I wouldn't do that. As we  
5 talked about earlier, I have a number of  
6 transgender patients, and I don't  
7 misgender them. We're talking here about  
8 something that's not within their hearing  
9 or I assume they -- I assume that they  
10 wouldn't be reading this. We're speaking  
11 as a professional to a professional  
12 review of this stuff, among other  
13 experts. So I think it's essential that  
14 we stick to the biological reality that  
15 -- that biological sex is immutable.

16 Q. In your expert report, you are  
17 misgendering several of the individual  
18 plaintiffs in this case; correct?

19 MR. KNEPPER: Objection, form.

20 A. I would say incorrect, because  
21 misgendering is something that's done to  
22 the person themselves or is something  
23 that they're going to read or hear or

1       see. And that's an abuse of the person's  
2       right to their name, and I don't do that  
3       to people. I don't misgender people.

4       Q. Well, in this report at least,  
5       you are referring to several of these  
6       plaintiffs, including a minor, in a way  
7       that does not align with their gender;  
8       right?

9       A. I would be --

10       MR. KNEPPER: Objection, form.

11       A. Again, I would be concerned to  
12       not do that if it was going to be  
13       something they were going to read or  
14       hear. But this expert testimony, in my  
15       understanding, is for the Court and for  
16       the other experts to review, in which  
17       case, I insist upon the -- the prevailing  
18       necessity of sticking to objective truths  
19       when talking about medical opinions,  
20       scientific opinions.

21       Again, I -- I'm not in the habit  
22       of -- of offending people or using names  
23       that they haven't chosen, because, again,

1 I treat transgender patients and I don't  
2 subject them to that kind of abuse. But  
3 when reviewing medical and biological  
4 realities like this, I have to insist  
5 upon it because medical care is not  
6 served by incorrectly naming biological  
7 realities and confusing people. I can  
8 give you an example if you like.

9 Q. That's all right.

10 A. Of a --

11 Q. That's all right.

12 A. Okay.

13 Q. You've used the phrase before,  
14 "You can't heal an interior wound with  
15 external surgery." Right?

16 A. Yes, I have.

17 Q. Do you remember giving a  
18 presentation at the Gospel of Life  
19 conference in Denver in 2018?

20 A. Yes.

21 Q. And that presentation was titled  
22 "Transgender Surgery & Christian  
23 Anthropology." Right?

1           A.     Yes.

2           Q.     All right. Let me introduce an  
3 exhibit. This will be Exhibit 33. Let  
4 me know when you have it.

5           (Exhibit 33 was marked for identification  
6 and is attached.)

7           A.     Okay. Yes, I have it.

8           Q.     Go to page 2.

9           A.     Okay.

10          Q.     These are slides you prepared;  
11 right?

12          A.     Yes.

13          Q.     On the bottom left corner,  
14 there's a red logo for Courage  
15 International. You see that?

16          A.     I do.

17          Q.     Why did you include that logo in  
18 this presentation?

19                 MR. KNEPPER: Objection, form,  
20 scope.

21          A.     This was a presentation for the  
22 Archdiocese of Denver, the Catholic  
23 Archdiocese of Denver, and it was to an

1 audience of pastors, teachers, school  
2 administrators, and so on. And I was  
3 there representing my position in the  
4 Catholic apostolate of courage, and so  
5 making a presentation to a church group,  
6 I wanted them to understand the resource  
7 so that they could investigate it  
8 themselves if they wanted to. So I put  
9 that up there for their benefit.

10 Q. Well, some of the topics you  
11 covered also included your views on what  
12 the scientific evidence on these issues  
13 is; right?

14 A. Yeah. The -- the talk is a  
15 combination of both the scientific  
16 evidence and the historic Catholic  
17 teachings on the nature of the human  
18 person.

19 Q. For example, go to page -- go to  
20 page 87, for example.

21 A. Okay. Let me hustle down there.  
22 Boy, no wonder people get bored when I  
23 give this talk. It's so long; right?

1       Let's see. 87. Here we are. Is that --  
2       let's see. This is -- I want to make  
3       sure I'm on the same page as you are.  
4       It's of the --

5           Q.     It's titled "The Swedish  
6       Study" --

7           A.     Yes.

8           Q.     -- at the top.

9           A.     Yes, yes.

10          Q.     And go to the next page.

11          A.     Okay. Yeah.

12          Q.     You cite from the abstract on  
13       that study; right?

14          A.     Yes. Well, I -- I'm not citing  
15       it. I'm showing them what this study  
16       looks like if they search for it online.

17          Q.     So part of the talk was your  
18       recitation of what you think the  
19       scientific evidence on these issues  
20       shows; right?

21                 MR. KNEPPER: Objection, form,  
22       scope.

23          A.     Yeah, I was asked to talk on

1       this -- on -- on both subjects, as I said  
2       earlier, both the -- the teaching in  
3       human anthropology as well as the  
4       scientific evidence that's used to  
5       support these services of transgender  
6       medicine and surgery. That's right.

7           Q.     Courage International is an  
8       organization that offers support for  
9       persons who experience same-sex  
10      attraction; right?

11           A.     Yes.

12                   MR. KNEPPER:   Objection, form,  
13      scope.

14           Q.     Courage International says that  
15      people should not act on same sex  
16      attraction and should strive for chastity  
17      instead; right?

18                   MR. KNEPPER:   Objection, form,  
19      scope.

20           A.     Actually, it's broader than  
21      that. So, Courage addresses chastity as  
22      something that's required of everyone.  
23      But it -- it particularly addresses the



1 struggles that persons who experience  
2 same-sex attraction experience in trying  
3 to maintain the same chastity that all of  
4 us are called to. So it's not an  
5 exceptional case; it's a particular  
6 apostolate to a particular group of  
7 people.

8 Q. There's a chapter of Courage  
9 International in Birmingham, Alabama;  
10 right?

11 A. That's correct.

12 MR. KNEPPER: Objection, form,  
13 scope.

14 Q. And their website lists you as  
15 the main contact for that chapter; right?

16 A. I'm not only the contact, I'm  
17 the chaplain for that chapter.

18 Q. Okay. Go to page 3 of this  
19 presentation.

20 A. Okay.

21 Q. Let me know when you get there.

22 A. Okay. Two, three. Yes. The  
23 Challenge?

1 Q. It's titled "The Challenge"?

2 A. Yeah.

3 Q. The first bullet says, "'Male  
4 and female He created them.'" Right?

5 A. Right.

6 Q. That's a quote from Genesis;  
7 right?

8 A. Correct.

9 Q. The capitalized "He" refers to  
10 God; right?

11 A. Yes.

12 Q. And this bullet reflects the  
13 church's position that God has created  
14 each individual as either a man or a  
15 woman; right?

16 A. Well, actually, so this -- these  
17 slides serve as jumping-off points for a  
18 discussion that I have at each slide. In  
19 this case, the point of the discussion  
20 was to disabuse the audience of the idea  
21 that they can rely on scripture when  
22 addressing this problem because the  
23 majority of the people that are seeking

1 to serve do not speak in Biblical  
2 language. So the point of this slide is  
3 to -- is to encourage them to understand  
4 that they have to learn a new language in  
5 order to be able to speak effectively to  
6 people suffering from gender discordance  
7 and to speak to their families on this  
8 same issue. That's what this slide is  
9 about. It's not a -- it's not a  
10 declaration about what God has said.  
11 It's a -- it's an explanation of the  
12 problem they're going to have if they're  
13 going to seek to serve people who  
14 experience same-sex -- I'm sorry, who  
15 experience cross-sex identification.

16 Q. All right. You say, "'Male and  
17 female He created them' has been replaced  
18 by a confusion of exceptional cases."  
19 Right?

20 A. Yes.

21 Q. And by the phrase "confusion of  
22 exceptional cases," one of the things  
23 you're referring to are patients with

1 gender dysphoria; right?

2 MR. KNEPPER: Objection, form,  
3 scope.

4 A. Right. I'm referring to the --  
5 the recently growing list of exceptional  
6 cases that is enumerated in the -- the  
7 acronyms of -- of this topic, LGBTQ add a  
8 plus and so on, which can be very  
9 confusing to people who are trying to  
10 help. And so I'm acknowledging that the  
11 -- the likelihood that they may be  
12 confused by those terms, and I'm also  
13 acknowledging the sources of those  
14 confusing terms. And the point of the  
15 slide, again, is to help them understand  
16 there's a language they need to learn and  
17 to not be daunted by the confusion that  
18 they may experience when they first look  
19 into this topic. Yeah. That's what this  
20 is.

21 Q. Go to slide 11. It's titled  
22 "Human Nature."

23 A. So slide 11, Human Nature, yes.

1       Okay.

2           Q.     So the first two bullets say,  
3       "Why must we consider first the nature of  
4       the human person?" Then it says,  
5       "Defines the 'end' of medical and  
6       surgical care."

7           A.     Yes.

8           Q.     What does it mean that it  
9       "defines the 'end' of medical and  
10      surgical care"?

11                  MR. KNEPPER:  Objection, form,  
12      scope.

13          A.     Okay.  So that's a -- that's a  
14      term that dates back to Aristotelian  
15      philosophy.  And what it has to do is  
16      what is the purpose or what is the  
17      ultimate arc of a particular thing.  So  
18      the "end" meaning what are you seeking to  
19      accomplish, what is the final goal of  
20      that -- of that medical or surgical  
21      treatment.

22                  So -- and the examples I use are  
23      you have to have an understanding, for

1       example, of normal blood pressure in  
2       order to know when to treat it and why  
3       normalizing blood pressure is important.  
4       Or we have to know that, you know, the  
5       human person has two legs, and if he has  
6       a poverty of legs, he has a poverty of  
7       human flourishing. And so in the one  
8       case, I might be treating with blood  
9       pressure medicine, and in the other case,  
10      I might be fitting him for a prosthesis.  
11      But the point is we have an objective  
12      understanding of the nature of the human  
13      person, which defines the goals of  
14      treatment, whether you're talking about  
15      orthopedics or transgender medicine.

16           Q.     Yeah. You think this concept  
17      also applies to the concept of treatment  
18      for gender dysphoria; right?

19           A.     It does. Yes, it does.

20                   MR. KNEPPER: Objection, form,  
21      scope.

22           Q.     All right. Go to slide 23.

23           A.     Okay. Okay.

1           Q.     The top left says, "Shaping the  
2     Conversation, & Grooming a Generation."

3           A.     Right.

4           Q.     You see that?

5           A.     Right.

6           Q.     What do you mean by "grooming a  
7     generation"?

8           A.     Grooming is a -- is a process by  
9     which ideas are introduced that make  
10    subsequent actions possible, so that's  
11    what -- that's what grooming is, yeah.

12          Q.     Grooming is sometimes used to  
13    refer to preparing to -- strike that.

14                 Grooming is sometimes used as  
15    preparing children for sexual abuse.  
16    Isn't that true?

17          A.     That's one of the --

18                 MR. KNEPPER:  Objection, form,  
19    scope.

20          A.     That's one of the uses of  
21    grooming, yeah, but it's not exclusive  
22    use of grooming.  Yeah.  And I discuss  
23    this in this -- in this slide.  Yes, I

1 do.

2 Q. And you think that discussing  
3 gender identity issues with children  
4 means sexualizing them; right?

5 A. Yes, I do. Absolutely, I do.

6 MR. KNEPPER: Objection, form,  
7 scope.

8 Q. And you think that discussing  
9 gender identity issues with children  
10 means grooming them for potential later  
11 sexual abuse; right?

12 MR. KNEPPER: Objection, form,  
13 scope.

14 A. No. No. What we're talking  
15 about here is grooming them for -- for  
16 future -- what's the word I would want to  
17 choose carefully? It's preparing them  
18 for these interventions is what it does.  
19 It lays the groundwork for it by  
20 sexualizing their thoughts in a way  
21 that's -- is not consonant with their  
22 best interest. That's what this slide is  
23 about, so --



1           Q.     Let me introduce another  
2     exhibit.

3           A.     Okay.

4           Q.     This will be Exhibit 34.  
5     (Exhibit 34 was marked for identification  
6     and is attached.)

7           A.     Could I back up to that last  
8     one?  Would that be all right?

9           Q.     Sure.

10          A.     Before we -- before we press on.  
11     One of the things I'm just recalling, the  
12     -- the -- the urgency of having that  
13     particular slide there is that when  
14     people take care of transgender persons,  
15     children in particular, we always -- but  
16     including adults.  But -- but children  
17     and adults, one always has to be on the  
18     lookout for signs of sexual abuse because  
19     it's a very -- it's a very commonly  
20     reported comorbidity in persons who  
21     experience these self-identifications.  
22     It's not uncommon to discover that  
23     they've suffered some form of abuse that

1        may be sexual but not necessarily sexual.  
2        And so this is -- one of the things I  
3        talk about in that slide is -- is for the  
4        people who are care providers,  
5        counselors, school administrators, to be  
6        alert to that possibility.

7                So I'm sorry, we were going to  
8        move on to the next one.

9                Q.     Do you have the next exhibit?

10              A.     And that is Exhibit 34?

11              Q.     Yeah.

12              A.     Okay.

13              Q.     All right. This is a printout  
14        from LifeSite, and the title is "Plastic  
15        surgeon: Sex-change operation 'utterly  
16        unacceptable' and a form of 'child  
17        abuse.'" Right?

18              A.     Yes.

19              Q.     And it says, "Dr. Patrick  
20        Lappert, a Catholic deacon in Alabama,  
21        says changing a person's sex is a lie and  
22        also a moral violation for a physician."  
23        Right?

1 A. Yes.

2 Q. And you hold those views --

3 A. I do.

4 Q. -- correct?

5 A. I do.

6 MR. KNEPPER: Objection, form,  
7 scope.

8 Q. Go to page 2.

9 A. Okay.

10 Q. This was published in September  
11 2019; right?

12 A. Yes.

13 Q. This is reporting on you  
14 appearing on a broadcast of something  
15 called the "Relevant Radio's Trending  
16 With Timmerie."

17 A. Yes.

18 Q. Right?

19 A. Yes.

20 Q. You made that appearance; right?

21 A. On the radio, yes.

22 Q. Okay. Look -- look to the fifth  
23 paragraph on page 2.

1           A.     Okay.

2           Q.     It says, "He called it 'utterly  
3 unacceptable' on moral grounds for a  
4 plastic surgeon, because it disregards  
5 the surgeon's call to balance respect for  
6 both form and function of the body in his  
7 or her work."

8           A.     Right.

9           Q.     Right?

10          A.     Yes, sir.

11          Q.     You don't deny saying that;  
12 right?

13          A.     Right. You should understand,  
14 though, that the use of the term "moral  
15 grounds" here is strictly from the  
16 standpoint of my training as a plastic  
17 surgeon. I'm not using this as a  
18 platform for a religious discussion.  
19 Speaking -- I'm speaking about form and  
20 function, which are both very crucial to  
21 an understanding of what plastic surgery  
22 means.

23                   And again, that speaks to the

1       end of plastic surgery, which is -- when  
2       you're speaking about reconstructive  
3       surgery, it's the restoration of form and  
4       function. And these operations lack  
5       moral basis precisely because they  
6       destroy essential human functions for the  
7       sake of achieving a cosmetic result,  
8       which is morally unacceptable. And I say  
9       that without reference to any religious  
10      teaching. This is strictly my training  
11      as a plastic surgeon, morally  
12      unacceptable. And from the first moments  
13      of my training as a reconstructive  
14      surgeon, that was drilled into me, that  
15      if you're planning a reconstructive  
16      operation and it involves the movement of  
17      tissue on the patient's body, you never  
18      do something that's going to compromise  
19      or destroy an essential human function.

20             You may challenge that function  
21      a little bit, as you do, for example, in  
22      a radial forearm flap, the same flap  
23      that's used to recon- -- to construct a

1        phalloplasty. I've used that flap many  
2        times to reconstruct head and neck cancer  
3        defects, the same neurotized vascular  
4        flap. And I would never dream of using  
5        that flap, for example, if I was going to  
6        compromise hand function. So it obliges  
7        me to be careful, to make sure that when  
8        I raise the flap, I don't harm the blood  
9        supply to the hand. That's an example of  
10       that.

11                    In the example of transgender  
12        surgery, by definition, you're destroying  
13        fertility for life, which is an immoral  
14        act in the eyes of plastic surgery as I  
15        learned it through 30-plus years of  
16        training.

17            Q.     I understand. Let me just ask  
18        you about the next two paragraphs --

19            A.     Okay.

20            Q.     -- of this article.

21            A.     Okay.

22            Q.     Then it says: "Regarding  
23        children, Lappert said, sexualizing them

1 at a young age with these ideas is  
2 grooming them for later abuse. 'It's  
3 atrocious,' he said. 'And no one even  
4 knows how that's going to play out.  
5 There's no body of scientific evidence to  
6 even support the safety of doing that to  
7 children. But it's being done.'" Right?

8 MR. KNEPPER: Objection, form,  
9 scope.

10 A. Okay. So, let's go through  
11 that. So in this case -- we talked about  
12 multiple uses of the word "grooming." In  
13 this case, the abuse that they're -- it's  
14 grooming them for is the abuse we just  
15 finished discussing, what I consider to  
16 be the abuse of transgender medicine and  
17 surgery and what it does to the life of  
18 that child. So that's the abuse I'm  
19 referring to here. I'm not speaking  
20 about this in terms of sexual abuse, I'm  
21 speaking about in terms of  
22 medical/surgical abuse of a child. So if  
23 you get a child -- if you sexualize a

1 child's thinking and encourage them to  
2 believe, for example, if -- if -- if I --  
3 and I don't want to take up your  
4 remaining time, but we can go into it in  
5 more detail if you wish. But the point  
6 I'm making here is this is grooming them  
7 for medical and surgical abuse.

8 Q. Okay.

9 MR. TISHYEVICH: We can go off  
10 the record.

11 THE VIDEOGRAPHER: This is the  
12 end of Media Unit 6. We are off the  
13 record at 5:07 p.m.

14 (Break taken.)

15 THE VIDEOGRAPHER: This is the  
16 beginning of Media Unit No. 7. We are on  
17 the record at 5:14 p.m.

18 Q. (By Mr. Tishyevich) Doctor,  
19 that's all the questions I have for you  
20 today. Thanks for your time.

21 A. Thank you. This was my first  
22 ever deposition, and you were very kind  
23 to me. Thank you for that.



1 Q. Okay.

2 MR. TISHYEVICH: All right.

3 Mr. Knepper?

4 MR. KNEPPER: Yeah, I'm ready to  
5 go. I'm sorry. I actually had you  
6 turned down, because when I put you on  
7 mute, I could still hear Lane and Andrew.  
8 I thought I saw their lips moving.

9 THE COURT REPORTER: Yeah, he  
10 said he was finished asking questions.

11 MR. KNEPPER: Oh, I'm sorry. I  
12 didn't hear that. I'm sorry, Dmitriy. I  
13 apologize. I had -- you know, Lane  
14 and -- and Andrew were talking to one  
15 another, and so I was -- I had to turn  
16 down my speaker.

17 So I guess why don't we -- why  
18 don't we take a -- I've got 4:15. Why  
19 don't we take a 15-minute break, and then  
20 I'll see if I have anything on redirect,  
21 and we'll come back at I guess it would  
22 be 6:30 your time, Dmitriy?

23 MR. TISHYEVICH: Yeah.

1 MR. KNEPPER: Okay.

2 MR. TISHYEVICH: Sounds good.

3 THE VIDEOGRAPHER: We are off  
4 the record at 5:15.

5 (Break taken.)

6 THE VIDEOGRAPHER: We are back  
7 on the record at 5:29 p.m.

8

9 EXAMINATION BY MR. KNEPPER:

10 Q. Dr. Lappert, I wanted to ask you  
11 a couple of questions about your CV and  
12 your biography.

13 A. Okay.

14 Q. On your biography, you identify  
15 yourself as the Specialty Leader for  
16 Plastic and Reconstructive Surgery, the  
17 Office of the Surgeon General - United  
18 States Navy, from 1997 to 2002. Could  
19 you describe what that position involved?

20 A. Yeah. So I advised the Surgeon  
21 General, first of all, with regard to the  
22 selection of physicians for advanced  
23 training in plastic surgery. I also

1        advised the Office of the Surgeon General  
2        on policy matters pertaining to the  
3        movement of patients and the availability  
4        of services in the various treatment  
5        facilities. I also advised him on policy  
6        relating to coverage of particular  
7        medical problems versus sending them out  
8        into the community for care or declining  
9        care.

10                So part of it was resource  
11        management, part of it was personnel  
12        management, and part of it was financial  
13        management. And all the time, it  
14        required to review the state of the  
15        literature regarding reconstructive  
16        surgery for combat-injured and as well as  
17        medically retired personnel and other  
18        retired people.

19                Q.     And I -- I note that also in  
20        your resumé is that from 1996 to 2002,  
21        you were the Chairman of the Department  
22        of Plastic and Reconstructive Surgery at  
23        Naval Hospital Portsmouth. Could you

1 describe that -- that facility and its  
2 role within the United States military?

3 A. Okay. Well, that -- as  
4 department head, I was -- I had a five --  
5 five staff plastic surgeons working for  
6 me. I had I think seventeen hospital  
7 corpsmen working for me. And we provided  
8 services, reconstructive surgical  
9 services on a referral basis from --  
10 essentially from the eastern  
11 Mediterranean all the way to Appalachia  
12 and from North Carolina -- I'm sorry,  
13 from -- from Maryland all the way down to  
14 Florida. So all persons requiring  
15 reconstructive surgery, including  
16 combat-injured or other, would be  
17 referred to us, people with congenital  
18 deformities, peop- -- you know, pediatric  
19 patients and -- and adults. And this was  
20 in a -- in the facility which at the time  
21 was the largest medical treatment  
22 facility in -- I think in the world,  
23 certainly in -- in the American purview.

1 I also -- I also established and  
2 ran congenital craniofacial deformity  
3 treatment. We ran a limb salvage  
4 treatment that involved a great deal of  
5 microvascular reconstructive surgery for  
6 wounds, cancer, that sort of thing. We  
7 also established the -- the wound care  
8 center for that facility, and that --  
9 again, we served that large catchment  
10 area with advanced wound care services.

11 Q. Dr. Lappert, you served as a --  
12 as a plastic and reconstructive surgeon  
13 for the United States Navy. Is that  
14 correct?

15 A. Correct.

16 Q. And you also served as a plastic  
17 and reconstructive surgeon in private  
18 practice. Is that correct?

19 A. Correct.

20 Q. Could you describe the -- or  
21 contrast or describe the similarities and  
22 differences in those two practices.

23 A. Certainly. Well, so both

1 practices involved both reconstructive  
2 surgery and aesthetic cosmetic surgery.  
3 But the difference is that in the  
4 military, because of the nature of the  
5 requirements, the experience level grows  
6 much more rapidly in the military than it  
7 does in the civilian world. So within  
8 the first couple of years of my practice  
9 as a reconstructive surgeon in the Navy,  
10 I was doing the most advanced  
11 reconstructive procedures, such as the  
12 mi- -- the neurotized microvascular flap  
13 operations that are often used, for  
14 example, in the phalloplasties of  
15 transgender surgery, or the perineal  
16 vaginal reconstruction for cancer, same  
17 operations that are used in the  
18 vaginoplasty for transgender  
19 self-identified persons. So a very  
20 advanced complexity.

21 In fact, when I sat for my  
22 boards, my oral boards, we had to present  
23 ten selected cases that the board

1       selected, and both of my examiners were  
2       startled at the level of complexity for a  
3       second-year person out of training, doing  
4       craniofacial surgery, free flap  
5       operations, massive limb salvage surgery.  
6       So that's the distinct difference, what  
7       you get in civilian versus what you get  
8       in the military. But both of them  
9       involved reconstructive as well as  
10      aesthetic cosmetic surgery.

11       Q.     Sure. Now earlier, you were  
12      asked about whether you had performed  
13      certain procedures in the context of  
14      transgender surgery. Is that correct?

15       A.     Yes, sir.

16       Q.     And your answer was that you had  
17      not. Is that correct?

18       A.     That's correct.

19       Q.     Have you done those procedures  
20      in the context of your practice of  
21      plastic surgery?

22       A.     I have.

23       Q.     Could you describe that --

1       those -- those circumstances.

2           A.     Well, as an example, a -- a very  
3       memorable case, a patient with what's  
4       called Fournier's gangrene, where  
5       essentially, they had a massive  
6       uncontrollable infection of the perineum  
7       that destroyed the scrotum, destroyed  
8       major portions of the penis, required  
9       what amounts to a reconstructive  
10      phalloplasty/scrotoplasty to reconstitute  
11      them after a long period of wound care.  
12      But the -- the operations to reconstruct  
13      the urethra is the same operation that's  
14      used to construct the urethra in a  
15      phalloplasty or construct the urethra in  
16      a metoidioplasty, same operations  
17      involving local flaps, mucosal grafts,  
18      tubularized flap operations. All of  
19      those are the same. Just the indication  
20      for the surgery is reconstructive rather  
21      than the surgeries for transgender.

22                 Same thing with the  
23      vaginoplasty. Again, often --



1 oftentimes, reconstruction for radiation  
2 injuries secondary to management of  
3 vagineal -- vaginal perineal malignancies  
4 that require removal of large areas of  
5 soft tissue, again reconstruction of the  
6 -- the perineum, the external genitalia,  
7 the vaginal introitus, the vaginal canal,  
8 same operations using flaps, grafts to  
9 reconstruct as are used in the  
10 transgender surgery world.

11 Q. So, do you feel that your  
12 professional experience and  
13 qualifications allow you to comment on  
14 the -- the medical operations involved in  
15 surgery for a transgender individual?

16 A. Yes. I'm -- I'm very familiar  
17 with all of those operations.

18 Q. And -- and you've performed  
19 those operations?

20 A. Yes, I have.

21 Q. Okay. Just not in the context  
22 of gender transition?

23 A. That's correct.

1           Q.     Okay.  There was a -- there was  
2     a brief question, and -- and we didn't  
3     get back to it, about one of the articles  
4     on your CV on breast reconstruction.  Is  
5     that -- is that correct?

6           A.     Right.  Yeah, that's one of my  
7     listed articles.  That's right.

8           Q.     Great.  Did you want to -- did  
9     you want to say more about that article?

10          A.     Yeah.  So, that's -- was really  
11     my entrance into the breast  
12     reconstruction world.  That actually  
13     started when I was still a general  
14     surgeon and I was collaborating with a  
15     plastic surgeon, and we examined the  
16     surgical planning for mastectomy in the  
17     setting of breast cancer or other causes  
18     and -- and the surgeon's role in  
19     designing those operations to get the  
20     best possible outcome.  And it was  
21     actually a seminal article, up until  
22     recently was the most quoted article in  
23     the literature on breast reconstruction.

1 And that was actually the first article  
2 that spoke about conservation surgery in  
3 surgical planning for the treatment of  
4 breast malignancies or other breast  
5 problems.

6 Q. Dr. Lappert, you were asked  
7 questions about the policy or position  
8 statements of several professional  
9 organizations. Do you recall those  
10 questions?

11 A. I do.

12 Q. Did those exhibits or any of the  
13 questions change your opinion that  
14 affirmative hormonal treatment and  
15 surgery remains unproven and  
16 experimental?

17 A. It has not changed my opinion.

18 Q. You were asked questions about  
19 the evidence supporting the provision of  
20 hormonal therapy and surgical  
21 interventions for the treatment of gender  
22 dysphoria. Is that correct?

23 A. Yes.

1           Q.     Were any of the questions or any  
2     of the studies that were presented to  
3     you, did they change your opinion that  
4     the existing medical evidence supporting  
5     those interventions is of very low  
6     quality and has methodological defects?

7           A.     That did not change my opinion  
8     about those, no.

9           Q.     And just to clarify, what is  
10    your opinion about the -- about the  
11    current state of the evidence supporting  
12    hormonal therapy for treatment of gender  
13    dysphoria?

14          A.     My opinion is that all of these  
15    published studies that are used to  
16    support or to justify the use of puberty  
17    blockade, cross-sex hormones, or  
18    transgender -- gender-affirming surgery  
19    are of the lowest quality scientific  
20    evidence and are not sufficient to  
21    support care and interventions that have  
22    such far-reaching and lifelong effects on  
23    the patient.

1           Q.     Are your opinions on that -- on  
2     that issue in this case based on anything  
3     other than your review of the scientific  
4     and medical literature and your training  
5     as a -- as a physician?

6           A.     No, they're not.

7           Q.     Dr. Lappert, you were asked  
8     about off-label use of Botox for certain  
9     muscle -- muscle groups. Is that  
10    correct?

11          A.     Yes, I was.

12          Q.     And you -- and you described --  
13    and you stated that you've actually used  
14    Botox off label for treatment of those  
15    muscle groups before that was approved by  
16    the FDA. Is that correct?

17          A.     That's correct.

18          Q.     But you have also said that you  
19    believe that it is significant and -- and  
20    relevant to this case that the use of  
21    hormone and puberty blockers for  
22    treatment of gender dysphoria is  
23    off-label. Is that correct?

1           A.     Yes.

2           Q.     Could you disting- --  
3           distinguish between why you hold the view  
4           that off-label uses of some  
5           pharmaceuticals is acceptable by a -- by  
6           a physician and when you consider that to  
7           be unacceptable by a physician?

8           A.     Right. So, the off-label use of  
9           medications when there's a low risk to  
10          the patient or that the -- the possible  
11          adverse effect may be brief and that a  
12          favorable result is likely where risk is  
13          low, then that's justifiable to go off  
14          label with medications. But when you're  
15          -- when you're talking about significant  
16          risk to the patient and irreversible  
17          changes, that the off-label use places a  
18          tremendous burden on the practitioner to  
19          -- to have scientific evidence to support  
20          his decision to do that. And to not have  
21          sufficient evidence when doing that is a  
22          -- is a -- is a great difficulty in terms  
23          of consent and in terms of just general

1 medical/surgical decision-making.

2 So the distinction is the  
3 risk/benefit equation. How much risk are  
4 you placing the patient under, is it  
5 irreversible, and is the benefit so great  
6 that it's worth taking the risk.

7 Q. Sure. Just to follow up, and  
8 these are going to be my final questions,  
9 is it your view that there are no -- and  
10 does it continue to be your view that  
11 there are no -- currently no competent --  
12 competently conducted long-term,  
13 peer-reviewed, reliable, and valid  
14 research studies documenting the number  
15 or percentage of patients who receive  
16 gender-affirming medical interventions  
17 who are helped by such procedures?

18 A. It's still my position that --  
19 that the medical literature does not  
20 support those interventions of medical  
21 and surgical treatment for  
22 self-identified transgender persons.

23 Q. Is it still your view that there

1 are no published, reliable, and valid  
2 research studies that document a valid or  
3 reliable biological, medical, surgical,  
4 radiological, psychological, or other  
5 objective assessment of a -- of a  
6 patient's gender identity or gender  
7 dysphoria?

8 A. Yes. It's still my position  
9 that there are no tests that will confirm  
10 or refute the diagnosis of transgender, a  
11 diagnosis made by the patient. There's  
12 no way to test for that.

13 Q. All right. Is it still your  
14 view, after the evidence and the  
15 questions that you've been presented,  
16 that an unknown percentage of patients  
17 who present with gender dysphoria also  
18 suffer from mental illnesses that  
19 complicate and may distort their  
20 judgments and perceptions of gender  
21 identity?

22 A. Yes. The -- the world  
23 literature demonstrates a consistent and



1 significant level of comorbidities,  
2 including severe anxiety, major  
3 depression, self-harm. The patient is  
4 very likely to be on the autism spectrum.  
5 Suicidal ideation. And -- and the world  
6 literature supports that. So -- and  
7 those are -- those are serious issues,  
8 not only in terms of decision-making, but  
9 even on the question of consent and  
10 competence for consent.

11 Q. Just one -- one more thing I  
12 wanted to follow up with. Your testimony  
13 -- we didn't cover this, but I want to  
14 make sure that it's still your view that  
15 medical treatments may differ  
16 significantly by sex according to your  
17 chromosomal assessment but not based on  
18 your gender identity and that  
19 misinforming physicians of a patient's  
20 biological sex could have deleterious  
21 effects on treatment for medical  
22 conditions?

23 A. Yes, that's correct. And when

1 we discuss the issue of misgendering,  
2 that's what we were talking about. We  
3 were talking about placing the patient at  
4 risk. If you're having a -- a discussion  
5 or conversation about medical  
6 decision-making, you have to distinguish  
7 between biological male and female  
8 because you run -- there -- there are  
9 illnesses that predominate in females  
10 that don't exist in males; there are  
11 conditions that affect males that do not  
12 affect females, and you have to know that  
13 if you're going to offer care. But  
14 again, that hasn't been changed by -- by  
15 what I've seen or heard here today.  
16 That's still -- is still the case.

17 Q. Okay. And it's still your view  
18 that the use of hormones and surgery to  
19 treat gender dysphoria is not supported  
20 by the relevant scientific communities as  
21 discerned by your literature review and  
22 your training as a physician in  
23 reconstructive and plastic surgery?

1           A.     Yes.

2                   MR. KNEPPER:   Those are my  
3       questions.   I don't think I have anything  
4       else.   Did you have follow-ups you  
5       wanted, Dmitriy?

6                   MR. TISHYEVICH:   Very, very  
7       briefly.

8                   MR. KNEPPER:   Okay.

9

10       EXAMINATION BY MR. TISHYEVICH:

11           Q.     Doctor, you were just asked  
12       about your views on why it's okay to use  
13       Botox off-label but you have a different  
14       view of puberty blockers.   Do you recall  
15       that?

16           A.     I do.

17           Q.     And one of your considerations  
18       is the risk/benefit profile of Botox;  
19       right?

20           A.     Right.

21           Q.     Do you know what a black box  
22       warning is, Doctor?

23           A.     Yes.

1           Q.     It's the strongest warning that  
2     the FDA can require; right?

3           A.     That's -- that's right.

4           Q.     And that warning is typically  
5     only used if studies indicate that the  
6     drug carries a significant risk of  
7     serious or even life-threatening adverse  
8     effects; right?

9           A.     Yes.

10          Q.     Do you know that Botox has a  
11     black box warning?

12          A.     Yes, I do.

13          Q.     It's for distant spread of toxin  
14     effect; right?

15          A.     Yes.

16          Q.     And the use of Botox has -- has  
17     resulted in reports of life-threatening  
18     injuries and death; right?

19          A.     I'm even familiar with the case  
20     reports that reported that. Yes, sir.

21          Q.     Okay. That's all I've got for  
22     you.

23                 MR. KNEPPER:   Okay. Thank you,

1 Dr. Lappert.

2 THE WITNESS: Thank you.

3 MR. KNEPPER: We're finished  
4 with your testimony.

5 Thank you, Dimitry. Thank you,  
6 Lane. Thank you, Andrew.

7 We can go off the record.

8 THE VIDEOGRAPHER: This is the  
9 end of Media Unit No. 7. We are off the  
10 record at 5:47 p.m. Thursday, September  
11 30th, 2021, and this concludes today's  
12 testimony given by Dr. Patrick Lappert.

13  
14 END OF DEPOSITION

15 ( 5 : 4 7 p . m . )  
16  
17  
18  
19  
20  
21  
22  
23

## C E R T I F I C A T E

STATE OF ALABAMA )

COUNTY OF JEFFERSON )

I hereby certify that the above and foregoing proceeding was taken down by me by stenographic means, and that the content herein was produced in transcript form by computer aid under my supervision, and that the foregoing represents, to the best of my ability, a true and correct transcript of the proceedings occurring on said date at said time.

I further certify that I am neither of counsel nor of kin to the parties to the action; nor am I in anywise interested in the result of said case.

/s/ Lane C. Butler

LANE C. BUTLER, RPR, CRR, CCR

CCR# 418 -- Expires 9/30/22

Commissioner, State of Alabama

My Commission Expires: 2/11/25

1 John G. Knepper, Esquire

2 john@knepperllc.com

3 October 13, 2021

4 RE: Kadel, Et Al v. Folwell

5 9/30/2021, Patrick Lappert, M.D. (#4814384)

6 The above-referenced transcript is available for  
7 review.

8 Within the applicable timeframe, the witness should  
9 read the testimony to verify its accuracy. If there are  
10 any changes, the witness should note those with the  
11 reason, on the attached Errata Sheet.

12 The witness should sign the Acknowledgment of  
13 Deponent and Errata and return to the deposing attorney.  
14 Copies should be sent to all counsel, and to Veritext at  
15 erratas-cs@veritext.com

16  
17 Return completed errata within 30 days from  
18 receipt of transcript.

19 If the witness fails to do so within the time  
20 allotted, the transcript may be used as if signed.

21  
22 Yours,

23 Veritext Legal Solutions  
24  
25

Kadel, Et Al v. Folwell

Patrick Lappert, M.D. (#4814384)

E R R A T A S H E E T

PAGE\_\_\_\_\_ LINE\_\_\_\_\_ CHANGE\_\_\_\_\_

REASON\_\_\_\_\_

PAGE\_\_\_\_\_ LINE\_\_\_\_\_ CHANGE\_\_\_\_\_

REASON\_\_\_\_\_

PAGE\_\_\_\_\_ LINE\_\_\_\_\_ CHANGE\_\_\_\_\_

REASON\_\_\_\_\_

PAGE\_\_\_\_\_ LINE\_\_\_\_\_ CHANGE\_\_\_\_\_

REASON\_\_\_\_\_

PAGE\_\_\_\_\_ LINE\_\_\_\_\_ CHANGE\_\_\_\_\_

REASON\_\_\_\_\_

PAGE\_\_\_\_\_ LINE\_\_\_\_\_ CHANGE\_\_\_\_\_

REASON\_\_\_\_\_

Patrick Lappert, M.D. Date



1 Kadel, Et Al v. Folwell

2 Patrick Lappert, M.D. (#4814384)

3 ACKNOWLEDGEMENT OF DEPONENT

4 I, Patrick Lappert, M.D., do hereby declare that I  
5 have read the foregoing transcript, I have made any  
6 corrections, additions, or changes I deemed necessary as  
7 noted above to be appended hereto, and that the same is  
8 a true, correct and complete transcript of the testimony  
9 given by me.

10  
11 \_\_\_\_\_  
12 Patrick Lappert, M.D.

\_\_\_\_\_ Date

13 \*If notary is required

14 SUBSCRIBED AND SWORN TO BEFORE ME THIS

15 \_\_\_\_\_ DAY OF \_\_\_\_\_, 20\_\_\_\_.

16  
17  
18 \_\_\_\_\_  
19 NOTARY PUBLIC  
20  
21  
22  
23  
24  
25

<b>&amp;</b>	<b>11-2</b> 63:16	<b>19.1</b> 390:1,5	<b>2.1</b> 302:21
<b>&amp;</b> 2:7 3:11 10:15 265:16 450:22 461:2	<b>116</b> 5:5	<b>1920s</b> 72:17	<b>2.7</b> 258:11
	<b>11:06</b> 166:17	<b>1972</b> 342:1,8	<b>2/11/25</b> 492:23
	<b>11:16</b> 166:21	<b>1972-2015</b> 6:19	<b>20</b> 6:17 339:16,18 339:21 340:2,7 372:14 495:15
<b>0</b>	<b>12</b> 4:13 5:13 7:20 230:12,14 411:9	340:10	
<b>0.3</b> 303:3 344:18 354:15	<b>120</b> 2:20	<b>1979</b> 182:22	<b>2000</b> 380:10
<b>0.6</b> 344:17 354:16	<b>127</b> 5:7	<b>1982</b> 227:12,17 228:19	<b>2001</b> 380:12
<b>08/02/2021</b> 4:17	<b>12:30</b> 254:16	<b>1987</b> 134:12	<b>2002</b> 31:17,20 32:3 32:5 136:22 137:2 137:23 139:16 240:13,17 472:18 473:20
<b>1</b>	<b>12th</b> 427:12	<b>1990</b> 106:19	
<b>1</b> 4:13 9:18 12:3,6 22:14,15 25:23 31:9 34:11 43:8 79:3 173:9 224:16 257:14,20 279:20 288:14 294:4 301:11,13,21 302:7,9,17,22 303:13 320:9 338:8 352:6 357:16 383:14 411:16 435:2,9	<b>13</b> 5:16 232:22,23 279:20 493:3	<b>1991</b> 106:18,19	<b>2005</b> 139:11,17
	<b>13.6</b> 304:12	<b>1992</b> 31:12	<b>2006</b> 140:18
	<b>14</b> 5:20 239:14,16 350:17 351:3 352:12,14 355:1,1 355:2	<b>1993</b> 136:11	<b>2007</b> 184:11,12
	<b>14.4</b> 357:11	<b>1994</b> 5:12 224:14 226:20,22	<b>2008</b> 23:8 30:11 300:11 302:13 303:2
	<b>15</b> 6:1 7:20 119:18 138:18 256:13,15 298:19 299:9 411:10 471:19	<b>1995</b> 132:22	<b>2009</b> 200:14
	<b>158</b> 2:14	<b>1996</b> 131:11 473:20	<b>2010</b> 139:8,13
<b>1.7</b> 303:3	<b>16</b> 6:4 56:15 263:8 263:10 359:22 366:6	<b>1997</b> 23:5 30:10 129:6 472:18	<b>2011</b> 185:17 186:4 383:1,5 389:15
<b>10</b> 5:8 6:10 110:9 171:7,11 255:10 297:23 298:9 300:7,10 303:12 440:1	<b>16,000</b> 360:19 364:23 365:11,15 366:2	<b>1998</b> 129:8 233:4	<b>2012</b> 183:4 185:16
<b>10/02/2017</b> 264:14	<b>17</b> 6:6 57:1,17 299:13,15 397:14 397:16	<b>19th</b> 2:20	<b>2013</b> 189:23 300:11 302:14 303:2
<b>100</b> 3:12 142:1	<b>171</b> 5:8	<b>1:19</b> 1:7 10:2	<b>2014</b> 85:8 202:14 257:3,14,14 380:9
<b>10017</b> 2:9	<b>1720</b> 3:6	<b>1:21</b> 254:20	<b>2015</b> 342:1,8,21 343:4
<b>1005</b> 2:21	<b>18</b> 5:12 6:11 42:6 58:1 224:14 257:4 257:5 325:23 326:2 399:13	<b>2</b> 4:14 27:9,14 28:16 64:4 110:4 166:16 225:2 231:2 242:13 264:17 265:3 286:4 288:14,22 294:4 295:11 302:5 303:22,23 304:11 306:13 307:13 384:9,16 405:11 415:6 430:21 435:12 451:8 465:8,23	<b>2016</b> 265:3 378:22 380:17 439:14
<b>105</b> 2:14	<b>18th</b> 430:17	<b>2,361</b> 341:22	<b>2017</b> 6:20 8:3 84:8 84:11 89:18 93:6 98:6 101:18 171:16 196:8,18 197:18,22 198:2 198:21 199:13,17 200:2,4,21 264:17 266:6 267:19
<b>108</b> 5:2	<b>19</b> 6:16 339:20 340:2 401:6	<b>2,773,770</b> 257:21	
<b>10:19</b> 115:11			
<b>10:21</b> 115:14			
<b>10th</b> 55:16			
<b>11</b> 4:4 5:11 43:12 110:6 223:16,18 458:21,23			

356:1 368:8 <b>2017-10-02</b> 6:5 <b>2018</b> 6:17 23:16,20 25:18 297:7 300:11 302:14,21 304:13,21 307:16 307:22 450:19 <b>2019</b> 6:6 25:2 100:13 148:22 149:1 256:19 299:19 440:9,11 440:12 441:15 465:11 <b>2020</b> 7:12,23 25:11 139:4,8 141:13,17 142:5 148:20 149:1 377:21 379:1,4 393:23 394:16 410:11 414:10 <b>2021</b> 1:21 5:5 7:6 9:10,17 25:10 38:5,11,16 55:17 108:15 109:3 110:6 115:23 359:18 377:13 379:6 380:18 381:10 382:4 410:22 424:8 427:12 430:17 435:2 491:11 493:3 <b>21</b> 6:20 38:11 320:11 322:16 355:17,18 380:11 413:6 <b>22</b> 5:12 7:1 359:14 361:4,11 <b>223</b> 5:11 <b>23</b> 7:5 129:11,15 130:18 375:14,16	397:6,12,13 460:22 <b>230</b> 5:13 <b>232</b> 5:16 <b>239</b> 5:20 <b>24</b> 7:7 388:18,20 399:13 <b>25</b> 7:12 108:15 171:16 347:10 394:7,9 401:6 404:23 <b>256</b> 6:1 <b>25th</b> 109:2 115:2 <b>26</b> 7:15 396:19,20 <b>26.3</b> 308:2 <b>263</b> 6:4 <b>27</b> 4:14 7:17 411:2 411:4 <b>27101</b> 3:13 <b>272</b> 1:7 10:2 <b>28</b> 7:23 414:20,22 <b>28.1</b> 257:21 258:12 <b>29</b> 8:2 35:11 419:15,17 <b>299</b> 6:6 <b>2:16</b> 320:3 <b>2:24</b> 320:7 <b>2nd</b> 38:5 <b>3</b> <b>3</b> 4:15 29:8 30:12 34:7 41:10,12,12 41:16 42:5 64:14 111:7 128:17 166:20 219:12 248:13 254:15 264:10 266:6 267:19 289:2,7,9 289:17,22 290:15 290:17 293:22,23 294:11 295:16 305:2 308:5 312:6	363:14 428:8 455:18 <b>3.2</b> 307:20 <b>3.8</b> 307:20 <b>3/2021</b> 377:13 <b>30</b> 1:21 8:4 344:8 426:22 427:1 443:7 468:15 493:17 <b>30030</b> 2:15 <b>30th</b> 9:9,17 491:11 <b>31</b> 8:6 257:14 430:7,9 <b>32</b> 8:9 434:7,10 <b>326</b> 6:11 <b>33</b> 8:12 451:3,5 <b>339</b> 6:17 <b>34</b> 4:15 8:14 463:4 463:5 464:10 <b>35</b> 298:16,17 402:16 <b>355</b> 6:20 <b>361</b> 7:1 <b>37</b> 4:16 <b>375</b> 7:5 <b>38</b> 36:1 <b>388</b> 7:7 <b>394</b> 7:12 <b>396</b> 7:15 <b>3:25</b> 388:8 <b>3:36</b> 388:12 <b>4</b> <b>4</b> 4:16 37:23 73:19 73:19 79:7 124:7 128:22 143:17 158:15 171:21,22 193:19 194:2 219:9 227:9 254:19 304:17 305:1,4 320:2 323:18 347:19	350:13 364:13 370:15 380:11 401:21 <b>4,432</b> 341:21 <b>4/5</b> 370:13 <b>40</b> 367:8 373:13 <b>41.7</b> 304:22 <b>411</b> 7:17 <b>414</b> 7:23 <b>418</b> 492:21 <b>419</b> 8:2 <b>427</b> 8:4 <b>430</b> 8:6 <b>434</b> 8:9 <b>45</b> 258:18 <b>45.5</b> 258:6 <b>451</b> 8:12 <b>46</b> 394:13 407:8 410:10 421:17,18 <b>463</b> 8:14 <b>472</b> 4:5 <b>48</b> 445:19 <b>4814384</b> 493:5 494:2 495:2 <b>489</b> 4:7 <b>4:07</b> 417:12 <b>4:15</b> 471:18 <b>4:20</b> 417:15 <b>5</b> <b>5</b> 4:18 35:1 43:10 55:9,12 59:14 73:7,13,16,17,20 124:1 189:18,20 189:23 190:12,17 191:8,14,19 192:1 192:9,22 193:15 194:2 219:2,18 255:10 283:20 284:8,12,21 285:13,22 301:12 301:14,21 305:2,5
--	--	---	--

320:6 323:18 327:6 332:17 344:13 363:15 364:1 370:14,15 383:10,12 388:7 <b>50</b> 255:10 298:1 351:21 369:8 <b>51</b> 446:2 <b>53</b> 445:11 <b>53.9</b> 258:7 <b>54</b> 258:18 419:20 419:21 421:7,13 445:2,11,13 <b>54.2</b> 258:7 <b>55</b> 4:18 <b>59</b> 5:11 <b>590</b> 3:6 <b>5:07</b> 470:13 <b>5:14</b> 470:17 <b>5:15</b> 472:4 <b>5:29</b> 472:7 <b>5:47</b> 491:10,15	<b>7</b> <b>7</b> 5:2 7:16 38:21 108:7 115:6 183:2 183:9 184:5,8,18 185:4 187:3,9,13 187:19 188:1,7,16 327:7 330:10 342:22 351:3 357:16 378:5 391:13 396:15 397:4 398:15 399:3 401:1 470:16 491:9 <b>7,000</b> 345:2 <b>7/19/11</b> 382:16 <b>70/30</b> 8:2 <b>73</b> 356:21 357:3 358:8 <b>74.7</b> 344:16 <b>779,270</b> 257:21	<b>9</b> <b>9</b> 5:7 127:16,17 158:16 405:2 437:5 <b>9/30/2021</b> 493:5 <b>9/30/22</b> 492:21 <b>90</b> 161:19 351:21 <b>900</b> 358:7 <b>90s</b> 100:21 161:12 <b>91</b> 31:14 273:21 <b>92</b> 31:14,14 69:17 101:13,16 <b>93</b> 101:14 102:22 <b>94</b> 69:17,18 <b>95</b> 101:7 342:15 <b>97</b> 102:6 262:19 <b>98</b> 129:20 <b>9:33</b> 79:4 <b>9:44</b> 79:8	<b>absence</b> 242:18 243:9 247:20 309:6 <b>absolute</b> 245:15 <b>absolutely</b> 43:19 60:19 61:12 114:12 267:22 315:6 353:11 462:5 <b>abstract</b> 240:22 328:18 341:17 356:8 411:16 453:12 <b>abundance</b> 293:21 <b>abuse</b> 8:17 70:17 120:13 314:19 449:1 450:2 461:15 462:11 463:18,23 464:17 469:2,13,14,16,18 469:20,22 470:7 <b>academy</b> 5:20 239:23 <b>acceptable</b> 313:18 484:5 <b>acceptance</b> 351:15 <b>accepted</b> 43:17 60:23 117:14 373:17,22 374:4 374:16 375:1,6 391:11 402:18 <b>access</b> 102:2 113:9 297:7,9 362:8 <b>accessible</b> 74:8,9 <b>accidentally</b> 256:1 <b>accomplish</b> 300:15 459:19 <b>account</b> 51:13 307:20 308:2 362:11
<b>6</b> <b>6</b> 4:20 40:23 41:14 62:19 172:2,3 349:16,19,23 356:21 357:4 388:11 470:12 <b>6,000</b> 345:2 <b>6,793</b> 341:21 342:6 343:11 350:17 <b>6,800</b> 345:1 <b>60</b> 17:10,12 359:22 369:8 372:11 <b>60,000</b> 359:18 360:18 <b>600</b> 3:12 <b>62</b> 4:20 <b>63</b> 35:12 <b>6:30</b> 471:22	<b>8</b> <b>8</b> 5:5 116:2 174:3 185:22 188:21,23 189:10 378:15 383:11 405:3 <b>80</b> 142:1 161:8 <b>80s</b> 230:8 292:15 <b>81</b> 422:12 <b>82001</b> 3:7 <b>83.8</b> 344:17 <b>87</b> 129:7 273:20 452:20 453:1 <b>884</b> 302:1 <b>889</b> 356:20 <b>89</b> 422:11 <b>8:30</b> 9:8 <b>8:31</b> 9:16	<b>a</b> <b>a.m.</b> 9:8,16 79:4,8 115:11,14 166:17 166:21 <b>abandon</b> 122:18 <b>abdominal</b> 121:23 <b>abdominoplasties</b> 142:20 <b>ability</b> 413:12 492:10 <b>able</b> 11:15 66:18 174:13,17 274:12 277:9 310:20 457:5 <b>abplasticsurgery...</b> 4:14 <b>abps</b> 27:22 28:8,19 28:23 29:12,23 30:10,13,15 31:3 <b>abreast</b> 69:12	

<b>accuracy</b> 493:9 <b>accurately</b> 28:18 28:23 <b>accuse</b> 127:13 <b>achieve</b> 66:15 287:7 334:8 <b>achieving</b> 467:7 <b>acknowledge</b> 230:1 327:9 413:17 <b>acknowledgement</b> 495:3 <b>acknowledges</b> 253:23 <b>acknowledging</b> 458:10,13 <b>acknowledgment</b> 493:12 <b>acne</b> 140:2 145:14 145:22 146:14 152:21 153:1 <b>acneiform</b> 145:13 <b>acronyms</b> 458:7 <b>act</b> 285:22 454:15 468:14 <b>acted</b> 329:4 <b>acting</b> 9:3 <b>action</b> 1:7 10:1 172:15 207:6 224:21 372:22 492:16 <b>actions</b> 461:10 <b>active</b> 24:23 26:5 26:20 100:16 137:11 140:8 171:19 322:21 <b>actively</b> 54:22 <b>activity</b> 265:11 267:19 <b>actual</b> 50:20 168:22 276:7	372:8 373:7 432:16 <b>acute</b> 134:13 135:10 <b>adamant</b> 71:12 <b>add</b> 62:11 398:20 458:7 <b>added</b> 283:21 <b>addition</b> 78:5 <b>additional</b> 13:14 215:22 265:7 <b>additionally</b> 243:2 <b>additions</b> 495:6 <b>address</b> 352:12 366:19 400:19 <b>addressed</b> 363:5 <b>addresses</b> 400:10 400:20 454:21,23 <b>addressing</b> 244:22 384:4,5 456:22 <b>adequately</b> 368:5 <b>adf</b> 79:11,15 80:21 80:22,23 81:5 82:17 83:3,11 84:4 98:7 <b>adf's</b> 81:11 <b>adjusting</b> 392:4 <b>adjustments</b> 212:20 <b>administration</b> 95:18,19 224:18 224:20 253:4 263:14 <b>administrative</b> 257:12 <b>administrator</b> 11:1 <b>administrators</b> 452:2 464:5 <b>admissions</b> 313:15	<b>admit</b> 112:9 <b>admits</b> 373:4,5 <b>admitting</b> 24:10 24:14 <b>adolescence</b> 161:8 205:3 319:11 <b>adolescent</b> 368:12 369:9,22 401:21 401:23 402:12,17 403:8,17,20 404:6 404:16 <b>adolescent's</b> 403:2 <b>adolescents</b> 36:19 51:5 157:19 158:9 161:1 162:14 238:15 239:6 241:6 258:23 399:16,20,23 400:12,21 401:13 402:4 428:16 429:1 <b>adopt</b> 49:3 <b>adopted</b> 114:9 310:22 <b>adopting</b> 51:13 <b>adrenal</b> 436:22 <b>adult</b> 368:12 369:9 369:22 <b>adulthood</b> 161:11 <b>adults</b> 157:23 158:5 259:7 463:16,17 474:19 <b>advanced</b> 472:22 475:10 476:10,20 <b>advancement</b> 310:13 <b>adverse</b> 202:19 334:21 484:11 490:7 <b>advice</b> 77:6 160:22 161:3	<b>advise</b> 210:3 <b>advised</b> 183:19,23 197:8 472:20 473:1,5 <b>advising</b> 204:19 214:15 <b>advisory</b> 378:17 380:15 <b>advocacy</b> 113:17 116:9 117:22 <b>advocate</b> 113:8 <b>advocates</b> 105:12 <b>aesthetic</b> 66:11 67:14 68:4,6,7 335:4,4 476:2 477:10 <b>aesthetically</b> 144:11,12 <b>aetna</b> 8:4 425:7,8 425:10,17,22 426:8,14 427:5,18 428:13,21 429:7 429:15 <b>aetna's</b> 428:1,5 <b>affairs</b> 263:23 <b>affect</b> 121:10 488:11,12 <b>affiliated</b> 59:8 96:6 <b>affiliations</b> 10:11 <b>affirmation</b> 5:3 43:14 51:4 109:18 110:8 149:10 151:15 373:19 376:13 379:20 382:23 384:22 387:2 395:16 <b>affirmative</b> 481:14 <b>affirming</b> 8:4 35:5 36:18,22 39:4 40:4 41:7,18 44:1
--	--	--	---

51:23 54:10 57:12 63:14 77:18 78:19 107:12,20 111:6 111:18 112:21 114:9 115:19 117:15 126:10 127:4 130:3 131:16 132:18 133:16 134:3,17 137:4,10,18 151:13 164:15 168:12,17,17 175:20 177:22 375:7 390:1,15 391:2 424:9 425:17 426:14 427:5,18 428:1,7 429:8 433:19 482:18 485:16 <b>afternoon</b> 97:17 <b>age</b> 242:19,22 249:6 257:4,5 319:10 346:4,5,8 347:9,11 402:1 469:1 <b>agencies</b> 30:17 224:10 <b>agency</b> 221:3 224:17,19 229:12 <b>agents</b> 201:2 203:16 204:17 211:10 212:14 213:18 406:13 <b>ago</b> 15:2,16,20 24:3,15,23 44:14 99:21,23 100:1 103:18 123:1 129:11 130:18 170:9,10 196:6 202:7,11,14 206:16 225:10	247:21 290:19 301:19 325:10 <b>agonist</b> 317:22 <b>agonists</b> 201:8 <b>agree</b> 22:6 36:8 42:18 111:17 112:20 113:3,4,5 128:11 135:13 179:2,6 221:1 229:11 249:11 250:11 252:12 296:17 314:23 315:1,6 316:7 317:16,23,23 318:5 321:2,22,23 340:18 371:5,9 393:2 407:5 408:6 <b>agreed</b> 265:23 <b>agreement</b> 248:23 <b>ahead</b> 126:6 227:5 281:2,14 327:20 327:21 <b>aid</b> 492:8 <b>aim</b> 300:5 <b>aimed</b> 68:6 <b>al</b> 1:9,14 9:21,22 493:4 494:1 495:1 <b>alabama</b> 4:20,23 9:3,7 10:5 24:18 62:5,10,23 63:2,5 63:11,18 76:4,6 109:23 110:15,22 117:7 138:12,14 455:9 464:20 492:2,22 <b>alarm</b> 71:15 <b>alcohol</b> 333:21 <b>alert</b> 464:6 <b>align</b> 111:10 447:10 449:7	<b>allergan</b> 263:21 264:7,9 270:19 <b>alliance</b> 79:11 <b>allotted</b> 493:20 <b>allow</b> 32:18 243:1 428:6 479:13 <b>allowed</b> 179:16 180:7 229:20 <b>allows</b> 222:15 256:2 <b>alphabetically</b> 422:3 <b>altering</b> 244:19 290:2,17 311:5 <b>alternative</b> 250:2 250:14 252:11 <b>altogether</b> 251:3,5 <b>ama</b> 47:5,7,14 48:5 <b>ambiguous</b> 436:7 436:15 <b>ambulatory</b> 258:7 <b>amend</b> 18:19 19:3 <b>amended</b> 265:21 <b>amendment</b> 264:2 <b>amer</b> 26:11 <b>america</b> 123:21 <b>american</b> 5:9,20 26:13,16 27:13 30:8 32:9,10,17 43:1,2 44:18 45:2 45:14,15 46:1,7,23 47:8 48:10,15,18 49:6 72:3 89:14 89:19 99:16 100:5 100:18 102:20 108:11 123:23 124:12 128:12,13 169:7 171:12 185:14 190:5 239:1,23 248:5	282:4 283:8 300:17 313:2 474:23 <b>amid</b> 109:14 <b>amount</b> 169:19 <b>amounted</b> 304:21 <b>amounts</b> 402:16 478:9 <b>amputating</b> 289:21 <b>amsterdam</b> 6:17 326:7 340:9 <b>analogues</b> 431:14 <b>analysis</b> 86:13,14 276:3 302:2 307:19 410:11 <b>andre</b> 86:6 <b>andrew</b> 3:20 10:5 471:7,14 491:6 <b>androgen</b> 146:18 <b>androgens</b> 431:13 431:14 <b>anecdotal</b> 218:23 219:1 244:14 245:20 246:7 270:16,16 279:23 280:6,15,20 281:4 281:8,10,21,23 282:17 323:22 362:21 363:16 <b>anecdotes</b> 343:13 <b>anesthesia</b> 142:22 <b>angle</b> 132:17 <b>animal</b> 135:11 <b>animate</b> 266:16 <b>anorexic</b> 74:23 <b>answer</b> 18:19 19:4 83:1 110:21 124:17 125:23 126:5,8,19,21 127:1 150:20
--	---	--	---



164:7,11 181:4 186:16 215:4 251:1 269:12 274:11 286:16 294:1,8 324:8 374:22 409:18 426:2 477:16 <b>answered</b> 126:14 426:4 <b>answering</b> 261:17 <b>answers</b> 4:18 55:14 104:19 <b>antacids</b> 122:6 <b>anthropology</b> 442:6,12,23 443:4 443:11 450:23 454:3 <b>anti</b> 431:14 <b>antibiotics</b> 122:6 <b>anticipated</b> 80:13 186:18 <b>anxiety</b> 154:10 155:6 165:16 405:19 487:2 <b>anxious</b> 160:19 <b>anybody</b> 205:9 <b>anywise</b> 492:17 <b>apa</b> 49:2 190:8 191:18 192:19 194:11 239:4,20 240:15 242:1 243:8,15 248:2 250:12,19 251:12 251:19 253:15,20 <b>apa's</b> 239:9 <b>apart</b> 189:3 260:8 276:14 331:4 <b>apologies</b> 18:23 <b>apologize</b> 434:13 471:13	<b>apostolate</b> 452:4 455:6 <b>appalachia</b> 474:11 <b>apparent</b> 317:4 318:3 <b>apparently</b> 39:13 40:22 43:20 56:1 117:9 306:8 439:22 <b>appear</b> 201:11 303:17 395:5 423:21 <b>appearance</b> 10:11 60:6 61:6,10 71:13 144:13 154:18 238:21 265:9 465:20 <b>appearing</b> 465:14 <b>appears</b> 39:19 240:20 259:3 264:19 376:20 378:4 428:6 <b>appended</b> 495:7 <b>applicable</b> 493:8 <b>application</b> 205:13 205:16 218:15 219:10,11,15 234:11 235:7,12 237:10 244:11,13 247:9,23 252:19 265:2,7,20 266:21 267:6 270:15 310:9 <b>applied</b> 148:13 206:10 291:21 300:19 311:4,22 333:9 <b>applies</b> 460:17 <b>apply</b> 225:23 236:3 276:12 316:8 436:6	<b>applying</b> 245:4 247:15 318:15 <b>appointment</b> 207:12 <b>appreciation</b> 56:20 <b>approach</b> 249:13 <b>approaches</b> 105:23 228:9 <b>approaching</b> 83:21 219:21 307:12 <b>appropriate</b> 26:3 26:7 40:5 41:19 44:3 61:11 216:21 228:7 231:13 232:1 246:14 251:20 335:23 406:4 <b>approval</b> 6:5 236:3 243:9 263:17 265:6,16 266:17 267:8 269:10 334:7 <b>approved</b> 5:14 63:12 216:9,15 225:13,16 226:16 230:22 231:5,18 233:21 243:2 248:1 253:4,5 257:4 262:9,15,23 265:21 266:4 270:21 332:1 333:12 334:9 483:15 <b>approves</b> 231:9 261:2 <b>approving</b> 261:3 <b>approximately</b> 9:8 <b>april</b> 109:10 435:2	<b>apt</b> 20:3 <b>arc</b> 459:17 <b>archdiocese</b> 451:22,23 <b>area</b> 173:13 178:5 178:20 200:17 201:21 203:18 205:5 287:4 307:8 319:20 363:1,19 475:10 <b>areas</b> 104:1 210:11 221:11 311:13 479:4 <b>aristotelian</b> 459:14 <b>arizona</b> 62:14,14 80:1 93:3 <b>arkansas</b> 33:6,10 36:16 37:4 38:5 39:11 51:23 52:11 52:22 54:9 61:17 63:7 72:19 99:7 109:22 117:6 <b>arrived</b> 44:9,9 <b>article</b> 20:18 62:22 67:5 134:20 135:14 186:4 222:12 283:16 298:17 301:1 307:4 323:6,19 324:20 325:7 327:10 328:22 331:12 332:9 345:15 360:6,23 361:14 364:13 368:7 369:16 370:14 371:13,16 372:20 380:16,17 396:11 410:21 468:20 480:9,21 480:22 481:1
--	--	---	---

<b>articles</b> 12:21 21:7 74:12 129:3 222:10 274:1 297:10 298:2 306:21 336:8 377:19,21 382:2 412:23 440:20 480:3,7 <b>aside</b> 92:13 132:16 181:22 <b>asked</b> 73:18,21 79:19 91:7 99:2 122:23 126:14,15 152:1 155:5 180:2 183:21 292:18 318:9 336:9 453:23 477:12 481:6,18 483:7 489:11 <b>asking</b> 97:4 104:8 134:22 144:20 155:1 180:1 198:16 205:8 266:20 269:15 278:8,11 286:17 288:9,16 321:8 346:21 471:10 <b>aspect</b> 275:12 <b>aspects</b> 92:10 <b>asps</b> 5:2,5 101:10 101:15 102:8,10 102:17,23 103:6 103:21 105:10,11 106:1,20 107:12 111:5,8,16 112:7 112:13,20 113:7 113:16,18,19 114:8,14 115:1,5 115:17,23 116:8 169:10,18,22 170:8,13,23	171:19 174:18 176:9,14 177:9 179:4 180:8,15,18 180:21 181:9 222:9 284:5 296:5 297:12 301:19 306:5 <b>asps's</b> 117:4 <b>assert</b> 28:1 <b>assessment</b> 486:5 487:17 <b>assessments</b> 406:1 <b>assigned</b> 341:22 341:22 442:13,22 446:17 <b>assistance</b> 59:3 <b>assisted</b> 279:9 <b>associated</b> 265:10 267:18 438:11 <b>association</b> 40:3 40:17 43:2 45:14 46:23 49:7 182:9 190:6 239:1 380:13 428:17 <b>associations</b> 51:10 <b>assume</b> 155:7 169:21 208:19 362:16 381:16 382:8 433:16 448:9,9 <b>assuming</b> 409:13 <b>asthma</b> 220:15 <b>atrocious</b> 469:3 <b>attached</b> 8:20 12:7 27:10 34:8 38:1 55:10 62:20 108:8 116:3 127:18 171:8 223:19 230:15 233:1 239:17 256:16 263:11 299:16	326:3 339:19 355:19 361:12 375:17 388:21 394:10 396:21 411:5 414:23 419:18 427:2 430:10 434:11 451:6 463:6 493:11 <b>attaches</b> 70:23 <b>attempting</b> 110:7 386:18 <b>attempts</b> 116:20 <b>attended</b> 94:15,15 <b>attending</b> 133:6 <b>attends</b> 218:1 <b>attention</b> 89:11 109:14 <b>attitude</b> 222:13 <b>attorney</b> 91:19 92:6 493:13 <b>attraction</b> 454:10 454:16 455:2 <b>audience</b> 90:5 452:1 456:20 <b>augmentation</b> 142:10 <b>august</b> 25:10 38:5 141:13 <b>author</b> 133:2,5,7 340:14 359:18 361:18 365:10,14 366:3 <b>author's</b> 365:18 389:4 <b>authority</b> 261:3 <b>authors</b> 191:7 328:16 342:5 415:9 <b>autism</b> 487:4	<b>autologous</b> 142:8 142:9 299:7 <b>automatically</b> 395:23 <b>availability</b> 473:3 <b>available</b> 99:4 160:18 177:1 183:1 185:18 196:21 248:20 249:4,14 250:3,14 250:22 251:14 252:6,14 329:9 381:21 415:17 416:4,8 431:4 441:12 493:6 <b>avenue</b> 2:8,14 3:6 <b>average</b> 345:5,18 346:2 353:19 357:10,21 <b>avoid</b> 338:3,4 <b>avoided</b> 165:19 <b>aware</b> 17:14,23 19:12,13,14 20:17 37:8,16 42:1,15,21 43:6 54:7 78:11 127:12 149:9 170:13 171:3 181:9 182:20 193:19 201:3 211:8 233:5,7 267:5,6 352:23 353:3,8 367:20 370:7,17 376:6 425:10 <b>awkward</b> 325:21 <b>b</b> <b>b</b> 4:10 20:23 33:2 58:2 <b>back</b> 14:14 18:23 19:3 21:12 26:12 30:12 31:9 43:7
--	--	--	---



53:20 72:16 73:1 100:21 101:7 106:18 115:13 119:16 143:10,16 148:15 157:4 158:13,15 166:1 200:21 202:13 207:8 216:5 248:8 252:16,17 264:20 266:19 279:19 292:5,11,15 293:14 319:18 320:9 323:3 326:6 344:23 346:1 359:8 367:6 373:11 380:10 396:12 397:16 404:22 407:7 417:14 420:5 421:6,18 459:14 463:7 471:21 472:6 480:3 <b>backbone</b> 308:10 <b>background</b> 378:6 378:11 380:3 <b>backpedal</b> 417:2 <b>backwards</b> 131:10 <b>bad</b> 92:11 <b>baker</b> 3:20 10:6 <b>balance</b> 466:5 <b>ballpark</b> 297:23 299:9 303:11 <b>ballparking</b> 262:20 298:15 <b>ban</b> 37:11 54:9 57:11 58:16 63:6 76:4,7,22 109:22 109:23,23 117:6,7 117:7 <b>bans</b> 36:16 52:5,23 54:23 61:20,22	76:16 <b>base</b> 120:7 233:23 281:21,22 398:9 399:9 <b>based</b> 71:22 117:21 124:3 140:12,13,13 161:4 177:7 178:1 185:10 220:3 228:19 246:2 249:1,20 250:7 292:12 305:12 331:14 355:14 378:12 405:23 432:16 436:11 438:23 441:8 443:5 444:14 483:2 487:17 <b>baseline</b> 392:5 412:20 <b>basically</b> 21:7 35:8 46:4 124:2 159:1 159:13,17 286:18 311:15 316:21 329:15 349:12 360:12 363:17 <b>basing</b> 119:21 <b>basis</b> 45:21 49:12 69:8 81:19 216:19 216:22 217:12 218:23 220:1,3 229:21 234:18 236:5,14 237:5 238:3,14 246:16 251:22 258:14,23 268:18 269:21 381:4,5 393:6 406:3 467:5 474:9 <b>battle</b> 77:23 <b>bcbs</b> 7:5	<b>bear</b> 388:17 <b>becoming</b> 19:19 20:11 <b>beginning</b> 79:7 91:15 166:20 245:12,13 246:13 247:1 284:14 308:17,23 309:3 320:6 329:21 383:18 386:18 388:11 403:16 445:18 470:16 <b>begins</b> 218:23 220:5 245:19 246:6 270:15 276:3 308:18 309:2 <b>behavior</b> 118:5 <b>behavioral</b> 77:22 <b>believe</b> 34:2 86:7 86:15 96:7 97:9 140:17 148:21 151:19 208:1 291:9 294:5 322:17 413:21 446:17,21 470:2 483:19 <b>believes</b> 111:9 112:13 <b>bell</b> 3:11 <b>belldavispitt.com</b> 3:14 <b>bells</b> 71:15 <b>beneficial</b> 150:12 <b>benefit</b> 70:23 82:22 206:12,20 206:23 222:21 223:4 241:12 248:21 285:20 291:10 310:6 311:10 330:8	331:9 385:11 387:20 413:4 414:2,3 420:18 423:1,6 431:4,18 435:19 437:8 452:9 485:3,5 489:18 <b>benefits</b> 8:3 204:21 207:19 208:14 214:16 215:1,7 223:1,2 235:15 260:4 293:18 386:1 420:12 438:13,15 438:22,23 <b>benign</b> 144:10 220:19 <b>benjamin</b> 380:12 <b>best</b> 97:5 122:14 124:20 125:19 248:20 253:9,14 381:17 382:9 416:4,8 462:22 480:20 492:10 <b>better</b> 71:14 119:12 289:16 290:3 343:5 372:6 381:21 <b>beyond</b> 69:11 125:11 210:3 219:18 246:20,20 247:16,21 313:12 314:11,12 337:13 337:15 352:2 <b>bias</b> 392:3 <b>biblical</b> 457:1 <b>big</b> 185:17 365:23 379:11 <b>bigger</b> 176:22 <b>bill</b> 4:20 62:23 63:12,20 64:2,11
--	---	---	--

<b>billroth</b> 123:11	<b>blocker</b> 201:3	30:9,10 31:7,11,23	119:21 128:17
<b>binary</b> 348:4	<b>blockers</b> 36:21	32:3,9,10,17,19,20	168:8 171:15
349:2 351:14,16	84:23 161:2,6	100:6,7,16,23	231:4 240:6
<b>biography</b> 472:12	163:12 203:21	101:2 102:5 128:7	242:16 256:3
472:14	204:21 205:2	128:12,13 234:13	316:12 322:16
<b>biologic</b> 443:12	207:20 208:15	235:20 476:23	326:11,14 350:6
<b>biological</b> 383:23	211:22 213:6	<b>boards</b> 476:22,22	373:15 382:11
443:20 446:22	374:5,9,12 396:1	<b>bodies</b> 30:16,16	405:12,13 422:14
447:2,17 448:14	483:21 489:14	47:9 66:15,22	428:10 437:8
448:15 450:3,6	<b>blocking</b> 63:13	111:11	440:4 451:13
486:3 487:20	81:23 162:16	<b>body</b> 67:19,23	<b>botulinum</b> 263:4
488:7	164:4 166:8 201:2	68:22 69:4,20	<b>box</b> 300:2 489:21
<b>biologics</b> 5:18	201:19 203:15	70:7,11 73:6,23	490:11
233:15 265:1,6	204:17 207:13	74:14,22 75:1,10	<b>boy</b> 452:22
<b>biology</b> 444:9	211:10 212:14	142:12 154:5,7	<b>boys</b> 165:13 369:8
<b>birmingham</b>	213:18 316:16,20	218:4 319:5,9	<b>brains</b> 404:10
455:9	317:21 318:2,11	363:8,9 466:6	<b>brandt</b> 4:15,16
<b>birth</b> 341:22,22	406:13,23 428:22	467:17 469:5	33:2,16,23 34:19
383:23 442:13,22	<b>blog</b> 408:8,17	<b>boilerplate</b> 384:14	36:10,15 42:17
446:18	409:5	<b>bold</b> 27:17 231:5	43:4 51:21 88:16
<b>bit</b> 93:12 97:2	<b>blogs</b> 408:11	422:8 430:23	99:7
99:15 101:20	409:20	<b>bones</b> 130:9	<b>branström</b> 276:17
442:5 467:21	<b>blood</b> 211:11	<b>book</b> 72:12	276:21
<b>black</b> 350:5 387:5	212:2,18 213:17	<b>booklet</b> 8:3 420:12	<b>break</b> 79:5 115:12
489:21 490:11	460:1,3,8 468:8	<b>bored</b> 452:22	115:16 143:23
<b>blanche</b> 104:21	<b>blue</b> 375:23 376:1	<b>borelli</b> 2:12	166:18 254:17
<b>blanket</b> 236:9	376:6,7 380:23,23	<b>bother</b> 179:7	319:22 320:4
<b>blind</b> 271:16	381:8,8 382:1,1,21	250:17	322:8 346:5 388:9
309:20,22 315:4	382:22 383:7,7,7,7	<b>botox</b> 6:4 139:21	390:6 417:13
315:16 317:17	429:14,15	140:19 141:1	470:14 471:19
319:14	<b>bluecross</b> 375:20	206:15 229:10	472:5
<b>blinded</b> 268:20	379:15,18 424:7	261:20 262:1,5,9	<b>breast</b> 44:15,23
271:12,19,21	425:5	262:21 264:8	142:10,19 147:15
273:18 309:19	<b>blueshield</b> 375:20	266:4,17 267:14	149:3 220:16,20
318:10	379:15,19 424:7	267:16 268:3,18	222:7 290:21
<b>blockade</b> 161:16	425:5	269:19 271:3	291:5,11,14,16,19
162:19 165:9	<b>board</b> 22:20 23:4	483:8,14 489:13	292:9,22 293:18
219:17 238:19	23:10,13,15,20	489:18 490:10,16	294:9,13 299:4,6
247:1,9 260:7	25:4,13,17 26:1,13	<b>bottom</b> 28:16	480:4,11,17,23
416:14 482:17	26:17,19 27:13	41:14 56:19 57:3	481:4,4
	28:10 29:12 30:8	57:17,19 64:7,8	

<b>breasts</b> 287:17,18 290:8 <b>brief</b> 480:2 484:11 <b>briefe</b> 96:21 <b>briefly</b> 489:7 <b>bring</b> 185:15 250:16 <b>bringing</b> 83:11 <b>brings</b> 250:15 <b>britain</b> 53:19 248:3 260:12 <b>broad</b> 131:22 290:10 <b>broadcast</b> 465:14 <b>broaden</b> 235:12 <b>broadened</b> 267:5 268:14 <b>broad</b> 454:20 <b>broadly</b> 88:14,18 152:5 <b>brow</b> 130:16 266:16 <b>brown</b> 216:7 280:5 368:18 377:19 395:6 <b>brown's</b> 18:22 <b>bucks</b> 379:12 <b>built</b> 95:13 <b>bulk</b> 124:14 291:9 <b>bullet</b> 28:22 29:8 116:19 117:1 432:2 435:8 456:3 456:12 <b>bulletin</b> 225:11 227:12 <b>bullets</b> 431:8 459:2 <b>bunch</b> 366:20 377:21 378:16 379:1 435:8	<b>burden</b> 235:13 484:18 <b>business</b> 125:17 385:13,22,23 438:9 439:3,21 <b>butler</b> 9:1 10:8 492:19,20 <b>bylaws</b> 101:6 <b>c</b> <b>c</b> 2:1 9:1 16:16 256:19 277:14 322:18 360:10 414:15,15 445:6 446:13 492:1,1,19 492:20 <b>calamitous</b> 346:23 <b>calendar</b> 14:15 <b>california</b> 103:19 272:16 <b>call</b> 49:14 98:23 182:19 267:2 271:3 284:17 343:12 360:19 363:7 365:6 366:8 366:12 381:18 432:21 433:3 436:10 466:5 <b>called</b> 12:18 79:11 99:1 102:3 120:8 138:11 143:4 186:10 388:1 407:12 455:4 465:15 466:2 478:4 <b>calling</b> 60:21 76:15 363:17 <b>camera</b> 255:23 256:7 <b>campos</b> 7:1 360:7 <b>canal</b> 479:7	<b>cancer</b> 142:14,14 143:1 178:19 289:14 299:5 468:2 475:6 476:16 480:17 <b>cancers</b> 143:5,6 144:14,15 <b>capacity</b> 183:20 184:1 197:9 404:7 404:10 <b>capital</b> 182:14 279:23 373:16 <b>capitalized</b> 456:9 <b>capsules</b> 222:8 <b>care</b> 7:15 40:4 41:7,18 53:8 54:2 63:14 72:23 77:18 109:13,18 113:10 113:20 116:7 122:11,14 124:23 132:8 138:1 139:3 150:17 151:13 152:11,12 154:23 157:4 165:18 182:16,19 183:2,9 184:5 186:10,11 189:11 196:14 199:7 213:2,11 223:6,8 258:4 272:23 351:11 363:19 394:22 395:16 396:15 397:4 398:15 399:3 401:1 424:17 444:5,6 448:2 450:5 459:6 459:10 463:14 464:4 473:8,9 475:7,10 478:11 482:21 488:13	<b>cared</b> 347:12 444:2 <b>career</b> 28:18 95:22 129:2 137:16 <b>careful</b> 359:7 406:3 468:7 <b>carefully</b> 202:13 251:11 363:18 462:17 <b>caregivers</b> 403:4 <b>caretakers</b> 402:2 402:23 403:10 404:17 <b>carey</b> 3:6 <b>carmichael</b> 7:17 35:18 410:22 <b>carolina</b> 1:2 3:13 10:1,20,23 11:1 375:20 376:8 379:16,19 420:14 424:8 425:6 474:12 <b>carries</b> 490:6 <b>carrying</b> 109:15 <b>carte</b> 104:21 <b>case</b> 11:20 12:11 16:6,17 17:2,15 18:1 22:10 33:1,5 33:8,14,16,23 34:17,19 35:9,22 36:10,12,15 37:4,9 37:11 39:12,16,22 42:17 43:4 45:22 46:16,20 48:17 51:21 53:18 57:22 58:6,12 72:19 77:19 88:16,16 98:19 99:7 114:7 118:12 122:12,17 170:19,22 180:7 189:5 196:23
---	---	--	--

204:11 206:21 209:1,10 217:1,1,5 217:5 219:16 220:1,4 221:16 238:16,18 243:22 246:7,9 249:16 252:18 259:16 260:17 270:10 278:21,23 279:3,6 279:17 280:19 281:9 282:20 283:11,20 284:7 284:12 285:22 286:19,19,21,22 287:11 290:9,9 293:18 304:18 306:13 308:2,9,13 308:19,20,21 309:9 310:11,20 311:15 312:2,18 314:6,9 322:16 323:11,12 328:9 329:16 335:14,18 336:13 339:8 343:6,11 355:5 364:2,4 387:18 406:3,3 410:6 417:19,21 448:18 449:17 455:5 456:19 460:8,9 469:11,13 478:3 483:2,20 488:16 490:19 492:18 <b>cases</b> 40:12 92:23 124:8 143:12 145:20 209:7 211:15 236:11 271:13 281:7 283:13 310:5 354:19 369:8 457:18,22 458:6	476:23 <b>catchment</b> 475:9 <b>categorically</b> 292:7 294:6 406:12,17 <b>categories</b> 144:6 290:10 431:9 <b>categorized</b> 219:2 <b>category</b> 66:22 106:3 122:9 146:3 267:4 270:23 279:6 312:10,16 316:6 327:16 329:18 372:13 385:5 <b>catholic</b> 64:19 65:2 451:22 452:4 452:16 464:20 <b>causality</b> 413:15 <b>cause</b> 9:11 154:18 210:10 369:21 373:7 <b>caused</b> 81:23 121:21 150:10 276:21 344:22 <b>causes</b> 480:17 <b>caution</b> 245:1,2 311:8 <b>caveat</b> 391:23 <b>cb</b> 445:20 <b>ccr</b> 492:20,21 <b>cecilia</b> 186:5 329:22 389:7 <b>center</b> 96:5 298:20 298:23 299:3 328:9 343:3 475:8 <b>central</b> 9:9 <b>certain</b> 62:14 86:2 146:23 206:8 209:7 228:7 258:3 261:5 310:14	376:22 386:22 407:2 477:13 483:8 <b>certainly</b> 26:15 27:3 31:5 40:14 102:14,19 105:19 137:3 152:11 153:2 176:23 247:13 283:6 284:18 286:9 289:14 310:11 313:3 314:3 329:20 342:23 343:5,19 355:9 385:22 474:23 475:23 <b>certificate</b> 23:10 23:16,20,23 25:4 32:20 <b>certification</b> 23:4 24:7 26:5,20 27:18 28:1,4,12,19 29:1,10,11,12 30:14 31:8,12,16 100:8,17 <b>certifications</b> 23:2 <b>certified</b> 22:21 25:13,17 26:1,19 28:3,10 30:8,10 31:23 32:3,19 100:6 101:2 102:5 128:8 <b>certify</b> 9:4 492:4 492:14 <b>cessation</b> 365:17 <b>chairman</b> 95:9,11 473:21 <b>challenge</b> 36:16 83:12 455:23 456:1 467:20	<b>change</b> 8:14 60:3 186:2 194:1,21 260:3 271:15,22 309:18 372:11 382:3 412:19 464:15 481:13 482:3,7 494:4,7,10 494:13,16,19 <b>changed</b> 107:15 110:21 122:22 123:2,18 186:6 247:7,8,10 380:21 380:22 443:20 446:18,23 447:3 481:17 488:14 <b>changes</b> 81:22 290:3 311:5 413:13 484:17 493:10 495:6 <b>changing</b> 67:23 71:12 119:22 125:1,20 259:20 359:4 464:21 <b>chaplain</b> 455:17 <b>chapter</b> 455:8,15 455:17 <b>character</b> 372:1 <b>characteristic</b> 339:4 416:21 <b>characteristics</b> 165:15 243:18 350:14 <b>characterizations</b> 380:11 <b>characterize</b> 81:10 82:17 118:22 132:5 385:18,20 <b>characterized</b> 68:2 74:6 235:15 336:4
---	--	--	--

<b>characterizes</b> 124:1 <b>chart</b> 343:1 344:1 <b>charts</b> 418:1 <b>chastity</b> 454:16,21 455:3 <b>check</b> 212:19 246:3 <b>cherry</b> 3:12 <b>chest</b> 167:19 178:4 <b>cheyenne</b> 3:7 <b>chief</b> 121:19 262:12 306:10,12 <b>child</b> 8:17 82:6 161:5 165:5 166:6 209:10 238:20 309:19 317:6,15 405:15 464:16 469:18,22,23 <b>child's</b> 470:1 <b>childhood</b> 394:23 397:10,18 398:12 398:17 <b>children</b> 5:23 76:10 77:19 94:7 157:19 158:9,18 159:4,9,12 160:19 160:23 162:13 163:6,8,11,17,19 205:19 238:15 239:5 240:3,11,17 241:5 243:5 258:22 259:7,10 262:15 318:12 395:10,22 397:20 397:23 398:17 399:21 400:2,5,18 400:20 401:3 404:4,6 406:20 461:15 462:3,9 463:15,16 468:23	469:7 <b>childrens</b> 241:5 <b>chimed</b> 46:4 <b>choose</b> 432:20 438:8 462:17 <b>choosing</b> 303:18 436:10 <b>chosen</b> 449:23 <b>christian</b> 442:6,11 442:23 443:3,10 443:11 450:22 <b>chromosomal</b> 487:17 <b>chronological</b> 15:15 <b>church</b> 452:5 <b>church's</b> 456:13 <b>cigna</b> 8:6 429:16 429:19 430:12 <b>cigna's</b> 431:18 432:7 <b>circle</b> 20:15 216:5 <b>circles</b> 283:6 <b>circumstance</b> 237:11 <b>circumstances</b> 210:8 216:20 228:8 251:7 285:18 407:2 424:3 478:1 <b>citation</b> 297:13 <b>cite</b> 13:9 108:18 109:5 238:6 322:16 377:18 389:22 399:8 407:11 410:21 414:9 415:4 453:12 <b>cited</b> 13:15 325:7 343:7 360:6 378:2 382:2 389:17	440:9,19 <b>cites</b> 227:11 327:6 335:14 <b>citing</b> 361:15 410:10 453:14 <b>civil</b> 1:7 9:5 10:1 <b>civilian</b> 476:7 477:7 <b>claim</b> 29:11 45:16 276:6 352:16 392:23 <b>clarifications</b> 364:16 <b>clarify</b> 482:9 <b>clarity</b> 300:22 <b>classification</b> 384:6 <b>classified</b> 348:9 349:4 384:7 <b>classifies</b> 232:13 <b>classify</b> 385:7 <b>clearance</b> 206:18 <b>cleared</b> 205:12 235:23 <b>clearer</b> 73:20 <b>clearly</b> 82:20 150:13 152:22 244:14 288:1 312:13 362:2 <b>clin</b> 400:16 <b>clinic</b> 138:1,4,17 139:3,20 140:6,13 152:12 342:1,7,14 345:3 <b>clinical</b> 73:9 120:10 229:6 235:22 236:15,17 236:19,21 237:3 237:22 243:4,11 245:10,20 246:11 246:17 247:20	249:3,13,18 250:3 250:21 251:13,23 252:6,9,10,13 269:4 291:8 292:19,23 364:8 364:10 398:16,21 400:4,16 412:1 422:23 440:4 441:6 <b>clinician</b> 245:23 <b>clinics</b> 138:6 400:1 <b>closed</b> 185:9 187:5 195:13 <b>closer</b> 289:8 <b>clue</b> 324:3,4 <b>cme</b> 69:22 <b>cochrane</b> 7:23 35:17 414:10 415:2,19 416:11 <b>code</b> 5:8 169:11,14 169:22 170:8,13 170:23 171:12 173:12 174:19 176:9 179:4,8 180:8,15,18,21 181:7,9,16 195:5,8 224:8 <b>cognitive</b> 77:21 <b>cohen</b> 380:17 <b>cohort</b> 6:18 7:10 7:20 249:23 250:1 250:8 257:11 270:8 277:23 278:2,5,8,10,19 279:14 281:17 289:11 291:12 292:13,18 298:10 298:13,23 299:4 304:1 305:8 312:1 323:9 340:9 345:19 411:9
--	--	---	---

412:4 415:13 <b>cohorts</b> 298:20 <b>coincidental</b> 19:16 <b>collaborating</b> 480:14 <b>colleagues</b> 287:3 <b>collected</b> 124:8 <b>collection</b> 328:10 329:16 355:6 407:22 408:1 <b>collections</b> 246:8,9 <b>colloquially</b> 168:8 316:12 <b>column</b> 224:16 225:4 242:15 248:16 252:21 307:15 326:17 350:23 391:20 <b>columns</b> 302:13 <b>combat</b> 473:16 474:16 <b>combination</b> 452:15 <b>come</b> 45:10 72:10 73:13,15 79:19 98:18 99:6 105:21 107:1 145:12 146:1 149:2 154:15 160:17 181:15 185:23 199:9 201:8 207:8 248:8 350:5 396:12 471:21 <b>comes</b> 270:18 275:11 297:13 340:7 <b>coming</b> 47:21 90:3 148:4 326:5 330:20 346:1 361:6 380:4	<b>commencing</b> 9:8 <b>commended</b> 303:20 305:23 <b>comment</b> 479:13 <b>comments</b> 187:17 191:18 199:11 224:22 <b>commercial</b> 434:19 <b>commission</b> 492:23 <b>commissioner</b> 492:22 <b>committee</b> 4:19 45:19 47:4 49:2 55:16 63:11,19,21 65:7,15 185:9,18 189:1 194:8,15,23 382:7 <b>committees</b> 45:8 46:11 <b>committing</b> 67:15 121:6 126:11,12 127:5 <b>common</b> 19:19 20:14 142:3,6,19 145:15 146:17,19 148:7 255:4,15 259:1,6,8,11 303:6 <b>commonly</b> 20:11 21:19,22 22:2 60:23 147:23 201:13 295:9,22 463:19 <b>communicated</b> 16:6 56:2 208:6 <b>communicating</b> 59:9 <b>communication</b> 56:11 77:1	<b>communities</b> 373:23 488:20 <b>community</b> 43:18 45:7 225:11 226:14 293:5 328:6 402:18,19 473:8 <b>comorbidities</b> 487:1 <b>comorbidity</b> 463:20 <b>companies</b> 291:23 292:14 385:4,21 437:1 <b>companion</b> 63:20 <b>company</b> 67:10 206:17 270:20 376:21 377:6 380:4 385:10 386:15 387:9,19 424:15 431:21 432:12 436:10 438:21 <b>comparable</b> 94:18 <b>comparative</b> 304:1 <b>comparator</b> 282:22 <b>compare</b> 250:8 354:9,19,21 <b>compared</b> 89:13 353:21 372:10 391:1,9 <b>comparing</b> 299:7 355:14 <b>competence</b> 487:10 <b>competent</b> 120:8 485:11 <b>competently</b> 485:12	<b>complaint</b> 12:19 292:4 <b>complete</b> 11:16 495:8 <b>completed</b> 265:19 493:17 <b>completely</b> 118:19 <b>completing</b> 398:10 <b>complex</b> 121:23 143:11 <b>complexity</b> 476:20 477:2 <b>compliance</b> 29:22 30:3 170:23 <b>complicate</b> 486:19 <b>complication</b> 244:18 329:5 334:16 336:17 <b>complications</b> 176:18 177:1,4 178:9,15 226:9 237:9,16 244:20 327:1 337:1,3 338:9,17 339:3,4,6 355:2 358:16 <b>complies</b> 180:14 <b>comply</b> 169:14 <b>components</b> 404:14 <b>comports</b> 31:2 <b>comprehensive</b> 342:18 <b>compromise</b> 467:18 468:6 <b>compromised</b> 119:8 <b>computer</b> 492:8 <b>conceal</b> 319:7 <b>concept</b> 460:16,17 <b>concern</b> 44:16 70:21 118:22
---	--	--	--



218:17 244:2,22 245:6 <b>concerned</b> 180:17 181:23 206:1 247:18,18 449:11 <b>concerning</b> 376:21 <b>concerns</b> 119:4 180:5 <b>conclude</b> 180:6 <b>concluded</b> 258:10 <b>concludes</b> 343:4 491:11 <b>concluding</b> 36:3 <b>conclusion</b> 38:11 357:14 393:11,17 <b>conclusions</b> 277:12 330:11,15 331:8 337:6 371:19 410:19 415:9 <b>condition</b> 72:22 114:2 122:5 150:16 151:9 157:7 194:12 205:14 211:1 217:19 218:8,14 220:20 231:19 249:15 291:22 292:10 422:21 <b>conditions</b> 66:4 74:18 75:9,15 144:16,18 145:13 154:2 155:13,15 157:10 210:9 215:14,14 252:4 318:15 436:18 487:22 488:11 <b>conduct</b> 211:7 320:15 <b>conducted</b> 185:4 187:2,12 198:7	275:5 485:12 <b>conducts</b> 119:14 <b>confect</b> 443:4 <b>conference</b> 8:12 69:23 79:17 81:15 92:15 103:22 104:4,16 222:12 450:19 <b>conferences</b> 69:9 103:15 106:22 107:7 188:5,11,14 192:6,7 200:1,2,8 <b>confidence</b> 345:22 <b>confident</b> 59:2 <b>confirm</b> 156:9 157:2 219:13 486:9 <b>confirmation</b> 116:21 <b>confirmed</b> 229:5 <b>conflating</b> 266:11 <b>conflicts</b> 199:5 <b>conformity</b> 400:13 <b>confused</b> 76:9 458:12 <b>confusing</b> 450:7 458:9,14 <b>confusion</b> 457:18 457:21 458:17 <b>congenital</b> 310:14 474:17 475:2 <b>connection</b> 61:22 <b>connor</b> 446:7 <b>consen</b> 49:13 <b>consensus</b> 41:3,22 41:23 42:13,14 44:8,11,20 45:5 46:7,12,12,17 47:12,14,21 48:5 48:16 49:3,14,14 50:10 112:17	<b>consent</b> 68:19 119:1,2,7 208:22 209:1,3 211:7 253:7 401:22 402:1,13,17,22 403:9,17 404:11 404:15,17 484:23 487:9,10 <b>consented</b> 402:3 403:4 <b>consenting</b> 314:10 359:7 <b>conservation</b> 481:2 <b>conservative</b> 284:16 285:6 <b>consider</b> 13:19 60:16 92:22 102:10 150:15 151:22 152:10 161:20 181:20 182:5 203:17 247:14 266:14,22 289:23 329:3 362:15 423:7 459:3 469:15 484:6 <b>considerable</b> 109:14 169:4,19 213:10 371:17 <b>consideration</b> 38:9 406:4 424:20 <b>considerations</b> 437:9 489:17 <b>considered</b> 232:17 253:6 254:2,5 267:11 281:8 283:4,6 285:14 286:5 288:11 289:6 316:1,2 381:9 382:1	384:23 387:3,14 408:12 424:10 436:19 441:22 442:2 <b>considering</b> 61:19 63:6 106:7 161:1 166:7,8 314:4 <b>considers</b> 113:19 425:17 426:14 427:18 428:13 429:7 433:18 435:22 437:21 <b>consist</b> 297:17 298:13 305:7 390:14 <b>consisted</b> 304:13 390:18 <b>consistent</b> 114:3 128:11 222:2 303:15 335:3 486:23 <b>consonant</b> 112:16 346:11 462:21 <b>consort</b> 277:13,20 <b>construct</b> 338:23 467:23 478:14,15 <b>constructed</b> 323:2 <b>consultant</b> 378:17 <b>consultation</b> 162:5 166:9 208:2 <b>consultations</b> 140:1 158:22 159:23 160:9 163:4 <b>consulted</b> 144:6 158:17 163:20 164:19 187:9 <b>consummately</b> 287:20 <b>contact</b> 297:11 455:15,16
---	--	---	--

<b>contacted</b> 58:23 98:20,22 99:13	390:10,13,18 412:8	<b>corporate</b> 7:5 376:12	198:8,10 200:4,6 200:15,18,22,23
<b>contagion</b> 367:17 368:1 369:18 370:10,20 371:6 373:3	<b>controlled</b> 268:20 269:4 270:2,19 271:2 272:19 273:7 274:21	<b>corporation</b> 263:21	204:4,5,7 207:14 208:7 213:20
<b>contained</b> 215:11 442:23	275:16 286:4 291:7 292:23	<b>corpsmen</b> 474:7	214:12,13,18,19
<b>containing</b> 257:12	293:10,20 298:3	<b>correct</b> 11:21 12:11 23:5,6,8,9 23:11,12,17,18 24:22 25:14,15,18 25:19,22 28:12 29:23 30:4 31:13 31:21,23 32:1,4 33:3,7 34:1 36:19 36:23 48:3 52:2 63:7 65:4 75:12 75:23 76:1,4 109:6 112:22 114:12 128:14 129:9,10,16,17 130:4 132:19 133:17 136:23 137:1,6,8,12,15,19 137:20 138:2 149:5 150:6,23 152:7 153:7,8,12 153:16,19,22 158:8,12 163:1,3 167:5,6,11,12 168:9,10,14,19 174:22 175:6,8,11 175:15,18,22 176:17 178:22 183:2,3,13 184:1,5 184:6,19 187:3 188:8,11,18 189:18,21 190:1 190:10,19 191:5,8 191:9,14,16,20,22 192:2,4 193:10,13 197:4,7,10,11,14 197:15,19 198:3,4	215:2 216:15,16 216:22 221:4,8 226:17 239:10,12 241:17 242:3 246:17 252:1 262:3 264:15 267:19 269:6 270:4,5,5,9 272:10 272:11 273:9 274:2,3,5,6 278:2 278:5 288:23 293:7 294:19 295:11 296:5,6,9 303:4,5 307:22 316:6,14 317:1 319:3,15 340:5 357:22 362:9 365:2 370:11,21 375:22 379:17 384:20 390:16,17 392:20 393:13 398:18 406:14 407:14 412:9 417:22 418:4,13 418:22 419:2,3,8,9 419:12,13 421:1 430:3 442:14 446:1 448:18 455:11 456:8 465:4 475:14,15 475:18,19 477:14 477:17,18 479:23 480:5 481:22 483:10,16,17,23 487:23 492:11 495:8
<b>contains</b> 12:9 13:17	305:8 412:1 415:13		
<b>contemplate</b> 403:7	<b>controls</b> 279:8 304:4 392:3		
<b>content</b> 492:7	<b>controversial</b> 324:6 363:19 369:12 373:9 398:6		
<b>contest</b> 77:17	<b>controversy</b> 44:14 125:3,6 222:6 363:21 410:3 412:16 413:23		
<b>context</b> 258:18 477:13,20 479:21	<b>conversation</b> 14:6 15:3,22 48:20 56:13 87:12 92:1 165:19,20 330:23 461:2 488:5		
<b>continue</b> 113:7 439:22 485:10	<b>conversations</b> 12:14,22 14:10 87:15 104:16 120:3 287:2		
<b>continued</b> 98:6 237:18 247:19,20 261:9	<b>conversely</b> 424:1		
<b>continuing</b> 100:7	<b>convey</b> 88:11 163:10		
<b>contouring</b> 142:12	<b>convincing</b> 252:16		
<b>contradictory</b> 114:1	<b>coordination</b> 317:12		
<b>contraindicated</b> 241:21 242:10	<b>copies</b> 15:6 493:14		
<b>contraindications</b> 406:7	<b>copy</b> 88:7 127:22		
<b>contrary</b> 39:11,14 39:20 40:10 42:9 118:11,19 395:5	<b>core</b> 116:13		
<b>contrast</b> 475:21	<b>corner</b> 171:15 263:13 451:13		
<b>contributed</b> 56:21 191:7			
<b>control</b> 52:8,10 270:11 271:8 278:21,23 279:3,6 279:17 280:8 302:17 307:20 309:6 316:6 390:2			



<b>corrected</b> 392:4	455:8	<b>cranial</b> 133:13	214:16 219:17
<b>correcting</b> 346:22	<b>course</b> 16:4,5,17	<b>craniofacial</b>	238:19 247:2,10
<b>correction</b> 372:18	18:20 71:15 73:2	309:12,16 310:19	260:7 318:6,20
<b>corrections</b> 495:6	75:1 92:1 99:18	475:2 477:4	319:14 370:1
<b>correctly</b> 288:18	146:23 165:2	<b>create</b> 60:6	375:23 376:6
<b>corresponded</b>	295:1	<b>created</b> 226:12	380:23 381:8
77:5	<b>court</b> 1:1 9:1,23	456:4,13 457:17	382:1,21 383:7,7
<b>correspondence</b>	10:8,12 16:11	<b>credentialing</b>	404:2 416:13
56:6	33:6 38:9 39:10	30:16	417:5 429:15
<b>corrugator</b> 263:3	43:4 53:20 182:13	<b>credentials</b> 172:12	437:14,22 457:15
266:12,17,18,23	260:11 325:13,16	<b>credible</b> 123:3	482:17
267:9	325:20 350:3,9	280:16	<b>crow</b> 268:5,7,8
<b>cosmetic</b> 6:4 45:1	389:13 414:15	<b>credits</b> 69:23	<b>crow's</b> 141:4
71:3 262:16 263:4	426:1,6 449:15	<b>crestwood</b> 24:17	262:5 268:10,11
267:15 296:20	471:9	<b>cretella</b> 94:23	<b>crr</b> 492:20
331:2 386:16	<b>courts</b> 54:1	<b>crime</b> 244:9	<b>crucial</b> 466:20
423:3,22 425:3	<b>cover</b> 215:6	<b>criminal</b> 109:17	<b>cs</b> 493:15
467:7 476:2	379:21 385:10	<b>criminalize</b> 4:21	<b>ct</b> 446:11
477:10	386:15,15,17	63:1 110:7 116:20	<b>culpable</b> 127:11
<b>counsel</b> 9:20 10:10	387:20 420:22,23	<b>criminally</b> 52:11	<b>cultural</b> 447:7,8
12:15,23 99:13	423:22 426:9	<b>criteria</b> 70:6,13	<b>cure</b> 422:21
492:15 493:14	432:14,16,20,23	71:4,8 72:9 73:22	<b>curing</b> 291:17
<b>counseling</b> 157:15	433:1,4 437:3,4	275:18 277:14,20	<b>current</b> 28:11
157:18,18,23	439:6 487:13	292:12 300:19	32:20 50:8 51:1
158:5 159:17	<b>coverage</b> 8:6	333:9 351:8	79:21 99:19
<b>counselors</b> 464:5	376:21 385:6	356:23 377:4	196:13,17 296:19
<b>count</b> 42:5 351:2,3	386:4 424:16,18	385:1 386:22	392:7 398:8 399:9
<b>counted</b> 348:17	430:13,21 437:13	387:10,11 401:9	439:20 482:11
<b>counterfeit</b> 60:6	473:6	401:15 427:20	<b>currently</b> 24:10
61:6,9 338:23	<b>covered</b> 377:2,3	428:18 429:2	25:13 31:22 32:23
<b>country</b> 104:1	385:23 421:10,22	435:9,15	43:15 61:18
324:22 433:14	422:18 423:15,18	<b>critical</b> 213:2,11	137:23 139:21
<b>county</b> 492:3	424:2 432:19	272:23	189:11 321:6
<b>couple</b> 14:13 15:1	435:18 436:19	<b>criticism</b> 352:3	367:12 371:7
15:16 63:8 93:23	438:12,14,22,22	<b>criticisms</b> 371:13	415:16 416:3
146:2 196:5,12	452:11	<b>criticize</b> 216:7	485:11
301:23 394:3	<b>covering</b> 385:14	<b>criticizing</b> 49:19	<b>cursor</b> 350:4
398:5 472:11	<b>covers</b> 435:21	183:10 359:11	<b>cv</b> 1:7 10:2 30:5,7
476:8	437:12	<b>cross</b> 36:22 82:1	127:20,21,22
<b>courage</b> 451:14	<b>coveted</b> 121:18	94:1 161:10 164:9	135:23 136:15
452:4 454:7,14,21		213:7,22 214:11	472:11 480:4

<b>d</b>	<b>dawning</b> 433:22	217:1,5 248:19	<b>defense</b> 2:13,19
<b>d</b> 4:1 20:23 33:2	<b>day</b> 9:9 104:5	285:22 286:19	<b>definable</b> 71:18
203:4 322:18,18	153:23,23 189:17	330:19 356:3	<b>define</b> 240:9
389:13	189:17 353:17	357:5 380:8 403:2	386:18 424:15
<b>dale</b> 1:14 10:21	495:15	404:11 444:12	438:8
<b>damage</b> 119:22	<b>days</b> 18:22 493:17	484:20 485:1	<b>defined</b> 173:12
<b>danger</b> 132:7	<b>de</b> 2:14 194:11,22	487:8 488:6	257:3 287:9
<b>dash</b> 360:9 446:12	195:7 242:5,9	<b>decisional</b> 357:15	390:11 423:11,14
<b>data</b> 86:12,13,13	359:19 360:20	357:22	431:21 438:11,20
161:23 212:8	<b>deacon</b> 64:19 65:2	<b>decisions</b> 208:16	<b>defines</b> 173:22
219:13 243:5,12	464:20	328:21	459:5,9 460:13
257:13 272:23	<b>deal</b> 475:4	<b>deck</b> 88:4,7	<b>definitely</b> 71:23
273:2 275:2 276:4	<b>dealing</b> 76:14	<b>declaration</b> 4:15	87:10 143:10
276:13,20 277:2	218:14 244:17	22:17 33:23 34:12	248:8 330:2,2
277:11 279:10	313:23	35:2,12 36:2	333:17 438:10
280:1,6,15 281:4	<b>dear</b> 264:22	457:10	<b>definition</b> 45:17
312:21 329:9	<b>death</b> 311:3	<b>declare</b> 283:15	174:3,7,16 218:19
344:6 352:19	490:18	495:4	288:17 422:11,15
361:22 371:18,20	<b>debate</b> 389:6	<b>declared</b> 53:22	423:16,21 428:5
381:5,21 406:18	<b>decade</b> 219:21	<b>declares</b> 436:6	436:12,13 438:7
406:22 407:22	225:10	<b>declined</b> 100:7	439:2 468:12
408:1 416:22	<b>decades</b> 229:18,18	226:20 305:3	<b>definitions</b> 423:12
417:3	312:5	<b>declining</b> 226:5	424:14,16 437:2
<b>database</b> 7:23	<b>decatur</b> 2:15 9:7	473:8	443:3
257:12	10:5 64:10 138:14	<b>dee</b> 10:23	<b>definitive</b> 157:4
<b>date</b> 9:4 93:7	138:22 139:11	<b>deemed</b> 253:8	219:8 249:5
108:21,22 185:21	140:11 160:14	422:6 495:6	251:15,15 283:23
186:8 190:3 196:7	<b>december</b> 257:14	<b>deems</b> 253:12	344:4 362:23
265:22 268:13	265:2	<b>deeper</b> 358:2	363:3,22
430:17 435:1	<b>deceptive</b> 172:13	<b>deeply</b> 358:21	<b>deformities</b>
492:12 494:24	172:19	<b>defect</b> 71:6 290:14	310:15 474:18
495:12	<b>decide</b> 23:19 100:2	<b>defective</b> 120:7	<b>deformity</b> 71:18
<b>dated</b> 38:5 55:16	221:6 284:12	<b>defects</b> 468:3	475:2
108:14 109:4,9	379:20	482:6	<b>degeneration</b>
224:13 265:2	<b>decided</b> 37:12	<b>defendant</b> 22:10	44:18
<b>dates</b> 459:14	49:2,13 146:22	<b>defendants</b> 1:15	<b>delayed</b> 133:11
<b>dating</b> 72:16	166:9 387:19	3:1 10:19 11:20	317:9
<b>daughter</b> 409:7	<b>deciding</b> 439:5	33:9,13,15	<b>deleterious</b> 487:20
<b>daunted</b> 458:17	<b>decision</b> 6:21 47:5	<b>defending</b> 11:2	<b>demand</b> 199:3
<b>davis</b> 3:11 273:12	53:23 121:11	79:11	312:17
	131:20 177:9		

<b>demanded</b> 313:21 <b>demands</b> 314:13 <b>demographic</b> 368:10,11 369:5 372:11 <b>demonstrate</b> 268:21 269:4 270:2 310:20 <b>demonstrated</b> 245:3 <b>demonstrates</b> 486:23 <b>demonstrating</b> 130:8 <b>denominator</b> 323:20 352:11 <b>denver</b> 8:12 450:19 451:22,23 <b>deny</b> 64:22 466:11 <b>department</b> 95:12 473:21 474:4 <b>depend</b> 286:8 <b>depending</b> 258:16 282:6,6,9 301:16 <b>depends</b> 321:7 <b>deponent</b> 493:13 495:3 <b>deposed</b> 14:19 17:16 18:2 <b>deposing</b> 493:13 <b>deposition</b> 1:19 9:19 10:3 11:3 12:16 13:13 14:23 15:8,11 17:19 18:5,6,12 19:2 181:8 470:22 491:14 <b>depressed</b> 154:15 <b>depression</b> 154:10 154:17,19 155:6 487:3	<b>derive</b> 176:13 177:8 <b>dermatologist</b> 143:3 <b>describe</b> 72:22 94:5 158:22 257:2 277:19 282:22 331:2 383:20 442:20 472:19 474:1 475:20,21 477:23 <b>described</b> 73:16 130:17 305:15 422:23 483:12 <b>description</b> 73:20 383:15 <b>descriptions</b> 29:13 <b>deserve</b> 444:4,4 <b>deserves</b> 150:17 <b>design</b> 274:8 276:2 276:4,19 277:18 309:7 319:13 391:23 413:10 <b>designed</b> 274:4 275:18 278:2,14 278:23 <b>designing</b> 275:11 480:19 <b>desire</b> 194:10,20 237:18 329:6 333:3 <b>desistance</b> 161:5 161:23 <b>desisting</b> 161:9 <b>despite</b> 309:9 406:21 <b>destroy</b> 119:23 467:6,19 <b>destroyed</b> 478:7,7 <b>destroying</b> 468:12	<b>destruction</b> 178:20 <b>detail</b> 65:18 84:1 470:5 <b>detailing</b> 432:22 <b>details</b> 37:18 82:11 90:9 160:16 163:17 210:18,21 409:11 <b>determine</b> 241:17 300:5 <b>determined</b> 423:12 <b>determining</b> 293:10 423:6 <b>detran</b> 366:5 <b>detrans</b> 364:19 <b>detransition</b> 7:2 367:1 <b>detransitioned</b> 322:11 <b>detransitioner</b> 86:18 87:3,4 151:4 <b>detransitioners</b> 320:21 324:9 364:22 <b>detransitioning</b> 147:16,19 149:2 151:7 365:13 366:2 <b>develop</b> 165:14 <b>developed</b> 165:15 188:16 189:12 190:5 193:15 200:13,21 382:18 <b>developing</b> 187:13 187:18 190:17 191:14,19 198:7 199:12 444:17	<b>development</b> 133:11 184:4 188:6 190:12 191:8 192:8,22 197:13,17 200:3 379:14 403:22 436:9,16,21 <b>developmental</b> 82:6 <b>developmentally</b> 317:8 <b>device</b> 234:11 <b>devices</b> 5:19 130:11 233:15 310:13 <b>devoted</b> 104:6 <b>dhejne</b> 7:7 186:5,5 329:22 389:6,7,7 389:10 390:23 <b>diag</b> 72:8 <b>diagnose</b> 69:3,20 73:22 153:6 154:1 155:6,14 157:10 195:4 <b>diagnosed</b> 156:2,8 205:14 330:17 405:15 <b>diagnoses</b> 155:20 194:14 <b>diagnosing</b> 66:3 73:5 74:14,17 75:9 155:12 <b>diagnosis</b> 22:3 68:2 155:23 156:9 156:11 157:2 194:21,22 313:14 329:4 366:15,17 373:10 383:19 385:8 386:19 422:20 432:17,18 486:10,11
--	--	---	---

<b>diagnostic</b> 70:6,12 71:8 72:8 194:16 195:5,8,8 282:8 301:20 377:3 406:4 <b>dialogues</b> 106:22 <b>differ</b> 392:2 487:15 <b>differed</b> 258:4 <b>difference</b> 94:8 135:14 322:9 365:23 387:13 476:3 477:6 <b>differences</b> 392:5 475:22 <b>different</b> 42:6 43:21 88:13 114:8 144:5 155:2 184:17 188:1,5 190:16,21 191:7 191:13 192:1,6 199:17 203:14 249:8 269:15 317:15 319:20 343:8 366:23 394:22 395:12 397:21 399:21 400:2 431:8,8 489:13 <b>difficult</b> 67:2 124:16 271:16 352:15 354:18 <b>difficulty</b> 44:7 47:23 91:2 92:2 102:18 104:10 105:4 112:6 484:22 <b>dig</b> 358:20 <b>dimitry</b> 491:5 <b>diocese</b> 64:20	<b>diplomates</b> 27:23 28:2,23 29:9 <b>direction</b> 165:9 <b>directly</b> 16:8,18 133:18 <b>director</b> 263:23 378:20 379:3,6 <b>disabuse</b> 456:20 <b>disagree</b> 234:21 308:13 <b>disagrees</b> 40:17 42:23 <b>disappeared</b> 96:10 <b>discerned</b> 488:21 <b>disciplinary</b> 172:14 <b>disclose</b> 280:5 <b>disclosed</b> 210:5 381:13,15 <b>disclosing</b> 14:5 216:8 <b>discomfort</b> 194:18 <b>discontent</b> 383:22 <b>discordance</b> 158:19 368:14 457:6 <b>discounted</b> 101:23 <b>discourage</b> 26:22 162:18,22 <b>discover</b> 463:22 <b>discovered</b> 67:12 229:2 <b>discovery</b> 308:19 <b>discrimination</b> 276:6 <b>discuss</b> 92:7 188:6 192:8 240:10 280:6 320:14 339:2 461:22 488:1	<b>discussed</b> 154:5 175:3 180:19 192:13 200:3,4 222:9 328:3 399:4 <b>discussing</b> 119:1 153:11 412:12 445:9,20 462:2,8 469:15 <b>discussion</b> 72:18 87:14 90:8,13,20 91:1 93:14 327:12 407:10 456:18,19 466:18 488:4 <b>disease</b> 156:3 231:19 422:22 <b>disorder</b> 67:19 68:1,23 69:4,21 70:7,12 73:6,23 74:15,22 75:11 154:6,8 193:20 242:20,22 <b>disorders</b> 192:18 192:21 436:8,15 436:21 <b>disparity</b> 89:18 <b>displaced</b> 131:6 <b>dispute</b> 358:22 <b>disregards</b> 466:4 <b>dissatisfaction</b> 337:12,17 338:4 <b>dissatisfied</b> 67:1 <b>distant</b> 490:13 <b>distinct</b> 281:15 477:6 <b>distinction</b> 275:8 432:12 485:2 <b>disting</b> 484:2 <b>distinguish</b> 398:22 438:21 484:3 488:6	<b>distinguishing</b> 437:3 <b>distort</b> 486:19 <b>distressed</b> 162:7 <b>district</b> 1:1,2 9:22 9:23 <b>disturbance</b> 70:15 <b>disturbances</b> 67:22 68:20 <b>disturbed</b> 120:3 <b>divergent</b> 398:7 <b>divided</b> 348:3 <b>djordjevic</b> 6:15 322:17 <b>dmitriy</b> 2:6 10:14 114:18 126:14 471:12,22 489:5 <b>doctor</b> 11:10 27:8 34:6 49:18 55:8 61:1,11 69:16 79:9 108:6 115:16 117:13 126:19 127:16 153:5 166:22 209:20 210:2 213:2 216:14 217:6 234:17 238:1 246:15 254:22 261:14 292:16 332:14 335:12 353:16 367:1 370:6 381:6 386:10 388:15 407:20 408:20 417:17 470:18 489:11,22 <b>doctorate</b> 86:16 <b>doctors</b> 26:18 32:12,18 36:17 51:22 52:12 53:23 78:18 81:6 118:3
--	---	---	---

118:16 121:6 122:18 155:11 156:5 214:21 215:20 217:11 219:23 220:2 226:15 236:23 244:15 251:14,20 <b>document</b> 13:23 26:23 27:2 50:20 55:12 108:14 112:7 114:23 115:4,22 174:11 184:22 185:15,19 185:20 186:9,11 186:12 189:2 223:21 233:3,9 245:22 248:12 264:19 275:20 284:6 301:18 305:18,19 327:3 330:11 332:10 335:1,7 341:1,6 350:4 363:23 375:12 376:11,18 376:21 379:8 380:19 384:12 400:9 401:6 402:9 408:4 413:1 419:23 420:8 440:21 445:15 486:2 <b>documented</b> 235:10 <b>documenting</b> 235:14 485:14 <b>documents</b> 12:18 187:6 233:6 380:6 380:7 <b>doing</b> 25:2 85:5 98:16 106:10,14 123:7 124:20	125:19 141:14 176:8 178:12 246:19 260:4 261:6,23 262:5 269:23 272:18 286:13 287:12 290:4,5 305:19 309:21 312:22 321:16 439:21 469:6 476:10 477:3 484:21 <b>dose</b> 145:3 <b>double</b> 268:20 271:12,19,21 318:10 319:14 <b>doubt</b> 439:15 <b>dozen</b> 94:18 146:13 147:11 <b>dr</b> 9:19 11:2 14:18 15:8 16:6,9,15,20 16:22 17:1,4,6 18:7,11,21 19:10 19:10 33:12,13,18 33:20 34:12 39:15 39:15,21,21 40:11 40:11 42:10,10,19 42:20 43:23,23 57:21 58:5,11 60:13 64:9 67:7 72:2 78:5,5,6 81:17 85:10,13,15 85:20 86:3,6 92:13 94:23 114:6 114:6 216:7,7 255:21 256:19 264:22 377:19,20 444:21 445:13 464:19 472:10 475:11 481:6 483:7 491:1,12	<b>drafting</b> 185:4 187:3,9 <b>drafts</b> 188:1 192:1 199:17 <b>dramatically</b> 322:20 <b>drastic</b> 289:20 <b>drawn</b> 392:10 <b>dreaded</b> 181:14,18 <b>dream</b> 468:4 <b>drill</b> 210:18 <b>drilled</b> 467:14 <b>drive</b> 285:21 444:11 <b>drives</b> 286:15 <b>drop</b> 320:19 321:4 321:21 <b>dropping</b> 24:3 <b>drs</b> 280:4 395:6 <b>drug</b> 201:11 202:21 205:11,16 205:17,19 207:13 209:23 210:5 216:14,21 218:6 219:11,15 220:19 221:7 224:17,20 225:10,12 227:11 228:9 231:5,10,11 231:18 234:10,17 234:19 235:12 236:4,13 237:5,10 238:2 241:3 246:15 247:15 253:4 257:3,20 258:14 259:19 260:20 261:12 263:14 314:19 318:15 338:5 490:6 <b>drug's</b> 242:21	<b>drugs</b> 5:15,18,22 119:5 162:16 201:3,19 203:15 206:10 209:20 216:19 217:12,15 218:15,19,23 219:6 220:2 221:3 221:5,13,18 222:2 222:16 226:15 229:1,20 230:22 233:14 238:14 239:5 240:2,17 241:7 244:4,8 245:5,8,16 248:1 251:3,21 252:19 255:4,6,11 258:22 259:22 260:1,17 260:21 261:9,13 318:11 406:20 447:21 <b>dsm</b> 72:12 73:7,13 73:16,17,19,20 74:1,6 189:15,18 189:20,23 190:12 190:17 191:8,14 191:19 192:1,9,22 193:15,19 194:2,2 380:11 <b>dtishyevich</b> 2:10 <b>duly</b> 11:6 <b>duration</b> 15:23 <b>dutch</b> 342:14 <b>duty</b> 76:8 154:19 386:3 <b>dysmorphic</b> 67:19 68:1,22 69:4,20 70:7,12 73:6,23 74:15,22 75:10 154:5,7 <b>dysphoria</b> 6:18 7:22 8:8,10 22:4
---	--	--	---

41:6,20 49:16 65:10 80:19 84:19 85:7 111:10 130:4 131:2,17 132:19 133:17 134:4,18 146:21 150:6,23 151:2,6 152:3,7 153:7,12 157:20 158:1,6,10 162:15 163:1 193:21 200:15 205:15 214:12,18,23 215:19 216:10 316:19 319:1,15 321:4 329:11 340:9 353:2,10,22 354:4 367:14,23 368:13 370:9,19 373:21 374:17 375:2,8 380:13 383:19,22 390:14 390:19 391:8 393:19 395:1,11 395:23 405:9 411:11 429:9,20 430:14 431:2 433:21 434:22 435:17 437:13 438:3,12 443:18 458:1 460:18 481:22 482:13 483:22 486:7,17 488:19 <b>dysphoric</b> 195:18 <b>dystonias</b> 262:14	340:15,15 360:9 389:13,13 414:15 425:7 445:6 446:12,13 492:1,1 494:3,3,3 <b>earlier</b> 46:9 57:8 76:12 78:4 110:1 112:19 152:1 154:5 169:6 180:19 181:17 189:14 204:15 215:5 216:17 232:9 261:20 267:13 270:14 290:18 300:20 301:11 303:11 324:15 345:11 347:3 352:1,9 354:12 363:9 380:21 421:3 424:6 448:5 454:2 477:11 <b>early</b> 97:16 205:2 228:18 285:4 319:11 328:10 394:23 397:9,17 398:11,17 <b>earns</b> 386:6 <b>ears</b> 105:20 <b>easier</b> 16:14 <b>eastern</b> 474:10 <b>eating</b> 332:12 <b>ectopic</b> 133:11 <b>ed</b> 76:3 <b>edgerton</b> 106:8 125:8 <b>editor</b> 135:16 136:9 <b>editors</b> 135:21 136:16	<b>eds</b> 76:15 <b>educate</b> 296:14 <b>education</b> 2:13,19 <b>educator</b> 87:7 <b>effect</b> 43:5 146:15 146:17 245:21 246:1 313:10 317:18 319:5 330:7 412:20 414:7 484:11 490:14 <b>effective</b> 41:4 116:7 265:21 268:22 270:3 284:13 285:14 346:22 430:17 435:1 <b>effectively</b> 457:5 <b>effectiveness</b> 269:5 392:10 <b>effects</b> 81:21,22 82:5 205:17,18 217:16 234:4 235:3,14 237:1 317:3 318:3 319:2 319:13 447:21,22 447:22 482:22 487:21 490:8 <b>efficacious</b> 291:17 <b>efficacy</b> 219:14 235:9 237:17 259:20 329:23 331:13 346:19 347:6 387:22 439:1 <b>efficient</b> 116:8 <b>efforts</b> 54:16 78:7 78:14 83:18 110:18 113:7 116:9	<b>eight</b> 45:23 313:11 337:13 <b>eighteen</b> 43:21 52:2 <b>eighty</b> 141:23 <b>either</b> 93:8 144:11 222:11 249:5 278:13,13 393:8 456:14 <b>electronic</b> 88:7 <b>element</b> 369:18 <b>elevated</b> 272:20 282:1 <b>eligible</b> 100:23 <b>emcee</b> 91:22 <b>emergencies</b> 436:22 <b>emery</b> 2:7 10:15 <b>emotional</b> 152:13 <b>emotionally</b> 119:8 <b>emphasized</b> 209:17 <b>employ</b> 420:16 <b>employees</b> 10:21 420:17 <b>enact</b> 76:7 <b>enactment</b> 57:11 <b>encapsulation</b> 220:17,21 <b>enclosed</b> 265:23 <b>encounters</b> 159:5 <b>encourage</b> 103:7 103:12 162:12,13 177:14 457:3 470:1 <b>encouraged</b> 95:6 165:21 <b>encouraging</b> 107:8 398:16 <b>endo</b> 195:16
<b>e</b>			
<b>e</b> 2:1,1 4:1,10 16:21,21 20:23 59:1,3,4 98:11,16 203:8,11 256:19 299:19 322:18			



<b>endocrine</b> 195:16 196:22 197:3,9,21 198:7,19 199:11 200:13,20 <b>endocrinol</b> 81:19 <b>endocrinologic</b> 81:19 <b>endocrinological</b> 81:21 156:2 <b>endocrinologist</b> 86:9 153:15 156:10 157:1 205:23 207:12 372:5 <b>endocrinologists</b> 149:19 198:16 203:22 204:1 207:18 208:13 277:1 418:20 <b>endocrinology</b> 81:18 204:3,7,10 213:1 <b>endocrinopathies</b> 162:21 213:9 <b>endoscopic</b> 129:22 130:8,17 <b>enforcement</b> 30:17 <b>enforcing</b> 37:11 <b>engaged</b> 83:11 <b>engine</b> 21:2,6 <b>england</b> 35:16 <b>enrolling</b> 237:3 <b>ensure</b> 116:6 <b>ensuring</b> 273:2 <b>enter</b> 153:1 176:19 <b>entered</b> 208:8 345:21 346:6,8 418:15 <b>entire</b> 46:14 95:22	<b>entirely</b> 104:6 <b>entitled</b> 240:2 <b>entrance</b> 480:11 <b>entry</b> 124:4 <b>enumerate</b> 209:7 <b>enumerated</b> 209:5 209:22 458:6 <b>equation</b> 206:12 222:22 485:3 <b>erectile</b> 333:2 <b>erections</b> 334:8 <b>errata</b> 493:11,13 493:17 <b>erratas</b> 493:15 <b>erroneous</b> 329:3 <b>error</b> 329:1,3 <b>erythromycin</b> 123:12 <b>esophagoplasty</b> 133:20 136:12 <b>esophagus</b> 133:23 <b>esq</b> 2:6,12,18 3:4 3:10 <b>esquire</b> 493:1 <b>essential</b> 275:22 448:13 467:6,19 <b>essentially</b> 44:21 112:2,9,12 146:15 161:13 165:21 271:17 282:23 380:19 395:15 474:10 478:5 <b>established</b> 311:12 475:1,7 <b>esthesia</b> 68:7 <b>estimate</b> 17:8,12 146:8 147:12 160:1 298:11 <b>estrogen</b> 214:2,21 215:18 318:23	<b>estrogens</b> 431:15 <b>et</b> 1:9,14 9:21,21 493:4 494:1 495:1 <b>ethical</b> 131:20 177:7,9 250:4 309:10 316:2 403:18 <b>ethically</b> 250:6 <b>ethics</b> 5:8 169:11 169:15,22 170:8 170:13 171:1,12 174:19 176:10,12 179:4,9 180:8,15 180:18,21 181:8,9 181:16,19 182:1,3 217:22 218:11 314:13 <b>europe</b> 123:5 <b>european</b> 89:12,14 89:20 124:13 247:3,22 250:10 313:4 <b>evaluate</b> 275:17 <b>evaluation</b> 72:7 275:16 <b>evening</b> 14:13,16 <b>event</b> 359:5 <b>events</b> 165:2 202:19 410:18 <b>everybody</b> 211:2 <b>evidence</b> 6:7 39:6 46:6 70:14,17,18 70:19 71:10 88:21 89:21 120:9 123:4 123:20,22 124:1 186:7 218:4 219:2 219:9,9,18 234:2 242:23 243:16,17 243:21,23 244:13 244:16 245:20 248:20 249:1,7	250:16 252:12,16 252:18 259:20 260:5,10 261:7 280:20 281:16,22 283:7,17,21 284:2 284:7,8,9,10,21 285:5 288:1,6,14 288:22 289:7,18 290:4 291:10 292:1 293:16,22 294:1,11 295:11 295:16 299:20 300:6,22,23 301:8 302:10,23 303:13 303:19,23 304:11 304:14,17 308:15 309:8 311:16 312:6,18 313:19 313:21,23 314:10 314:14,17 317:18 323:14,16 324:16 327:15 328:10 329:14 337:19 341:8 352:17 359:12 362:16,21 363:3,14 365:16 366:22 370:13 374:19 398:9 399:9 408:12 410:3,18 412:18 413:23 414:3,3 415:16 416:4,8,9 439:1,19 440:4 441:6,8,12 444:15 447:16 452:12,16 453:19 454:4 469:5 481:19 482:4,11,20 484:19,21 486:14 <b>evidencing</b> 145:12
--	--	--	--

<b>evident</b> 89:17 271:23 310:6 404:3 <b>evolution</b> 82:13 181:18 <b>exact</b> 196:6 259:12 268:13 <b>exactly</b> 15:2,17,18 15:20 42:14 56:12 77:3 114:4 156:22 324:5 371:1,3 400:22 408:10 <b>examination</b> 4:3 9:11 11:9 70:16 119:12,13 312:13 363:1 447:18 472:9 489:10 <b>examinations</b> 406:5 <b>examine</b> 165:22 251:10 344:5 <b>examined</b> 11:7 312:12 358:13 480:15 <b>examiners</b> 477:1 <b>examining</b> 71:16 <b>example</b> 44:13 45:13 71:9 77:20 81:17,23 83:22 103:17 104:3,20 121:15 130:15 136:8 140:14 155:18 156:1,14 156:23 178:4 205:10,11 206:15 206:23 207:23 220:15,18 226:10 229:9 270:13 271:18 276:16 281:6 283:11 284:5 287:13	292:1 310:12,23 312:2 316:8 322:9 328:8,10 331:11 331:16 334:9 336:6,8 343:16 344:1 351:13 360:13 368:8 412:18 436:9 437:1 439:9,10,12 450:8 452:19,20 460:1 467:21 468:5,9,11 470:2 476:14 478:2 <b>examples</b> 142:3 331:6 336:2 459:22 <b>exception</b> 154:4 165:7 315:21 <b>exceptional</b> 455:5 457:18,22 458:5 <b>exchanges</b> 98:11 <b>exclude</b> 236:18 <b>excludes</b> 425:1 <b>exclusive</b> 461:21 <b>excuse</b> 279:17 <b>executed</b> 229:5 <b>executive</b> 10:23 317:13 403:21 404:9 <b>exemption</b> 234:12 <b>exercise</b> 295:2 <b>exhaustive</b> 210:15 381:7 <b>exhibit</b> 6:11 <b>exhibit</b> 4:13,14,15 4:16,18,20 5:2,5,7 5:8,11,13,16,20 6:1,4,6,16,16,17 6:20 7:1,5,7,12,15 7:17,23 8:2,4,6,9 8:12,14 12:3,6	22:15 27:6,9 34:5 34:7 37:22,23 43:8 55:7,9,12 62:17,19 108:5,7 114:15 115:6 116:2 127:15,16 127:17 170:11 171:5,7,11 223:15 223:16,18 230:12 230:12,14 232:21 232:23 239:14,16 255:19 256:13,15 263:7,8,10 279:20 299:12,13,15 308:6 320:9 325:23 326:2 339:14,14,16,18 339:20 355:17,18 361:4,11 375:14 375:16 388:14,18 388:20 394:7,7,9 396:9,18,20 404:23 411:2,4 414:20,22 417:8 419:15,15,17 426:21,22 427:1 430:7,9 434:7,7,10 451:3,3,5 463:2,4 463:5 464:9,10 <b>exhibits</b> 8:20 15:7 256:4 481:12 <b>exist</b> 219:18 488:10 <b>existing</b> 482:4 <b>exists</b> 410:3,4 <b>expect</b> 21:21 34:22 47:11 61:2 71:19 122:16 154:11 173:6 211:17 215:19 237:15 300:23	<b>expectation</b> 154:14 196:13 209:19 215:5,16 216:3 287:8 <b>expected</b> 206:13 209:9 287:20 <b>expend</b> 24:6 <b>expensive</b> 23:23 102:1 <b>exper</b> 281:11 <b>experience</b> 73:10 93:19 94:4 121:18 124:3 132:8 136:21 148:16 159:18 162:14 168:16,22 169:5 173:11,14,23 178:2,17 181:1,12 204:18,19 211:20 212:1,17 213:10 214:14 220:22 243:5,11 246:10 246:21 270:16,17 272:8 275:1 278:6 278:17 279:12 281:5,11,15,19 282:1 284:17 287:1,4 309:16 329:12 348:19 383:21 395:11 405:17 417:18 443:8 454:9 455:1 455:2 457:14,15 458:18 463:21 476:5 479:12 <b>experienced</b> 94:1 <b>experiences</b> 364:23 366:6 <b>experiencing</b> 158:19 162:3 344:20 348:18
---	---	--	--



<b>experiment</b> 271:8 <b>experimental</b> 35:6 43:15 112:22 113:2 117:16 120:5 161:16 217:22 218:11 232:10,14 253:15 254:6,11 288:17 289:6 294:2 295:5 423:2,9,17,22 424:2,22 425:2 481:16 <b>experimentation</b> 253:3 <b>experimenter</b> 272:1 <b>expert</b> 4:13 11:20 11:23 17:9 18:12 22:15 29:21 31:2 31:9 33:1,15,22 40:2,16 50:14 57:22 58:5,12 75:8 86:12 90:15 91:3,8,11,13 92:16 92:20,22 98:19 126:8 127:2 170:15,18 171:2 172:6,21 173:10 174:13,17,22 176:7,17 177:19 180:22 181:10 188:15 189:10 193:14 200:12,20 203:13,18 204:7 204:10 221:23 243:20 249:6 254:9 259:5,14 260:19 261:11 274:8 275:12 322:3 329:8 374:3 374:15,23 375:5	443:4 444:13,17 444:20 448:16 449:14 <b>expertise</b> 65:8,16 66:3 74:16 75:14 193:11 200:18 201:22 204:3,12 307:9 <b>experts</b> 18:1 22:10 33:14 38:19 187:8 198:12,14,20 199:9 203:19 205:5 409:19 448:13 449:16 <b>expired</b> 23:16 25:4 28:4 29:9 31:16 <b>expires</b> 492:21,23 <b>explain</b> 324:9 <b>explained</b> 100:8 <b>explanation</b> 159:14 369:5 457:11 <b>explanations</b> 355:4 <b>exploration</b> 215:9 <b>explored</b> 399:2 <b>exposito</b> 7:1 360:7 <b>express</b> 56:20 275:4 406:18 <b>expressing</b> 92:14 92:19 217:10,14 222:1 289:4 <b>expression</b> 397:23 <b>expulsion</b> 172:15 <b>extensive</b> 90:8 107:6 288:4 309:15 <b>extensively</b> 228:10 <b>extent</b> 51:12 127:9 155:22 209:14 211:15 218:21	<b>external</b> 310:12 450:15 479:6 <b>extra</b> 397:1 <b>extracted</b> 352:14 <b>extremely</b> 326:22 <b>extremities</b> 142:16 <b>eyes</b> 105:20 468:14 <b>f</b> <b>f</b> 174:5 203:8 446:11,13 492:1 <b>face</b> 71:20 131:1 142:9,15 143:7 256:8 289:13 310:14,18 <b>faces</b> 146:5 195:1 <b>facial</b> 130:9 145:13 146:1 147:5 152:9 166:23 167:3,7 175:4,9 290:14 <b>facilities</b> 473:5 <b>facility</b> 474:1,20 474:22 475:8 <b>fact</b> 40:15,19 44:2 46:15 54:21 59:2 68:18 114:13 118:2 137:9 161:18 166:3 179:13 181:15 222:18 228:8 237:19 250:16 260:11,22 299:11 314:16 319:7 328:22 339:9 344:5 380:6,23 391:11 402:7 433:15 439:15 476:21 <b>facto</b> 242:5,9	<b>factor</b> 368:9 <b>factors</b> 423:9 424:19 <b>factual</b> 37:15 128:4 <b>failed</b> 280:5 <b>fails</b> 493:19 <b>failure</b> 320:14,15 <b>fair</b> 34:15 74:18 78:16,21,21 114:5 136:17 148:1 149:4 160:4 162:16 168:11,15 189:12,13 193:16 193:18 203:16 215:23 <b>fairly</b> 22:8 59:2 75:2 90:20 91:1 131:21 159:6 259:1,8,11,18 435:4 <b>faith</b> 444:16 <b>fall</b> 252:16 <b>fallback</b> 53:12 <b>falling</b> 252:17 260:8 <b>falls</b> 260:23 261:2 <b>false</b> 172:13,19 <b>familiar</b> 50:8 76:10 79:10,14 127:9 178:8,9 203:1,2,6,10 211:15 212:6 213:4,8 255:7 341:2 479:16 490:19 <b>familiarity</b> 212:22 <b>families</b> 81:4 97:20 158:18 159:1,7 164:18 205:1,21 457:7
--	--	--	--

<b>family</b> 82:4 93:23 94:6 209:2 210:20 309:22 <b>famous</b> 85:22 <b>far</b> 22:7 144:8 178:12 185:6 247:15 313:16 381:3 482:22 <b>fastidious</b> 292:8 306:16 <b>fat</b> 44:15,22 142:8 142:9 <b>favor</b> 64:10 105:12 351:19 <b>favorable</b> 63:15 484:12 <b>fda</b> 5:13,16 6:4 80:17,20 205:12 206:18 207:2 216:8,15 218:5 220:7,12,22 221:2 221:12,17 222:4 222:12,15 223:9 225:6,10 226:1,13 226:16,20 227:11 227:17,21 228:18 229:19 230:2,8,19 231:8,9,22,23 232:12,13,16 233:4,5,8 234:16 235:11 240:15 243:2,9 245:22 253:5 257:4 261:1 262:8,23 263:21 266:4 269:11 270:21 483:16 490:2 <b>fda.gov</b> 230:18 <b>fear</b> 95:10 162:9 <b>feasible</b> 309:10	<b>february</b> 108:15 109:2 115:2 <b>federal</b> 5:11 9:5 33:5 221:2 224:1 224:3,8,9,10 <b>feel</b> 54:3 104:9 351:11 372:6 420:4,4 479:11 <b>feeling</b> 348:4 349:2 351:16 <b>feelings</b> 68:7,8 <b>feels</b> 114:14 194:19 <b>fees</b> 100:11 <b>feet</b> 141:4 262:5 268:10,11 <b>felt</b> 195:3 <b>female</b> 6:12 322:23 323:2 341:23 390:7,8 456:4 457:17 488:7 <b>females</b> 368:12 369:9,23 372:14 488:9,12 <b>feminization</b> 130:15 166:23 167:4 175:9 <b>fensolvil</b> 203:7 <b>fertility</b> 468:13 <b>fetal</b> 131:11,12 136:8 <b>fiduciary</b> 386:3 <b>field</b> 21:19 22:3 61:1 132:11 212:4 305:7 322:22 409:19 415:17 <b>fif</b> 332:18 <b>fifteen</b> 332:20 <b>fifth</b> 465:22	<b>fifty</b> 445:4,7 446:3 <b>figure</b> 272:7 324:11 364:4 <b>file</b> 396:23 <b>filed</b> 9:22 409:8 <b>final</b> 302:2 459:19 485:8 <b>finalized</b> 188:2 192:2 199:18 <b>finally</b> 134:11 147:14 227:3 419:4 <b>financial</b> 109:16 199:5 473:12 <b>find</b> 21:15,23 51:6 51:19 53:21 72:11 72:14 77:16,23 104:18 113:11 179:19,19 180:2 317:17 335:11 353:19 360:18 365:5,21 366:7 391:7 <b>finding</b> 39:10 91:3 311:9 354:15 <b>findings</b> 37:16 38:12 371:21 <b>fine</b> 19:4 97:5 384:16 <b>finish</b> 227:4 248:12 <b>finished</b> 469:15 471:10 491:3 <b>finland</b> 35:16 248:4 394:1,17 395:4 396:11 404:23 405:9 406:11 407:11 410:12,15,18,20 <b>finnish</b> 7:12 394:19	<b>fired</b> 95:16 <b>firm</b> 10:6 234:1 <b>firmly</b> 111:8 112:13 <b>first</b> 11:6 28:22 38:8 59:22 63:10 84:8,15 85:9 86:1 86:4 89:1 91:19 94:9 95:1 96:3 97:1 101:9 107:3 109:12 111:8 116:5 127:19 129:6 130:7,7 170:12 172:10 192:18 202:12 225:9 229:2 233:18 245:9 248:13 257:19 262:8 264:20,22 268:17 272:5 284:23 285:1 300:2 307:18 308:8,9 317:19 324:3,4 326:14 330:16 341:17 347:10 358:2,4,6 367:10 396:16 419:22 420:5 435:14 436:4 439:9 440:8 456:3 458:18 459:2,3 467:12 470:21 472:21 476:8 481:1 <b>firsthand</b> 49:20 51:9 193:14 204:19 214:14 <b>fistula</b> 336:18,19 338:10 <b>fistulas</b> 178:16 338:21
--	--	---	---

<b>fit</b> 77:4 270:22 279:6	<b>folder</b> 115:5	266:6,15,22 267:1	184:20 187:4,14
<b>fitting</b> 372:12 460:10	<b>follow</b> 7:7 28:17 143:15 146:22	267:17 268:21	187:20 188:12
<b>five</b> 51:3 122:4 123:1,5 138:21	161:11 164:17	<b>forgive</b> 293:2	190:18,23 191:4
139:10 143:19	208:20 209:12	325:18 332:12	191:10,15,21
160:2,3 184:12	313:8 327:18	<b>form</b> 8:16 21:14	192:3,10,23 193:9
196:16 202:11	331:16 336:5,10	21:20 22:5,12	193:17 198:9,23
281:7 313:8 333:9	337:22 339:21	26:6,21 28:13	199:15,21 200:5
336:15 337:18	345:5,9,18 346:3	29:7,15,19 30:1,22	200:10,16 204:14
345:19 352:2	346:13,16 347:9	31:4 32:14,21	204:22 206:7
391:17 425:11	347:14 352:13,18	34:20 36:13 37:5	207:16,21 208:18
431:8,10 446:4	352:20 485:7	39:18 40:21 41:21	211:13 212:5,21
474:4,5	487:12 489:4	42:12 47:6 48:7	215:3 216:1 217:3
<b>fixation</b> 129:23 130:11 310:13	<b>followed</b> 164:22 169:22 322:10,12	49:23 50:6 52:6	217:8 221:10
<b>flags</b> 71:21	<b>following</b> 9:12 38:12 321:17	52:14,19 53:1	222:5 226:19
<b>flap</b> 142:20 178:3 178:4,10,10,15,16	322:14 401:15	54:13 55:3 57:14	227:19 228:15
467:22,22 468:1,4	427:20 431:3	58:17 60:20 62:1	229:22 232:7
468:5,8 476:12	435:16	65:17 73:14 74:19	234:20 236:6
477:4 478:18	<b>follows</b> 11:7	76:18 77:13 78:8	237:6 238:4,9
<b>flaps</b> 143:1 299:7 338:16 339:5,5	<b>folwell</b> 1:14 9:21 10:21 493:4 494:1	78:20 81:8 83:6	239:11 240:19
478:17 479:8	495:1	83:15 88:17 89:3	242:4,12 243:13
<b>fleck</b> 446:7	<b>food</b> 221:5 224:17 224:19 263:14	90:17 91:16 92:17	245:11,17 251:4
<b>flip</b> 285:8	<b>footnote</b> 41:10,12 41:12,16 42:5,8	96:18 97:12,23	252:7,11,18
<b>flood</b> 123:3	227:9	98:8 99:8 102:12	253:18 259:2
<b>floor</b> 2:20	<b>footnotes</b> 327:6	103:10 107:22	266:9 267:21
<b>florida</b> 474:14	<b>forbidding</b> 44:22	110:3 111:20	269:1,7 270:6,12
<b>flourishing</b> 460:7	<b>force</b> 51:17	112:23 113:21	273:10 274:9
<b>fluid</b> 134:13 135:9	<b>forces</b> 398:2	114:11 117:3,10	275:14 281:1
<b>fluidity</b> 400:11	<b>forearm</b> 339:5 467:22	117:19 118:6,20	283:7 284:9
<b>fly</b> 358:5	<b>foregoing</b> 492:5,9 495:5	120:20 126:13	285:16 286:20
<b>focus</b> 5:2 65:5 116:8 137:21	<b>forehead</b> 130:10 130:12 131:7	127:7 128:15	288:15 293:13
172:9 174:15	140:22 262:1,10	135:18 136:18	294:20 295:12,18
<b>focused</b> 356:13	262:22 265:10	137:13 148:2	297:20 298:5,14
<b>focusing</b> 145:5		149:14,18 151:14	303:9 305:11
		154:3 155:16	307:6 311:18
		157:12 158:7,11	318:4 323:3 324:2
		162:17 163:2	333:15 342:20
		166:12 168:20	352:7 357:23
		173:5 175:1,7,12	359:2 362:19
		175:14,17,23	364:7 367:2 371:8
		176:11 179:5,18	374:8 376:10
		180:9,16 181:2,13	381:11 382:22

383:2 385:17 387:6,16 395:13 399:22 406:15 407:6 408:14 409:10,16,22 410:13 412:14 413:20 416:1,6 424:5,12,23 425:15,20 426:17 427:22 428:4 429:3,22 431:19 432:10 436:1 438:4,17 439:7 440:14,17 441:10 442:16 443:15,21 447:1,12 448:19 449:10 451:19 453:21 454:12,18 455:12 458:2 459:11 460:20 461:18 462:6,12 463:23 464:16 465:6 466:6,19 467:3 469:8 492:8 <b>formal</b> 69:10,19 383:19 <b>formality</b> 96:23 <b>formally</b> 75:5 <b>format</b> 87:13 93:17 <b>formed</b> 170:18 259:5 <b>former</b> 107:18 179:14 181:19 <b>forming</b> 196:23 221:15 232:11 239:3 <b>forms</b> 70:20 131:19 144:9 252:16	<b>formulated</b> 424:14 <b>forth</b> 435:8 <b>forty</b> 307:12 <b>forward</b> 105:21 415:22 <b>found</b> 53:18 122:5 344:8 359:19 416:15 <b>foundational</b> 93:14 <b>four</b> 14:9 58:14 73:12 97:2 103:17 202:11 299:2 336:15 364:14 391:17 401:18 431:10 445:4,7 <b>fournier's</b> 478:4 <b>fourth</b> 57:16,18,19 348:1 <b>fracture</b> 129:22 131:6 <b>francisco</b> 86:14 272:17 278:7 <b>frankly</b> 313:1 <b>free</b> 178:10 339:5 339:5 420:4,4 477:4 <b>freedom</b> 79:11 <b>frequency</b> 257:2 <b>friend</b> 67:7 <b>friends</b> 48:18 49:1 104:3 151:18 <b>front</b> 324:21 <b>frontal</b> 129:21 133:12 <b>frontalis</b> 265:10 266:14,18 267:10 267:18 <b>full</b> 4:23 11:12 51:17 63:2 83:17 94:16 97:15	100:23 101:2 102:4 113:9 308:8 325:7 347:5 391:20 435:14 445:12 <b>fuller</b> 159:14 <b>fully</b> 314:4 346:18 416:19 <b>function</b> 319:9 333:3,4 345:12 403:22 466:6,20 467:4,19,20 468:6 <b>functions</b> 47:7 119:23 317:13 467:6 <b>fund</b> 2:13,19 <b>further</b> 38:9 172:18 227:7 228:2 237:10 240:9 324:18 337:19 364:16 390:6 414:4,5 492:14 <b>future</b> 159:3,11 462:16	54:10 57:12 60:16 60:21 61:4 63:14 65:10 76:9 77:18 78:19 80:19 81:20 84:18 85:7 107:12 107:20 109:18 110:8 111:6,10,18 112:21 114:9 115:19 116:20 117:15 126:10 127:4 130:3,3 131:2,16,16 132:18,19 133:16 133:17 134:3,3,17 134:17 137:4,10 137:18 146:21 149:10 150:5,23 151:2,13 152:3,7 153:6,12 154:6,6 157:19 158:1,5,10 158:19 162:15 163:1 164:15 168:12,17 175:20 177:22 178:13 192:17,20 193:20 193:21 195:18,18 200:15 205:15 214:12,18,22 215:18 216:10 312:3 316:18 319:1,15 321:4 329:11 340:9 341:23 342:7,14 353:2,10,22 354:4 367:14,22 368:13 368:14 370:9,19 373:21 374:17 375:2,7,7 376:13 379:20 380:12 382:23 383:19,21 383:23 384:22
		<b>g</b>	
		<b>g</b> 3:4,5,10 16:16 299:19 493:1 <b>gained</b> 109:14 <b>gangrene</b> 478:4 <b>gary</b> 80:11 <b>gatherer</b> 279:11 <b>gathering</b> 272:23 <b>gears</b> 99:15 182:8 442:5 <b>gender</b> 5:3 6:18 7:2,22 8:4,7,10 22:4 35:5 36:18 36:22 39:4 40:4 41:6,7,18,20 44:1 49:16 51:4,23	

387:2 390:1,14,15 390:19 391:2,8 393:18 395:1,11 395:12,22 397:21 398:1,11,18 400:11 405:9,18 410:10,17 411:11 424:9 425:17 426:14 427:5,18 428:1,7 429:8,9,20 430:14 431:1 432:3,7 433:19,21 434:21 435:17 437:13 438:2,12 443:18 447:11 449:7 457:6 458:1 460:18 462:3,9 479:22 481:21 482:12,18 483:22 485:16 486:6,6,17 486:20 487:18 488:19 <b>genderreport</b> 407:19 408:17 <b>genderreport.ca.</b> 407:13 <b>general</b> 106:5 121:17 122:2 123:10 165:1 208:11 209:13,19 210:12 213:1 223:5 247:11 272:5 273:8 274:17,18 277:20 294:21 295:7,8 321:8,11,15 322:5 326:21 391:3,10 436:14 472:17,21 473:1 480:13 484:23	<b>generally</b> 43:16 92:20 117:14 136:4 163:15,16 211:2,6 213:7 215:19 219:7 231:10 233:4,7 238:18 284:22 323:21 334:1 373:16 374:4,16 374:23 375:6 408:11 <b>generated</b> 276:18 379:8 <b>generates</b> 46:11 <b>generating</b> 50:13 199:7 372:20 <b>generation</b> 461:2 461:7 <b>generic</b> 201:11 <b>genesis</b> 456:6 <b>genetic</b> 201:10 <b>genital</b> 178:5,20 <b>genitalia</b> 323:2 436:8,15 479:6 <b>genitals</b> 290:7 <b>georgia</b> 2:15 <b>germane</b> 13:20,22 51:3 238:10 277:17 <b>getting</b> 119:2 208:22 289:8 355:8 402:22 <b>girls</b> 409:8 <b>give</b> 11:16 68:19 82:14 88:22 104:21 111:21 121:14 123:12 142:3 150:19 157:4 160:23 161:6 215:20,22 273:13 312:14	339:14 340:22 383:13 384:10 403:8 445:8 450:8 452:23 <b>given</b> 13:6 34:21 53:22 54:5,5 85:1 122:2 165:11 176:3 177:15 185:20 196:16 209:9 217:18 220:13 291:11 305:2 314:7 319:4 319:12 322:2 371:4 401:22 418:16 436:23 491:12 495:9 <b>giving</b> 63:15,15 86:18 94:4 97:7 159:16 235:11 402:12 450:17 <b>glabellar</b> 267:2,3 <b>glasses</b> 41:11 <b>gleaned</b> 195:12 <b>gloss</b> 340:20 <b>glossary</b> 173:12,21 173:22 <b>glossed</b> 13:19 <b>gn</b> 431:14 <b>gnrh</b> 431:14 <b>go</b> 16:13 19:3 26:12 27:14 31:8 35:1,11 36:1,7 38:21 43:10 56:15 57:1 58:1 59:14 64:4,14 71:16 72:13 74:11,11 78:23 87:15 110:4 111:7 115:8 116:16 119:16,16 119:18 126:6 128:17 129:18	143:16,17 149:22 154:11 158:13 166:4 171:21 174:3 188:19 202:12 207:3 210:2 218:7 225:2 227:5 231:2 242:13 245:2 248:13 254:12 256:9 264:10,20 279:19,20 281:2 281:14 289:22 297:8 302:5 308:5 314:9 319:18 320:8,11 327:20 327:21 330:10 332:15 340:7 341:13 347:19 349:15 350:10 358:1 359:8,13 364:13 367:6,8 373:11 378:5,14 380:10 381:12 383:9 384:9,16 388:3 391:12 396:11 397:15 398:17 399:11 401:5 404:22 405:2 407:7,8 413:6 415:6 417:9 419:19 420:5 421:6,6 422:11 428:8 430:21 435:12 437:5 440:1,23 445:2,2 446:2,8 451:8 452:19,19 453:10 455:18 458:21 460:22 465:8 469:10 470:4,9 471:5 484:13
---	--	---	--

491:7 <b>goal</b> 206:13 459:19 <b>goals</b> 460:13 <b>god</b> 456:10,13 457:10 <b>goes</b> 36:4 266:19 303:10 424:20 <b>going</b> 9:16 15:14 17:12 27:5 31:1 37:4 46:11 55:6 73:1 102:9 121:11 123:14 125:23 131:10 156:17 180:2 185:23 218:7 219:20 223:14,15 230:11 232:21 239:14 256:13 261:4,15 262:16 263:7 271:15 283:10 287:5 289:22 291:16 298:7 299:9 306:11 313:9 315:12 316:21 317:2,7,8 317:11,12 319:1,6 319:20 325:23 328:9,14 353:5,6 353:16 361:3 364:10 375:13 379:21 383:12 385:10 386:5,7 387:20 388:14 396:8,10 397:13 403:8 414:16 415:20,21 420:22 423:7,18 426:21 426:22 430:6 434:7 448:23 449:12,13 457:12	457:13 464:7 467:18 468:5 469:4 485:8 488:13 <b>gold</b> 249:3 <b>gonadectomy</b> 344:13,19 345:7 345:16 <b>gonadotropin</b> 201:7,9 317:22 428:14 <b>gonzalez</b> 2:18 <b>good</b> 9:15 11:10 11:11 52:16 87:11 92:10 124:23 133:21 135:6,6,6 164:1 251:8 261:6 276:18 290:5 311:15 312:23 379:9 439:21 472:2 <b>gorney</b> 67:7 72:2 <b>gosh</b> 170:9 186:15 202:10 298:7 313:6 <b>gospel</b> 450:18 <b>gotten</b> 124:10 <b>government</b> 77:4 <b>grabs</b> 123:2 <b>grafting</b> 44:15,23 142:8,10 <b>grafts</b> 478:17 479:8 <b>grand</b> 67:8 <b>grasp</b> 403:21 <b>great</b> 53:19 56:9 89:16,18 104:5,10 105:3 106:9 161:20 177:12 244:2 248:3 260:12 286:12	287:12 290:6 389:5 475:4 480:8 484:22 485:5 <b>greater</b> 287:7,8 311:7 390:2 402:16 410:5 <b>greatest</b> 122:1 <b>greatly</b> 68:3 444:3 <b>griffin</b> 35:17 <b>grooming</b> 461:2,6 461:8,11,12,14,21 461:22 462:10,15 469:2,12,14 470:6 <b>grounds</b> 466:3,15 <b>groundwork</b> 462:19 <b>group</b> 45:11 88:12 192:18,21 193:3 242:19 249:6 271:8,9 309:6 322:21 367:15 368:19 390:3,10 390:13,18 412:8 452:5 455:6 <b>groups</b> 184:17 190:16,21 191:13 192:7 266:15 271:8 280:8 346:8 368:20 483:9,15 <b>grow</b> 121:14 <b>growing</b> 109:15,20 260:9 328:1 341:8 360:14 363:8,9 458:5 <b>grows</b> 476:5 <b>growths</b> 144:10 <b>guardians</b> 402:2 402:23 403:10 404:18 <b>guess</b> 12:18 69:5 74:21 83:19 93:16	127:20 152:8 160:15 176:16,21 226:3,7 264:1 279:8 288:9 297:22 298:7 301:2 303:20 331:23 379:9 471:17,21 <b>guessing</b> 98:3 142:1,18 298:19 <b>guidance</b> 28:8 29:22 31:3 32:8 128:12 227:16 233:3,5,9 238:7 282:3 394:20 398:21 <b>guide</b> 249:8 <b>guided</b> 248:19 <b>guideline</b> 186:12 186:14 <b>guidelines</b> 7:12 27:17 28:17 73:12 195:17 196:15,22 197:14,17 200:14 200:22 394:1 395:5,10,15,21 401:2 402:10 403:6 404:23 406:11,22 407:11 410:12,16 <b>guy</b> 125:8 <b>gynecomastecto...</b> 148:11
			<b>h</b>
			<b>h</b> 4:10 16:12,16,16 55:20 182:13 389:13 414:15 446:12 494:3 <b>habit</b> 449:21 <b>hair</b> 139:22 146:1 146:5 147:5



151:12 152:9,17 153:2 <b>half</b> 25:20 146:13 147:10 336:16 <b>halfway</b> 359:16 <b>hampshire</b> 111:1 <b>hand</b> 16:9 77:15 176:21 287:12 417:4 468:6,9 <b>handed</b> 269:10 <b>handle</b> 54:21 346:15 <b>happen</b> 220:2 259:15 358:14 <b>happened</b> 102:6 164:23 186:3 <b>happening</b> 60:4 61:5 <b>happens</b> 185:9 <b>happy</b> 333:8 <b>hard</b> 352:17 <b>hardware</b> 310:17 <b>harm</b> 67:4 70:18 162:9 223:7 290:6 313:13 314:19 333:21 334:10 347:2 413:4 468:8 487:3 <b>harms</b> 244:1,2 <b>harry</b> 380:12 <b>hazard</b> 297:22 390:4 <b>head</b> 109:8 131:5 279:5 468:2 474:4 <b>headed</b> 4:22 63:2 165:8 <b>header</b> 279:22 420:1 <b>heading</b> 434:2 <b>heal</b> 450:14	<b>health</b> 10:20 11:2 21:3 40:7 63:11 65:12 66:4 74:17 75:9,15,18,22 82:6 111:13 116:7 149:16 154:2,12 155:8,12,14 157:7 157:10 182:10,17 241:4 392:8 398:8 418:9 420:13 422:21 423:1 425:11 428:18 429:18 433:10,13 <b>healthcare</b> 7:4 8:9 57:12 80:18 149:12 153:21 231:10 376:3 434:9,18,18 <b>healthy</b> 120:1 289:21 392:2 <b>hear</b> 47:3 49:18 54:19 159:13 160:13 325:14 359:11 426:2 448:23 449:14 471:7,12 <b>heard</b> 14:20 17:17 37:6,13 50:15 63:19 73:12 85:2 96:9,14 98:13 102:22 160:11 230:6 233:10 269:12 425:7 442:5 488:15 <b>hearing</b> 38:11,16 38:19 63:20 65:14 71:15 162:8 447:13 448:8 <b>heart</b> 90:1 218:13 <b>heartache</b> 105:9 108:2	<b>heartbreaking</b> 95:21 <b>heartburn</b> 177:11 <b>heavily</b> 185:13 261:1 343:21 <b>held</b> 37:9 398:7 <b>help</b> 68:16 111:10 112:10 172:19 332:14 458:10,15 <b>helped</b> 485:17 <b>helpful</b> 83:2 308:14 355:7 <b>helping</b> 145:14 <b>hembree</b> 380:17 <b>hereto</b> 495:7 <b>hey</b> 333:8 <b>hhs</b> 224:18,20 <b>high</b> 88:10,22 116:13,16 117:4 145:3 158:23 161:17 166:4 206:20 218:10,16 222:21 223:3 258:18 312:11 314:5 359:6 420:21 <b>higher</b> 103:5 223:3,4 250:15 258:6 281:20 288:22 303:19 305:22 312:17 313:20,21 314:14 317:13 354:2,10 391:9 <b>highest</b> 415:16 <b>historic</b> 452:16 <b>historically</b> 72:1 <b>history</b> 70:15,17 220:14 226:10 247:16 324:15 368:13 427:9	<b>hold</b> 75:8 189:9 204:6 274:7 325:4 465:2 484:3 <b>holding</b> 252:8,10 <b>holland</b> 248:4 <b>home</b> 63:5 <b>honor</b> 447:16 <b>hope</b> 98:16 179:21 211:16 222:20,21 223:8 237:20 246:18 292:3 <b>hoped</b> 104:2 <b>hopefully</b> 246:2 <b>hoping</b> 124:23 <b>hopkins</b> 106:11 125:10 <b>hormonal</b> 416:22 431:12 481:14,20 482:12 <b>hormone</b> 84:23 159:20 164:4,9 201:7,10 212:19 212:23 214:3,7 317:22 319:10 345:7 374:16 375:1 376:13 379:21 384:22 387:3 400:5 416:13 424:9 425:18 426:15 428:14 433:19 437:14,17,23 483:21 <b>hormones</b> 36:22 82:1 213:7,22 214:11,17 216:9 219:17 238:19 247:2,10 260:7 316:16,20 317:4 318:2,7,20 319:4,8 319:14 373:20
---	--	--	---

394:21 401:10,14 404:2 416:13 417:5 428:22 447:22 482:17 488:18 <b>hospital</b> 24:11,14 24:16,17,21 95:18 140:12 142:17,21 262:17 473:23 474:6 <b>hospitals</b> 24:1,3 <b>hour</b> 15:5 16:1,2 87:20 319:21 <b>hours</b> 17:7,10,13 <b>house</b> 63:18 <b>hruz</b> 14:18 16:7,9 17:1 33:12,13 39:15,21 40:11 42:10,19 43:23 57:20,21 78:5 81:17 85:10 86:3 87:10 92:13 114:6 <b>hruz's</b> 15:8 <b>ht</b> 344:14 <b>huge</b> 147:13 287:18,19 <b>hugely</b> 286:12 <b>huh</b> 264:9 361:16 365:4 396:17 420:20 <b>human</b> 131:23 132:2,6,15 134:13 444:8 452:17 454:3 458:22,23 459:4 460:5,7,12 467:6,19 <b>hundreds</b> 121:1 <b>huntsville</b> 24:17 <b>hustle</b> 452:21 <b>hyperfunctioning</b> 156:8,12	<b>hyperhidrosis</b> 206:17 229:10 267:12 <b>hyperplasia</b> 436:23 <b>hypotheses</b> 372:23 <b>hypothesis</b> 372:20 372:21 <b>hypothesizing</b> 373:7 <b>hypothetical</b> 371:7,10 372:8  <b>i</b>  <b>idea</b> 48:4,14 49:12 52:17 159:12 177:13 188:9 192:12 255:13 269:3 307:7 379:18 380:1 381:10 402:16 425:16 426:13 433:18 456:20 <b>ideas</b> 461:9 469:1 <b>ideation</b> 487:5 <b>identification</b> 12:6 27:9 34:7 37:23 55:9 62:19 94:1 108:7 116:2 127:17 161:10 171:7 223:18 230:14 232:23 239:16 256:15 263:10 299:15 326:2 339:18 355:18 361:11 368:15 370:2 375:16 388:20 394:9 396:20 411:4 414:22 419:17 427:1 430:9 434:10	451:5 457:15 463:5 <b>identifications</b> 463:21 <b>identified</b> 145:1 145:21 318:11 344:19 348:10 349:5 356:21 369:1 374:10 428:16 429:1 476:19 485:22 <b>identify</b> 136:1 355:11 413:12 444:1 472:14 <b>identifying</b> 405:17 <b>identity</b> 154:6 192:17,20 193:20 341:23 342:7,14 398:1 462:3,9 486:6,21 487:18 <b>idiosyncratic</b> 22:8 <b>ignore</b> 415:21 <b>ignored</b> 348:11 349:7 <b>ii</b> 35:4 123:11 225:5 <b>illegal</b> 241:21 242:10 <b>illness</b> 384:7 422:22 <b>illnesses</b> 486:18 488:9 <b>imagine</b> 46:10 198:15 236:9 <b>immoral</b> 124:18 468:13 <b>immutable</b> 448:15 <b>impaired</b> 317:14 <b>imperative</b> 66:17 <b>impinge</b> 82:20 132:10 215:15	447:21 <b>impinges</b> 68:3 <b>implant</b> 148:8 220:17,20 222:8 <b>implants</b> 299:5 <b>implementation</b> 382:13 <b>implementing</b> 198:21 <b>implication</b> 254:2 <b>implications</b> 7:3 <b>imply</b> 28:2 241:20 242:3,5,7,8 <b>implying</b> 254:4 <b>importance</b> 248:21,23 <b>important</b> 93:20 162:1 213:3 241:3 247:12 353:14 392:6 399:7 400:11 460:3 <b>impossible</b> 319:6 <b>impression</b> 46:14 <b>improper</b> 206:5 216:18 241:21 242:9,21 <b>improve</b> 40:6 111:12 <b>improved</b> 6:9 300:7 <b>improvement</b> 66:16 265:8 266:5 <b>improvements</b> 295:20 <b>improving</b> 152:13 <b>inadequacy</b> 337:20 <b>inappropriate</b> 111:19 <b>incarceration</b> 313:14
--	---	--	---



<b>incisions</b> 134:7 <b>inclined</b> 294:23 <b>include</b> 38:12 144:9 209:3,4 215:10 331:3,7 358:9 363:2 412:15 415:12 431:2 436:22 451:17 <b>included</b> 72:17 107:9 210:13 225:16 267:3 302:2 327:22 452:11 <b>includes</b> 301:14,19 303:23 437:14 <b>including</b> 36:21 145:16 172:12,15 173:14 274:20 328:22 358:15 379:5 431:13 437:22 441:14 449:6 463:16 474:15 487:2 <b>inclusion</b> 243:1 356:22 <b>incongruent</b> 195:18 <b>inconsistent</b> 176:9 179:3 222:3 <b>incorrect</b> 46:5 150:16 448:20 <b>incorrectly</b> 447:23 450:6 <b>increase</b> 328:14 345:3 393:19 <b>increases</b> 328:13 392:17 393:1,12 405:19 <b>increasing</b> 328:6 355:10	<b>increasingly</b> 328:5 <b>incredible</b> 86:20 <b>incumbent</b> 68:10 <b>indicate</b> 490:5 <b>indicated</b> 112:5 <b>indicating</b> 267:1 268:10 <b>indication</b> 216:15 221:8 233:21 243:10 265:8 268:4 314:17 333:19,23 334:3 478:19 <b>indications</b> 226:16 228:21 334:5 335:2 351:17 406:5 <b>individual</b> 13:4 17:14 241:13 248:22 253:8,13 417:18 431:1 448:17 456:14 479:15 <b>individually</b> 36:8 188:20 <b>individuals</b> 41:5 41:19 436:7 <b>industry</b> 19:8 20:20 21:11 22:2 291:14 293:4,8 386:2 434:4 <b>infants</b> 241:4 <b>infection</b> 478:6 <b>infectious</b> 178:19 <b>infer</b> 199:1 413:15 <b>inferences</b> 392:9 <b>inferring</b> 237:8 <b>inflection</b> 122:20 185:17 <b>inform</b> 209:21	<b>informal</b> 164:20 <b>information</b> 55:15 57:9 58:15,20 74:10 77:6,7,10 123:6 194:10 241:7 249:5 251:16 280:16 296:19 324:1 380:20 381:17 382:14 418:14 <b>informative</b> 392:7 <b>informed</b> 68:19 119:2 209:1,2 225:11 233:23 235:1 401:22 402:12,22 403:9 404:11,15,16 <b>informs</b> 176:12 223:7,9 444:9 <b>inherent</b> 113:23 <b>initial</b> 156:11 235:4 <b>initially</b> 196:1 337:16 <b>initials</b> 446:10 <b>initiated</b> 406:2 407:1 <b>injectables</b> 140:1 <b>injection</b> 266:12 266:13 <b>injections</b> 140:23 261:20 262:1,5,22 <b>injured</b> 473:16 474:16 <b>injuries</b> 178:6 479:2 490:18 <b>injury</b> 422:22 <b>innovations</b> 229:4 <b>innovative</b> 294:22 <b>innovators</b> 295:6 295:14	<b>inpatient</b> 257:13 258:7 <b>input</b> 128:4 134:8 198:17 <b>insert</b> 202:2,6 206:3 209:6,9 210:14 215:11 <b>inserts</b> 210:16 <b>insist</b> 449:17 450:4 <b>insisted</b> 283:9 <b>instance</b> 244:10 <b>instances</b> 273:12 <b>institute</b> 21:3 53:20 260:13 <b>institution</b> 282:19 308:22 312:19 <b>institutional</b> 234:12 235:20 246:10,21 <b>instrument</b> 140:17 282:13 324:11 332:23 333:1,12 333:17 <b>instruments</b> 332:1 332:3 <b>insufficient</b> 339:1 398:9 399:9 <b>insurance</b> 291:13 291:23 292:14 376:20 385:4,6,9 385:21 386:2,6,14 387:9,19 423:13 424:15,18 425:11 429:18 431:21 432:11,19 434:4 436:10,12 437:1 438:21 <b>insurer</b> 376:3,8 420:22 425:7 433:10,14
--	--	--	--

<b>insurers</b> 385:12 425:12 439:4 <b>insuring</b> 438:9 <b>intake</b> 70:20 <b>integrity</b> 273:2 280:10 <b>intend</b> 12:10 226:2 <b>intended</b> 316:23 <b>intensifies</b> 5:4 <b>intent</b> 234:8 <b>intentional</b> 60:5 60:17,22 <b>interchange</b> 56:14 <b>intercourse</b> 333:4 <b>interest</b> 81:3 92:15 199:5 253:9,14 284:15 462:22 <b>interested</b> 82:18 122:10 492:17 <b>interesting</b> 125:8 335:11 337:9 338:6 351:6,18 416:10 436:2 <b>interestingly</b> 357:8 <b>interim</b> 4:19 55:16 <b>interior</b> 67:21 351:10 450:14 <b>internal</b> 130:10 279:8 439:2 <b>international</b> 451:15 454:7,14 455:9 <b>internet</b> 359:20 360:20 <b>interpret</b> 274:19 274:21 275:6 276:4 277:11 352:15 <b>interpretation</b> 212:23 276:14	<b>interpreted</b> 392:16 <b>interpreting</b> 212:7 276:13 <b>interval</b> 345:22 346:13 347:4,14 <b>intervention</b> 106:21 112:4 124:6 271:22 400:17 <b>interventions</b> 89:22 90:7 104:12 145:16 315:20 330:8 369:14 399:16 462:18 481:21 482:5,21 485:16,20 <b>intraabdominal</b> 315:21 <b>intracranial</b> 272:20 315:23 <b>intrathoracic</b> 315:22 <b>intrinsic</b> 442:14 443:12 <b>introduce</b> 27:5 37:21 55:6 62:16 95:20 108:4 114:15 127:14 170:11 171:5 223:14 230:11 255:19 263:6 299:12 325:4 375:13 388:14 394:6 396:8 411:2 414:16 417:7 426:21 434:6 451:2 463:1 <b>introduced</b> 110:9 310:12 461:9	<b>introducing</b> 414:19 <b>introduction</b> 184:22 240:5 326:12 328:19 334:23 <b>introductory</b> 87:16 91:14 403:13,14 <b>introitus</b> 479:7 <b>invalid</b> 319:16 <b>investigate</b> 221:16 452:7 <b>investigated</b> 118:4 118:16 120:12 235:17 <b>investigating</b> 306:1 <b>investigation</b> 118:23 119:11 235:5 279:5,9 <b>investigational</b> 5:17 218:20 232:10,14,17 233:14 234:10,11 234:19 241:22 242:3 423:2 425:2 <b>investigations</b> 229:6 <b>investigative</b> 235:6 <b>investigator</b> 272:10 273:3 274:15 278:5 279:3 309:20 315:4,17 <b>investigators</b> 273:1 276:23 <b>investors</b> 386:3 <b>invitation</b> 80:8	<b>invite</b> 84:15 <b>invited</b> 79:16,18 80:4 81:16 <b>involve</b> 149:15 336:9 <b>involved</b> 56:8 58:19 78:6,13 98:18 99:6 110:22 143:7 184:4,18 190:12,16 197:12 197:16,21 272:13 278:18 279:13 306:20,23 334:5 371:23 402:4 441:19 472:19 475:4 476:1 477:9 479:14 <b>involvement</b> 54:15 78:10 379:14 <b>involves</b> 36:15 51:21 271:7 274:12 467:16 <b>involving</b> 478:17 <b>ir</b> 235:23 <b>irb</b> 236:3 237:12 237:14,19,20 246:12 <b>irbs</b> 235:23 <b>irrelevant</b> 186:1 <b>irreversible</b> 119:6 287:15,17 484:16 485:5 <b>isolated</b> 129:21 351:12 <b>isolation</b> 70:19 71:11 <b>issue</b> 47:14 56:9 65:9 67:18 77:15 89:17 92:8 95:8 95:10 106:17 114:14 163:21
--	--	--	--

177:13 194:17 218:13 241:4 243:22 244:21 251:11 259:21,23 287:11 346:19 385:8,9 398:7 400:11 457:8 483:2 488:1 <b>issued</b> 264:16 <b>issues</b> 53:16 66:12 66:13 82:7,8,19 85:6 92:11 119:10 123:9 199:6 213:3 233:5 291:15 346:10 351:13 438:7 452:12 453:19 462:3,9 487:7 <b>italicized</b> 59:19 <b>items</b> 401:18 421:11 422:2 <b>iteration</b> 415:14 <b>iv</b> 172:4,5,6	296:17 297:1,3,17 298:12,17,22 300:10 302:22 303:6 304:13 305:14,20 306:3,4 306:22 307:1,11 307:22 331:12 364:3 <b>journals</b> 128:19 129:4 274:1 <b>judge</b> 37:9,15 38:4 179:12,21 180:2,4 231:12 <b>judge's</b> 42:4 <b>judgment</b> 241:16 295:3 <b>judgments</b> 486:20 <b>julie</b> 444:21,21 <b>july</b> 7:6 33:23 37:8 38:11,16 141:15 141:20 383:1,5 <b>jump</b> 285:4 <b>jumping</b> 456:17 <b>june</b> 55:16 <b>justice</b> 77:3 444:4 444:5 <b>justifiable</b> 484:13 <b>justifiably</b> 309:7 <b>justified</b> 294:5 314:4 <b>justify</b> 287:21 293:22 482:16	<b>kept</b> 37:3 <b>kettenis</b> 380:17 <b>kevin</b> 3:10 <b>key</b> 71:8 291:15 345:9 413:11 <b>kicks</b> 337:12 <b>kin</b> 492:15 <b>kind</b> 20:15 32:12 52:4 54:23 76:22 81:6 82:12 87:9 91:22 98:16 110:18 119:11 125:10 150:4 153:21 154:2 164:14 168:12 175:4,9,20 176:5 179:17 185:2 186:6 187:1,7,11 187:16 191:11,17 198:6,11,14 199:10 201:19 208:2 220:17 223:5 229:7 285:21 286:14 288:7 332:7 355:5 358:13,23 366:7 369:21 390:20 416:21 450:2 470:22 <b>kinds</b> 52:9 208:23 <b>kitchen</b> 131:4 <b>knepper</b> 3:4,5 4:5 10:17,18 14:3,23 15:4 21:14,20 22:5,12 26:6,21 28:13 29:7,15,19 30:1,22 31:4 32:14,21 34:20 36:13 37:2,5 39:18 40:21 41:21 42:12 44:5 47:6	47:16 48:7 49:23 50:6 51:15 52:6 52:14,19 53:1 54:13 55:3 57:14 58:17 60:20 62:1 65:17 73:14 74:19 76:18 77:13 78:8 78:20 80:2 81:8 83:6,15 88:17 89:3 90:17 91:16 92:17 96:18 97:12 97:23 98:8,20 99:8 102:12 103:10 107:22 110:3 111:20 112:23 113:21 114:11,18 115:9 117:3,10,18 118:6 118:20 120:20 126:3,6,13,20 127:7 128:15 135:18 136:18 137:13 148:2 149:14,18 151:14 154:3 155:16 157:12 158:7,11 162:17 163:2,14 166:12 168:20 173:5 175:1,7,12 175:14,17,23 176:11 179:5,10 179:18 180:9,16 181:2,13 184:20 187:4,14,20 188:12 190:18,23 191:4,10,15,21 192:3,10,23 193:6 193:9,17 198:9,23 199:15,21 200:5 200:10,16 204:14 204:22 206:7
<b>j</b>			
<b>j</b> 322:18,18 340:15 389:13 <b>january</b> 141:20 257:13 427:12 <b>jeff</b> 91:20,23 <b>jefferson</b> 492:3 <b>john</b> 3:4,5,8 10:17 493:1,2 <b>johns</b> 106:11 125:9 <b>join</b> 101:9 <b>joined</b> 101:11 <b>joint</b> 4:19 55:15 <b>jones</b> 10:23 <b>journal</b> 12:21 102:2 135:17 284:5 296:2,8,13	<b>june</b> 55:16 <b>justice</b> 77:3 444:4 444:5 <b>justifiable</b> 484:13 <b>justifiably</b> 309:7 <b>justified</b> 294:5 314:4 <b>justify</b> 287:21 293:22 482:16		
	<b>k</b>		
	<b>k</b> 256:19 445:6 446:13 <b>kadel</b> 1:9 9:21 12:23 493:4 494:1 495:1 <b>karolinska</b> 260:13 <b>keep</b> 69:12 88:4 332:7 378:23		

207:16,21 208:18	425:15,20 426:17	136:5 141:23	277:13 282:14
211:13 212:5,21	427:22 428:4	142:2 145:12,16	283:22 285:3
215:3 216:1 217:3	429:3,11,22	146:12 148:8	286:22 290:6
217:8 221:10	431:19 432:10	156:17 159:19	295:23 296:22
222:5 225:22	436:1 438:4,17	160:7,8,15 163:8	298:16 299:10,10
226:19 227:19	439:7 440:14,17	164:3,6,8,11,13	299:13 307:3
228:15 229:22	441:10 442:16	165:12 166:23	313:6 315:12
232:7 234:20	443:15,21 446:19	167:7,13 169:10	317:20 318:18
236:6 237:6 238:4	447:1,12 448:19	169:13,17 170:21	319:19 321:18
238:9 239:11	449:10 451:19	171:6 173:21	326:1 328:1
240:19 242:4,12	453:21 454:12,18	176:20 180:13,20	331:18 334:6
243:13 245:11,17	455:12 458:2	180:21 182:8,15	338:3 339:16
251:4 252:7	459:11 460:20	184:7,14,15,16	351:13 354:1,9
253:17 255:20,23	461:18 462:6,12	185:2 187:1,6,7,11	355:21 359:3
256:5,11 259:2	465:6 469:8 471:3	187:16,23 188:4	361:4,18 368:4,6
266:7,9 267:21	471:4,11 472:1,9	189:20 190:2,4,15	369:2 372:2
269:1,7 270:6,12	489:2,8 490:23	190:20 191:6,11	375:14,23 376:16
273:10 274:9	491:3 493:1	191:17,23 192:5	376:17,18,23
275:14 280:22	<b>knepperllc.com</b>	192:19 193:2,5,11	381:6,23 382:4
281:1 285:16	3:8 493:2	193:23 194:9	383:15 388:19
286:20 288:15	<b>knew</b> 259:6,7	195:16,20,23	391:6 394:8
293:13 294:20	<b>know</b> 12:4 14:18	196:3,6 197:20,23	395:17 396:19
295:12,18 297:19	15:17,18 19:20,21	198:1,5,11,18	399:1 400:23
298:5,14 303:9	19:22 20:5,13,14	199:10,16 200:7	405:4 408:16,19
305:11 307:6	20:22 26:11,13,16	201:12 202:2,12	408:21,22 409:2,4
308:1 311:18	27:7 33:20 34:5	202:15 203:20	409:5,11,17,17
318:4 324:2	38:18,20 43:3,6	205:15,17 207:17	411:2 414:20
333:15 340:2	47:13 50:2 51:11	208:5,12 211:8	418:11 419:1,11
342:20 352:7	55:7,20,22 56:10	213:22 214:20	420:18 426:23
357:23 359:2	61:18 62:7,17	220:11,11 221:20	429:16,19 430:2,7
362:3,19 364:7	65:21 68:10,15	221:23 222:18	433:6,7,15 434:15
367:2 371:8 374:8	70:9 78:9,12,15	223:6,16 224:1	436:14,20 439:15
376:10 381:11	83:17 84:14 88:3	226:3,21 230:6,13	440:6 441:21
383:2 385:17	93:16 96:1 98:10	232:9,15,18,22	447:4 451:4
387:6,16 395:13	99:16 100:9 102:6	235:19 238:23	455:21 460:2,4,4
399:22 406:15	104:13 107:11	239:9,15 249:23	471:13 474:18
407:6 408:14	108:5 111:11	254:22 255:4,9,15	488:12 489:21
409:10,16,22	114:16,20 119:11	256:13 259:4,8,11	490:10
410:13 412:14	120:17,22 121:3	262:8 263:8,19	<b>knowing</b> 104:13
413:20 416:1,6	124:20 125:8,16	268:3,12,13,14	205:10 322:13
424:5,12,23	127:15 131:8	271:4 276:10	354:6 367:4 382:5

442:1 <b>knowledge</b> 47:17 47:19 48:8,22 49:4,20 51:9 68:14 80:16 83:5 86:19 121:10 131:8,9 156:21 170:1 177:8 193:15 209:14,18 408:7 <b>known</b> 102:15 168:8 177:1 316:12 321:11 404:5 <b>knows</b> 185:22 188:22 189:3 205:18 469:4 <b>kwilliams</b> 3:14	242:9 243:1,18,22 243:23 244:4,8,11 244:23 245:2 246:4,16 247:9,12 247:19 250:17 251:22 253:2,13 255:3,5,12,16 256:20 257:2,20 258:3,5,13,14,17 258:23 259:9,18 259:21,23 260:2 260:15,22 261:4 262:23 263:4 267:11,23 268:2 268:18 269:9,21 270:3 483:8,14,23 484:4,8,14,17 489:13 <b>labeling</b> 209:23 210:3,6 215:21 225:16 233:21 241:8 242:19 243:3 265:16 266:1 <b>laboratory</b> 212:8 437:16 <b>labs</b> 212:2,7,18 <b>lack</b> 21:17 120:10 237:17 243:3 329:23 330:7,8 346:19 371:4 467:4 <b>lambda</b> 2:13,19 <b>lambdalegal.com</b> 2:16,22 <b>lane</b> 9:1 10:8 471:7,13 491:6 492:19,20 <b>language</b> 59:18 74:9 78:2 112:1,3 194:22 228:1	331:1 335:3,5 385:4 386:12,14 457:2,4 458:16 <b>lapper</b> 9:10 <b>lappert</b> 1:20 4:13 4:15 5:7 8:12 9:19 11:5,14 22:18 34:12 57:4 60:11 60:14 64:9 137:23 138:11,16 139:3,6 140:5 255:21 464:20 468:23 472:10 475:11 481:6 483:7 491:1 491:12 493:5 494:2,24 495:2,4 495:12 <b>lappert's</b> 11:3 <b>lapse</b> 99:21 100:3 <b>lapsed</b> 100:11 <b>large</b> 9:3 95:12 121:3 290:16 342:23 348:12 349:8,19 404:6 475:9 479:4 <b>larger</b> 287:21 352:11 396:23 <b>largest</b> 376:7 425:11 429:17 433:13 474:21 <b>laser</b> 139:22,23 142:11 145:19 146:2,4 147:4 151:11 152:9,17 153:2 <b>lasted</b> 97:11 <b>late</b> 394:23 <b>lately</b> 19:19 412:23 <b>latest</b> 183:1 196:21	<b>law</b> 3:5 30:17 36:16 51:22 52:5 53:13 242:23 <b>lawsuit</b> 409:9 <b>lawsuits</b> 83:12 <b>lay</b> 45:20 218:17 <b>lays</b> 462:19 <b>lcb</b> 1:7 10:2 <b>lead</b> 133:4,7 272:9 273:3 389:3 <b>leader</b> 472:15 <b>leaders</b> 72:3 <b>leading</b> 270:18 329:5 381:17 <b>leads</b> 246:11 324:18 <b>learn</b> 425:14 457:4 458:16 <b>learned</b> 122:15 125:18 284:23 468:15 <b>learning</b> 70:1 <b>leave</b> 396:10 <b>leaves</b> 395:15 <b>left</b> 137:22 171:15 242:15 248:16 252:21 349:20 451:13 461:1 <b>legal</b> 2:13,19 10:6 10:9 83:8,19 99:12 493:23 <b>legislation</b> 77:11 109:15,21,22 110:7 117:6 <b>legislative</b> 54:16 77:2 78:7 110:18 113:15,17 <b>legislators</b> 54:8 76:7 <b>legislature</b> 4:18 57:10 58:15,21
<b>l</b>			
<b>l</b> 2:12 16:21 203:8 203:8,11 356:2 446:13 <b>lab</b> 211:11 <b>label</b> 5:15,16,22 6:1 119:5 205:13 205:16 206:4,8,10 207:1,3 216:5,13 216:19,22 217:12 217:16 218:2,7,18 218:22 219:6,20 219:23 220:3,15 220:19 221:17 222:2,4,16 226:2,6 226:23 228:17,19 229:21 230:23 231:23 232:9,16 233:13 234:17 236:4,14 237:5 238:2,14 239:5 240:2,10,16 241:3 241:12,20 242:2,6			

59:8,13 <b>legislatures</b> 76:16 113:8 <b>legs</b> 460:5,6 <b>length</b> 345:8 346:16 347:13 352:13 <b>lengthy</b> 159:6 <b>leon</b> 2:14 <b>lesser</b> 252:15 267:3 <b>letter</b> 6:5 135:16 136:9 263:20 265:22 <b>letters</b> 27:17 135:21 136:1,16 279:23 373:16 <b>level</b> 56:11 88:10 88:22 124:1,4,7,11 158:23 219:2,9,12 219:18 250:15 281:21,23 282:1 282:11 283:17,20 284:3,6,8,12,21 285:13,22 286:3 286:14 288:6,14 288:14,21 289:2,7 289:9,17,22 290:15,17 293:16 293:22,23 294:3,4 294:4,10 295:11 295:16 300:17 302:10,17,22 303:13,22,23 304:5,11,17 305:1 305:2,2,4,4 306:13 310:6 312:6,6 313:21,23 323:13 323:15 329:14 337:12 362:21 363:3,14,15 364:1	370:13,13,14,15 414:6 416:9 420:21 439:11 476:5 477:2 487:1 <b>levels</b> 6:6 212:19 212:23 287:23 299:20 300:21,22 301:7,11,13 303:19 312:17 313:19 314:14 319:10 324:16 414:3 <b>levine</b> 16:20,23 17:5,6 19:10 33:19,20 39:15,22 40:12 42:10,20 43:23 58:2,5 78:5 85:13,16 114:7 <b>lgbtq</b> 458:7 <b>liability</b> 67:11 <b>library</b> 415:3 <b>license</b> 265:1 <b>licensed</b> 153:20 <b>licensing</b> 30:16 <b>lie</b> 464:21 <b>lies</b> 284:2 <b>life</b> 67:2 68:9 71:11,14 119:22 152:13 156:3 182:2 244:19 290:2,17 311:5 314:2,7 322:13 359:4 450:18 468:13 469:17 490:7,17 <b>lifelong</b> 482:22 <b>lifesite</b> 464:14 <b>lifesitenews.com</b> 8:18 <b>lifetime</b> 220:14 286:23	<b>light</b> 97:15 139:22 140:14 145:17 181:15 259:19 260:2 328:15 <b>likelihood</b> 161:7,9 161:17 458:11 <b>likes</b> 72:2 434:5 <b>liking</b> 104:23 105:2 <b>limb</b> 475:3 477:5 <b>limit</b> 172:19 <b>limitation</b> 173:14 <b>limitations</b> 342:11 391:16 412:12 413:7,11,18 <b>limited</b> 29:9 66:5,5 66:7 68:13 96:21 143:15 148:15 152:5 267:8,9 306:6 413:12 431:13 <b>line</b> 30:2 237:23 264:13 320:17 494:4,7,10,13,16 494:19 <b>lines</b> 143:19 158:16 166:2 265:10 266:6 267:18 268:5,7,8 <b>lipoplasty</b> 142:12 <b>lips</b> 471:8 <b>lisa</b> 368:7,17,17 370:14 371:12 <b>list</b> 41:16 62:11 110:11,16 111:3 116:10 136:4,15 172:22 210:15 224:3 381:7 421:10 422:2 458:5	<b>listed</b> 112:19 133:1 135:20 372:23 380:2,2 423:14 441:11 480:7 <b>listen</b> 292:17 353:17 <b>listening</b> 261:16 <b>lists</b> 42:6 128:23 455:14 <b>literature</b> 12:21 13:8 45:9 46:19 47:20 50:3,8,11,12 51:2,12,17,19 69:13 72:14,16 86:20,22 89:8,12 89:14,15,19,20 117:22 124:13,14 127:10,12 129:15 135:12 161:4 177:2,3,16 185:3 185:14 186:2 187:2 191:12 194:6 198:6 205:4 228:11,20 247:4 247:22 250:10 260:3 268:19 270:17 274:13,20 283:22,23 297:12 313:3,5 329:1 336:3 337:21 338:2 343:20 346:12 353:18 356:13 358:11 368:6 370:23 410:4,7 414:1 416:12 439:5,11 439:20 441:13 443:6,7 473:15 480:23 483:4 485:19 486:23
---	--	--	--



487:6 488:21 <b>litigation</b> 90:15 176:20 <b>little</b> 15:5 16:14 93:12 97:2 101:20 142:20,23 340:3 358:2 442:5 467:21 <b>littman</b> 369:16 371:12 372:18 <b>littman's</b> 368:7,17 370:14 <b>live</b> 38:15,19 277:8 <b>lives</b> 66:17 <b>living</b> 71:11 <b>llc</b> 3:5 <b>llp</b> 10:16 <b>load</b> 339:22 <b>lobbied</b> 54:22 <b>local</b> 30:15 64:20 142:20 178:10 478:17 <b>located</b> 10:4 138:13 <b>loe</b> 301:8 <b>logo</b> 101:3 451:14 451:17 <b>long</b> 7:7 15:3,21 41:16 85:5 87:20 88:4 89:10 90:20 91:1 97:10 101:5 102:8 124:11 138:3,16 164:22 202:14 206:15 249:20 291:12 292:12 311:22 312:11 313:10 314:15,16 332:8 345:14 352:18 353:17 397:22 398:10 399:10	404:7 452:23 478:11 485:12 <b>longer</b> 24:8 47:2 122:7 125:7 165:3 166:3 296:23 352:20 <b>longitudinal</b> 124:12 219:13 249:19 281:17 291:12 292:13 299:4 311:9 <b>longitudinally</b> 250:1 <b>longstanding</b> 230:2 <b>look</b> 14:15 17:11 22:14 27:20 28:15 30:12 34:4 38:23 40:1,23 41:1 43:7 57:16 64:6,16 110:4 111:5,22 113:6 119:20 125:10 136:7 152:9 159:11 173:8 174:2 223:11 232:11,20 239:4,13 240:5,22 242:15 248:16 250:6 252:20 256:3,4 257:7,17 275:21,23 276:1,7 297:13 307:13,15 309:5 311:23 312:21 313:11 314:14 317:7 322:15 323:19 326:17,17 330:11 337:10,14 344:8 344:11,23 345:20 347:4 356:7,17 360:3,23 363:17	383:6 391:19 394:13 396:5 405:11 411:1,15 422:10 428:10 429:6 430:22 439:5 440:18 458:18 465:22,22 <b>looked</b> 201:23 202:5 277:2 345:14 358:7 <b>looking</b> 106:6 107:3 110:15 160:20 173:20 176:15 202:13 219:12 249:22 282:10 284:1 301:2 311:8 313:5 337:3 344:6 345:19 347:7 356:9 363:21,22 364:3,9 379:1 445:16 <b>lookout</b> 463:18 <b>looks</b> 263:20 304:23 305:3 341:2 453:16 <b>lose</b> 170:5 <b>losing</b> 325:17 <b>loss</b> 178:15 287:17 348:12 349:7 <b>lost</b> 95:22 297:11 <b>lot</b> 24:3 36:9 56:6 56:7 96:12 104:4 105:9 108:2 143:3 143:11 144:7 148:7,10 165:11 252:4 298:21 346:12 351:21 380:21,22 412:11 <b>low</b> 120:9 206:19 218:8 219:5	222:14,17,21 270:15 285:5 287:23 288:6 295:21 310:8 327:1 329:13,14 381:19 482:5 484:9,13 <b>lower</b> 309:8 314:18,19,19 354:2 358:12 414:2 <b>lowest</b> 252:11,17 283:7 284:9 323:13,15 482:19 <b>lpa</b> 1:7 10:2 <b>luminaries</b> 310:19 <b>lump</b> 156:6 <b>lunch</b> 97:15 255:2 <b>lupron</b> 201:5,13 201:15 202:6 205:11 <b>m</b> <b>m</b> 16:16 20:23 360:10 422:5 445:6 <b>m.d.</b> 1:20 9:10 11:5 57:4 58:2,9 60:11 493:5 494:2 494:24 495:2,4,12 <b>madison</b> 138:12 138:18,19,21 139:7 140:10 <b>mail</b> 59:1,3,4 98:11,16 <b>main</b> 23:22 338:21 455:15 <b>maintain</b> 24:7 195:7 234:2 236:23 455:3 <b>maintained</b> 21:2
--	--	--	--

<b>maintaining</b> 23:23 24:9 <b>major</b> 40:2,16 95:11 210:22 215:10 478:8 487:2 <b>majority</b> 330:17 335:19 456:23 <b>maker</b> 131:3 <b>making</b> 6:21 45:16 53:23 121:11 131:20 177:9 236:8 248:19 250:12 261:18 275:9 356:3 357:5 360:21 380:8 381:9 382:3 398:15 444:12 452:5 470:6 485:1 487:8 488:6 <b>male</b> 6:12 148:15 322:23 323:3 341:22 348:13 349:9 390:7,8 456:3 457:16 488:7 <b>males</b> 488:10,11 <b>malignancies</b> 479:3 481:4 <b>malignancy</b> 144:10 <b>malignant</b> 44:17 <b>malleable</b> 336:19 <b>malpractice</b> 66:23 316:2 <b>man</b> 71:9 95:21 456:14 <b>man's</b> 71:20 <b>manage</b> 53:8 67:10 112:14 145:14,19	<b>manageable</b> 310:8 <b>management</b> 145:22 147:4 213:11 272:20 473:11,12,13 479:2 <b>managerial</b> 432:17 <b>managers</b> 54:2 <b>managing</b> 53:16 178:18,18,19 <b>mandate</b> 27:22 <b>mandatory</b> 173:3 <b>manipulated</b> 367:15 368:1 370:10,20 <b>manner</b> 234:8,23 <b>manufacturer</b> 264:7 <b>march</b> 377:13 379:6 380:18 381:9 424:8 <b>marginal</b> 267:10 <b>mark</b> 67:7 72:2 381:1 <b>marked</b> 4:12 12:6 27:9 34:7 37:23 55:9 62:19 108:7 116:2 127:17 171:7 223:18 230:14 232:23 239:16 256:15 263:10 299:15 326:2 339:18 355:18 361:11 375:16 388:20 394:9 396:20 411:4 414:22 419:17 427:1 430:9 434:10 451:5 463:5	<b>market</b> 229:1 267:7 <b>marketed</b> 5:18 221:7 233:14 234:7 <b>marketing</b> 225:13 <b>marks</b> 21:12 <b>maryland</b> 474:13 <b>masculine</b> 130:16 <b>masculinization</b> 167:8 175:5 <b>massive</b> 60:1 217:15 477:5 478:5 <b>mastectomy</b> 134:7 480:16 <b>match</b> 334:2 <b>matched</b> 378:16 <b>material</b> 131:13 <b>materials</b> 275:23 331:22 <b>matter</b> 9:21 10:19 16:9 34:22 88:19 96:13 105:3 117:21 208:12 <b>matters</b> 68:12 83:21 473:2 <b>matured</b> 249:22 317:12 <b>maxwell</b> 1:9 <b>mccaleb</b> 80:11 <b>mcdermott</b> 2:7 10:15 <b>mchugh</b> 16:15 19:11 58:9,11 78:6 85:20 <b>mchugh's</b> 18:8,11 <b>mckeown</b> 444:21 445:14 <b>md</b> 22:18	<b>mean</b> 66:8 88:19 92:19 179:23 217:18 225:20,23 230:6 236:14,16 242:21 251:8 266:18 336:22 355:1 358:21 459:8 461:6 <b>meaning</b> 122:10 122:13 403:14,15 432:13,15 459:18 <b>meaningless</b> 404:12 <b>means</b> 29:5,18 30:21 117:1 173:2 173:6 228:13 242:23 440:6 447:9 462:4,10 466:22 492:6 <b>meant</b> 50:23 <b>measure</b> 63:22 235:10 331:19 <b>measured</b> 328:23 334:12 <b>measures</b> 331:13 332:12 333:2 334:13 <b>measuring</b> 300:16 332:1 333:13,18 334:4 <b>mechanism</b> 195:2 372:22 <b>media</b> 9:18 79:3,7 166:16,20 254:15 254:19 320:2,6 367:16 368:21 373:1,2 388:7,11 470:12,16 491:9 <b>median</b> 347:9 <b>medic</b> 240:11 438:1
---	---	---	--



<b>medical</b> 5:19 7:5 8:6,9 13:3 39:5 40:2,16 41:3,17 42:6,16 43:22 45:14 46:23 52:1 54:2,10 64:23 65:8,15 86:13,19 86:21 104:14 112:8 114:1 115:18 122:5 128:19 129:4 144:16 159:15 161:18 194:14 208:9,21 215:14 223:6,8 225:11 226:14 228:10,20 231:19 233:15 234:2 248:3 271:21 272:19 274:20 280:10 296:7 327:14 342:6 363:19 369:13 373:20 376:12 378:20 379:3,5 380:16 384:7 385:5,8 386:13,19 402:1 402:19 406:5 410:7 418:16,23 419:10 421:3 422:16 424:16,17 430:13 432:17 434:19 436:13,14 436:17,17 438:23 444:11 447:15,18 448:2 449:19 450:3,5 459:5,9,20 469:22 470:7 473:7 474:21 479:14 482:4 483:4 485:1,16,19	485:20 486:3 487:15,21 488:5 <b>medically</b> 40:5,19 41:19 44:2 103:8 105:13 107:13,20 111:7,19 112:5 113:9,20 114:10 144:5 231:12 232:1 374:5,11,12 374:18 375:2,8 383:9 384:6,23 385:14 387:4,7,15 387:17 388:1 422:6,7,15 423:7 424:11 425:18 426:15 427:19 428:2,6,14,22 429:9,21 430:23 431:17,20 432:8 432:13,14,18,21 433:4,20 435:17 435:23 436:11,19 438:1,15,20 473:17 <b>medication</b> 6:1 235:8 256:20 258:5 <b>medications</b> 63:13 145:18 220:16 240:11 253:2 258:4 437:15 438:1 484:9,14 <b>medicine</b> 64:18 79:22 81:2 82:4 89:6 132:11 151:22 234:9 249:1 412:17 444:18 454:6 460:9,15 469:16 <b>medicines</b> 226:11	<b>mediterranean</b> 474:11 <b>meet</b> 14:7 95:6 163:7 387:9,11 417:20 428:16 429:1 <b>meeting</b> 84:15,17 84:21 85:10,11,14 85:18 86:1,5,6,8 89:1 90:14 91:6 91:10,15 93:3,10 93:21 94:9,15 95:1,2,3 96:2,16 97:1,8,11,20 98:4 103:18 222:9 <b>meetings</b> 14:13 80:1 84:1,3,6 98:5 102:9 153:4,10 165:10 188:5,10 192:6,13 200:1,8 418:7,13,15,19 419:2,6,12 <b>member</b> 45:2 46:22 48:11 49:8 65:7 99:19 100:4 101:12 169:17,18 171:19 190:8 296:23 <b>members</b> 48:18 93:23 102:14,15 103:7 105:18,21 169:13 170:14 171:1 172:11,21 173:9 180:22 181:10 189:4 190:21 193:2,7 194:15 296:14 297:3 365:1 <b>membership</b> 45:17,22 46:4,14 99:20 100:3,9,11	100:12,22 101:1,3 101:22 102:4 108:3 177:12 <b>memorable</b> 478:3 <b>memory</b> 56:9 332:8 400:8 <b>men</b> 67:9 214:6 <b>mental</b> 40:7 65:11 66:4 74:17 75:9 75:14,18,22 111:13 149:15 153:20 154:1,12 155:8,12,14 157:7 157:10 418:8 486:18 <b>mention</b> 66:23 68:18 118:9 335:23 412:10 <b>mentioned</b> 14:1 15:15 20:10 72:9 97:18 213:21 219:22 290:21 393:23 <b>mentioning</b> 335:17 <b>merely</b> 46:19 283:19 307:11 338:12 343:15 <b>merited</b> 293:7 <b>message</b> 163:11 <b>met</b> 14:2 17:1,6 85:15,19 94:23 95:1 96:1 292:11 356:22 385:2 386:23 401:15 427:20 435:15 <b>meta</b> 307:19 <b>metaanalyses</b> 302:18 <b>meter</b> 86:10
--	--	---	--

<b>methodo</b> 120:6	406:13	<b>modeled</b> 368:21	<b>morally</b> 467:8,11
<b>methodological</b> 482:6	<b>minus</b> 44:10	<b>modeling</b> 367:16 373:3	<b>morbidity</b> 393:20
<b>methodologically</b> 120:7	<b>minute</b> 27:7 115:8 210:21 272:4 397:1 471:19	<b>moderate</b> 265:9 266:5 267:17	<b>morbidity</b> 392:18 393:1
<b>methodology</b> 309:11 352:4	<b>misconduct</b> 118:5 118:17 120:12 121:7 126:12 127:6	<b>modern</b> 149:9	<b>morning</b> 9:15 11:10,11 97:15
<b>methods</b> 257:7 276:1 331:22 411:18	<b>misdiagnosed</b> 328:20	<b>modification</b> 71:10 75:2 130:11	<b>morph</b> 88:5
<b>metoidioplasty</b> 168:4 175:16 316:8 478:16	<b>misdiagnosis</b> 328:23 329:19	<b>modified</b> 134:7 236:10	<b>mortality</b> 334:20 392:18 393:2
<b>metric</b> 301:8,10 331:18	<b>misgender</b> 448:7 449:3	<b>modify</b> 66:14,22	<b>mother</b> 93:22
<b>metrics</b> 331:1	<b>misgendering</b> 447:5,9 448:17,21 488:1	<b>mohs</b> 143:4	<b>motivated</b> 398:2
<b>mi</b> 476:12	<b>misinforming</b> 487:19	<b>mol</b> 86:7	<b>motivators</b> 67:17
<b>microvascular</b> 178:2 475:5 476:12	<b>misinterpreted</b> 276:20 277:3	<b>moment</b> 91:12 111:22 264:3 273:14 340:22 384:10	<b>move</b> 186:21 194:21 319:20 347:15 370:4 464:8
<b>mid</b> 161:8 310:14	<b>mislead</b> 172:20	<b>moment's</b> 92:4	<b>moved</b> 256:1 262:17
<b>middle</b> 1:2 9:23 27:16 224:16	<b>misleading</b> 172:14 172:20	<b>momentarily</b> 339:23	<b>movement</b> 467:16 473:3
<b>midwest</b> 95:12	<b>misrepresentation</b> 60:1	<b>moments</b> 467:12	<b>movements</b> 317:11
<b>military</b> 136:22 137:2,5,11,17,22 474:2 476:4,6 477:8	<b>misrepresents</b> 30:14	<b>money</b> 24:6 386:6 386:8	<b>moving</b> 54:6 114:19 207:6 471:8
<b>milton</b> 106:8 125:7	<b>missing</b> 273:16 340:3 346:4	<b>monitor</b> 437:16	<b>mucocoele</b> 133:12 133:14,14
<b>mind</b> 184:23 439:14	<b>mississippi</b> 111:2	<b>monitored</b> 211:11 211:16,17,18 213:5,17	<b>mucosal</b> 478:17
<b>mine</b> 67:7 87:21	<b>missouri</b> 111:2	<b>monitoring</b> 211:20 217:23	<b>multidisciplinary</b> 149:11 150:4,14
<b>minimum</b> 245:15 401:15	<b>mistake</b> 128:10 138:20	<b>montana</b> 111:1	<b>multiple</b> 308:21 335:18 469:12
<b>minor</b> 407:1 445:20,22 449:6	<b>misunderstanding</b> 44:7 45:12	<b>month</b> 25:7 84:12 141:15	<b>murky</b> 97:2 101:20
<b>minors</b> 4:22 7:13 40:5 54:11 55:14 57:12 63:2,14 78:19 84:23 405:8	<b>misunderstood</b> 293:3	<b>monthly</b> 296:10	<b>muscle</b> 265:11 266:15,19 267:18 483:9,9,15
	<b>model</b> 135:11 439:3	<b>months</b> 110:6 141:22 166:1 325:10 351:21	<b>muscles</b> 263:3 266:13,14,15 267:1,1
		<b>moody</b> 38:4	
		<b>moral</b> 81:5,12,12 82:18,19,23 92:10 151:22 464:22 466:3,14 467:5	

<b>mute</b> 105:17 471:7 <b>mutilation</b> 60:5,17 60:22 <b>mwe.com</b> 2:10	<b>naval</b> 473:23 <b>navy</b> 130:20 139:19 472:18 475:13 476:9  <b>nc</b> 7:5 <b>near</b> 59:15 377:11 394:16 421:21 <b>nearly</b> 107:2 336:16 358:7 <b>nebraska</b> 138:15 <b>necessarily</b> 234:18 236:16,20 242:20 286:7 464:1 <b>necessary</b> 24:8 40:6,19 103:9 105:13 107:13,21 111:7 113:9,20 114:10 285:11 310:4 374:5,11,13 374:18 375:3,8 383:9 385:1,15 387:4,8,15,18 388:2 422:7,7,16 423:7 424:11 425:19 426:16 427:19 428:2,6,15 428:23 429:10,21 430:23 431:17,20 432:8,13,15,19,21 433:4,20 435:18 435:23 436:11,20 438:2,15,20 495:6 <b>necessities</b> 423:14 <b>necessity</b> 49:15 114:2 115:18 199:8 236:8,18 237:14 385:6 386:13 421:4 422:16 449:18 <b>neck</b> 156:6 292:5 292:11 468:2	<b>necrosis</b> 178:16 <b>need</b> 36:7 90:14 106:12 126:16,17 134:8 143:14 290:14 292:17 310:5 358:18,20 363:1 458:16 <b>needed</b> 142:22 143:14 195:3 212:20 414:5 <b>needs</b> 363:5 <b>neither</b> 253:2 404:9 409:23 492:15 <b>netherlands</b> 342:16 343:3 <b>network</b> 373:1 <b>networks</b> 368:20 369:20 371:23 <b>neurologic</b> 121:21 <b>neurophysiologi...</b> 317:10 <b>neurosurgical</b> 272:17 <b>neurotized</b> 468:3 476:12 <b>never</b> 16:18 17:6 45:1,4 91:11,12 148:6 149:2 150:3 150:22 151:1 152:2,6,20 153:3,9 157:17,22 167:3 167:10,16,23 168:3,7,11 169:1 170:1 176:1 178:21,23 182:3 183:15,17,19,21 183:23 197:5,8 201:15,17,18 204:16 207:11,15 214:10 233:11	272:9 273:23 274:4 278:1,4 284:23 306:23 310:3,3 402:18 418:3 447:3 467:17 468:4 <b>new</b> 2:9,9,21,21 105:20,22,23 111:1 228:23 234:10 235:7 262:17 284:20 289:15 295:1 296:14 368:9,11 369:8,21 382:18 394:19 419:14 457:4 <b>newer</b> 311:19,20 <b>nice</b> 237:23 <b>night</b> 15:4 <b>nine</b> 184:23 <b>nineteen</b> 32:6 <b>ninety</b> 262:18 <b>nobody's</b> 322:14 <b>nodule</b> 156:9,12 <b>non</b> 348:4 349:2 351:14,16 402:13 415:13 <b>noncontrolled</b> 416:3 <b>nonexperimental</b> 286:6 288:12,21 293:12 428:3 <b>nonresponsive</b> 186:22 <b>nonsatisfaction</b> 331:20 <b>nonsurgical</b> 144:7 <b>normal</b> 71:18 114:20 205:19 212:3 460:1
---	--	---	--

<b>normalizing</b> 460:3	431:12 448:5	117:18 118:6,20	286:20 288:15
<b>north</b> 1:2 3:12,13	485:14	120:20 126:13	293:13 294:20
9:23 10:19,22	<b>numbered</b> 171:23	127:7 128:15	295:12,18 297:19
11:1 375:20 376:8	<b>numbers</b> 259:12	135:18 136:18	298:5,14 303:9
379:15,19 420:14	303:15 328:11,13	137:13 148:2	305:11 307:6
424:8 425:5	342:23 368:4	149:14,18 151:14	308:1 311:18
474:12	<b>numerous</b> 229:14	154:3 155:16	318:4 324:2
<b>northwest</b> 62:8	<b>nyu</b> 306:11	157:12 158:7,11	333:15 342:20
<b>nose</b> 71:10,13	<b>o</b>	162:17 163:2,14	352:7 357:23
<b>notary</b> 9:2,3	<b>o</b> 203:4,8 277:14	166:12 173:5	359:2 362:3,19
495:13,19	277:14 322:18	175:1,7,12,14,17	364:7 371:8 374:8
<b>note</b> 303:16	356:2 360:9,9,10	175:23 176:11	376:10 381:11
351:18 358:3,6	414:15 445:6	179:5,10,18 180:9	383:2 385:17
392:6 473:19	446:12	180:16 181:2,13	387:6,16 395:13
493:10	<b>oath</b> 254:23	184:20 186:19	399:22 406:15
<b>noted</b> 56:21 120:9	<b>object</b> 44:5 119:4	187:4,14,20	407:6 408:14
371:14 495:7	253:17	188:12 190:18,23	409:10,16,22
<b>notice</b> 92:4 224:22	<b>objection</b> 21:14,20	191:4,10,15,21	410:13 412:14
<b>noticed</b> 338:7	22:5,12 26:6,21	192:3,10,23 193:6	413:20 416:1,6
<b>notices</b> 224:10	28:13 29:7,15,19	193:9,17 198:9,23	424:5,12,23
<b>notify</b> 30:15	30:1,22 31:4	199:15,21 200:5	425:20 426:3,17
<b>november</b> 5:12	32:14,21 36:13	200:10,16 204:14	428:4 429:3,11,22
25:9 224:14	37:2,5 39:18	204:22 206:7	431:19 432:10
<b>number</b> 6:16	40:21 41:21 42:12	207:16,21 208:18	436:1 438:4,17
17:11 61:18 103:3	47:6,16 48:7	211:13 212:5,21	439:7 440:14,17
120:22 121:2,3	49:23 50:6 51:15	215:3 216:1 217:3	441:10 442:16
125:17 147:13	52:6,14,19 53:1	217:8 222:5	443:15,21 446:19
160:4 164:2 173:9	54:13 55:3 57:14	225:22 226:19	447:1,12 448:19
184:22 197:23	58:17 62:1 65:17	227:19 228:15	449:10 451:19
213:4 241:7 246:8	65:20 73:14 74:19	229:22 232:7	453:21 454:12,18
255:8 283:7 285:7	76:18 77:13 78:8	234:20 236:6	455:12 458:2
320:18 321:3,10	78:20 80:2 81:8	237:6 238:4,9	459:11 460:20
321:20 322:4	81:12 83:6,15	239:11 240:19	461:18 462:6,12
328:7 330:2 331:4	88:17 89:3 90:17	242:4,12 243:13	465:6 469:8
331:5 352:11,16	91:16 92:17 96:18	244:6 245:11,17	<b>objections</b> 81:5,13
352:22 354:8,10	97:12,23 98:8	251:4 252:7 259:2	95:17 126:17,18
354:13 358:15	99:8 102:12	266:7 267:21	160:14
360:14 366:22	103:10 107:22	269:1,7 270:6,12	<b>objective</b> 81:13,22
367:5,13,22 370:8	110:3 111:20	273:10 274:9	82:8,19,22 257:1
375:10 377:19	112:23 113:21	275:14 280:22	331:8 334:13
401:21 405:11	114:11 117:3,10	281:1 285:16	336:6 409:14

436:16 444:14 447:16 448:2 449:18 460:11 486:5 <b>objectively</b> 71:17 436:7 <b>obligation</b> 288:2 <b>obliged</b> 447:16 <b>obliges</b> 468:6 <b>observable</b> 317:3 <b>observational</b> 258:6 411:20 413:14 414:6 <b>observations</b> 229:3 <b>obtain</b> 149:3 <b>obtainable</b> 309:11 <b>obtaining</b> 119:7 402:17 <b>obviate</b> 199:4 <b>obvious</b> 75:3 310:1 317:14,19 <b>obviously</b> 131:2 235:16 238:7 244:3 273:3 309:21 310:2 322:3 323:7 362:1 379:10,13 418:6 <b>occasion</b> 144:23 211:5 <b>occasions</b> 229:14 <b>occur</b> 136:3 <b>occurring</b> 335:16 492:12 <b>october</b> 264:17 266:6 267:19 493:3 <b>offending</b> 449:22 <b>offer</b> 12:10 65:16 66:11,21 72:4,5 176:18 177:19,20	181:5 205:22,23 208:23 488:13 <b>offered</b> 35:9 39:12 39:16 67:6 68:17 77:6 89:9,11 112:17 140:15 159:8 238:12,16 238:18,22 <b>offering</b> 34:17,18 36:10,11 39:22 40:12 42:11,20 88:15 107:6 114:7 118:12 122:14 123:10 130:14 140:20 150:11,15 154:23 159:17 176:7 179:2,9,17 180:7,22 181:10 204:9 285:23 322:3 398:21 447:15 <b>offers</b> 454:8 <b>office</b> 3:5 138:11 138:18,19,21,22 138:23 140:10,13 142:7,13 159:6 211:5 472:17 473:1 <b>official</b> 224:7 230:18 232:18 296:4 <b>oftentimes</b> 132:13 149:21 245:23 249:14 479:1 <b>ogonzalez</b> 2:22 <b>oh</b> 19:13 80:22 95:3 108:22,22 135:4 146:12 170:9 171:23 202:17,22 212:6 268:10 269:14,20	288:16 292:20 293:2 340:1 397:15 420:4 421:15 434:13 445:16 446:10 471:11 <b>ohio</b> 96:7 <b>okay</b> 12:8 14:5 16:3 17:23 18:17 19:6 21:17 22:14 26:10 27:5 31:1,6 31:10 36:1 37:20 38:3 39:2 43:7,9 43:11 56:18 57:2 62:12,17 63:10 64:5,15 78:16 80:15 93:2 97:6 98:5,21 99:15 102:7 108:9,9 109:11 111:4,22 114:15 116:18 119:17 126:22 133:19 135:4,13 136:20 143:13,18 143:19,23 144:21 145:7 146:14 147:3,14 149:9 151:3 154:9 155:3 165:6 166:6,13 170:17 171:6,9,11 173:2 174:2,4,10 174:12,16 179:23 185:2 189:6,14 197:2 199:10 201:1 202:8 203:7 207:10 212:15 213:15,21 215:17 220:10 221:2 223:11,13,15,20 225:3 230:10,16 231:3 233:12,18	239:13,18 240:7 241:1,11 242:14 242:17 248:9,11 248:15,17 252:23 254:7 256:5 257:18 259:13 261:18 264:11,21 269:14,17 272:6 273:23 277:19 278:16 279:19,21 279:21 285:10 288:16 289:2 294:15 295:23 299:17 302:5,6 303:22 304:8 307:14 308:5,7 315:9 316:17 318:6,19,21 320:10,12,17 323:6 325:3,15,21 325:22 326:4,4,5,8 326:19 330:12,15 332:9,11,16 335:13 339:12 340:6,8,22 341:11 344:10,23 345:3,3 347:16,21 349:10 349:14,21 350:15 350:20 353:12,15 354:11 355:17,20 355:22 359:8,10 359:23 360:2 361:2,3,9,13 364:14 367:6,7,9 372:17 373:12 375:12,13,18,19 377:9 378:5 383:12,12,18 384:9,13,17 386:8 388:5,16,18,22,23 389:11,14 391:21
--	---	---	---

393:22 394:5,11 394:15 396:7,14 396:22 397:2,3,7 397:15,16 399:5 399:11,12,14 400:15 401:5,7 404:20 405:1,6,13 405:13 408:5,5,16 410:21 411:6,6,7 414:18 415:1,2,7 415:10 419:14,16 419:21 420:7,10 420:10,17 421:2,8 421:19 422:13 423:4 425:4 426:6 426:12,22 427:3 428:8,9,11,21 429:14 430:5,11 430:11 433:2 434:14,16 435:7 435:13,21 437:6 440:1,2 441:1,1 442:4 445:7,17 446:5 450:12 451:7,9 452:21 453:11 455:18,20 455:22 459:1,13 460:23,23 463:3 464:12 465:9,22 466:1 468:19,21 469:10 470:8 471:1 472:1,13 474:3 479:21 480:1 488:17 489:8,12 490:21 490:23 <b>oklahoma</b> 111:1 <b>old</b> 7:20 67:8 342:22 344:6 380:11,19 381:5 411:10	<b>older</b> 196:18 <b>oldest</b> 134:11 <b>omar</b> 2:18 <b>once</b> 225:12 231:9 288:21 <b>one's</b> 69:6 133:10 233:13 340:3 <b>ones</b> 13:5,21 142:6 <b>ongoing</b> 69:5,8 <b>online</b> 296:12 297:8 364:10 368:20,21 369:20 408:9 453:16 <b>onset</b> 394:23,23 405:16 <b>op</b> 76:3,15 <b>open</b> 12:4 105:20 106:1 355:17 <b>opening</b> 138:7 171:10 <b>operate</b> 130:9 138:6 <b>operated</b> 138:3 <b>operating</b> 123:21 <b>operation</b> 8:15 106:13 123:11 148:10,12,17 176:19 178:21 289:20 293:7 299:1 334:1 464:15 467:16 478:13 <b>operations</b> 60:2 122:3 168:23 169:3 177:5,7,15 178:7,13,14 292:9 312:17 467:4 476:13,17 477:5 478:12,16,18 479:8,14,17,19 480:19	<b>operatory</b> 140:9 <b>opinion</b> 13:22 35:8 42:4 44:11 45:10 67:23 81:1 88:20 88:21 95:23 117:20,20 120:15 126:9 127:2 176:13,17 177:17 177:20 183:21 194:14 217:11,14 238:22 243:20 249:6 259:14 260:19 261:11 275:1,4 289:4 374:3,15,23 375:5 395:9 410:2 443:5 443:5 444:14,18 481:13,17 482:3,7 482:10,14 <b>opinions</b> 12:10 22:9 34:16,18 35:21 36:3,9,11 39:11,15,21 40:11 42:9,19 44:8,12 45:21 65:16 78:17 88:15 111:18 112:17,21 114:6 118:11 124:3 170:19,22 176:7 177:21 179:3,9,17 181:11 196:23 204:10 221:15 222:1 232:11 238:13 239:3 259:5 322:4 343:18 395:6 409:21 449:19,20 483:1 <b>oppose</b> 117:5 <b>opposed</b> 136:1	<b>opposing</b> 116:19 <b>optional</b> 173:3 <b>options</b> 153:12 165:23 <b>oral</b> 9:11 476:22 <b>order</b> 4:16 15:15 24:2 37:15 38:4 40:16 60:6 66:15 100:4 129:19 155:21 195:5 199:3 209:3 218:5 287:7,21 288:11 292:3 294:4 347:5 401:12 417:2 457:5 460:2 <b>ordinary</b> 145:22 <b>organization</b> 42:16,22 79:10 83:4,8 102:11,20 103:12 104:11 107:18,19 111:17 118:1 177:14 179:14,15 207:7 371:15 454:8 <b>organizations</b> 41:4 41:17 42:3,7 43:22 47:10 49:19 49:21 53:15 54:21 83:20 112:2,18 481:9 <b>organized</b> 84:4 <b>organs</b> 120:1 <b>orgasmic</b> 333:3 <b>origin</b> 369:15 <b>original</b> 129:14 135:15 136:2,17 197:13 200:14 227:16 323:3 338:11 <b>originally</b> 23:3 69:7
--	---	--	---



<b>originated</b> 19:22 19:23 <b>orthopedic</b> 291:17 291:22 292:4,10 <b>orthopedics</b> 460:15 <b>outbreaks</b> 368:19 368:23 369:21 <b>outcome</b> 287:10 399:10 480:20 <b>outcomes</b> 7:18 89:10 90:10 287:20 326:23 332:11 334:21 398:10 404:8 411:8 413:13 <b>outer</b> 129:21 <b>outlaw</b> 63:13 <b>outright</b> 44:22 <b>outside</b> 52:22 61:20 69:15 74:13 75:10 86:3 152:17 155:20 156:16 187:8 198:12,14 198:19 199:4,9 204:11 208:10 215:23 216:14 226:16 271:3 278:16 279:12 353:1,4,9 418:23 419:10 441:22 <b>outward</b> 67:23 271:15,22 309:18 <b>overall</b> 82:5 92:6 111:13 255:6 258:12 321:19 326:23 333:5 <b>overlap</b> 34:16,23 36:9 <b>overlooked</b> 134:22 377:20	<b>overreaching</b> 105:15 <b>overrepresentation</b> 67:13 <b>oversight</b> 221:12 <b>overview</b> 441:7 <b>overwhelm</b> 210:19 <b>overwhelming</b> 241:6 <p style="text-align: center;"><b>p</b></p> <b>p</b> 2:1,1 20:23 55:20,20,20 182:13 203:4 340:15 360:9,10 <b>p.m.</b> 254:16,20 320:3,7 388:8,12 417:12,15 470:13 470:17 472:7 491:10,15 <b>pablo</b> 360:7 <b>pace</b> 54:6 <b>package</b> 202:1,2,6 206:2 209:6,8 210:14,16 215:11 <b>packet</b> 77:8,12 <b>pagan</b> 2:18,22 <b>page</b> 4:3 22:14 25:23 27:13,14,16 28:16 29:8 30:12 31:9 34:11 35:1 35:11 36:1 38:21 40:23 41:14 43:10 56:15,19 57:1,3,17 58:1 59:14 64:4 64:14 108:10 110:4 111:7 115:4 119:18 127:19 128:7,17,18,22 143:17 158:13,15 171:21,22 172:2,3 174:3 224:16	225:2 231:2 240:6 242:13 248:13 252:22 264:10,20 279:20 300:2 302:5 308:5 320:11 322:16 326:11,14 330:10 330:10,14 332:15 332:17,21 337:2,5 337:6 341:17 347:19 349:15,17 349:18,19 359:13 364:13 367:8,11 373:13 375:19 378:5,14,15,15 382:11 383:10,11 383:12,14 384:9 384:16,18 391:13 394:13 397:6,11 397:12,13,14,16 399:11,13,13 401:5,6,6 405:2,7 407:8 410:9 411:16 413:6 415:6 419:19,21 420:5 421:7,12,13 421:17,18 422:11 422:12 428:8,10 430:21 435:9,12 437:5 440:1 445:2 445:11,13,19 446:2,8 451:8 452:19,20 453:3 453:10 455:18 465:8,23 494:4,7 494:10,13,16,19 <b>pages</b> 36:6 <b>pain</b> 292:5,11 <b>pancreatitis</b> 134:14 135:10	<b>panel</b> 378:17 380:15 <b>panels</b> 218:11 <b>paper</b> 130:8,18 131:22 132:2,17 134:23 135:10 306:12 355:15,15 371:21 439:13 <b>papers</b> 72:21 74:4 185:7 305:21 337:20 <b>paragraph</b> 27:20 35:12,15 38:8 39:1,4 41:1 43:12 59:23 63:10 64:6 64:16 65:6 108:20 110:5 116:6 119:21 158:16 172:10 225:9 233:19 242:16 252:21 264:22 265:5 308:9 320:13 359:17 364:15 367:10 391:20 428:12 429:7 430:22 435:14 437:11 445:13 465:23 <b>paragraphs</b> 468:18 <b>parent</b> 409:6 <b>parental</b> 367:17 <b>parentheses</b> 320:21 <b>parents</b> 97:19 160:7,23 162:1,3,7 163:5,18 165:5,20 166:7 209:2 402:2 402:22 403:3,9 404:17
---	--	--	--

<b>part</b> 27:2 37:14 44:6 50:13 67:19 87:23 102:7,13,23 112:11 120:4 150:4 174:16 183:13,15,17 185:4 187:3,13,18 188:13 191:13 192:21 194:11 195:6 197:2,5 199:12 235:6 272:21 274:11 275:15,22 328:4 342:5 363:20,20 370:22,22 372:17 403:14 404:11 423:5 453:17 473:10,11,12 <b>participant</b> 315:17 <b>participants</b> 92:21 96:15 273:4 <b>participate</b> 91:8 150:13 <b>particular</b> 27:1 80:6,7 89:11 103:13 105:22 108:20 124:5,5 145:20 160:15,16 168:23 173:16 174:18 177:4 185:6,15 186:4 209:10,11,15,16 210:10,10 212:17 215:8,12 221:7,8 236:10 238:17 243:10 244:10,10 250:20 259:16 260:1,2 263:22 284:15 288:12 293:11 294:14 297:9 309:15	310:9 313:19 321:9,10 332:9 358:12 363:3 366:7 374:13 439:16,18 440:19 440:19 455:5,6 459:17 463:13,15 473:6 <b>particularly</b> 51:2 104:19 131:19 142:15 146:18 162:8 249:12 260:16 319:10 328:15 332:4 401:23 403:22 454:23 <b>particulars</b> 90:9 99:11 <b>parties</b> 199:4 492:16 <b>parts</b> 289:21 <b>party</b> 195:6 <b>pass</b> 76:16 <b>passed</b> 54:23 <b>passing</b> 52:22 61:20 <b>pastors</b> 452:1 <b>patch</b> 133:20 136:12 <b>pathologies</b> 144:2 144:2,7,8 145:2,8 146:9 <b>pathologize</b> 194:11,22 195:7 <b>pathology</b> 156:15 194:20 <b>patient</b> 6:22 12:19 13:2 60:4 61:4 68:8 70:13 71:16 74:23 82:22 112:12 120:13	123:12 124:10 130:23 145:6 149:2,22 150:5,22 151:1 152:3,6,14 153:5,6,10 154:9 154:11 155:4 156:17 157:1,6 160:16 162:2 167:5,11,17,21 168:1,5,9 175:22 194:18 207:14 208:6 209:11 210:9,19,20,23 215:13 217:7,19 217:20,22 225:15 231:13 241:13 246:4 248:22 257:21 258:11 261:6 271:16,23 280:1,7,14 285:19 285:20 286:13 287:6,6,19 288:2 290:2,4,5 295:4 309:22 310:7 311:2,4 312:23 314:8,11,16 315:4 315:11,12 317:5 323:17,22 328:6 330:1,4 333:7 353:1,9,20 355:7 355:10 356:4,13 356:21 357:3,9 359:7 374:14 447:20 448:1 478:3 482:23 484:10,16 485:4 486:11 487:3 488:3 <b>patient's</b> 253:9,14 310:18 467:17 486:6 487:19	<b>patients</b> 51:5 67:1 67:14 68:15,18,22 80:18 81:3 111:10 120:4 131:12 136:21 137:19 142:22 143:5 145:1,10,11,23 146:2,7,7,21 147:11,16,17,20 148:20 150:11 154:21 155:12 162:13 168:13,18 169:1 179:2 195:3 204:20,23 207:19 208:13 209:21 211:9,20 212:13 212:16 213:6,11 213:17 214:15,22 214:23 226:6 232:1 237:3 249:13 251:21 257:4 258:12 260:2,18,21 261:13 283:15 286:1 313:8 314:6 316:18 320:19 321:3,17,20 322:23 326:22 328:2,7,12,14,20 330:18 331:15 335:15,19 336:16 337:8,16,23 341:9 343:2 350:17 351:10 352:12,14 352:21 357:17,21 358:23 360:14 363:8,10 367:13 368:11 369:1,6,22 372:12,14 389:23 390:14,19 391:2,7 404:4 407:1 448:3
--	---	---	--



448:6 450:1 457:23 473:3 474:19 485:15 486:16 <b>patrick</b> 1:20 9:10 9:19 11:5,14 22:18 34:12 57:4 60:11 64:9 464:19 491:12 493:5 494:2,24 495:2,4 495:12 <b>pattern</b> 134:21 <b>patterns</b> 6:2 256:21 <b>paul</b> 57:20 58:8 87:10 <b>pay</b> 195:6 297:9 297:13 379:11 387:10,11 <b>payers</b> 195:6 <b>paying</b> 385:23 386:7 <b>pdf</b> 330:10 332:17 397:13 399:13 401:5 405:2 419:19,21 421:7 421:13 422:11 <b>peace</b> 66:16 <b>peculiar</b> 178:10 210:23 <b>pediatric</b> 43:1,1 45:15 48:10,15,19 51:5 86:8 133:12 249:2,12 250:20 251:21 252:4 255:17 400:1 474:18 <b>pediatricians</b> 43:2 203:23 277:2 <b>pediatrics</b> 5:21 6:3 239:1,23 241:8	255:14 256:21 258:17 <b>peer</b> 20:18 128:18 129:4,14 187:11 274:1 296:7,18 331:12 361:23 362:6 364:3 367:15,21 368:19 368:20 369:19 370:7,17 373:1,2 407:20 408:7 485:13 <b>peers</b> 287:3 317:8 317:16 <b>penalties</b> 109:17 <b>pending</b> 33:5 261:15 <b>penis</b> 478:8 <b>peop</b> 474:18 <b>people</b> 7:21 20:15 40:7 53:9 56:7,11 64:19 65:1 66:14 74:8,9 85:23 90:21 91:2,6 93:18 94:14 119:8 122:11 124:18,22 125:13,15 145:14 145:21 146:3 148:18 151:17 154:15 155:21 160:12,18 162:4 182:17 188:23 189:4 194:7 195:11 197:20 220:14 276:22 306:1 321:16 329:10 341:21 342:6 343:11 344:12 350:14 355:11 365:6,12 365:15 366:12,13	366:14,23 367:5 367:22 368:20 370:8,18 411:10 438:9 443:17 449:3,3,22 450:7 452:22 454:15 455:7 456:23 457:6,13 458:9 463:14 464:4 473:18 474:17 <b>percent</b> 102:22 161:9,19 255:10 255:10,11 258:12 258:19 297:16 298:1,1,9,19 299:10 302:21 303:3,13 304:12 304:22 307:21 308:3 342:15 344:18 352:6 354:16,16 367:12 369:8 372:12,14 <b>percentage</b> 161:12 298:11 302:9 320:19 321:3,20 322:5 329:10 344:12 367:13 370:18 485:15 486:16 <b>percentages</b> 303:3 <b>perception</b> 112:11 <b>perceptions</b> 486:20 <b>perfect</b> 256:11 <b>perfectly</b> 120:1 <b>perform</b> 103:7 105:19 277:7 294:17 295:10,15 315:2 <b>performed</b> 24:20 55:14 117:16	141:11,19 142:4 147:17,20,23 167:3,10,16,20,23 168:3,7,12 169:1 173:16 174:20 175:4,20 176:1,4 290:20 300:12 356:12 358:14 477:12 479:18 <b>performing</b> 25:8 81:6 120:19 126:10 127:3 140:4 168:17 <b>performs</b> 315:10 <b>perineal</b> 476:15 479:3 <b>perineum</b> 178:3 478:6 479:6 <b>period</b> 257:22 300:11 337:10 347:9 403:23 404:2 478:11 <b>peritoneal</b> 134:13 135:9 <b>permanent</b> 287:14 287:17 311:5 <b>permanently</b> 244:19 290:2,7,16 <b>permissible</b> 220:8 <b>permissive</b> 222:13 <b>permit</b> 440:18 <b>persist</b> 123:7 400:13 <b>persistent</b> 7:21 405:16 411:10 <b>person</b> 65:10 70:11,22 75:17 80:7 85:22 148:14 259:17 319:7 347:1 408:19,21 444:8 447:10
--	---	---	--

448:22 452:18 459:4 460:5,13 477:3 <b>person's</b> 60:3 442:13 443:12 446:17,22 447:2 449:1 464:21 <b>personal</b> 47:17,19 48:8,22,22 78:17 87:1 93:19 94:4 94:10,12 97:19 124:3 150:8 159:5 209:17 220:21 246:21 275:1 280:13 281:5,11 281:11,15,19 284:17 359:19 360:20 <b>personally</b> 47:13 55:22 150:3,21 152:2,20 153:3 175:3,19 176:4 184:3 187:1 190:11 197:12,16 198:5 207:17 208:12 213:16 214:20 272:9,12 274:4 275:5 278:1 278:4,22 284:11 381:23 417:20 418:2 446:16,21 <b>personnel</b> 473:11 473:17 <b>persons</b> 7:8 66:19 67:20 83:14 93:23 104:17 122:10,12 131:23 132:2,7,13 195:19 245:4 348:17 366:8 383:20 390:5 392:1,8 443:23	454:9 455:1 463:14,20 474:14 476:19 485:22 <b>perspective</b> 79:20 82:5 87:2 231:9 283:2 <b>perspectives</b> 6:23 356:4 <b>pertaining</b> 224:4 473:2 <b>pertains</b> 212:10 <b>pertinent</b> 12:21 13:19 <b>ph.d.</b> 263:22 <b>phalloplasties</b> 476:14 <b>phalloplasty</b> 315:7 315:11,16 338:22 468:1 478:10,15 <b>phallus</b> 339:1 <b>pharmaceuticals</b> 484:5 <b>phase</b> 235:4 <b>phases</b> 94:3 <b>phenomena</b> 373:5 <b>phenomenon</b> 363:14,15 369:15 371:6 372:10 <b>philosophy</b> 459:15 <b>phrase</b> 21:10,13 61:9 450:13 457:21 <b>physical</b> 40:6 67:4 70:16 317:3 318:3 319:2,12 399:16 <b>physician</b> 6:23 30:14 67:10 86:15 119:14 206:1 225:13 253:12 274:17 356:4,14 356:22 357:4	464:22 483:5 484:6,7 488:22 <b>physicians</b> 67:10 67:14 122:13 132:4 210:17 219:5 229:20 233:20 273:5 277:1 472:22 487:19 <b>pick</b> 283:13 <b>picture</b> 176:23 <b>pieces</b> 110:6 <b>pin</b> 25:6 <b>pitt</b> 3:11 <b>pizza</b> 131:3 <b>place</b> 14:11 91:4 <b>places</b> 389:18 484:17 <b>placing</b> 235:13 295:4 485:4 488:3 <b>plaintiff</b> 9:20 173:17 444:21 445:20,22 446:7 <b>plaintiffs</b> 1:10 2:3 4:12 10:16 13:4 17:15 207:23 208:11 417:19,21 418:3,8,19 419:4,7 445:10 448:18 449:6 <b>plan</b> 8:2 10:20 11:2 420:13,18 421:7,17,18 422:12 423:1,6,15 423:19 424:3 425:1 431:4 437:12 <b>planned</b> 229:5 <b>planning</b> 134:9 204:9 467:15 480:16 481:3	<b>plans</b> 394:22 <b>plastic</b> 5:9 6:7 8:14 22:21 23:2,4 23:13,15 25:3,3,13 25:17 26:2,14,17 27:14 28:10 31:6 32:9 44:13,19 45:3 46:2 47:8 64:10 66:9,18,20 66:21 67:9,15 68:3,10 69:7,16 72:4 73:2 79:20 90:6 95:4,7,11 96:12 99:17 100:5 100:17,19 102:20 102:22 103:19 106:9 108:11 111:9 120:18,23 122:20 123:16,20 123:23 128:8,13 134:8 138:10,11 138:17 139:6 140:5 149:21 154:16,20 155:19 159:3,18 160:13 169:7 171:13 189:3 198:17 274:16 282:4 283:5,9 293:5 294:16,21 295:9 295:14 299:20 300:6,18 306:10 306:12 310:23 311:13 332:5 436:14 464:14 466:4,16,21 467:1 467:11 468:14 472:16,23 473:22 474:5 475:12,16 477:21 480:15 488:23
--	--	--	--

<b>plastics</b> 262:12 296:1 300:9 <b>platform</b> 466:18 <b>play</b> 469:4 <b>please</b> 181:6 264:23 <b>pleased</b> 336:14 <b>plus</b> 140:16 161:19 232:5 296:11 307:20 443:7 458:8 468:15 <b>point</b> 19:2 25:21 27:3 57:8 122:20 123:16 156:22 185:17 232:12 235:17 247:3,16 264:4 309:15 335:16 360:21 380:5 390:20 403:16 432:2 434:2 456:19 457:2 458:14 460:11 470:5 <b>pointing</b> 349:1 <b>points</b> 215:10 324:6 345:10 389:21 435:8 456:17 <b>policies</b> 430:1 <b>policy</b> 5:5,21 7:6 8:5,7,10 109:12 115:23 137:10 182:6 220:12,23 223:9,12 225:6 229:14 239:19,22 240:1 260:20 261:12 376:12 377:1,6,17 378:10 378:11 379:15 380:5 382:3,13,18	382:23 383:4 384:4,18 386:6,21 424:7 427:4,8,17 428:1 430:4,13,22 431:22 432:6 433:5 434:19 436:5,6 439:16,18 441:9,20,22 473:2 473:5 481:7 <b>political</b> 447:6,7,8 <b>poll</b> 45:6 <b>polled</b> 45:2,4 <b>ponce</b> 2:14 <b>pool</b> 328:1 355:10 365:15 <b>poor</b> 354:20 <b>poorly</b> 186:13 <b>pop</b> 92:2,4 419:15 <b>pops</b> 184:23 <b>population</b> 76:9 120:14 145:6 147:6 249:2,8,20 249:21 250:7,20 252:5 255:6,17 278:10 321:9,11 321:15,19 322:5 341:8 342:16 374:14 391:4,8,10 <b>populations</b> 225:15 <b>portion</b> 17:19 18:5 59:22 97:20,22 98:2 327:10 337:3 <b>portions</b> 15:11 18:21 478:8 <b>portman</b> 53:19 <b>portsmouth</b> 262:13 473:23 <b>position</b> 40:18 41:18 50:16 51:10 51:14,18 53:12	65:2 80:20 81:11 107:11,14,19 111:5 112:3 114:8 115:17 221:17,21 227:17,22 229:19 230:2 231:22 232:4,15,19 239:9 240:16 242:2 260:6 288:11 289:3 429:19 452:3 456:13 472:19 481:7 485:18 486:8 <b>positions</b> 42:2 49:22 <b>positive</b> 80:12 87:8 148:22 <b>positively</b> 107:16 <b>possibilities</b> 210:17 <b>possibility</b> 464:6 <b>possible</b> 20:8 315:2,15 318:1,17 318:17 319:13 322:8 461:10 480:20 484:10 <b>possibly</b> 118:23 132:4 287:1 370:15 <b>post</b> 219:11 362:10,11,14 <b>posts</b> 366:20 <b>postsurgery</b> 347:5 <b>postsurgical</b> 351:20 358:16 <b>postsurgically</b> 345:12 <b>posttest</b> 304:18,19 <b>posttreatment</b> 281:20 282:2,12	<b>potential</b> 57:11 58:16 61:22 70:23 118:5 153:11 204:20 206:20 208:14 209:5 210:4 214:16 215:9 217:15 223:1,2 244:1,18 246:3 285:20 293:17 359:5 400:12 462:10 <b>potentially</b> 75:10 126:11 127:5 215:22 244:19 314:1 <b>pouring</b> 123:4 <b>poverty</b> 90:20 243:16,17,21,23 244:12,16 460:6,6 <b>power</b> 71:2 276:5 <b>ppo</b> 8:2 <b>practice</b> 24:9 25:1 69:6 119:15 137:22 140:9 143:21 148:5 151:22 154:1 189:17 234:8 244:4 249:9 259:1 276:12 402:15 475:18 476:8 477:20 <b>practices</b> 475:22 476:1 <b>practicing</b> 249:1 <b>practitioner</b> 23:22 67:3 206:11 281:6 282:18 484:18 <b>practitioners</b> 53:16 241:15 248:22 249:4
--	--	--	--

<b>pre</b> 219:10 281:19 282:12 304:18	238:2,14 245:16 246:15 251:20	97:8 148:15 450:18,21 451:18	<b>printout</b> 27:12 230:18 464:13
<b>precautions</b> 210:13	<b>prescribed</b> 201:15 201:18 203:21	451:21 452:5 455:19	<b>prior</b> 265:6 368:13 405:15
<b>precedes</b> 159:21	204:16 207:13	<b>presentations</b> 87:14 96:17,21	<b>priorities</b> 5:6 116:1,13,13,14,16 117:5
<b>preceding</b> 446:8	211:9 214:3,8,10	103:15 104:5 105:22 160:12	<b>prioritizes</b> 394:20
<b>precisely</b> 68:4 132:12 228:6 369:17 467:5	217:17 245:8 255:11 257:20 258:13,13 259:9 259:23 267:14	<b>presented</b> 82:9 259:22 330:1 343:15 482:2 486:15	<b>private</b> 143:21 376:7 475:17
<b>precocious</b> 162:20 318:16	<b>prescribes</b> 209:20 216:14 234:17	<b>presenter</b> 79:18 82:7	<b>privileged</b> 189:2 <b>privileges</b> 24:2,11 24:14
<b>predict</b> 398:9 399:10	<b>prescribing</b> 6:2 208:16 217:12	<b>presenting</b> 283:18	<b>privy</b> 194:9
<b>predicted</b> 324:10	219:23 234:23 236:4,13 237:4 245:4 251:2 256:20 258:22	<b>presents</b> 70:14 71:9 75:1 157:6	<b>probably</b> 32:15 59:3 71:7 94:17 101:13 105:1,14 143:9 146:12 152:12 156:3 185:17 201:5 202:10,11,14 237:8 259:11 298:8,8 319:16 325:10 327:13 336:20 377:1 379:7 434:1
<b>predominate</b> 488:9	<b>prescription</b> 203:14 218:19 221:3,13 222:16 251:9 255:3,5	<b>press</b> 463:10	<b>problem</b> 78:1 82:23 112:4,11,15 119:7 123:20 152:22 194:23 291:18 324:4 338:22 352:9 355:9 358:11 363:4,5 370:23 386:1 403:12 447:14 456:22 457:12
<b>prefer</b> 53:3 54:20	<b>prescriptions</b> 258:17	<b>pressure</b> 162:4,6 165:12 272:21 367:18 368:2 369:19 370:11,21 371:17 373:2 460:1,3,9	<b>problematic</b> 144:12 218:3 259:19 260:17 261:10
<b>preference</b> 53:7 76:13	<b>presence</b> 363:4	<b>pressured</b> 165:13	
<b>premarked</b> 12:3	<b>present</b> 3:17 81:1 85:10,13,23 89:6 152:15 156:17 182:4 195:13 208:3,16 211:4 306:14 329:1 336:2 343:17 351:11 357:16 367:4 369:4 373:6 406:6 418:6,18 419:6 476:22 486:17	<b>pretreatment</b> 282:2	
<b>premier</b> 296:18		<b>pretty</b> 185:13 205:20 207:6 316:4 342:18	
<b>preoperative</b> 134:9		<b>prevailing</b> 449:17	
<b>preoperatively</b> 324:10		<b>prevalence</b> 340:10 345:21 357:11	
<b>prepare</b> 12:15 14:23 27:1 128:5		<b>previous</b> 182:2	
<b>prepared</b> 11:23 128:2,3 451:10		<b>previously</b> 140:11 369:23	
<b>preparing</b> 13:13 14:3 461:13,15 462:17		<b>primacy</b> 53:22	
<b>prepubertal</b> 400:2		<b>primarily</b> 291:11	
<b>prepubescent</b> 400:5,18,20 401:2		<b>primary</b> 386:2	
<b>prerequisite</b> 100:18		<b>principle</b> 223:5 294:21 295:7,8	
<b>prescribe</b> 214:21 216:19,21 220:2 225:14 226:15 229:20 231:11	<b>presenta</b> 96:16 <b>presentation</b> 8:13 87:19,20 88:1,12 88:14,23 90:1		

<b>problems</b> 66:20 89:16 121:21 140:2 156:21 226:12 237:17 260:21 346:23 351:10 352:2 473:7 481:5 <b>procedure</b> 9:5 141:11 147:23 148:7 161:18 173:16 174:18,20 175:21 271:20 285:1,2,12 286:3,5 288:13 289:5 290:20 291:20 293:11,23 294:3 312:11 313:20 315:3,5,13 334:2 347:7 351:17 359:1 387:22 393:18 <b>procedures</b> 55:13 104:15 105:12,18 107:8 119:2 126:11 127:4 140:13 141:14,18 142:13 150:10 162:23 163:13 164:15 176:2,5 177:23 179:1 286:11 294:17 295:10,16,21 309:18 316:5 339:9 353:21 383:9 419:5 425:3 435:16 476:11 477:13,19 485:17 <b>proceed</b> 10:13 286:10 311:7 <b>proceeding</b> 492:5	<b>proceedings</b> 9:12 492:12 <b>procerus</b> 263:3 266:12,19,23 267:9 <b>process</b> 48:21 50:13 82:13 156:19 184:13 208:20 235:7 277:18 307:3 320:20 321:5,22 346:7,8 402:5 403:16 461:8 <b>processes</b> 367:18 <b>produced</b> 188:14 492:7 <b>produces</b> 206:18 <b>product</b> 45:7,19 185:11 188:14 225:12 233:20,23 234:7 235:2 <b>product's</b> 234:3 237:1 <b>profession</b> 305:18 <b>professional</b> 42:6 42:16,22 43:21 45:6 47:9,10 53:4 53:15 54:20 65:12 75:18,22 76:13 83:3 95:23 104:10 107:17 109:16 111:16 112:1,18 117:23 118:10,18 124:2 127:6 129:2 153:23 154:12 155:8 158:3 177:14 179:14,15 181:19 182:9 199:6 208:21 241:16 276:9 301:4 307:8 316:3	428:17 448:11,11 479:12 481:8 <b>professionals</b> 56:21 383:20 398:8 418:9 <b>profile</b> 489:18 <b>profound</b> 319:5 <b>progestins</b> 431:15 <b>prognostic</b> 282:9 <b>program</b> 95:13 121:12 <b>programs</b> 95:15 106:6 107:10 149:10 <b>progress</b> 219:8 <b>progression</b> 324:16 <b>prohibit</b> 226:5 406:12 <b>prohibited</b> 37:10 227:1 <b>prohibition</b> 46:3 <b>prohibits</b> 51:22 180:22 181:10 220:23 <b>prominently</b> 322:21 <b>promise</b> 248:10 <b>promised</b> 289:16 <b>promises</b> 363:18 <b>promote</b> 44:17 77:17,19 104:12 <b>promotion</b> 225:6 <b>pronounce</b> 389:3 <b>proper</b> 216:18 238:13 <b>properly</b> 120:11 145:17 276:5 280:6 330:17 <b>propose</b> 254:8	<b>proposed</b> 54:8 224:9 235:8 <b>proposes</b> 265:7 284:19 <b>proposing</b> 386:17 <b>proprietary</b> 201:12 <b>props</b> 336:22 <b>prosecute</b> 52:12 <b>prospective</b> 278:12,18 279:14 304:1,9 411:19 <b>prosthesis</b> 336:20 336:21 460:10 <b>protect</b> 76:8 <b>protections</b> 280:9 <b>prove</b> 312:22 <b>proven</b> 144:13 218:4,16 313:2,4 435:18 <b>provide</b> 15:6,10 41:7 112:8 137:10 137:17 158:4 170:15 171:1 174:13,17 400:4 400:16 401:1 415:15 <b>provided</b> 17:18 18:4 157:17,22 422:20 474:7 <b>provider</b> 153:4,10 153:21 261:1,5 279:10 308:21 312:19 423:13 <b>providers</b> 7:4 149:12 231:10 246:8 248:5 308:22 314:3 429:18 464:4 <b>provides</b> 378:10 405:7 441:6
---	---	---	---

<b>providing</b> 36:17 51:23 57:9 58:14 58:20 78:18 80:17 104:17 137:3 151:11,13,17 157:14 195:2 <b>provision</b> 109:17 481:19 <b>provisional</b> 101:21 <b>provisions</b> 170:18 <b>prudential</b> 295:3 <b>psych</b> 156:4,7 <b>psychiatric</b> 49:7 66:13,20 68:2,14 72:6 159:16 190:5 282:16 313:14 384:6 <b>psychiatrist</b> 65:22 153:17 154:22 <b>psychiatrists</b> 189:21 <b>psychiatry</b> 75:5 <b>psychological</b> 66:13 67:22 68:14 68:16,20 70:14 72:6 77:21 82:8 112:10,14 282:16 394:20 395:18 486:4 <b>psychologically</b> 71:1 317:9 <b>psychologist</b> 154:22 364:9,11 372:3 <b>psychology</b> 75:6 <b>psychotherapy</b> 157:15,18,23 158:4 437:14 <b>pubertal</b> 7:18 411:8	<b>puberty</b> 36:21 63:13 81:23 161:2 161:6,15 162:16 162:19,20 163:12 165:9 166:8 201:2 201:3,19 203:15 203:21 204:17,21 205:2,3 207:13,20 208:15 211:10,21 212:14 213:6,18 219:17 238:19 247:1,9 260:6 316:16,20,21 317:21 318:2,11 318:16 374:4,9,12 395:23 397:22 401:10,14 404:1 405:16,20 406:1 406:13,23 413:4 428:15,22,23 437:15,23 482:16 483:21 489:14 <b>public</b> 9:2 63:19 85:4,6 160:11 187:17 191:18 199:11 241:4 495:19 <b>publication</b> 130:2 131:1 133:15 134:12 136:11 182:18 190:2 224:7 227:7 228:1 240:12 275:23 283:16 296:4 306:7 307:1 355:13 356:1 360:18 362:1 368:17 407:20 <b>publications</b> 12:22 85:3 106:23 128:18,23 135:20	136:6,14 283:10 297:16 298:12 302:22 304:12,22 307:21 380:13 <b>publicly</b> 125:5 183:1 <b>publish</b> 46:18 50:20 283:11 303:18 306:9,11 306:14,17 307:5 <b>published</b> 46:13 46:17 72:21 76:3 84:18,22 129:3,13 135:16 183:4 185:16 186:3 189:23 196:1 219:4 220:12 228:20 273:23 274:13 275:20 296:10 298:2 300:9 301:19 302:10 305:14 306:21 322:22 326:6 364:2 371:16 378:1,2 465:10 482:15 486:1 <b>publishes</b> 182:16 <b>publishing</b> 76:15 182:21 284:4 301:4 305:20,21 306:3 331:5 <b>pubmed</b> 20:22 21:10 <b>purport</b> 334:19 <b>purporting</b> 277:10 <b>purports</b> 177:20 <b>purpose</b> 93:9 240:8 241:12 296:13 459:16	<b>purposes</b> 238:20 269:9 423:3 431:22 <b>pursuant</b> 9:4 <b>pursuing</b> 162:23 <b>purview</b> 474:23 <b>pushing</b> 305:4 <b>put</b> 122:8,8 136:5 312:9 327:15 350:4 362:20 371:16 375:10 382:9 395:23 452:8 471:6 <b>puts</b> 282:5 <b>putting</b> 107:5 360:13 <b>pyramid</b> 309:8
<b>q</b>			
<b>qualification</b> 244:7 <b>qualifications</b> 29:14 172:13 479:13 <b>qualified</b> 65:11 75:18,22 358:8 <b>qualifier</b> 251:6 254:4 <b>qualify</b> 250:13 274:10 318:9 <b>qualifying</b> 416:16 <b>quality</b> 71:1 89:21 120:9 123:20 285:5 300:6 354:20 381:20,21 415:16 482:6,19 <b>quantifiable</b> 331:9 <b>quantification</b> 363:13 <b>quantifies</b> 330:7 367:21 370:8,18			



<b>quantify</b> 311:10 330:4 369:3 413:4 <b>quantifying</b> 349:11 <b>quentin</b> 86:10 <b>question</b> 26:8 80:14 83:1 118:14 122:23 124:16 126:4,7,19,23 134:22 155:2 156:5 164:7,12 174:21 176:21 180:1 181:4,6 186:17,23 205:6 208:4 212:12 213:13 215:4 261:15 266:10 269:8,13,16 286:16 288:10 293:3 294:2,9 318:8 321:8 332:21 348:23 365:7 366:9,13 370:4,6 374:22 386:4 409:18 424:21 426:11 441:2 480:2 487:9 <b>questioned</b> 65:8 <b>questioning</b> 65:15 <b>questions</b> 55:15 56:7 134:21 135:2 188:20 261:17 272:5 292:17 314:22 346:21 353:17 394:4 470:19 471:10 472:11 481:7,10 481:13,18 482:1 485:8 486:15 489:3	<b>quick</b> 319:21 <b>quickly</b> 421:19 <b>quite</b> 178:8,8 276:14 309:23 313:1 395:5 404:3 <b>quotation</b> 21:12 <b>quote</b> 60:22 61:5 227:8,9,23 277:16 291:19 351:4 366:1 367:23 456:6 <b>quoted</b> 227:23 480:22 <b>quotes</b> 59:18,19  <b>r</b>  <b>r</b> 2:1 16:12 33:2 203:4,4,11,11 277:14 299:19 322:18 414:15 492:1 494:3,3 <b>radial</b> 339:5 467:22 <b>radiation</b> 479:1 <b>radically</b> 122:22 123:3 284:20 <b>radicularis</b> 267:10 <b>radio</b> 465:21 <b>radio's</b> 465:15 <b>radiological</b> 486:4 <b>raging</b> 125:6 412:16 <b>raise</b> 70:21 124:7 284:2 468:8 <b>raised</b> 65:20 119:4 119:10 <b>raising</b> 160:14 <b>ramifications</b> 213:9 <b>ran</b> 21:10 475:2,3 <b>randomization</b> 304:6	<b>randomized</b> 120:10 251:23 252:5,9,10,13 268:20 269:3 270:1 271:2 272:18 273:7,18 274:21 275:16 279:7 280:8 291:7 292:19,23 293:6,9 293:20 294:10 298:3 302:17 307:19 310:16 316:5 <b>randomly</b> 412:1 <b>ranges</b> 257:4 <b>ranked</b> 301:21 <b>ranks</b> 309:7 <b>rapidly</b> 125:2 476:6 <b>rate</b> 101:23 161:5 161:19 314:5,18 327:1 329:3 334:16 354:7 355:14 390:2 391:1 <b>rates</b> 258:5 329:2 352:5 353:9,19 354:1,3 <b>ratio</b> 390:4 <b>rational</b> 228:7 <b>rationale</b> 234:1 <b>rattled</b> 73:11 <b>rct</b> 271:7 272:10 272:14 274:5,8 275:12,13,20,22 276:23 285:13 294:18 315:15 318:1 319:14 323:7 <b>rcts</b> 271:3,11 272:8 274:2	297:18 303:7 305:8,16 315:2 <b>reach</b> 48:5 49:21 96:10 160:8 161:8 <b>reached</b> 125:2 402:1 <b>reaches</b> 288:21 289:6 <b>reaching</b> 482:22 <b>read</b> 18:14,16,21 37:17 42:7 101:6 101:7 111:21 174:7 181:16 182:6 197:1 202:17 206:2 207:22 208:1 227:20 233:11 264:2,3 277:15 301:1 307:11 324:19 325:6 340:21 358:12 371:11 376:23 377:7 402:8 410:9 430:1 448:23 449:13 493:9 495:5 <b>readily</b> 74:8,9 75:3 <b>reading</b> 117:13 184:21 185:11 194:6,7 195:11 206:6 239:21 240:20 277:11 298:16 338:8 356:10 357:1 358:4 418:23 436:3 448:10 <b>ready</b> 74:7 156:18 471:4 <b>real</b> 123:9 364:5 409:8 421:19
--	--	---	--

<b>realities</b> 82:10 447:17 450:4,7 <b>reality</b> 252:3 258:21 448:14 <b>realizing</b> 348:20 348:21 <b>really</b> 89:23 93:14 98:12 106:12 121:7 186:13 205:1 235:4 276:2 277:5 291:21 314:20 337:12 439:8 480:10 <b>realm</b> 294:13 <b>reason</b> 11:15,18 23:22 132:12 155:5 177:6,6 193:23 194:5 218:2 231:17 314:7 321:14,14 327:22 330:22 333:23 350:22 363:2 393:9 493:11 494:6,9,12 494:15,18,21 <b>reasonable</b> 276:19 <b>reasons</b> 100:8 105:4,7 108:1 177:10 180:18 250:4 328:21 348:2,10 349:6,12 358:15 <b>reassigned</b> 390:5 <b>reassignment</b> 6:14 7:9 59:16,23 60:16,21 61:4 337:11 346:17 392:2,9,11,17,20 393:12 432:3,7 <b>rec</b> 416:2	<b>recall</b> 15:21 56:4 56:12 58:22 69:11 70:2,4 80:6 92:14 93:1,21 96:11 97:1 98:14 99:11 101:5,19,21 102:4 111:2 115:19 149:7 169:8 216:10,12 222:11 262:11 334:17 345:17 347:7 394:1 421:4 481:9 489:14 <b>recalling</b> 463:11 <b>receipt</b> 493:18 <b>receive</b> 69:2 114:16 401:13 485:15 <b>received</b> 23:3 31:11 69:19 124:22 265:2 268:4 329:10 350:17 <b>receiving</b> 213:6 259:17 <b>recertified</b> 23:7 <b>recitation</b> 453:18 <b>reckoning</b> 404:7 <b>recognize</b> 66:18 154:20 406:22 416:2 <b>recognized</b> 228:18 <b>recognizes</b> 40:3 243:15 250:19 <b>recognizing</b> 74:23 243:8 <b>recoll</b> 84:5 <b>recollection</b> 97:5 110:17 <b>recom</b> 395:17	<b>recommend</b> 53:5 161:13,15 395:10 395:17,22 <b>recommendation</b> 41:3 72:1 118:23 396:3,4 <b>recommendations</b> 41:23 42:1 54:18 72:23 398:16 400:4,17 405:4,8 <b>recommended</b> 265:23 <b>recommending</b> 44:21 <b>recon</b> 142:8 467:23 <b>reconstitute</b> 478:10 <b>reconstruct</b> 468:2 478:12 479:9 <b>reconstructing</b> 289:13 290:13 <b>reconstruction</b> 44:16,23 133:23 142:15,23 167:19 169:4 178:3,4 299:6 476:16 479:1,5 480:4,12 480:23 <b>reconstructions</b> 142:21 178:11 299:5 <b>reconstructive</b> 6:8 44:19 46:2 142:23 143:8 274:16 291:20 296:1,19 299:21 300:9 311:14 334:7 335:5 443:8 467:2 467:13,15 472:16 473:15,22 474:8	474:15 475:5,12 475:17 476:1,9,11 477:9 478:9,20 488:23 <b>record</b> 9:16 10:12 11:13 79:1,4,8 86:13 115:8,11,14 166:14,17,21 176:23 189:9 207:23 208:9,9 254:13,16,20 312:12 319:23 320:3,7 388:4,8,12 417:10,12,15 418:16 447:18 470:10,13,17 472:4,7 491:7,10 <b>recorded</b> 10:4 <b>recording</b> 256:6 <b>recordkeeping</b> 235:3,18 237:15 <b>records</b> 12:20 13:2 13:3 208:1 234:3 237:1 342:6 355:7 419:1,10 <b>recourse</b> 53:12 252:14 <b>rectangle</b> 350:5 <b>red</b> 71:21 451:14 <b>reddit</b> 361:19,23 362:11,14 364:19 <b>redirect</b> 471:20 <b>reduced</b> 333:20,21 333:21 <b>reduction</b> 129:22 291:6,11,15,16,19 292:9 293:19 294:9,13 <b>reductions</b> 142:19 290:22 292:22
--	--	---	--



<b>reexamination</b> 4:6 <b>refer</b> 65:11 67:5 75:17 155:7 264:23 444:20 445:13,22 446:13 461:13 <b>reference</b> 50:21 86:21 109:20 144:1 280:13 320:18 378:6 380:3 394:17 413:22 444:16 467:9 <b>referenced</b> 301:11 301:14 493:6 <b>references</b> 50:11 72:15 301:7 364:18 378:16,19 407:18 416:15,17 439:17 <b>referencing</b> 410:17 <b>referral</b> 72:5 474:9 <b>referred</b> 68:16 233:10 474:17 <b>referring</b> 13:8 144:3 145:9 146:14 271:4 441:4 447:9 449:5 457:23 458:4 469:19 <b>refers</b> 131:18 456:9 <b>refined</b> 93:13 <b>reflect</b> 228:8 397:23 <b>reflects</b> 456:12 <b>refresh</b> 110:16 400:8	<b>refute</b> 486:10 <b>regard</b> 355:12 472:21 <b>regarding</b> 248:23 468:22 473:15 <b>regimens</b> 225:15 <b>register</b> 5:11 224:2 362:10 <b>regret</b> 6:20 328:14 328:20 329:5,12 329:17 330:4,20 331:4 335:16 343:17 344:20 345:10 346:20 347:20 348:2,3,3,6 348:9,18,19 349:2 349:2,5,12 350:14 350:18,22 351:4 352:5,20 353:1,4,9 353:20 354:3,7,19 354:22 355:4,14 356:2,14 357:4,9 357:15,22 358:14 358:22 359:5 363:10 365:16 366:14,15 <b>regretful</b> 6:12 <b>regrets</b> 340:11 352:1 <b>regretters</b> 351:19 354:7 355:2,3 366:17,18 <b>regretting</b> 360:14 <b>regulates</b> 221:3 <b>regulations</b> 224:4 <b>regulatory</b> 263:23 <b>rehearsed</b> 368:22 369:20 371:22 372:2 <b>reintroduce</b> 339:13	<b>reintroducing</b> 339:15 <b>reject</b> 150:10 <b>rejected</b> 248:2 <b>rejecting</b> 247:4 <b>rejuvenation</b> 142:9 <b>relate</b> 74:5 130:2,5 131:15 132:18 133:16 134:2,16 205:20 <b>related</b> 85:6 145:2 146:9,10 229:8 405:18 432:3,8 <b>relating</b> 66:13 447:20 473:6 <b>relationship</b> 103:21 143:2 <b>relatively</b> 45:11 357:10 <b>relatives</b> 348:12 349:8 <b>releasing</b> 201:7,9 317:22 428:14 <b>relevant</b> 43:17 118:9,17 173:15 373:23 465:15 483:20 488:20 <b>reliable</b> 89:13 90:3 180:3 280:11 323:23 362:16 366:22 371:4 408:12 485:13 486:1,3 <b>relied</b> 35:20,20 50:3,18 293:20 297:4 343:14,18 <b>relief</b> 422:21 <b>relies</b> 294:10 305:7	<b>relieving</b> 292:4 <b>religious</b> 466:18 467:9 <b>rely</b> 73:6,8,9 203:18 249:4 251:14 284:11 293:6 294:9 343:12,21 360:11 409:20 410:1 456:21 <b>relying</b> 125:18 286:23 287:1 305:15 359:13 360:12 <b>remained</b> 344:14 <b>remaining</b> 470:4 <b>remains</b> 241:3 481:15 <b>remarks</b> 87:17 91:15 <b>remedy</b> 67:21 154:16 <b>remember</b> 59:4,7 59:11 65:18 77:1 77:3 80:5 84:13 85:19 86:4,6 87:5 90:19,19 91:18,20 93:7 94:20,23 95:5,6,8,23 96:3,5 97:7,14 99:14 100:20 106:4,11 106:16 109:8 110:23 222:6 324:19,22 334:23 341:4,7 372:15,17 450:17 <b>remembered</b> 85:18,21 <b>remembering</b> 92:3 <b>remote</b> 1:18 2:3 3:1,17 9:6 10:4
--	--	---	--

70:1 210:16 <b>removal</b> 139:22,23 143:4 146:1,5 151:12 152:9,18 153:2 287:16 479:4 <b>removals</b> 148:8 <b>remove</b> 336:21 <b>removing</b> 290:6,8 <b>renew</b> 23:20 <b>renewed</b> 31:19 <b>rep</b> 55:19 <b>repair</b> 130:12 131:12 133:22 136:8 <b>replaced</b> 457:17 <b>report</b> 4:13 12:1,9 13:9,16,17 17:9 18:18 19:6 22:15 25:23 29:21 31:2 31:9 43:7 56:22 59:14 63:15 108:18 109:6 117:13 119:16 143:17 158:15 177:19 183:8 206:6 216:6 230:1 230:4 238:7,11 279:20 282:20 284:7,12 285:23 299:2 303:7 320:9 322:22 327:10 328:4 334:16 335:14 341:4 343:6,7 345:2,8,18 346:2,13 347:8 357:21 359:9 360:17 361:15 364:2,4 367:6 373:11 377:18 389:18 393:23	394:14 407:8,18 410:11,17 412:11 413:18 415:4 444:20 445:3,19 447:23 448:16 449:4 <b>reported</b> 228:10 326:21 336:14,23 341:9 345:5 348:10 349:6 350:18 351:4 357:9,15 359:17 363:16 368:5,10 369:6 463:20 490:20 <b>reporter</b> 9:2 10:8 10:12 16:12 182:13 325:13,16 325:20 350:3,9 389:13 414:15 426:1,6 471:9 <b>reporting</b> 202:19 281:7,9 282:15 283:13 299:3 300:21 327:16,17 331:10 336:5,7,7 336:10 337:17 343:16 345:6,10 349:11,13 362:21 364:11 367:14 368:14 370:1 383:4 465:13 <b>reports</b> 19:11 120:2 135:15 194:7 219:1,1,3 220:1,4 244:14 246:7 280:7,20 281:9 282:18 283:20 308:20 324:17 329:19 343:10 352:5	490:17,20 <b>represent</b> 10:18 21:9 26:18 32:18 416:4 <b>representation</b> 26:4 <b>representations</b> 32:13 <b>representative</b> 55:23 <b>representatives</b> 229:13 <b>representing</b> 28:9 452:3 <b>represents</b> 440:16 492:10 <b>reputable</b> 102:11 102:16 <b>request</b> 59:3 151:21 224:22 <b>requesting</b> 323:1 328:7 <b>require</b> 234:9 237:12,13,14,19 237:20 479:4 490:2 <b>required</b> 24:1 66:10 169:14 237:11 242:23 245:1 284:4 454:22 473:14 478:8 495:13 <b>requirement</b> 24:4 236:9 238:1 300:21 404:15 <b>requirements</b> 172:23 476:5 <b>requires</b> 174:19 <b>requiring</b> 474:14 <b>reread</b> 331:21 384:11	<b>res</b> 273:8 <b>rescinded</b> 46:3,7 <b>research</b> 6:9 106:14 120:7,9 129:14 135:10,15 136:2,17 253:3,6 299:21 300:7,8 305:6,14 308:11 308:18 309:1 321:16 324:18 390:21 485:14 486:2 <b>researcher</b> 276:11 <b>researchers</b> 326:21 <b>residency</b> 69:8,11 69:16 73:3 95:15 100:21 101:12 106:6 107:9 121:12 122:3 125:14 273:9,20 278:17 <b>resident</b> 121:19 133:8,8 156:1 272:15 <b>residents</b> 101:22 <b>resource</b> 86:21 257:13 381:8 409:15 452:6 473:10 <b>respect</b> 59:10 125:22 145:9 247:8 392:8 466:5 <b>respective</b> 270:7 <b>respectively</b> 303:4 <b>response</b> 371:12 <b>responsibility</b> 233:22 235:1 260:23 261:2 <b>responsible</b> 53:17 272:22 276:13
---	---	--	---

<b>responsive</b> 126:1 370:4	278:19 279:14 289:10 311:23 341:12,14 343:1 343:23 344:8 355:6	449:16 473:14 483:3 488:21 493:7	22:11,13,16 24:21 25:12,21 26:14 27:15,21 28:7 29:5,14,18 30:6,20 30:21 31:17,20 32:7,23 33:6,10,16 33:19 34:4,10,11 34:13,19 35:3,6,9 35:22 36:12 37:14 37:19 38:22,23 39:7,12,16,22 40:8 40:13,20,23 41:20 42:11,20 43:18 44:3 47:1,5 48:6 48:12,16 49:10 51:14 52:5,12,13 52:17,23 57:6,13 57:22 58:3,6,9,12 58:16 59:12 60:11 60:14,18 61:7,14 61:16 62:22 64:2 64:12,13 65:3,5,16 65:23 66:4 68:21 68:23 69:1,18,21 70:4 73:7,13 74:2 75:11,15,19 76:2 76:17,19,20 77:14 78:7 79:12 80:1 81:7 83:4,9,14,23 84:6,7,9,23 88:22 90:16 91:8 93:2,4 93:5 99:17 102:8 102:11 103:2 107:21 108:12,15 108:18 110:1,2,12 111:4,19 113:20 114:10 115:15,22 117:1,8,17,20 118:1,5,12 120:15 120:19 123:17 125:14 127:14,19
<b>rest</b> 217:23 246:12 310:22	<b>return</b> 493:13,17	<b>reviewed</b> 12:17,19 12:20 13:11,14,18 20:18 47:20 50:12 51:1 53:21 106:23 128:19 129:4,14 170:4,8 185:7 205:4 274:1 296:7 296:18 331:12 342:6 361:23 362:6 364:3 367:21 370:7,17 402:9 407:20 408:7 412:22 485:13	
<b>restated</b> 229:13	<b>returned</b> 331:15		
<b>restating</b> 229:8	<b>returning</b> 328:2 348:13 349:9		
<b>restoration</b> 467:3	<b>returns</b> 113:22,22		
<b>restriction</b> 226:3	<b>reversal</b> 6:11 147:15 149:3 328:2,7 329:6 330:1 338:13 363:11 429:8		
<b>result</b> 247:14 287:7 289:16 412:19,19 467:7 484:12 492:17	<b>reverse</b> 15:14 129:19 320:20 321:5,21	<b>reviewing</b> 212:2,7 212:18 258:11 439:23 450:3	
<b>resulted</b> 490:17	<b>reversed</b> 311:6	<b>reviews</b> 8:1 35:16 35:17 96:22 120:8 174:11 327:3 332:10 335:1,7 341:1,6 355:6 378:20 384:12 400:9 408:4 413:1 420:8 440:21 445:15	
<b>results</b> 21:13,18 245:9 246:17 249:21 250:21 251:13 252:6 257:17 270:1 276:8 285:13 291:7 292:22 293:9 294:18 297:18 298:13 303:7 305:8 309:23 341:19 344:9 356:17 357:8 392:16	<b>revert</b> 148:14		
<b>resumé</b> 5:7 473:20	<b>review</b> 6:22 13:6 45:9,22 70:15 89:7,9 93:15 135:11 170:17 177:3 183:8 187:12 191:12 196:20 198:6 199:3 234:12,13 235:20 253:7 265:20 274:13 283:21,23 300:8 307:19 343:2 344:1,8 356:3,12 357:3,20 377:10 379:3,6 408:3 410:20 412:21 414:9,12 415:3,14 415:14,20 416:11 416:12 417:23 418:17 427:11 443:6 448:12		
<b>retained</b> 11:19 33:8 174:22		<b>revise</b> 29:13	
<b>retired</b> 24:23 136:22 139:18 140:8 141:12 473:17,18		<b>revised</b> 196:4 427:15	
<b>retirement</b> 24:6		<b>revision</b> 196:16	
<b>retract</b> 371:18,18 371:19,20		<b>revoked</b> 29:11	
<b>retraction</b> 276:21		<b>rex</b> 55:19	
<b>retro</b> 341:10 343:23		<b>richmond</b> 264:23	
<b>retrospective</b> 257:11 278:9,12		<b>ridge</b> 130:16 <b>right</b> 12:1,13 14:19 16:3 17:2,7 17:16 18:17 19:8 20:12 21:4,7 22:4	

127:23 128:9,10	207:8,20 208:17	273:19,22 274:8	354:16,17 355:23
128:23 129:1,4,5,6	209:23 210:6,11	277:23 279:15	356:7 357:5,12,13
129:11,12,18,19	211:22 212:4,20	280:19,20 285:8	357:19 358:1
129:23 131:2,15	213:19,23 214:4,8	286:19 288:14	359:1,15,16
133:2,5,23 135:7	214:9 216:4,13	290:18 291:1,3,5,8	360:10,11,21,22
135:21 136:9,10	217:2,7,9,13	292:16 293:8,12	361:13,14,15,17
136:12,13,19	219:22 220:4	294:12 295:17	361:20,22 362:1,5
137:5,7,21 138:1	221:9,13,14	296:2,8,10,15,22	362:8,9,12,13,17
139:5,9,12,14,22	222:19 224:11,12	299:17,18 300:1	362:22 364:5,6,12
139:23 140:3	225:2,5,9 227:13	300:15 301:8,12	364:18,19,20
141:5 144:19	227:14,15,17,18	301:13,22 302:14	365:3,9,10,13,21
146:16 147:1,2,7,8	228:14,21,22	302:16,19,20,23	365:22 366:2,20
147:9,22 149:16	229:6 230:16,17	303:1,8,22 304:2,4	367:1,9,10,18,19
149:23 150:1,18	230:19,20,23	304:10,14,17,19	368:2 371:1,3
153:14,15,18,21	231:1,20,21 232:2	304:20,22,23	374:6 375:11,18
154:2,13 155:9,15	232:3,5,6,8,20,21	305:9 306:5,6	375:21 376:1,2,4
155:22 157:2,3,7	233:12,18 234:6	307:5,23 308:3,4,8	376:11,14,15
157:11,15,16,20	234:19 235:23	308:15 309:4	377:12,14,16,21
157:21 158:1,2,6	236:1,5,15,18	311:17 315:8,13	377:22 378:3,8,12
158:10 166:10,14	237:5,7 238:3,7,12	315:18 316:9,13	378:17,21 379:2,6
167:1 168:13	238:15,23 240:3	316:15,22 317:5	379:8,16,22
169:15,19,23	240:15,18,22	318:3 319:18	381:10,14 382:4
171:19,20 172:7	241:13,22 242:6,7	320:22 321:2,6	382:19,20 383:6
173:4,8,20 174:7	242:10,11,13	322:2,6,15 323:4,7	384:1,3,4,19 385:3
175:2,10,13,16	243:12 245:7,10	323:8,8,10,14	385:15 387:1,4,13
176:3,10 180:15	245:16 248:7,13	324:1,5 325:8	387:15 388:3,13
182:7,15,17 183:5	248:14 250:22,23	326:5,7,8,9,18	389:1,15,20 390:3
183:6,7,12,16,20	251:3,16,18 252:2	327:4,7,8,11,18	390:11,19,22
184:9 185:5 187:9	252:6,20 253:16	329:14 330:3,5,14	391:4,5,10,12,19
187:13,21 188:2,7	254:21,23 255:9	330:20,21 332:20	391:22 392:14
188:17 189:15	255:12 256:17,18	332:23 333:5,6,10	393:20,21,22
190:3,9,13,17,22	257:1,7 258:10,14	333:11,14 334:21	396:1,18 397:4,8
191:3 192:9,11,14	258:15,19,21	336:11,12 337:21	397:17,19 398:14
192:15 193:8,12	259:1 261:19,21	339:10,15 340:17	398:23 399:17,18
195:15 196:9,20	262:2,6 263:1,7,12	341:16 342:4,8,10	399:21 400:6,14
197:3,6,18 198:13	263:13 264:6,8,17	342:16,17,19	400:18 401:3,19
199:19 200:9,19	265:12,15,17	343:7,9,13 344:15	402:23 403:5,10
201:1,16,20,23	266:3,8 267:23	347:15,18 348:16	404:18,22 405:7,9
202:3 203:13,20	268:15 269:22	348:20 349:18	405:11,14,22
203:22 204:2,12	270:8,11,13,22	350:11,19,21,23	406:10,16 407:3,4
204:15,21 206:5	271:1,5,9,12	351:1,5 352:3,6	407:7,19,21 408:5

408:8,9,13 409:3 410:14,23 411:12 411:13,15,20,22 411:23 412:2,3,5,6 412:7,8 413:2,3,19 413:21 414:8,12 414:13,19 415:4,5 415:8,11,19,22,23 416:5 417:7,16 418:2,9,21 419:23 420:9,13,14,17,19 420:23 421:6,12 422:8,9,10,14,16 423:3,10,19,20 424:3,11,22 425:1 425:4,8 427:3,4,9 427:12,15,20,21 427:23 428:3 429:2 430:2,6,12 430:16,17,19 431:7,9,15,18 432:9 433:8,11,14 433:17 434:3,8,17 434:17,19,22 435:2,5,10,23 438:3,15 440:2 441:9,17,18,23 442:3,4,6,9 443:13 443:20 444:22 445:10,14,16,17 445:20,21,23 446:5,7,14,23 447:11 449:2,8 450:9,11,15,23 451:2,11 452:13 452:23 453:13,20 454:6,10,17 455:10,15 456:4,5 456:7,10,15 457:16,19 458:1,4 460:18,22 461:3,5	462:4,11 463:8 464:13,17,23 465:11,18,20 466:8,9,12,13 469:7 471:2 480:6 480:7 484:8 486:13 489:19,20 490:2,3,8,14,18 <b>rights</b> 83:13 101:3 <b>rigorous</b> 39:7 <b>rise</b> 294:3 310:5 <b>rises</b> 281:20 <b>risk</b> 41:5 67:11 90:22 206:12,19 206:19 207:4 222:13,17,21 223:1,3 251:11 260:4 270:15 285:19 286:9,12 286:14 287:5,8,12 287:19 290:1 293:17 295:3,21 301:17,20 310:7 311:2,4 312:11 313:20 314:8,15 334:10 391:9 393:1,13,19 404:8 484:9,12,16 485:3 485:3,6 488:4 489:18 490:6 <b>risks</b> 84:22 91:4 177:21 204:20 205:2 206:14,22 207:19 208:14 209:5,8,22 210:4 210:10,22,22 214:16 215:1,6,9 215:12 217:17,18 218:8,9,16 219:4 246:3	<b>risky</b> 288:3 <b>rocketcitynow.c...</b> 5:1 <b>role</b> 348:13 349:9 367:16 373:3 395:12 397:22 398:11 403:1 474:2 480:18 <b>roles</b> 398:18 <b>room</b> 94:17 106:20 208:4 235:11 <b>rooted</b> 444:7 <b>rosacea</b> 140:2 <b>rotate</b> 349:22 <b>roughly</b> 15:21 84:12 97:11,21 101:15 139:7,13 141:17 345:1 <b>round</b> 87:14 <b>route</b> 72:13 149:22 <b>rows</b> 307:18 <b>rpr</b> 492:20 <b>rule</b> 173:3 316:4 <b>rules</b> 9:5 170:14 173:9 224:9,10 <b>ruling</b> 38:10 53:21 <b>run</b> 95:14 137:23 138:16 488:8 <b>running</b> 292:14 <b>rutledge</b> 33:2 <b>s</b> <b>s</b> 2:1 4:10 55:20 202:16 203:8,11 277:14 299:19 340:15 356:2 360:9,10 492:19 494:3 <b>sacrifice</b> 348:12 349:8	<b>safe</b> 268:22 270:3 <b>safety</b> 219:14 221:12 235:9 269:5 437:17 469:6 <b>sake</b> 437:2 438:9 439:3 467:7 <b>salem</b> 3:13 <b>salvage</b> 475:3 477:5 <b>sample</b> 413:11 <b>san</b> 86:14 272:16 278:7 <b>sanction</b> 177:15 <b>sanctions</b> 176:16 <b>sat</b> 153:3,9 207:11 476:21 <b>satisfaction</b> 299:8 331:14,19 332:2,4 333:4,5,13 <b>satisfactory</b> 104:19 <b>satisfied</b> 326:22 330:18 335:20 <b>save</b> 347:17 <b>saved</b> 156:3 <b>saw</b> 18:7 78:4 95:7 106:7 341:3 407:17 471:8 <b>saying</b> 54:20 92:21 124:17,19,19 209:15 234:16 236:12 237:13 244:9 250:13 274:11 284:22 288:20 289:1 310:1,2,4 313:6 365:11,14,18 366:4 415:20 466:11
---	---	--	---

<b>says</b> 22:17,20 26:1 27:16,22 28:15,16 28:22 29:8 30:13 34:11 38:8 39:4,9 40:2,8,9 41:2,2 52:11 55:19 56:20 57:3 59:23 60:10 63:10,18 64:9,17 65:7 104:22 108:10 109:12 110:5 111:8 113:7 115:4 116:6,19 128:7,18 171:1,15 172:11,18 173:9 174:23 179:15 224:17,21,21 225:10 227:7,11 227:23 228:5,23 229:12 230:8 231:4,8,17 232:12 233:19 234:7,22 236:2,7,19,22,23 238:3,5 239:4 240:8 241:2,11,15 241:19,23 242:18 248:18 251:13,19 253:1 257:10,19 258:3 260:10 263:14,16 264:13 264:22 265:5,16 265:19 279:23 300:4 302:1 304:15 305:23 306:1,2 308:9 309:6 326:20 328:19 330:16 341:21 347:19 348:1,2,8 356:11 356:20 357:6,8,14 361:1 364:21 365:5,20 367:11	375:19 377:10 378:6 382:12,16 383:18 384:18,21 386:22 387:5,20 391:23 392:15 397:19 398:6 401:9,12,21 404:21 405:23 411:18 413:9 415:12 421:9,22 422:5,18 424:8 427:11,17 428:13 429:7 430:16,23 432:2 434:8,17,21 435:15 437:8,11 440:4 454:14 456:3 459:4 461:1 464:19,21 466:2 468:22 <b>scarless</b> 131:11 136:8 <b>scarring</b> 145:20 <b>schechter</b> 216:7 280:4 377:20 395:6 <b>school</b> 165:12 166:4 409:7 452:1 464:5 <b>schools</b> 83:13 <b>science</b> 46:6 51:6 78:2 82:15 86:16 90:2,3 92:9,11,11 93:15 94:11 122:17 124:4 125:20 177:8 280:11 <b>scientific</b> 20:18 21:7 43:17 44:10 45:6,9,21 46:18 47:20 50:3,11 51:17,19 72:15	81:13 83:4 86:12 86:12 89:7,21 103:14 104:13 112:8 123:4,22 135:14,17 185:3 186:7 187:2 191:12 198:6 218:4 219:8 234:1 244:12 275:2 280:9,16 281:16 281:22 282:13 283:2 284:8 287:22 288:1,5 308:14 311:16 323:23 362:16 363:23 373:23 374:19 378:6,11 380:3,7 381:4,5,8 381:19 382:9 387:21 408:12 410:19 439:5 441:7,12 443:6 444:15 449:20 452:12,15 453:19 454:4 469:5 482:19 483:3 484:19 488:20 <b>scientifically</b> 44:10 287:9 366:21 <b>scientist</b> 408:23 409:3 <b>scope</b> 52:7,15,20 53:2 54:14 55:4 62:2 81:9 83:7,16 83:17,18 89:4 90:18 91:17 92:6 92:18 96:19 97:13 98:1,9 99:9 117:11,18 120:21 126:14 137:14	151:21 204:12 297:19 298:6 425:21 426:18 429:23 438:5,18 442:17 443:16,22 451:20 453:22 454:13,19 455:13 458:3 459:12 460:21 461:19 462:7,13 465:7 469:9 <b>score</b> 161:3 <b>scottsbluff</b> 138:15 138:23 139:16 <b>screen</b> 256:3 <b>screened</b> 416:19 <b>scripture</b> 456:21 <b>scroll</b> 344:10 345:13 <b>scrotoplasty</b> 478:10 <b>scrotum</b> 478:7 <b>se</b> 151:8 178:22 213:7 392:17 <b>search</b> 21:2,6,10 268:19 353:18 453:16 <b>searches</b> 297:12 <b>second</b> 39:3 58:1 64:6,8 70:22 93:3 93:10 94:9,15 95:2,3 96:2,15 97:8 110:5 119:20 134:20 233:19 241:2 255:20 320:17 328:18 339:15 360:4 364:15 383:13 384:11 391:22 413:9 428:12 440:10 445:8,12
---	---	--	--



477:3 <b>secondary</b> 165:14 479:2 <b>section</b> 35:4 36:3 59:15 116:17 172:4,5,6 225:5 240:5 257:8,17 265:16 326:12 330:13 339:3 341:17,19 342:11 344:9 378:9 382:12 391:16 397:8 399:15 400:3,15,19,23 401:8 405:3 413:7 415:9 437:7 440:3 440:16 441:6 <b>sections</b> 116:12 <b>see</b> 13:20 22:17,18 22:22 25:9 27:3,6 27:18 28:5,20 29:2,16 30:18 34:9 35:12,18 36:2 38:6,7,13 39:7 41:1,8,10,12 41:13,15 43:12 53:4 55:17,23 56:22 59:12,14,19 60:8 63:3,16,22 64:20 65:12 70:16 71:5,6,6,7,19 74:20 80:22 91:23 92:8,9 95:21 104:2 108:14,22 109:18 110:9 111:14 113:1,10 113:14 116:1,10 116:14,21 123:13 123:19 128:19 131:13 132:22 134:9,14 141:22	143:19 146:1 150:12 158:20 171:13,16 172:15 172:23 173:18 174:5 202:18 212:19,20 224:13 224:14,16,19,23 225:5,7,17 226:8 227:6,11,22,23 228:2,11 229:15 230:17 231:6,14 232:12 233:15 234:4,13 237:16 239:4,21 240:13 241:9 243:6 246:1 247:13 249:10 253:9 256:22 257:5,8,15,23 258:8 262:11 263:13,16 264:12 265:3,13 266:1 268:19 279:22 280:2,11,17 299:21 300:1,12 301:23 302:2,7,11 308:11 309:12 313:9,12 320:13 320:23 322:18 323:5,19 324:13 326:12,16 327:2,4 327:4 328:11,17 330:14 332:6 334:22 337:8 339:6,7 340:11,20 341:16,19 342:1 342:10 344:7,20 344:23 345:4 346:3 348:4,14 349:23 350:1,7,22 351:20 352:1,20 356:4,15,17,23	357:17 358:12 359:12 361:10 364:15 365:8 366:5 373:17 374:1 377:10 378:5,13,15,18,22 379:3,4,7 382:12 382:15 383:3,11 383:14 384:2 385:2 391:14,15 392:13,21 394:17 394:18 395:1,7 397:10 398:3,12 400:7 401:8,16 402:6 405:20 406:8 407:15 411:16,20 412:21 413:6,8,15 414:1,6 415:8,12,17 419:14 420:1 421:9,22 422:3,15 427:6,8 428:18 429:7,12 430:14 431:5 432:4,4 434:9 435:1,7,19 437:7,17 440:3,8 440:12,22 441:3 446:9 447:14 449:1 451:15 453:1,2 461:4 471:20 <b>seeing</b> 71:17 114:21 237:9 355:1 386:8 <b>seek</b> 66:14 334:19 351:8 457:13 <b>seeking</b> 67:20 71:9 74:10 132:8 146:4 152:14 154:16 165:9 276:11 300:22 363:11	456:23 459:18 <b>seen</b> 17:21 18:13 77:8,11 96:8 123:6 162:5 165:4 165:4 219:4 223:21 233:8 249:21 309:11 338:1 340:19 388:23 420:2 436:5 488:15 <b>sees</b> 245:21 <b>select</b> 307:4 <b>selected</b> 7:19 191:2 193:8 198:2 411:9 476:23 477:1 <b>selecting</b> 306:21 <b>selection</b> 472:22 <b>selective</b> 306:8,19 <b>self</b> 70:18 94:1 120:2 145:1 161:10 162:9 313:13 314:19 318:11 333:21 334:10 341:9 347:2 355:11 357:9,15 362:21 363:16 368:10,15 369:1,6 370:1,2 374:10 444:1 463:21 476:19 485:22 487:3 <b>seminal</b> 480:21 <b>sen</b> 378:20 <b>senate</b> 4:23 63:2 63:11 <b>send</b> 143:5 154:21 156:23 157:8 <b>sending</b> 473:7 <b>senior</b> 378:20
---	--	--	---

<b>sense</b> 24:4 66:15 66:16 80:23 81:14 117:12 152:15 206:5 226:4 235:5 266:10 348:19 355:8 386:9 <b>sent</b> 80:8 156:10 157:3 493:14 <b>sentence</b> 39:3 40:1 41:2 65:6 109:12 111:8 113:6 116:5 119:20 143:20 172:18 231:16 233:19 234:6 241:2 257:19 258:2 300:4 308:9 309:5 326:20 328:18 330:16 348:1,2 356:11 357:7 384:11 391:22 395:4 402:12 403:13,15 405:23 413:9 <b>sentences</b> 172:10 302:1 344:11 398:5 <b>separate</b> 365:11 <b>separately</b> 136:5 <b>september</b> 1:21 9:9,17 171:16 465:10 491:10 <b>sequential</b> 283:12 283:14 <b>sequitur</b> 402:13 <b>serendipitous</b> 229:3 245:23 247:14 308:19 <b>series</b> 283:11,14 304:18 308:2,10 308:14,20,21 309:9 310:21	311:15 312:18 314:6,9 322:17,23 323:12 324:13 335:15,18 343:6 343:11 <b>serious</b> 109:16 487:7 490:7 <b>serve</b> 189:4 456:17 457:1,13 <b>served</b> 194:8 450:6 475:9,11,16 <b>service</b> 151:17 432:9 <b>services</b> 95:17 104:18 111:9 140:15 195:2 248:3 376:22 384:21 385:14 422:5,19 431:3,3,9 434:5 435:9 437:22 438:11 454:5 473:4 474:8 474:9 475:10 <b>serving</b> 33:1,15 92:15 172:21 173:10 <b>session</b> 187:5 195:13 <b>sets</b> 420:21 <b>setting</b> 258:16 356:15 374:10 435:8 480:17 <b>settings</b> 258:5,8 <b>seven</b> 45:23 123:1 141:22 166:1 322:23 325:10 335:15 336:16 337:7 343:6,12 357:20 391:18 <b>seventeen</b> 474:6	<b>severe</b> 265:9 266:5 267:17 487:2 <b>severity</b> 405:19 <b>sex</b> 6:13 7:9 8:14 36:22 59:15,23 60:3,7 61:7 81:20 82:1 94:1 145:3 146:10 147:1 161:10 164:9 165:14 213:7,22 214:11,16 219:17 238:19,21 247:2 247:10 260:7 318:6,20 319:4,8,9 319:14 337:10 346:16 370:1 383:23 392:1,9,10 392:17,19 393:11 404:2 405:18 416:13 417:5 437:14,22 442:13 442:21 443:12,20 446:17,22 447:2 447:20 448:1,15 454:9,15 455:2 457:14,15 464:15 464:21 482:17 487:16,20 <b>sexual</b> 192:17,20 333:3 436:8,16,21 461:15 462:11 463:18 464:1,1 469:20 <b>sexualize</b> 469:23 <b>sexualizing</b> 462:4 462:20 468:23 <b>sham</b> 250:5 316:1 <b>shaping</b> 461:1 <b>share</b> 364:22 <b>shared</b> 270:16	<b>shareholders</b> 381:2 <b>sheet</b> 493:11 <b>shield</b> 376:1,7 381:1,9 382:1,22 383:8 429:15 <b>shift</b> 99:15 400:12 442:4 <b>shifted</b> 305:1 369:7 <b>shipp</b> 55:20 56:3 <b>short</b> 7:17 48:4 53:10 271:4 327:17,17 336:4 336:10 411:8 <b>shortcut</b> 188:21 <b>shorter</b> 150:20 <b>shortly</b> 361:10 <b>shoulder</b> 292:5,11 <b>shoulders</b> 261:3 276:9 <b>show</b> 37:19 114:13 230:8 264:19 325:1 327:23 336:2 339:11 363:7 366:22 371:21,22 375:12 396:13 412:16 426:20 430:4 433:5 <b>showed</b> 32:8 181:7 354:15,15 371:23 424:6 439:12 <b>showing</b> 90:4 92:9 247:23 346:14 453:15 <b>shown</b> 312:15 415:15 439:18 <b>shows</b> 122:17 258:20 313:7 329:23 352:19
--	--	--	--



355:9 368:8,16,18 369:17 374:20 405:18 414:4 453:20 <b>sic</b> 12:23 <b>side</b> 77:2,3 94:12 99:13 142:17 146:15,17 151:16 159:15 217:16 282:16 285:9 349:20 <b>sided</b> 222:23 <b>sign</b> 493:12 <b>signature</b> 264:12 <b>signed</b> 27:2 493:20 <b>significant</b> 206:22 207:4 295:2 368:9 383:21 483:19 484:15 487:1 490:6 <b>significantly</b> 487:16 <b>signify</b> 243:3 <b>signs</b> 463:18 <b>similar</b> 46:10 52:23 54:9 61:20 63:6 76:23 77:7 77:10 88:14,19 93:11,16 99:11 140:4 <b>similarities</b> 475:21 <b>simple</b> 289:12 <b>simply</b> 124:17 151:16 <b>single</b> 20:17 42:8 42:15 150:22 152:2,6 298:20,23 299:3 308:20,21 312:19,19,20 323:16 328:9 416:20	<b>singulair</b> 222:7 <b>sinus</b> 129:21 133:12 <b>sir</b> 11:11 18:16 31:15 32:5 34:23 35:10,13,19 36:5 39:9 40:9 42:14 48:1 64:3 76:19 77:9 118:14 119:19 120:16 133:3 174:23 296:12 331:17 466:10 477:15 490:20 <b>sit</b> 183:8 <b>site</b> 407:23 408:1 <b>sitting</b> 70:3,9 170:21 173:21 221:20 239:8 297:15 310:17 <b>situation</b> 179:20 244:1 <b>situations</b> 206:9 251:2 253:1,20 254:1,5,10 <b>six</b> 56:17,18 128:23 129:3 136:14 158:16 160:2,3 163:23 164:1 336:15 337:14 380:19 391:17 <b>sixteen</b> 56:16 360:22 <b>size</b> 355:8 372:9 413:10,11 426:8 <b>skin</b> 131:12 134:7 136:8 137:23 139:3,20 140:1,2 142:14,14 144:1,2 144:4,7,8,15,18	145:2,8,13 146:9 <b>skipping</b> 231:16 258:2 <b>slide</b> 88:3,7 456:18 457:2,8 458:15,21 458:23 460:22 461:23 462:22 463:13 464:3 <b>slides</b> 87:23 451:10 456:17 <b>slightly</b> 155:1 <b>slipped</b> 131:4 <b>slow</b> 161:14 165:22 207:6 381:1 388:17 <b>slowing</b> 384:15 <b>slowly</b> 114:20 <b>small</b> 20:15 45:8 45:11 290:13 295:20 352:16 413:11,12 <b>smaller</b> 317:7 <b>social</b> 70:19 71:11 348:3,6,9 349:1,5 351:15 362:7 366:21 367:15,17 367:17 368:1,1,7 368:21 369:18 370:10,10,20,20 371:6 373:1,2,3 397:9,17,21 <b>socially</b> 351:12 <b>societies</b> 53:5 76:14 <b>society</b> 5:9 44:18 45:3,15,18 46:1,7 47:8 48:11,15,19 72:3 99:16 100:5 100:19 103:19 104:22 108:11 118:10,18 123:23	169:7 171:12 181:19 182:1,3 195:16 196:22 197:3,6,9,21 198:7 198:19 199:11 200:13,20 282:4 283:8 300:18 301:4 404:5 <b>soft</b> 479:5 <b>sole</b> 410:1 <b>solely</b> 331:14 <b>solicited</b> 187:18 191:19 199:12 <b>solo</b> 23:21 <b>solution</b> 324:4 <b>solutions</b> 10:7,9 493:23 <b>solve</b> 351:9 <b>solved</b> 313:13 <b>somebody</b> 121:11 245:21 250:5 276:11 284:19 318:22 322:9,11 <b>sorrow</b> 194:18 <b>sorry</b> 57:18 77:9 108:20 138:19 142:11 144:18 163:16 170:5 172:2 201:10 212:9,11 227:4 268:6,11 280:23 281:3,13,14 318:19 325:19 327:20 340:1 353:7 373:2 379:12 384:14,14 385:19 397:15 409:1 421:16,19 426:1,7 440:22 441:2 445:17 446:20 457:14
---	--	--	---

464:7 471:5,11,12 474:12 <b>sort</b> 19:18 70:20 71:2 87:18 88:5 89:13 94:4 96:22 96:22 101:4,21,23 103:16,20 107:4 127:11 140:3 159:3,13,21 165:8 165:10,22 208:20 301:15 323:16,17 324:6 372:7 475:6 <b>sorts</b> 53:5 104:12 334:11 <b>sound</b> 22:11 76:10 170:5 194:13 196:9 202:23 203:2 234:2 <b>sounds</b> 22:13 84:9 190:3 203:5,9 472:2 <b>source</b> 74:1,3 296:18 361:22 407:18 <b>sources</b> 378:7 380:4 458:13 <b>space</b> 306:6 <b>speak</b> 14:7 79:19 81:16 82:11 87:1 87:6 96:13 161:21 163:16,17 328:16 366:18 416:8 445:1 447:17 457:1,5,7 <b>speaker</b> 82:3 471:16 <b>speakers</b> 81:16 <b>speaking</b> 20:1 85:4,6 93:18 107:16 126:17,18 338:20 448:3,10	466:19,19 467:2 469:19,21 <b>speaks</b> 73:3 95:9 351:23 358:10 369:12 373:8 466:23 <b>special</b> 253:7 <b>specialist</b> 74:16 75:13 87:18 155:22 156:20 <b>specialists</b> 149:16 206:2 <b>specialized</b> 66:2 204:2 <b>specialty</b> 155:21 156:16 378:16 472:15 <b>specific</b> 26:9 135:2 170:14 174:20 180:1 212:12 213:14 242:19,20 288:10 365:19 <b>specifically</b> 70:4 132:17 144:20 145:5 163:20 192:16 198:18 209:22 210:5 255:15 334:18 376:23 417:19 418:11 <b>specifics</b> 27:23 <b>specified</b> 437:12 <b>specimen</b> 292:2 <b>spectrum</b> 152:10 313:18 487:4 <b>speculating</b> 47:4 <b>speech</b> 368:21,22 369:20 371:22 372:2 <b>speeches</b> 261:18	<b>spell</b> 16:13 <b>spelling</b> 445:6 <b>spend</b> 135:3 412:11 <b>spent</b> 17:8 <b>spoke</b> 14:2,16,22 64:10 81:18,20 481:2 <b>spoken</b> 15:16 16:8 16:10,16,18,22 64:17,23 205:5,8 206:1 418:3 <b>spread</b> 490:13 <b>spring</b> 207:5 <b>srs</b> 322:22 330:19 <b>stable</b> 344:14 <b>staff</b> 13:1 56:3 98:23 99:1 307:1 474:5 <b>stage</b> 107:4 122:19 125:2 <b>stainless</b> 131:5 <b>stake</b> 286:14 287:18 386:20 447:19 <b>stamp</b> 339:14 340:4 <b>stand</b> 61:13 120:16 <b>standalone</b> 410:16 <b>standard</b> 183:2 209:13 244:23 249:3 <b>standards</b> 7:15 182:16,19,21 183:9 184:5 186:9 186:10,11 189:11 196:14 199:7 316:3 396:15 397:4,14 398:14 399:2 401:1	<b>standpoint</b> 194:17 387:8 447:15 466:16 <b>stands</b> 87:10 <b>start</b> 23:2 84:7 85:9 156:18 162:15 163:11,12 164:4,9 237:9 254:19 302:16 316:19 324:17 351:20 383:14 <b>started</b> 24:3 67:9 106:14 107:3 146:23 148:3 184:8 202:12 216:4 226:8 268:17 345:1 372:7 408:16 409:6 480:13 <b>starting</b> 106:16 143:20 161:1 165:14 166:8 228:1 236:15,17 236:20 237:4 320:14 328:11 344:13 345:7 <b>startled</b> 477:2 <b>starts</b> 228:3 405:14 <b>state</b> 5:2,5 9:2 10:10,20,21,22 11:1,12 27:23 28:2,19,23 33:9 37:10 51:22 52:5 53:8,10 54:4,7 57:10 58:15,21 59:8,13 63:5 76:16 78:14 79:21 81:1 82:15 89:6 90:2 96:8 113:8 115:23 116:8
---	---	--	--

284:5 376:8 396:3 397:20 420:13,16 473:14 482:11 492:2,22 <b>stated</b> 227:7 228:2 349:3 483:13 <b>statement</b> 5:21 44:20 45:16 46:8 46:15,20 47:15,22 48:6,16 49:3,15 105:15 113:12 114:1,3 239:20,22 240:1,9,13 250:12 253:22 254:3 331:8 377:2 <b>statements</b> 45:5 46:12,13,17 47:12 50:10,16 51:11,14 117:23 199:2 247:11 444:16 481:8 <b>states</b> 1:1 9:22 30:7 52:21 54:23 61:19,23 62:4 110:9,12,19 111:3 429:4 472:18 474:2 475:13 <b>stating</b> 27:17 <b>statistic</b> 102:21 <b>statistically</b> 392:4 <b>status</b> 27:18 29:1 30:15 240:10 365:7 366:9,13 <b>stay</b> 98:6 <b>stayed</b> 53:10 <b>stays</b> 256:7 <b>steel</b> 131:5 <b>stenographic</b> 492:6 <b>step</b> 53:8 339:8	<b>stephen</b> 58:2 <b>stepped</b> 260:12,13 <b>stepping</b> 54:1 105:9 <b>steps</b> 69:15 <b>sterilization</b> 287:15,16 <b>sterilizing</b> 290:7 <b>steroids</b> 145:3 146:9,10,16 147:1 <b>stick</b> 261:16 448:14 <b>sticking</b> 449:18 <b>stomach</b> 121:22 <b>stop</b> 251:2,8 <b>stopped</b> 25:8 <b>stopping</b> 366:10 <b>stories</b> 280:1,14 323:22 365:6,21 366:1,2,7,11,16 <b>story</b> 95:21 <b>street</b> 2:20 3:12 <b>strength</b> 413:7 <b>strengths</b> 342:11 391:15 <b>strictly</b> 424:17 466:15 467:10 <b>stricture</b> 338:10 <b>strictures</b> 338:21 <b>strike</b> 13:12 14:17 16:4 18:10 23:13 33:13 49:5 84:2 90:12 125:23 147:17 158:14 174:14 177:17 186:21 202:1 228:17 267:15 268:15 272:12 289:3 314:23 326:10 348:6 370:5 377:17	433:6 461:13 <b>stringent</b> 281:16 <b>strive</b> 454:16 <b>strong</b> 78:17 290:3 <b>strongest</b> 490:1 <b>strongly</b> 114:14 <b>struck</b> 106:13 131:4 <b>struggles</b> 455:1 <b>stuck</b> 361:8 <b>student</b> 101:11 <b>studies</b> 13:9,11,15 13:18 35:21 108:17 109:5,9 124:12 248:10 249:20,23 250:7 270:8,11 271:17 278:1,15,22 292:18 298:10,13 298:21 301:20,20 302:1 304:2,9 305:9 321:10 329:22 331:20 343:20 353:1,8 354:22 356:20,21 356:22 357:3,4,11 358:8 367:21 371:5 378:2 391:7 412:13 415:13,15 415:21 416:3,18 441:14 482:2,15 485:14 486:2 490:5 <b>study</b> 6:19 7:10 39:7 50:17 109:10 250:1 256:18 257:11,22 258:10 258:20 271:19,21 273:18 275:17 276:1,5,17,19,22 277:4,7,18 278:2,5	278:8,10,19,23 279:3,7,15,17 281:17,18 282:7,8 282:9,9,14 286:4 289:11 291:12 292:13 298:23 299:18 300:5,15 309:11 311:10 313:7 317:17 318:10 319:17 321:9 323:9 324:20 329:16 330:3,6,22 334:15 334:17,18 339:11 340:8,10,19 341:14 342:5,18 342:22 343:5,8,10 343:15,17,19 346:14 347:8 348:18 352:5,10 352:15 354:14,21 355:9 358:3,10 363:7 370:7,17 388:23 389:14,17 389:22 390:10,23 391:16 392:7 393:10,17 410:22 411:20 412:4 413:10,14 414:4,5 414:8,9 416:20 440:9,10,11 453:6 453:13,15 <b>stuff</b> 101:4 107:1 148:8 220:18 359:13 363:16 372:7 448:12 <b>subcategories</b> 74:21 <b>subcategorizing</b> 301:15
--	---	---	---

<b>subcategory</b> 154:7 <b>subgroups</b> 390:7 <b>subject</b> 20:2 34:21 39:6 51:4 79:17 82:3 88:19 104:17 172:14 176:14 205:21 272:1 274:14 287:5,6 389:5 416:12 450:2 <b>subjective</b> 112:4 114:2 282:15 327:16,17 331:10 336:5,7,10 349:13 <b>subjects</b> 87:21 454:1 <b>submission</b> 234:10 <b>submitted</b> 33:22 34:3 42:17 43:3 55:19 292:3 <b>subreddit</b> 364:19 364:21 365:13 366:5 <b>subscribed</b> 495:14 <b>subscribing</b> 297:1 <b>subscription</b> 297:4 <b>subscriptions</b> 100:10 <b>subsection</b> 174:5 <b>subsequent</b> 122:3 185:22 461:10 <b>subsequently</b> 74:6 226:22 229:4 270:21 <b>subset</b> 68:15 <b>subsidiary</b> 103:21 <b>subspecialty</b> 173:15 <b>substance</b> 14:6 70:17 77:14,15 363:6	<b>substantive</b> 98:12 98:17 168:16,21 173:11,23 181:1 181:12 <b>success</b> 161:19 300:17 331:2 <b>successful</b> 95:15 301:3 303:18 <b>succinctly</b> 127:1 <b>sudden</b> 368:23 <b>suddenly</b> 368:14 369:7 372:13 <b>suffer</b> 132:13 444:3 486:18 <b>suffered</b> 463:23 <b>suffering</b> 41:6 53:9 66:19 122:11 122:13 151:5 260:18 457:6 <b>sufficient</b> 294:1 358:9 482:20 484:21 <b>sufficiently</b> 310:8 311:22 <b>suggest</b> 414:4 <b>suggesting</b> 118:2 <b>suggestion</b> 173:4 <b>suggestive</b> 362:23 <b>suggests</b> 394:22 <b>sugrue</b> 6:6 299:19 <b>suicidal</b> 487:5 <b>suicidality</b> 313:13 333:20 334:20 338:5 347:2 <b>suicide</b> 119:9 162:9 314:5,18 334:10 372:4 390:2 391:1,9 393:13,20 <b>suitability</b> 416:17	<b>suitable</b> 398:23 <b>suite</b> 2:14 3:6,12 <b>summary</b> 82:15 88:23 89:5,5 300:2 303:8 327:14 405:3,3 <b>supervision</b> 492:9 <b>supplement</b> 263:17 <b>supplemental</b> 4:16 38:4 264:1 265:1 265:6,20 <b>supplements</b> 38:10 296:11 <b>supplies</b> 422:6,19 <b>supply</b> 339:2 468:9 <b>support</b> 48:16 49:13 51:18 52:4 52:8 57:10 58:16 64:1 72:6 77:21 88:21 89:8,22 103:14 104:11 112:9 244:13 284:21 287:23 303:19 314:17 336:3 352:17 380:7,18 381:19 382:10 387:21 393:7,11,17 395:18,19 403:5 406:19 409:20 410:1,19 416:22 439:14 444:6,6 454:5,8 469:6 482:16,21 484:19 485:20 <b>supported</b> 39:5 45:17 50:10,17 120:6 123:19 186:14 243:11	245:9 251:23 285:12 286:3,12 287:9 288:13 294:18 295:10 488:19 <b>supporting</b> 46:18 76:4,21 117:8 402:4 403:2 481:19 482:4,11 <b>supportive</b> 417:4 <b>supports</b> 46:15 338:2 487:6 <b>suppose</b> 50:23 53:11 226:8 311:19 323:18 381:3 <b>supposed</b> 28:9 <b>supposedly</b> 117:14 <b>suppress</b> 428:15 428:23 <b>suppressing</b> 401:10,14 437:15 437:23 <b>suppression</b> 7:19 404:1 406:1 411:9 413:5 <b>sure</b> 15:2,20 32:15 94:19 97:6 113:5 115:9 118:13 121:2 126:23 139:1 181:4 184:14,15 256:7 273:15,16 277:18 288:19 297:21 325:12 340:23 343:1 360:5,5 434:4 453:3 463:9 468:7 477:11 485:7 487:14 <b>surgeon</b> 8:14 24:5 64:10 66:18 95:4
--	--	--	--

95:7 106:5 119:14 121:16 123:10 130:20 133:6 154:20 155:19,19 159:18 160:13 174:19 198:17 213:2 274:16,17 281:7 284:16 315:10,12 402:15 443:8 464:15 466:4,17 467:11 467:14 472:17,20 473:1 475:12,17 476:9 480:14,15 <b>surgeon's</b> 79:20 466:5 480:18 <b>surgeons</b> 5:10 44:19 66:10 67:16 68:10 96:12 99:17 100:5,19 102:23 108:11 120:18,23 122:14 123:7,21 126:9 127:3 130:14 132:3,5 149:21 154:16 169:7 171:13 285:3 294:17,22 294:23 295:9,15 299:3 312:4 419:8 474:5 <b>surgeries</b> 24:21 25:2,8 59:16 90:9 90:10,11 103:8,13 118:3 119:22 120:19,23 121:23 122:1 125:14 140:12 142:4 143:8 147:15 148:11 176:8 177:4 315:22,23 336:4 338:18	358:13 379:20 478:21 <b>surgery</b> 6:8,11,14 7:10 8:5 22:21,22 23:3,4,15 25:3,14 25:17 26:2,14,17 27:14 28:11 30:9 31:7,8,12,23 32:3 32:10,11,17,19 36:23 44:13 45:1 45:3 46:2 47:8 60:1,17,22 61:5 64:18 66:11,21,21 67:9 68:4,5,6,17 69:7,16 71:3 72:4 72:4 73:2 79:22 81:2,6 82:10,12,14 89:7 90:7 95:12 100:17 102:20 103:19 104:7 106:2,9,10,17 107:13,20 111:9 111:18 112:10,14 112:22 114:10 115:19 121:17,19 122:2,7,9,21 123:8 123:17,23 125:9,9 128:8,8,13,14 130:3,15 131:16 131:19 132:1,18 133:17 134:3,17 138:10,11,17 139:7 140:5 141:13 143:4 147:20 149:3 151:8,23 152:5 159:3 166:23 167:4,8,14,20 168:8,13,18 175:5 175:10 176:22 178:2 181:21	189:3 250:5 273:8 273:8 282:4 283:5 283:9 287:13 290:11 291:6,15 291:19 293:5,19 296:1,20 299:21 300:6,10,18 306:11,13 309:12 309:16,21 310:19 310:23 311:14,14 312:3 314:11,18 316:1,12 323:1 328:3,8 331:3,9,13 332:5 333:8,14,19 334:3,6 335:4,20 337:11 338:11,14 346:17,22 351:9 351:19 358:17 366:14 373:21 375:7 376:13 382:23 384:22 386:16,17 387:2 387:14 390:1,16 391:3 392:23 393:12 394:22 423:22,23 425:17 426:14 427:6,18 428:2,7 429:8 432:3,8 433:19 437:21 444:19 450:15,22 454:6 466:21 467:1,3 468:12,14 469:17 472:16,23 473:16 473:22 474:15 475:5 476:2,2,15 477:4,5,10,14,21 478:20 479:10,15 481:2,15 482:18 488:18,23	<b>surgery's</b> 159:19 159:21 <b>surgical</b> 6:21 24:23 65:1 104:15 105:12 112:3 117:15 121:18 126:10 127:4 134:8 140:9 141:11,18 142:13 144:8 154:23 159:15 162:23 163:13 164:14 174:18 175:21 176:5 177:21,22 220:20 271:19 284:13 285:12 286:2,4 288:12 289:5 290:19 293:11 295:15 296:14 308:10,23 315:3,20 316:5 322:21 326:23 330:8 334:2,7 336:17 353:10,20 353:21 354:3 356:2,14 357:5,16 357:21 358:23 369:13 393:18 400:17 402:18 419:5 424:10 435:16 436:14,17 444:11 459:6,10 459:20 469:22 470:7 474:8 480:16 481:3,20 485:1,21 486:3 <b>surgically</b> 144:4 151:2 152:4 323:2 328:12 329:4 <b>surprise</b> 20:4,9 21:23 32:16,22
---	--	--	---

103:4 196:11 425:13,22 <b>surprised</b> 303:12 <b>surprising</b> 21:15 113:12,15 <b>surroundings</b> 348:11 349:7 <b>survey</b> 331:14 <b>surveys</b> 299:8 332:4 <b>suspect</b> 26:23 151:5 196:18 220:13,22 <b>suspend</b> 140:8 <b>suspicion</b> 58:23 185:12 433:22 <b>suspicious</b> 144:13 144:14 <b>swear</b> 10:12 184:23 <b>swede</b> 329:21 <b>sweden</b> 7:11 35:16 248:4 329:20 <b>swedish</b> 313:7 329:21 330:6 346:14 389:23 391:3 453:5 <b>sweet</b> 131:3 <b>swissophone</b> 389:9 <b>switch</b> 182:8 <b>sworn</b> 11:6 495:14 <b>symptoms</b> 152:7 405:18 <b>system</b> 116:7 280:10 319:6 345:21 <b>systematic</b> 6:22 8:1 300:8 307:18 356:3,12 357:3,20	<b>t</b> <b>t</b> 4:10 33:2 182:13 202:16 203:4,4,11 203:11 277:14 360:9 372:7 425:7 446:12 492:1,1 494:3,3 <b>table</b> 87:14 129:21 131:5 302:7,9 307:13 337:6 338:8 349:20,23 350:13,16 <b>take</b> 14:11 24:20 69:14 90:22 115:17 131:17 140:16 143:11 176:6 204:18 282:11 294:12 312:15 315:7 316:15 318:6,20 319:21 367:20 397:1 408:13 463:14 470:3 471:18,19 <b>taken</b> 9:20 40:18 41:17 42:2 51:12 79:5 115:12 166:18 227:22 229:19 232:4 240:16 254:17 320:4 322:12 388:9 417:13 470:14 472:5 492:5 <b>takes</b> 42:8 80:17 80:23 107:12,19 111:5 112:3 118:10,18 221:17 222:13 231:23 232:16 242:1 429:20 442:12	443:11 <b>talk</b> 23:1 31:7 35:15 83:23 118:15 136:20 163:5 201:2 210:21 271:1 290:1 331:10 347:11,11,13 381:4 452:14,23 453:17,23 464:3 <b>talked</b> 61:16,17 87:22 110:1,14 169:6 189:14 204:23 232:8 261:19 267:12 268:1 290:18 300:20 324:14 345:11 347:3 351:23 352:8 354:12 363:9 380:20 421:3 424:13 429:14,15 448:5 469:11 <b>talking</b> 13:3 20:15 68:21 109:21 115:16 144:5 159:7 166:3 206:21 212:13 216:4 255:2 270:14 271:14 277:6 278:9 287:14 289:10,12 289:19 290:12,15 291:18 293:15 295:19 312:10 313:17 314:20 328:5 338:15,16 361:19 366:16 369:11 372:3,5 386:12 425:4 446:6 448:1,7	449:19 460:14 462:14 471:14 484:15 488:2,3 <b>talks</b> 131:22 240:12 402:21 <b>tangential</b> 132:10 132:16 <b>tangentially</b> 130:5 <b>tara</b> 2:12 <b>tattoo</b> 139:23 <b>tavistock</b> 53:19 <b>tborelli</b> 2:16 <b>teachers</b> 10:20 420:15,16 452:1 <b>teaching</b> 121:13 454:2 467:10 <b>teachings</b> 452:17 <b>team</b> 149:11 150:5 150:14 272:22 336:23 <b>teams</b> 83:14 151:9 <b>technical</b> 82:11 295:20 <b>technique</b> 130:9 130:17 284:13,15 289:12,15 299:1 310:10,21 311:3 311:11,21 312:14 <b>techniques</b> 130:13 286:11 290:11 295:1 296:15 311:12,20 338:3 <b>telephonic</b> 192:7 200:1 <b>tell</b> 21:18 22:8 68:5 76:21 114:19 174:8 196:8 207:18 208:13 214:23 292:6 341:4 352:21 372:3,6 434:2
--	---	--	---



<b>telling</b> 12:13 59:13 226:14 237:2 306:15 433:16 <b>tells</b> 244:11 <b>temporary</b> 265:8 <b>ten</b> 23:11 46:8 86:2 138:20,21 139:7 140:16,20 140:23 141:7 262:2,6 263:1 266:21 351:22 476:23 <b>tend</b> 210:14 284:16 285:4,5 <b>tends</b> 345:11 <b>term</b> 7:7,17 18:18 19:7,11,17,19 20:3 20:6,19 21:18,19 21:22 22:2,7 61:11 89:10 119:12 124:11 141:5 164:22 193:20 241:20 249:20 291:12 292:12 313:10 314:15,16 332:8 398:10 399:10 404:7 411:8 442:6 442:8,21 447:4,6,7 447:8 459:14 466:14 485:12 <b>terminology</b> 60:23 194:13 <b>terms</b> 24:8 26:7 89:20 93:17 119:10 148:12 152:22 176:20 277:21 311:16 355:13 413:22 424:17 446:21 458:12,14 469:20	469:21 484:22,23 487:8 <b>test</b> 219:10,11 324:11 332:3,22 333:1 486:12 <b>testified</b> 11:7 38:19 64:1 91:11 91:13 308:16 <b>testify</b> 38:15 90:21 173:13 <b>testifying</b> 90:23 91:5 95:10 274:23 <b>testimonies</b> 359:18 360:19 365:12 <b>testimony</b> 1:19 11:16 17:20 18:6 50:14 63:19 97:19 170:15 171:2 172:7,11,12,20 174:14,17 177:2 180:3,6,14,23 182:5 216:11 254:9 329:8 363:6 449:14 487:12 491:4,12 493:9 495:8 <b>testing</b> 281:20 282:2,12 437:16 <b>testosterone</b> 214:7 214:22 215:17 318:23 <b>tests</b> 124:9 211:11 486:9 <b>texas</b> 62:5,7,11 76:20,22 77:5 78:10 110:15,22 <b>text</b> 266:1 416:19 <b>textbooks</b> 73:1 <b>thank</b> 10:13 19:5 98:15 133:15 275:10 325:5,17	445:4 470:21,23 490:23 491:2,5,5,6 <b>thanks</b> 470:20 <b>theirs</b> 196:13 <b>therapeutic</b> 229:4 248:18 282:8 291:10 301:16 <b>therapies</b> 52:9 105:23 106:21 110:8 147:4 150:15 208:22 324:7 <b>therapy</b> 77:22 124:5 139:22 140:14 145:17,19 159:20 163:17 164:5,10 215:8 228:9 238:17 243:4 247:17 249:22 289:14 345:8 376:14 379:21 384:23 387:3 394:21 400:5 425:18 426:15 431:12 437:15,17,23 481:20 482:12 <b>thing</b> 59:1 70:20 93:21 94:10 96:22 98:17 103:16 114:21 125:11 127:13 140:3 145:15 159:22 162:1 164:21 222:23 303:16 358:3,6 364:5 380:14 403:18 436:3 440:8,10,11 459:17 475:6 478:22 487:11	<b>things</b> 16:13 20:16 46:10 50:21 53:6 54:6 68:11 77:22 83:12 101:8 102:1 102:16 103:23 105:20 106:1 119:11 121:13 122:22 123:2 144:11,14 159:15 178:7,17 209:16 210:1 218:12 224:4 226:11 247:6 260:5 262:14 271:14 281:9 282:16 288:7 290:21 299:8 301:6,17 313:15 332:7 333:2,18,20,22 334:4,11 347:3 369:17 392:18 402:8 404:8 421:2 432:13,15 447:19 457:22 463:11 464:2 <b>think</b> 14:9,13,14 15:17 16:1 18:15 18:15 19:18,21 25:8 26:2 32:11 45:12 46:20 48:19 52:16,21 54:4,17 58:7 61:10 62:9 62:10 65:19,19 69:9 72:11,17,18 73:12,20 74:5 82:3 84:6,11 85:2 85:15 86:10,15 87:1,6,19 88:6 93:11,15,17,20 94:10,11,14,16,17 94:22 96:20 97:10
--	--	---	---

98:10,13 99:10	460:16 462:2,8	336:15 337:23	182:12 186:20
100:12 101:7,11	474:6,22 489:3	364:14 381:22	254:12,21 256:12
101:17,19 102:21	<b>thinking</b> 106:12	391:17 431:10	319:23 320:8
103:6,20 105:11	154:17 166:2	455:22	325:22 340:5
105:14 106:16	372:4 470:1	<b>throttling</b> 143:10	370:3 388:13
107:1,14 110:20	<b>thinks</b> 154:9 383:8	<b>thursday</b> 9:17	389:12 414:14
110:20,21 115:4	<b>third</b> 27:20 41:2	491:10	417:9,16 445:5
117:17 118:8,17	64:16 65:6 71:4	<b>thyroid</b> 156:8,12	470:9,18 471:2,23
118:21 119:1,3,3	98:4 133:1 195:6	<b>thyroidectomy</b>	472:2 489:6,10
121:5,8,9 122:19	300:4 309:5 348:1	156:13	<b>tissue</b> 467:17
141:14,18 149:5,6	356:11 357:7	<b>time</b> 14:22 19:2	479:5
152:3 160:4,10	391:19 430:22	20:2 24:7,13 29:9	<b>title</b> 230:21 464:14
163:19 165:23	437:11 440:11	88:5 100:10 101:5	<b>titled</b> 36:3 55:12
166:11 171:22	<b>thirteen</b> 416:18	102:8 121:20	59:15 62:23
179:12 180:4	<b>thirty</b> 107:2 195:6	133:8 135:5 137:9	115:23 129:20
184:11,12 196:5	232:5 246:19	141:10 161:7	131:11 133:10,20
196:12 202:9,11	<b>thonen</b> 446:7	169:19,21 170:3,7	134:6,12 225:6
206:4 218:12,18	<b>thought</b> 50:15	202:7 226:7,13	233:13 256:19
222:10,15 227:21	95:20 103:4	267:7 269:18	299:19 326:12
238:8,10 245:7	121:20 180:10,12	273:6 311:23	340:8 350:13
256:5 262:22	266:20 471:8	332:13 344:14	356:2 376:12
273:11,13,17	<b>thoughtful</b> 126:21	345:12,14,18	397:9 399:15
279:4 280:19	<b>thoughts</b> 462:20	347:17 351:18	411:7 415:9 427:5
281:12 282:20	<b>thousand</b> 360:22	412:12 416:16	430:13 450:21
285:11 286:2	416:15	436:4 447:22	453:5 456:1
290:20 297:17,23	<b>thousands</b> 120:18	470:4,20 471:22	458:21
298:12 306:15	<b>threaten</b> 67:3	473:13 474:20	<b>today</b> 11:17 12:16
318:18 322:7	<b>threatening</b> 119:9	492:13 493:19	13:14 14:3 70:10
323:22 327:13,22	314:2 490:7,17	<b>timeframe</b> 493:8	92:1 120:17
328:3 334:15	<b>three</b> 10:18 14:9	<b>times</b> 13:1 14:7,9	123:11 126:9
335:2,21,22 341:3	15:19 19:17 24:5	29:1 159:6 206:10	127:5 170:21
345:23 346:2,9	51:3 73:11 103:17	390:1 468:2	173:22 180:13
359:23 365:14,18	110:6 116:12	<b>timing</b> 139:2	181:8 192:19
366:3 377:1 380:8	122:21 123:17	<b>timmerie</b> 465:16	221:20 230:9
386:11 389:6,7	124:15 125:12	<b>tipping</b> 123:16	233:9 239:8
392:22 399:4,8	138:22 160:6	<b>tishyevich</b> 2:6 4:4	252:18 288:8
402:14 408:2	165:1 174:21	4:7 10:14,15 11:9	297:16 313:17
409:14 410:15	175:5,22 176:6	15:19 16:11 78:23	470:20 488:15
420:3 434:1 439:4	229:18 247:7	79:9 114:22 115:7	<b>today's</b> 491:11
439:8 443:17	260:8 261:7 299:2	115:15 125:22	<b>told</b> 48:20 165:17
448:13 453:18	312:14 327:6	126:16 166:13,22	261:23 262:4



409:7 443:19 <b>top</b> 58:2 59:15 108:10 109:8 128:7 130:14 167:14 224:13 240:23 263:13 337:7 367:11 375:19 377:11 384:18 394:16 421:9,21,21 430:16 434:8,17 453:8 461:1 <b>topic</b> 239:10 458:7 458:19 <b>topics</b> 90:13 180:23 181:11 452:10 <b>total</b> 338:22 345:15 <b>totally</b> 19:4 229:11 314:7,8 <b>touch</b> 98:6 <b>touched</b> 216:17 <b>toxin</b> 263:5 490:13 <b>track</b> 312:12 <b>trade</b> 201:9 203:5 203:9 <b>tradition</b> 8:2 <b>train</b> 106:6 155:7 157:8 <b>trained</b> 68:11 75:5 104:2 155:8 157:1 157:9,14 211:6 274:18 275:6 <b>training</b> 66:3,6,8,9 66:12 67:20 69:3 69:5,10,19 73:3 74:4,13,16 75:14 95:15 101:22 107:7 121:12,16 122:4,15 124:21	125:15 155:13 156:2 158:4 204:3 274:11,15 284:19 284:23 466:16 467:10,13 468:16 472:23 477:3 483:4 488:22 <b>trajectory</b> 152:23 <b>tran</b> 18:9 365:12 <b>trans</b> 145:21 148:13 151:12 370:1 428:15 429:1 <b>transcript</b> 8:20 15:12 18:7,11,12 18:22 492:7,11 493:6,18,20 495:5 495:8 <b>transcripts</b> 17:19 18:5 <b>transfeminine</b> 167:13 <b>transform</b> 323:1 <b>transformative</b> 71:2 <b>transgender</b> 4:22 19:7 20:19 21:11 22:1 40:4,7 55:13 63:1 64:19 65:1 79:17,21 81:2 82:12 83:13 89:6 95:17 104:6 106:2 106:10,17 109:13 122:9,12 123:7 130:14 131:23 132:7,11,12 136:21 145:1,10 146:7 147:5 151:9 160:21 167:4,11 167:17,21 168:1,4 168:9,13,18 169:1	175:21 178:22 179:1 181:20 182:10,17 214:2,6 247:17 314:6 318:12 341:9 342:15 343:16 347:1 348:20,22 351:9 353:3 354:7 355:12 365:7 366:8,9,12 368:10 368:15 369:1,6 374:11 386:17 412:17 428:17 444:1,18 448:6 450:1,22 454:5 460:15 463:14 468:11 469:16 476:15,18 477:14 478:21 479:10,15 482:18 485:22 486:10 <b>transgendered</b> 259:17 <b>transgenderism</b> 194:16 <b>transition</b> 55:13 113:10,19 153:1 165:18 169:2 176:22 287:13 353:4 359:19 360:20 363:10 365:17 366:10,18 395:12,19 397:9 397:17,21 398:11 398:18,23 479:22 <b>transitioned</b> 148:14 328:13 <b>transitioning</b> 82:13 94:3 146:4 178:13 238:20 312:3 320:20	321:5,21 360:15 373:22 416:23 <b>translation</b> 7:14 <b>transmen</b> 344:17 344:18 345:15 <b>transsexual</b> 7:8 330:18 392:1,8 <b>transsexualism</b> 392:12 <b>transsexuals</b> 6:13 <b>transwomen</b> 344:16,18 345:15 348:8 349:4 416:14 417:6 <b>trauma</b> 133:13 143:1 178:18 272:18 279:5 <b>traumatic</b> 178:6 <b>treasurer</b> 10:22 <b>treat</b> 65:9 131:22 132:1 144:23 151:7 215:18 220:19 231:19 435:17 436:20 450:1 460:2 488:19 <b>treatable</b> 122:6 <b>treated</b> 131:1 132:14 144:1 146:8 150:22 151:1 152:2,6 212:13 217:20 318:23 400:1 <b>treating</b> 75:14 136:21 146:21 200:14 218:9 249:7 262:9 273:5 460:8 <b>treatment</b> 4:21 8:7 8:11 19:7 20:19 21:11 22:1,3 39:5
--	--	--	---

40:19 41:5 49:16 52:1 54:10 63:1 65:1 78:19 80:18 81:7 89:10 111:6 117:15 129:20 137:4,11,18 146:23 151:16 153:11 178:6 186:12,14 195:17 196:15 206:16 211:21 214:11,17 215:1 216:9 219:19 220:16 225:14 266:4 267:17 268:4,7 316:19 329:11 340:11 345:22 350:17 353:2,10 353:21 354:3 373:10 374:17 375:1 392:11 394:21 402:3,5 405:8 406:2,6,23 422:20 423:8,17 424:1,10,21 429:21 430:13 431:1 433:20 434:22 435:22 437:13 438:2 459:21 460:14,17 473:4 474:21 475:3,4 481:3,14 481:21 482:12 483:14,22 485:21 487:21 <b>treatments</b> 35:5 36:18 43:15 44:2 65:21 89:8 119:6 120:5 139:21 140:5 150:16 319:3 373:20	487:15 <b>treats</b> 342:14 <b>trelstar</b> 203:11 <b>tremendous</b> 70:23 162:4,6 165:16 290:1 484:18 <b>trend</b> 109:15,21 <b>trending</b> 465:15 <b>trends</b> 340:10 <b>trial</b> 217:21 236:15,17,19,21 237:4,22 246:17 249:13 250:3 251:13 252:6,9,10 252:13 268:21 270:2,19 272:19 273:7 274:21 275:17 291:8 292:19 293:1,6,10 301:16,17 310:16 316:6 341:12 412:1 <b>trials</b> 120:11 218:12 235:22 245:10,20 246:11 246:22 247:20 249:3,18 250:21 251:23 269:4 271:2 280:8 293:20 294:10 298:3 302:18,18 307:20 422:23 <b>tried</b> 96:10 <b>triptodur</b> 203:3 <b>trivial</b> 244:18 <b>troubled</b> 179:13 179:22 <b>troublesome</b> 381:2 <b>troubling</b> 179:20 402:8	<b>true</b> 17:4 30:5 33:18 151:19 196:11 270:7,10 348:3 349:2 351:4 409:13 461:16 492:11 495:8 <b>truth</b> 444:7 <b>truthful</b> 11:16 <b>truths</b> 449:18 <b>try</b> 16:12 69:12 288:3 289:15 294:23 334:1 443:1 <b>trying</b> 19:20 88:11 91:18,20 94:5,16 149:6 153:5 273:11,13 276:3 279:4 300:15 324:19,21 334:22 340:20 345:4 348:22 455:2 458:9 <b>tubularized</b> 478:18 <b>turn</b> 151:20 397:6 471:15 <b>turned</b> 150:8 471:6 <b>turns</b> 45:23 <b>twenty</b> 107:2 219:21 320:12 <b>twice</b> 165:5 <b>two</b> 25:20 84:3,5 98:11 99:23 100:1 136:15 139:17 144:5 147:21,22 148:18 172:10 271:7 307:18 336:15 337:22 344:11 364:14 391:17 404:14,16	407:17 431:10,12 455:22 459:2 460:5 468:18 475:22 <b>type</b> 202:21 282:7 333:13 335:20 343:8 350:18 <b>types</b> 36:17 203:14 316:11 343:19 358:17 <b>typical</b> 90:10 160:22 315:19 <b>typically</b> 50:17 149:10 165:2 203:21 207:18 211:10 214:3,8 271:7,11 337:22 385:13 490:4 <b>typo</b> 359:21,22 <b>typology</b> 7:1
<b>u</b>			
<b>u</b> 16:12,16 20:23 203:4 299:19,19 <b>u.s.</b> 137:2 425:12 <b>uc</b> 86:14 273:12 278:7 <b>uh</b> 264:9 361:16 365:4 396:17 420:20 <b>uk</b> 7:22 411:11 <b>ulcer</b> 121:19,23 122:7 123:11 <b>ulcers</b> 121:20 <b>ultimate</b> 459:17 <b>ultimately</b> 53:17 156:13 <b>ultrasound</b> 142:11 <b>unable</b> 413:3 <b>unacceptable</b> 8:16 464:16 466:3 467:8,12 484:7			

<b>unapproved</b> 5:14 225:7 228:4,5 230:22 231:6,11 <b>unbiased</b> 409:14 <b>unborn</b> 131:12 <b>uncertain</b> 412:19 <b>uncertainty</b> 406:18 <b>unchangeable</b> 442:14 443:13 <b>uncommon</b> 255:5 255:16 294:16 357:10 358:22 463:22 <b>uncontrollable</b> 478:6 <b>uncontrolled</b> 411:19 413:10,14 <b>undergo</b> 316:21 330:19 390:15 <b>undergoes</b> 61:4 <b>undergoing</b> 7:9 60:5 211:21 213:18 <b>undergone</b> 419:5 <b>underlying</b> 194:19 210:8 211:1 215:14 217:19 368:19 <b>underneath</b> 60:10 <b>underpinnings</b> 104:14 <b>understand</b> 26:8 28:7,14 29:4,17 30:20 99:3 100:14 116:23 143:16 156:15 159:2,8,10 162:2 182:7 225:19 228:13 229:17 234:15 239:19 247:13	264:16 266:3 274:12,22 275:8 277:9 288:18 297:6,15 300:14 342:4,13 346:19 348:23 357:2 369:15 377:16,23 378:9 382:21 384:3 390:9 399:20 404:13 406:10 419:22 423:5 427:14 437:20 440:16 441:5 443:9 452:6 457:3 458:15 466:13 468:17 <b>understanding</b> 5:13 21:5 33:17 83:10 90:6 149:20 150:2,9 160:20 184:10 195:9,14 230:21 275:19 347:6 402:20 444:10 449:15 459:23 460:12 466:21 <b>understands</b> 207:2 <b>understood</b> 14:1 118:13 130:21 133:10 195:15 373:4 <b>undertook</b> 411:19 <b>underwent</b> 344:12 344:19 345:6,16 389:23 391:2 <b>unethical</b> 118:4 120:12 <b>union</b> 420:15 <b>unit</b> 9:18 79:3,7 166:16,20 254:15 254:19 272:18,23	320:2,6 388:7,11 470:12,16 491:9 <b>united</b> 1:1 8:9 9:22 433:18 434:8,18 435:21 437:20 441:8,21 472:17 474:2 475:13 <b>unitedhealthcare</b> 433:7 <b>university</b> 95:13 95:19 96:8 272:16 368:18 <b>unknown</b> 320:18 321:6,12,15,22 322:1 330:2 367:12 486:16 <b>unlabeled</b> 228:6 <b>unofficial</b> 7:13 <b>unproven</b> 120:4 206:22 481:15 <b>unquote</b> 291:20 351:4 367:23 <b>unreliable</b> 280:15 <b>unsupported</b> 243:4 <b>untenable</b> 250:6 <b>untested</b> 120:4 <b>unusual</b> 106:13 <b>unverified</b> 120:2 280:7 <b>update</b> 6:3 7:6 31:1 256:21 381:10 382:13 <b>updated</b> 171:16 197:17 378:1 430:19 435:4 <b>updates</b> 197:22 198:2,8,21 199:13 199:18 200:2,4,21 <b>updating</b> 198:20 441:20	<b>ups</b> 337:22 489:4 <b>upset</b> 409:6 <b>urethra</b> 478:13,14 478:15 <b>urethral</b> 336:17 336:18 338:10,20 <b>urgency</b> 463:12 <b>urinary</b> 178:16 <b>usage</b> 258:3 <b>use</b> 5:14,17,22 18:18 19:7,11 44:15,22 61:11 64:18,23 73:22 84:22 87:23 101:3 112:13 119:5 130:8,10,16 145:2 145:18 161:15 162:18 189:18 194:12 205:13 206:4,8,9,9,10,18 207:1,3 216:5,13 218:2,5,6,18,22,22 219:6,10,16 221:17 222:2,4,7 222:16 226:2,6,12 226:23 228:17,19 229:9 230:22 231:6,11,23 232:9 232:16 233:14,20 234:1,3,7,19 237:1 237:18 238:2 239:5 240:2,10,16 241:3,8,12,16,22 242:2,3,6,9,21 243:10,18,22,23 244:3,8,11,23 246:5 247:12,19 249:7 250:17 251:22 253:2,5,13 253:15 254:11 255:3,5,16 257:3
---	---	--	--

257:13 258:6 259:18,21 260:16 260:23 261:9 262:9,16,23 263:4 265:22 267:11,12 267:23 268:22 269:5 270:3 316:23 333:21 338:5 354:19,21 385:4 389:10 406:12,19 417:5 438:19,19 442:21 443:3,10 446:20 459:22 461:22 466:14 482:16 483:8,20 484:8,17 488:18 489:12 490:16 <b>useful</b> 310:3 330:22 344:2 354:23 355:1,13 374:20 <b>useless</b> 355:16 <b>uses</b> 225:7,14 226:15 228:6 229:1 241:17 461:20 469:12 484:4 <b>usually</b> 88:2 145:23 149:15 162:6 210:14 298:20 299:2 <b>utah</b> 4:18 54:8,16 56:1,12 57:10 58:15,20 59:7 61:17,20 77:8,11 78:7 109:23 110:14,23 117:7 <b>utterly</b> 8:15 220:23 247:11 464:15 466:2	<b>uva</b> 106:7,9,10 125:9  <b>v</b> <b>v</b> 1:12 9:21 16:21 33:2 202:16 203:8 322:18 493:4 494:1 495:1 <b>vaginal</b> 476:16 479:3,7,7 <b>vagineal</b> 479:3 <b>vaginoplasty</b> 168:1 175:13 476:18 478:23 <b>vague</b> 87:9 <b>valid</b> 23:11 199:3 209:4 228:23 288:4 310:21 314:7,9 485:13 486:1,2 <b>validated</b> 282:13 282:14 <b>validity</b> 274:19,22 275:2,19 282:17 358:9 <b>valuable</b> 333:17 <b>value</b> 305:22 <b>values</b> 334:14 <b>van</b> 86:7,10 <b>vanderbilt</b> 2:8 <b>vantas</b> 202:15 <b>variation</b> 71:19 <b>variety</b> 145:15 201:8,12 332:2 <b>various</b> 13:1 36:17 94:2,2 144:9 160:12 208:23 473:4 <b>vascular</b> 339:1 468:3 <b>vast</b> 330:17 335:18	<b>vehemently</b> 247:4 <b>venues</b> 160:12 <b>veracity</b> 274:19 <b>verbiage</b> 185:12 400:8 <b>verify</b> 493:9 <b>veritext</b> 10:6,9 493:14,23 <b>veritext.com</b> 493:15 <b>version</b> 7:16 183:2 183:9 184:5,8,18 185:4 187:3,9,13 187:18 188:1,7,16 188:20,23 189:10 196:21 396:15 397:4 398:15 399:3 401:1 <b>versus</b> 77:18 92:11 135:15 299:6 432:14 473:7 477:7 <b>vertical</b> 349:20 <b>veterans</b> 137:7,12 <b>victory</b> 161:20 <b>video</b> 256:6 <b>videoconference</b> 1:18 2:4 3:2,18 9:7 <b>videographer</b> 3:20 9:15 10:7 79:2,6 115:10,13 166:15 166:19 254:14,18 320:1,5 388:6,10 417:11,14 470:11 470:15 472:3,6 491:8 <b>videorecorded</b> 9:18 <b>videotaped</b> 1:18	<b>view</b> 42:9 79:21 80:17 118:10,19 186:6 428:1 431:18 432:7 442:11 443:9,10 484:3 485:9,10,23 486:14 487:14 488:17 489:14 <b>views</b> 398:7 452:11 465:2 489:12 <b>violated</b> 170:2 171:3 182:3 <b>violating</b> 182:1 <b>violation</b> 179:8 182:5 316:3 464:22 <b>violence</b> 67:13,15 <b>vir</b> 292:6 <b>virginia</b> 262:13 <b>virtually</b> 102:14 369:7 <b>visible</b> 319:12 328:5 <b>visit</b> 347:10 <b>visited</b> 341:23 342:7 <b>visiting</b> 343:2 <b>visits</b> 257:22 258:11 <b>vital</b> 309:9 <b>vocal</b> 125:5 <b>vol</b> 5:11 <b>volume</b> 74:7 <b>vote</b> 63:16,21 <b>vs</b> 394:23 <b>vulnerable</b> 76:9 120:13
--	--	---	--

<b>w</b>	<b>warnings</b> 215:22	<b>weight</b> 284:1	400:9 408:4 413:1
<b>w</b> 182:13 340:15	<b>warrant</b> 217:17	292:2	420:8 426:4,7
356:2 445:6	218:6 253:7 310:9	<b>weighted</b> 185:13	440:21 445:15
<b>wait</b> 289:15,17	<b>warranted</b> 217:18	<b>welcome</b> 351:2	491:2 493:8,10,12
313:22	<b>watchful</b> 77:20	<b>welcomed</b> 443:18	493:19
<b>waiting</b> 77:20	<b>wave</b> 260:9	444:2	<b>witnesses</b> 90:15
<b>waits</b> 293:9	<b>way</b> 38:15 54:3	<b>went</b> 74:1,3 94:5,6	91:3,8 92:20
<b>walk</b> 377:8 444:23	73:1 88:13 132:10	97:14 103:18,23	172:21 173:10
<b>wall</b> 2:20	134:19 151:9	104:4 139:18	<b>woman</b> 456:15
<b>walter</b> 11:14	171:4 181:21	164:4,9,14 165:17	<b>woman's</b> 156:3
<b>wandered</b> 186:15	206:19 225:4	188:1 192:1 200:7	<b>women</b> 151:12
<b>want</b> 15:1,19 19:3	243:3 244:14	336:20 361:9	152:15 214:2
72:13 80:11 90:12	245:5 261:9	<b>west</b> 2:14	348:10 349:6
101:13 126:23	266:19 311:9	<b>whatsoever</b> 61:21	<b>wonder</b> 393:6
135:1 150:13,19	317:17 322:13	<b>white</b> 102:2	452:22
151:18 172:9	338:3 346:18	298:22 387:5	<b>wondered</b> 134:21
181:3 210:19,21	350:2,21 354:5,9	<b>who've</b> 145:12	<b>word</b> 176:15,17
256:6 262:18	367:4 382:5,12	<b>widely</b> 189:21	228:3 438:20
272:7 273:14	385:18,21 429:6	201:6	462:16 469:12
289:22 344:23	438:8 442:1 443:2	<b>wider</b> 410:7	<b>words</b> 60:13 61:13
349:22 359:12	447:10 449:6	<b>wiepjes</b> 6:17	209:16 392:15
362:12 396:13	462:20 474:11,13	340:15	402:11 443:10
397:20 420:5	486:12	<b>williams</b> 3:10	<b>work</b> 45:7,18
453:2 462:16	<b>we've</b> 61:16,17	<b>willing</b> 90:21 91:7	61:21 76:21
470:3 480:8,9	77:8,11 125:2,11	96:13 286:10	184:17 191:13
487:13	175:2 180:19	<b>wilson</b> 6:20 356:1	192:18,21 193:3
<b>wanted</b> 82:10 90:5	182:6 268:1 344:5	<b>winston</b> 3:13	198:2 211:12
95:19 159:2,7,9,12	439:10	<b>wisdom</b> 436:15	212:2,18 213:17
159:13 194:12	<b>weak</b> 51:6,19	<b>wise</b> 311:10	466:7
440:22 441:3	<b>weakest</b> 382:10	<b>wish</b> 470:5	<b>worked</b> 110:17
452:6,8 472:10	<b>wealth</b> 292:1	<b>withdrawn</b> 108:3	273:6 382:7
487:12 489:5	<b>web</b> 27:13	177:12	<b>working</b> 16:5,17
<b>wanting</b> 159:19	<b>website</b> 230:19	<b>witness</b> 9:10 10:13	17:2,8 143:2
235:18	361:19 362:7	91:11,13 92:16,22	156:20 184:8,18
<b>wants</b> 148:14	366:21 407:12	174:11,22 255:22	190:16,21 192:7
149:22 166:4	455:14	256:2,9 280:23	272:17 273:1
219:7	<b>wednesday</b> 63:12	281:3 325:15,18	474:5,7
<b>ward</b> 156:4,7	<b>weeks</b> 15:2,16,20	327:3 332:10	<b>works</b> 48:21 311:1
<b>warning</b> 215:20	37:7 156:7	335:1,7 340:6	<b>world</b> 117:22
489:22 490:1,4,11	<b>weigh</b> 206:12	341:1,6 350:7,11	121:14 123:16
	207:1 226:2,9	384:12 385:19	125:1 161:4



177:16 182:9	397:11	186:8,18 188:15	344:3 345:17,23
260:3 329:1 332:5	<b>wrote</b> 183:7 408:3	189:7 195:21	346:9 347:10
410:5,8 412:16	<b>wyoming</b> 3:7	196:19 205:7,9	349:10 350:3
428:16 474:22	<b>x</b>	208:2,5,9 211:3,19	351:6,22 352:8
476:7 479:10	<b>x</b> 4:1,10 360:9	212:10 213:12,13	353:11,15 358:19
480:12 486:22	<b>y</b>	220:6,7 221:1	359:21 360:15,22
487:5	<b>y</b> 256:19,19	224:6,12 228:5	361:8,21,22 362:4
<b>worldwide</b> 416:11	<b>yackey</b> 6:1 256:19	229:7,11 236:12	362:18 367:3
<b>worry</b> 135:8 264:5	<b>yeah</b> 18:15 22:1,7	236:22 237:12,21	371:2 375:9,10
<b>worse</b> 392:19	22:13 32:16 41:22	237:22 238:5,6	377:5,7 378:18,22
393:8	42:5,23 48:2	240:21 242:1,6	378:23 379:9
<b>worst</b> 381:18	51:20 54:19 65:19	243:14 245:14	382:6,11,17 384:5
<b>worth</b> 485:6	69:14 73:17 78:12	246:18 251:5,12	384:8,13 385:12
<b>worthless</b> 282:23	83:2,18 84:5,9,11	251:19 253:21	387:7 390:4,9,20
283:3,4	91:23 92:5,12	256:1 263:2	390:23 391:12
<b>wound</b> 289:13	96:20 97:4 99:5	264:19 266:22	392:14,21,22
450:14 475:7,10	99:21 100:1,15	267:4,13 268:12	393:2,4,10 394:18
478:11	101:4,9,17,19	268:12 272:2,3,3	395:20,21 396:5
<b>woundedness</b>	102:13,14,21	273:19 280:21	396:12 398:19
67:21	103:1,5 105:5	281:4,10 285:3	399:4,7,23 400:3
<b>wounds</b> 475:6	107:10,17,23	286:15,18 289:21	400:10,14,22
<b>wpath</b> 7:15 182:8	108:3 109:1,4,7	290:14 294:8	402:7,10 403:1,3,6
182:16 183:13,16	110:20 111:23	295:5,19,21 297:4	403:11,19 404:12
183:18,19,23	113:3,4,5,11,13,14	297:10,21 300:16	404:13 406:21
184:8,17 185:3,22	114:4,4,23 118:15	301:5 303:10,14	407:23 408:5,6
187:2,8,12,17	119:3 128:1,10	303:15,21 304:5	411:14 413:2,2
188:6,16 189:5,10	130:22 133:9	305:5,6 307:10	416:7 417:1 418:1
313:3 395:7,10,14	135:9,12 143:9	309:1,14 311:6,19	418:18 420:4,11
395:21 396:13	144:17,19 145:4	313:16,17 315:6,9	421:14 423:16
397:3 398:14	146:18 147:2,13	315:19 318:14	424:6,13,18
402:10 428:18	148:3,5,6,21 149:5	321:13,23 322:1,7	426:10 428:5
429:2	150:21 151:10	323:13,21 325:1,9	429:17 431:23
<b>wpath's</b> 184:4	152:16 153:2	326:4,5,8 328:4,17	434:1 435:11
<b>wrinkles</b> 262:10	154:23 155:1	329:7,13,20	436:2 438:6,10
<b>write</b> 144:22 280:4	156:22 157:5	332:18,18,19	441:5 443:23
<b>writing</b> 185:19	160:3 162:10,12	333:1,16 334:11	445:2,8,12 452:14
441:20	162:18 163:7,9	335:2,6,8,9,10	453:11,23 456:2
<b>writings</b> 195:11	164:1,7,21 166:11	336:11 338:7,8,18	458:19 460:16
<b>written</b> 130:19	171:4,20 179:19	338:19 339:23	461:11,21,22
<b>wrong</b> 43:23 62:10	179:23 185:23	340:16 341:2,7,12	464:11 471:4,9,23
184:11,13 379:23		341:13 343:10	472:20 480:6,10

<b>year</b> 7:20 24:15,19 24:22 34:1 37:9 57:9 63:7 76:3 117:5 138:5 139:3 143:11 148:4 184:7,12 196:16 300:10 302:10 317:6,19 342:22 344:8 345:19 346:5 380:10,11 380:19 411:10 427:15 477:3	313:8,11 337:13 337:14,18,23 344:13 346:7 347:12 351:22,22 352:2 381:22 402:15 443:7 468:15 476:8
<b>yesterday</b> 14:12 14:19,21	<b>york</b> 2:9,9,21,21
<b>young</b> 7:21 161:11 368:12 369:7,9,22 411:10 469:1	<b>younger</b> 142:22 347:10
<b>years</b> 6:10 23:11 24:2,5 25:20 32:6 44:14 46:1,8 51:3 63:9 69:9 72:21 95:14 97:3 99:21 99:23 100:1 102:17 103:17 106:2,20 107:2 122:4,21 123:1,5 123:18 124:15 125:12,17 129:11 129:15 130:18 138:19,20,21,22 138:23 139:7,10 140:16,20,23 141:8 148:9 160:5 165:1 170:9,9 174:21 175:6,22 176:6 181:17 196:6,12 202:11 213:4 219:21 232:5 246:19 247:7,21 257:5 260:8 261:7 262:2 262:6 263:1 266:21 283:8 297:5 298:16,17 300:8,10 301:19 307:12 312:14	<b>youtube</b> 367:16
<b>z</b>	
<b>z</b> 16:12 <b>zantac</b> 123:13 <b>zero</b> 21:12 284:7 <b>zoom</b> 10:4 325:17	

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:

(A) to review the transcript or recording; and

(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1, 2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.



VERITEXT LEGAL SOLUTIONS  
COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at [www.veritext.com](http://www.veritext.com).